Syntheses and structure-activity relationships of novel P2X3 receptor antagonists by Rashed, Mahmoud Sayed Ahmed Mahmoud
  
Syntheses and structure-activity relationships  
of novel P2X3 receptor antagonists 
 
 
Dissertation 
zur 
Erlangung des Doktorgrades (Dr. rer. nat.) 
der 
Mathematisch-Naturwissenschaftlichen Fakultät 
der 
Rheinischen Friedrich-Wilhelms-Universität Bonn 
 
vorgelegt von 
Mahmoud Sayed Ahmed Mahmoud Rashed 
aus 
Kairo, Ägypten 
 
 
Bonn 2017 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Angefertigt mit Genehmigung der Mathematisch-Naturwissenschaftlichen Fakultät der 
Rheinischen Friedrich-Wilhelms-Universität Bonn. 
 
 
 
 
 
 
 
 
 
 
 
 
1. Gutachter: Prof. Dr. Christa E. Müller 
2. Gutachter: Priv.-Doz. Dr. Anke C. Schiedel  
Tag der Promotion: 15.01.2018  
Erscheinungsjahr: 2018 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Die vorliegende Arbeit wurde in der Zeit von November 2013 bis Mai 2017 am 
Pharmazeutischen Institut der Rheinischen Friedrich-Wilhelms-Universität Bonn unter der 
Leitung von Frau Prof. Dr. Christa E. Müller durchgeführt. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mein besonderer Dank gilt Frau Prof. Dr. Christa E. Müller für das interessante 
Promotionsthema, ihre Unterstützung, ihre Diskussionsbereitschaft und ihre Anregungen, die 
zum Gelingen dieser Arbeit beigetragen haben. 
Ebenso bedanke ich mich an dieser Stelle bei PD Dr. Anke Schiedel für die freundliche 
Übernahme des Korreferates. 
Ich danke der Kulturabteilung und Studienmission der Ägyptischen Botschaft für die 
finanzielle Unterstützung in Form eines Promotionsstipendiums. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
To My Parents, My Dear Wife 
and My Daughter Layan 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Table of contents 
 
9 
 
1 Table of Contents 
Table of Contents ........................................................................................................................... 9 
1. Introduction ........................................................................................................................... - 1 - 
1.1. Purinergic signaling and purinergic receptors ..................................................................... - 1 - 
1.1.1. Purinergic signaling .......................................................................................................... - 1 - 
1.1.2. Purinergic receptors .......................................................................................................... - 2 - 
1.1.2.1. P0, P1 and P2 receptors ................................................................................................. - 3 - 
1.1.3. G protein-coupled receptors (GPCRs) .............................................................................. - 4 - 
1.1.4. P2 receptors (nucleotide receptors) ................................................................................... - 5 - 
1.1.4.1. P2Y receptors ................................................................................................................. - 5 - 
1.1.4.2. P2X receptors ................................................................................................................. - 6 - 
1.1.4.2.1. P2X receptor crystal structures ................................................................................. - 10 - 
1.1.4.2.1.1. P2X4 receptor crystal structure .............................................................................. - 10 - 
1.1.4.2.1.2. P2X3 receptor crystal structure
49
 ........................................................................... - 13 - 
1.1.4.2.1.3. P2X7 crystal structure ............................................................................................ - 16 - 
1.1.5. P2X1, P2X2 and P2X4 receptors .................................................................................... - 18 - 
1.1.5.1. P2X1 receptor subtype ................................................................................................. - 18 - 
1.1.5.2. P2X1 receptor antagonists ........................................................................................... - 18 - 
1.1.5.3. P2X2 receptor subtype ................................................................................................. - 19 - 
1.1.5.4. P2X2 receptor antagonists ........................................................................................... - 20 - 
1.1.5.5. P2X4 receptor subtype ................................................................................................. - 21 - 
1.1.5.6. P2X4 receptor antagonists ........................................................................................... - 21 - 
1.1.5.7. The P2X5 receptor subtype .......................................................................................... - 24 - 
1.1.5.8. The P2X6 receptor subtype .......................................................................................... - 25 - 
1.1.5.9. The P2X7 receptor subtype .......................................................................................... - 26 - 
1.1.5.10. P2X7 receptor antagonists ......................................................................................... - 26 - 
Table of contents 
 
10 
 
1.1.6. The P2X3 receptor subtype ............................................................................................. - 27 - 
1.1.6.1. Distribution of P2X3 receptors .................................................................................... - 28 - 
1.1.6.2. Screening of P2X3 receptors ....................................................................................... - 28 - 
1.1.6.3. P2X3 receptor antagonists ........................................................................................... - 29 - 
1.1.7. P2X receptors and pain ................................................................................................... - 34 - 
1.2. Anthraquinone (AQ) derivatives........................................................................................ - 36 - 
1.2.1. Anthraquinone derivatives and their applications ........................................................... - 37 - 
1.3. Microwave chemistry......................................................................................................... - 42 - 
1.3.1. Microwave-assisted organic synthesis (MAOS) ............................................................. - 42 - 
1.4. Ullmann reaction ................................................................................................................ - 43 - 
1.5. Goldberg condensation reaction ........................................................................................ - 44 - 
1.6. Triphenylmethanes ............................................................................................................. - 45 - 
2. Research objectives ............................................................................................................. - 47 - 
2.1. Anthraquinone derivatives ................................................................................................. - 47 - 
2.2. Bisacodyl-derived compounds ........................................................................................... - 48 - 
3. Results and Discussion ........................................................................................................ - 50 - 
3.1. Anthraquinone derivatives ................................................................................................. - 50 - 
3.1.1. Synthesis of 1-amino-4-(aryl)alkylamino-2-methylanthraquinone derivatives .............. - 50 - 
3.1.2. Condensation with liquid amines using solvent-free Ullmann reaction ......................... - 50 - 
3.1.3. General synthetic procedure (I) used for anthraquinone derivatives 2-17 ...................... - 52 - 
3.1.4. Optimization of the reaction conditions for 1-amino-4-bromo-2-methylanthraquinone 
derivatives ................................................................................................................................. - 56 - 
3.1.4.1. Condensation with solid amines .................................................................................. - 56 - 
3.1.5. Optimization of the reaction conditions for some 2-substituted anthraquinone 
derivatives ..........................................................................................................................................  - 56 - 
3.1.5.1. Optimization of the reaction conditions for 1-amino-2,4-dibromoanthraquinone (26) - 58 - 
3.1.5.2. Optimization of the reaction conditions for 1-amino-2-methylanthraquinone (1) ...... - 59 - 
Table of contents 
 
11 
 
3.1.5.2.1. Optimization of the reaction conditions using ethanol as a solvent.......................... - 61 - 
3.5.2.1.2. Use of ethyleneglycol as a solvent ............................................................................ - 62 - 
3.5.2.1.3. Use of methanol as a solvent .................................................................................... - 63 - 
3.1.6. Optimization of the reaction conditions using methanol as a solvent ............................ - 65 - 
3.1.6.1. Effect of concentration ................................................................................................. - 65 - 
3.1.6.2. Effect of the catalyst .................................................................................................... - 66 - 
3.1.7. General synthetic procedure (II) used for anthraquinone derivatives 18-25 .................. - 69 - 
3.2. Bisacodyl-derived compounds ........................................................................................... - 71 - 
3.2.1. Synthesis of bisacodyl..................................................................................................... - 71 - 
3.2.2. Development of P2X3 receptor antagonists ................................................................... - 72 - 
3.2.3. Alkylation of the bis-phenol metabolite of bisacodyl ..................................................... - 73 - 
3.2.4. Preparation of a triarylcarbinol derivative ...................................................................... - 77 - 
3.2.4.1. Confirmation of structures ........................................................................................... - 78 - 
3.2.4.2. Plausible mechanism for the formation of 3-methoxy-10-(4-methoxyphenyl)-
pyrido[1,2-a]indole (73) ........................................................................................................... - 80 - 
3.2.5. Miscellaneous modifications .......................................................................................... - 85 - 
3.2.5.1. Synthesis of N
4
-(4-methoxyphenyl)2,4,6-triamino-pyrimidine ................................... - 85 - 
3.2.5.2. Synthesis of diindolylmethane derivatives .................................................................. - 86 - 
3.2.5.3. Synthesis of 5,5'-(4-(benzyloxy)-1,3-phenylene)-bis-(3-ethyl-1,2,4-oxadiazole) (99) - 87 - 
3.2.5.3.1. Deprotection of the methoxy group of compound 97 ............................................... - 88 - 
3.2.5.3.2. Proposed mechanism of the formation of the bis-oxadiazole ................................... - 89 - 
3.3. Pharmacological evaluation ............................................................................................ - 90 - 
3.3.1. Anthraquinone (AQ) derivatives ..................................................................................... - 90 - 
3.3.1.1. Biological evaluation of anthraquinone derivatives (previous results) ........................ - 90 - 
3.3.1.2. Potency of newly synthesized AQ derivatives on the human P2Y4 receptor............... - 91 - 
3.3.1.3. Potency on the human P2X3 receptor .......................................................................... - 92 - 
3.3.2. Bisacodyl-derived compounds ........................................................................................ - 96 - 
Table of contents 
 
12 
 
3.3.2.1. Biological evaluation of the synthesized bisacodyl-derived compounds .................... - 96 - 
3.3.2.1.1. Inhibitory potency of bisacodyl-derived compounds on the human P2X3 receptor 
and study of structure-activity relationships ............................................................................. - 96 - 
3.3.2.1.2. Effects of symmetrical substitution of the bisacodyl-derived drug 46 on the 
inhibitory activity ...................................................................................................................... - 99 - 
3.3.2.1.3 Effects of asymmetrical substitutions of leads structure 46 on the inhibitory activity .......  - 100 - 
3.3.2.1.4. Effects of simplification of the lead structure (46) ................................................. - 105 - 
3.3.2.1.4.1. Replacement or removal of the pyridine ring ...................................................... - 105 - 
3.3.2.1.5. Miscellaneous modifications .................................................................................. - 106 - 
3.3.2.2. Pharmacophore model ............................................................................................... - 109 - 
3.3.2.2.1. Pharmacophore model features ............................................................................... - 110 - 
4. Summary ............................................................................................................................ - 114 - 
4.1. Anthraquinone derivatives ............................................................................................... - 114 - 
4.1.1. Synthesis and optimization of 1-amino-4-(aryl)alkylamino-2-methylanthraquinone 
derivatives ............................................................................................................................... - 114 - 
4.1.2. Biological evaluation of the synthesized anthraquinone derivatives ............................ - 115 - 
4.2. Bisacodyl-derived compounds ......................................................................................... - 116 - 
4.2.1. Synthesis of Bisacodyl-derived compounds ................................................................. - 116 - 
4.2.2. Inhibitory potency of bisacodyl derivatives on the human P2X3 receptor and study of 
structure-activity relationships ................................................................................................ - 117 - 
5. Experimental part ............................................................................................................. - 120 - 
5.1. General considerations ..................................................................................................... - 120 - 
5.2. Pharmacological Assays .................................................................................................. - 121 - 
5.2.1. Evaluating the pharmacological actions of the compounds at human P2Y4 receptors . - 121 - 
5.2.2. Measurement of Ca
2+
 in transfected 1321N1 astrocytoma cells ................................... - 122 - 
5.3. Pharmacophore modelling ............................................................................................... - 123 - 
5.4. Chemistry of anthraquinone derivatives .......................................................................... - 124 - 
5.4.1. General synthetic procedure (I) used for anthraquinone derivatives (2-17) ................. - 124 - 
Table of contents 
 
13 
 
5.4.2. Characterization of 1-amino-4-(aryl)alkylamino-2-methylanthraquinone derivatives (2-
17)  .................................................................................................................................. - 125 - 
5.4.3. General synthetic procedure (II) used for anthraquinone derivatives (18-25) .............. - 136 - 
5.4.4. Characterization of 1-amino-4-(aryl)alkylamino-2-methylanthraquinone derivatives 
(18-25) - 136 - 
5.5. Chemistry of bisacodyl-derived compounds ................................................................... - 142 - 
5.5.1. General synthetic procedure (III) (48-66, 68, 69, 72, 78a, 80, 81, 83, 85, and 99) ...... - 144 - 
5.5.2. Characterization of the bisacodyl-derived compounds ................................................. - 145 - 
5.5.3. General synthetic procedure (IV).................................................................................. - 161 - 
5.5.4. Characterization of compounds 71-74 .......................................................................... - 161 - 
5.5.5. General synthetic procedure (V) (75-78) ...................................................................... - 164 - 
5.5.6. Characterization of the synthesized derivatives (80, 81, 83, 85, 87 and 88) ................ - 167 - 
5.5.7. General synthetic procedure (VI) used for the synthesized compounds 89, 90 and 95 - 171 - 
6. Abbreviation ...................................................................................................................... - 178 - 
7. References .......................................................................................................................... - 180 - 
Introduction 
 
- 1 - 
 
2 1. Introduction 
2.1 1.1. Purinergic signaling and purinergic receptors 
1.1.1. Purinergic signaling 
The extracellular signaling theory of adenosine 5′-triphosphate (ATP), which can bind to receptors 
and act as a cotransmitter was postulated almost half a century ago.
1 
Before that, it was considered 
for a long time that ATP only plays a role as a universal intracellular source of energy and as a 
building block for nucleic acid synthesis.
2 
However, ATP can be released into the extracellular space 
in response to certain physiological or pathological stimuli.
3
 
The extracellular effects of nucleotides such as ATP were originally described by Drury and Szent-
Györgyi in 1929, based on the observation that purine nucleotides and nucleosides were effective 
when applied extracellularly to heart and blood vessels.
4 
Subsequent studies investigated the action 
of extracellular ATP. Buchthal and Folkow, showed that ganglia are sensitive to extracellular ATP, 
which results in tetanus-like contractions.
5
 In 1954, this was further corroborated by Holton during 
mechanical and electrical stimulation of the great sensory nerve of the ear artery in rabbits.
6 
She 
showed that ATP released from sensory nerves resulted in vasodilatation changing the tone of blood 
vessels. This observation was on early sign that ATP may be a neurotransmitter in the peripheral 
nervous system.
7
 
It has also been recognized that ATP is co-released with different classical transmitters within the 
nervous system such as the inhibitory neurotransmitter γ-aminobutyric acid (GABA)8 and 
acetylcholine.
9
 The ATP released into the extracellular space is subject to breakdown to adenosine 
5'-diphosphate (ADP) and adenosine 5'-monophosphate (AMP)
10
 by different types of ecto-
nucleotidases (E-NTPases).
11,12 
Now, there is plentiful evidence that ATP is an important neurotransmitter in both the central and 
peripheral nervous system.
7,13 
A strong relation between purinergic signaling and neural 
transmission, inflammation, malignancy, angiogenesis and diabetes has been observed since then.
14
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1.1.2. Purinergic receptors 
In 1972, Geoffrey Burnstock proposed the purinergic nerve hypothesis, which supported the 
existence of non-adrenergic, non-cholinergic autonomic nerves which would be responsible for the 
neuronal transmission to smooth muscles of the gastrointestinal tract and bladder.
15
 ATP, a purine 
nucleotide, emerged as the most likely neurotransmitter for these neurons and was soon after termed 
“purinergic” in 1976.16 Two years later, purinergic receptors were divided into two families, P1 
(adenosine sensitive receptors) and P2 (ATP and its analogues sensitive receptors).
17
 Burnstock’s 
theory was not confirmed until the first ATP receptor was cloned from embryonic chick whole brain 
in 1993.
18 
In addition to P1 receptors and P2 receptors P0 receptors, were recently identified in 
rodents suggesting a third family of purinergic receptors (Figure 1.1).
19  
 
Figure 1.1. Illustration of the structural relationships between the physiological agonists for the 
three purinergic families. Adenine (red) which is considered as a partial structure of the P1 receptor 
agonist adenosine (green), which itself is a partial structure of the P2 receptor agonists ATP and 
ADP (blue).
20
 UTP: uridine triphosphate; UDP: uridine diphosphate. 
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1.1.2.1. P0, P1 and P2 receptors 
In the following work, these types of purinergic receptor families are classified based on their 
molecular structure, sensitivity to different agonists and their tissue distribution. Two adenine, four 
adenosine, eight P2Y and seven P2X receptors have been cloned and characterized.
17
 The P0 
receptors, known as the adenine receptors (Ade1R and Ade2R), are sensitive to adenine,
21
 the P1 
receptors, known as the adenosine receptors (A1, A2A, A2B and A3), are sensitive to adenosine
22 
and 
the P2 receptors, classified into P2X and P2Y are activated by various nucleotides. The P2Y 
receptors (P2Y1,2,4,6,11-14) are activated by ATP, ADP, UTP, uridine diphosphate UDP or UDP-
glucose.
19,
 All these receptors are G protein-coupled receptors (GPCRs). The P2X receptors (P2X1-
7) are ligand-gated ion channels activated by ATP
22
 (Figure 1.2). 
 
Figure 1.2. Classification of the purinergic receptor family. *ATP (endogenous ligand for P2Y2 and 
P2Y11); ADP (endogenous ligand for P2Y1, P2Y12, and P2Y13); UTP (endogenous ligand for P2Y2, 
and P2Y4); UDP (endogenous ligand for P2Y6); UDP-glucose (endogenous ligand for P2Y14).
16-18
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1.1.3. G protein-coupled receptors (GPCRs) 
The name G-protein-coupled receptors was suggested because these receptors primarily act via 
activation of guanine nucleotide binding proteins (G proteins).
23
 GPCRs also commonly referred to 
as seven transmembrane (TM) receptors (Figure 1.3), are a family of integral membrane receptors 
which play a substantial role in signal transmission in the cells. Information provided by 
extracellular stimuli is transduced into intracellular second messengers by GPCRs through coupling 
with G proteins.
24
 GPCRs have important physiological roles, and the impairment of their function 
leads to a variety of diseases.
25
 Different types of ligands can activate GPCRs effectively, such as 
peptide and non-peptide neurotransmitters, growth factors, hormones, odorant molecules and light.
25
  
 
Figure 1.3. Schematic view of basic structural features of GPCRs. Seven transmembrane helices 
numbered 1-7 are described as cylinders connected by loops which are drawn as lines, while the 
membrane is shaded. The left part of the diagram demonstrates, in a very simplified style, the three 
dimensional packing of the seven helices together. The right part of the diagram shows the 
transmembrane topology of a GPCR (unfolded receptor). The intracellular loops (ICLs) which are 
formed between transmembrane domains are marked ICL1 to ICL3, and the extracellular loops 
(ECLs) are marked ECL1 to ECL3.
23 
 
Four families of proteins (ion channels, rhodopsin-like GPCRs, protein kinases, and nuclear 
hormone receptors) have been described to represent 44% of all human protein drug targets (Figure 
1.4, left). These privileged families mediate the pharmacological effects of 70% of small-molecule 
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drugs. Rhodopsin-like GPCRs have grown to be one of the leading areas of research. They represent 
33% of all drug targets (Figure 1.4, right).
26 
 
Figure 1.4. Proportions of the main gene families as targets for drugs. A. Attribution of human drug 
targets in the main families. B. Attribution of drugs (small-molecules) that target those families.
26 
1.1.4. P2 receptors (nucleotide receptors)  
The current PhD thesis focuses on the P2 receptor family. The P2 receptors are ubiquitously 
distributed in the body.
27
 Seven subtypes of ionotropic P2X receptors, which can form 
homomultimers and heteromultimers, and eight subtypes of metabotropic P2Y receptors are known 
to exist. 
1.1.4.1. P2Y receptors  
P2Y receptors are widely distributed and found in various tissues including smooth muscle (vascular 
and visceral), autonomic, central, enteric and sensory neurons, glia and astrocytes, epithelium and 
endothelium, heart, as well as soft tissues (kidney, liver, lung, pancreas, prostate and thymus), and 
bone (Table 1.1).
28,29
 
P2Y subtypes can be subdivided into Gq-coupled receptors (P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11) 
and Gi-coupled receptors (P2Y12, P2Y13 and P2Y14).
30
 Based on sequence similarity, P2Y receptors 
can be grouped into two subfamilies: P2Y1,2,4,6,11 and P2Y12,13,14. The percentage of amino acid (AA) 
sequence identity is relatively low (19-55%). The P2Y12 receptor shows only 19% homology with 
the other P2Y receptor subtypes.
2 
P2Y receptors are activated by different nucleotides based on the 
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receptor subtype: P2Y1,12,13 are activated by ADP; P2Y2 is activated by UTP and ATP; P2Y4 is 
activated by UTP; P2Y6 is activated by UDP; P2Y11 is activated by ATP; P2Y14 is activated by 
UDP-glucose.
28
 
Table 1.1. Human P2Y receptors
19,31
 
P2Y Subtype Main distribution Agonist No. of AA 
P2Y1 
Epithelial and endothelial cells, blood 
platelets, immune cells, osteoclasts, brain 
ADP 372 
P2Y2 
Epithelial and endothelial cells, immune 
cells, renal tubules, osteoblasts 
UTP/ATP 376 
P2Y4 Endothelial cells, spleen, placenta UTP 365 
P2Y6 
Airway and intestinal epithelial cells, spleen, 
placenta, thymus 
UDP 328 
P2Y11 spleen, intestine, granulocytes ATP 371 
P2Y12 Platelets, brain (glial cells), microglial cells ADP 342 
P2Y13 
Spleen, brain, erythrocytes lymph nodes, 
bone marrow 
ADP 334 
P2Y14 
Placenta, adipose tissue, stomach, intestine, 
discrete brain regions, mast cells, 
UDP-glucose 338 
1.1.4.2. P2X receptors 
P2X receptors belong to the class of ligand-gated ion channels. Ion channels are a group of 
membrane proteins which are expressed in virtually every living cell. More than 400 putative ion 
channels have been recognized in the human genome sequences. Ionotropic channels may be 
classified on the basis of their regulatory mechanisms into different subclasses. There are mainly 
two subfamilies. One is the family of voltage-gated ion channels (VGICs), and the other one are the 
ligand gated ion channels (LGICs). Regulation of the VGIC is controlled by voltage changes, while 
LGICs are controlled by chemical transmitters.
32 
LGICs are transmembrane ion channels that 
convert the binding of a ligand (released from the presynaptic neuron and bound to the postsynaptic 
neuron), into an ion influx in the postsynaptic membrane. They consist of at least two domains, a 
transmembrane domain which contains the ion channel and an extracellular domain which 
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comprises the ligand binding site. Upon excitation, the binding of the ligand triggers conformational 
changes that allow the opening of the ion channel and subsequently the influx of ions across the cell 
membrane. Besides their prominent role in neurotransmission, they are also found on some 
nonexcitable cells such as endothelial cells, indicating a wider regulatory role of theses receptors 
outside the nervous system.
33
 
LGICs are related to membrane proteins which can either form homomeric or heteromeric channels. 
Homomeric channels are formed by several member of the same subunit, while heteromeric 
channels occur through the association of different subunits. The composed subunits define both 
pharmacological properties and functional characteristics of ligand-gated channels.
34
 Three major 
superfamilies of LGICs are existing, (i) Cys-loop receptors which are pentameric ion channels, (ii) 
ionotropic glutamate receptors which are tetrameric ion channels, and (iii) P2X receptors which are 
trimeric ion channels.
33
 
Up till now, seven homomeric P2XRs (P2X1-7) and five heteromeric assemblies (P2X1/2, P2X1/5, 
P2X2/3, P2X2/6 and P2X4/6) have been identified or proposed.
22 
Recently, it has been reported a 
P2X2/4/6 heterotrimer as the first P2X receptor containing three different subunits.
35
 P2XRs have 
been cloned both from human and rat complementary deoxyribonucleic acid (cDNA) libraries or, 
mouse and guinea-pig and, in some cases, also from chick and zebrafish libraries.
36  
Several non-selective antagonists of P2X receptors were discovered. Suramin, 2',3'-O-(2,4,6-
trinitrophenyl)adenosine 5'-triphosphate (TNP-ATP), Reactive Blue-2 (RB-2), pyridoxalphosphate-
6-azophenyl-2'-4'-disulfonic acid (PPADS), and iso-PPADS structures are presented in Figure 1.5.
37
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Figure 1.5. Structures of nonselective P2X receptor antagonists.
37
 
Each subunit topology is composed of two hydrophobic transmembrane domains, positioning both 
N- and C-terminal intracellularly with two transmembrane regions (TM1 and TM2), one of them 
related to channel opening and closing and the other lining the ion pore; a large extracellular loop, 
containing ten conserved cysteine residues forming five disulfide bridges and the ATP binding sites. 
The hydrophobic H5 region near the pore passageway is responsible for the modulation of 
receptor/channel by various cations including Ca
2+
, Mg
2+
, Zn
2+
 and Cu
2+
, while the ATP-binding 
site may involve areas related to the extracellular loop (Figure 1.6).
13
 Conformational changes 
happen in response to binding of the agonist ATP, which leads to the opening of the ion channel 
pore and enables the flow of Ca
2+
, Na
+
 and K
+
 across the membrane.
38 
Their protein sequence size 
lies between 384 (P2X4) and 595 (P2X7) amino acids with 30-50% sequence identity.
13 
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Figure 1.6. The P2X purinoreceptors (NH2 and COOH termini are located intracellularly; S-S; 
disulfide bonds; M1 and M2, transmembrane domains).
13,39
 
The P2X receptors are widely expressed in different tissues such as immune cells, platelets, vascular 
smooth muscle cells and importantly in the peripheral and central nervous system. They are 
involved in a wide variety of physiological processes, including smooth muscle contraction, cell 
death, synaptic transmission and presynaptic modulation, cell proliferation, taste, nociception and 
platelet aggregation (see Table 1.2).
40,41
 
Table 1.2. P2X receptor subtypes including distribution and localization
42,43
 
P2X 
subtype 
Main distribution 
Desensitization 
kinetics 
No. of amino 
acids 
P2X1 
Smooth muscle, sympathetic & parasympathetic 
ganglia, cerebellum, platelets, pituitary  
fast 
399 
 
P2X2 
Smooth muscle, central and peripheral nervous 
system, brain, pancreas, retina 
slow  472 
P2X3 
Nociceptive sensory neurons, some sympathetic 
neurons 
fast 397 
P2X4 Microglia, testis, colon, endothelial cells slow  384 
Introduction 
 
- 10 - 
 
P2X 
subtype 
Main distribution 
Desensitization 
kinetics 
No. of amino 
acids 
P2X5 
Proliferating cells in skin, gut, bladder, thymus, 
spinal cord, heart, adrenal medulla 
slow 417 
P2X6 Brain, motor neurons in spinal cord slow 
379 
 
P2X7 
Macrophages, mast cells, microglia, pancreas, skin, 
endocrine organs 
   slow pore formation 595 
1.1.4.2.1. P2X receptor crystal structures 
In the following part, crystal structures of P2X receptors will be discussed. The first one is the 
zebrafish P2X4 receptor (zfP2X4) structure which was discovered in the apo state, later it was co-
crystalized with ATP. The second one is the human P2X3 (hP2X3) receptor which has been 
discovered with different states and it was co-crystalized with ATP and orthosteric inhibitors. The 
third one is the mammalian P2X7 crystal structure which was co-crystalized with five different 
allosteric inhibitors.  
1.1.4.2.1.1. P2X4 receptor crystal structure 
The first crystal structures of a P2X receptor was that of the zebrafish P2X4 receptor (zfP2X4) in the 
closed and the open state.
44,45
 The crystal structure (zfP2X4) receptor confirmed the trimeric 
structure of P2X receptors, including the following features: (1) two transmembrane (TM1 and 
TM2) domains, (2) large extracellular loop containing ATP binding sites, and (3) intracellular N- 
and C-terminals. It showed that the transmembrane ion channel pore is composed of six α-helices in 
the extracellular region, two larger helices in the transmembrane region.
44
 
The zfP2X4 receptor structure proposed that the TM2 forms the ion pore. The TM2 helices line the 
central ion channel pore containing the channel gate in the closed resting state. The TM1 was in a 
peripheral ring to the pore region. The TM domains might exist as the fluke and the upper body 
domain which is the extracellular region. In the extracellular region the core domain which consist 
of two β-strands which are connected to each other very tightly with strong interactions. Each 
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subunit showed as a shape of dolphin consisting of the head domain, which contains three β strands 
and one α-helix, the body domain, the dorsal fin, both right and left flippers (see Figure 1.7). 
The homomeric zfP2X4 receptor was crystallized by Kawate et al. at a 3.1 Å resolution in the closed 
state with no bound antagonist, and ATP-binding sites were not identified. The zP2X4 receptor is 
shaped like a chalice with a large extracellular domain about 70 Å above and comparatively smaller 
transmembrane domains spanning roughly a 28 Å through the membrane.
46
 
 
Figure 1.7. Dolphine-like shape of one subunit of the zP2X4 receptor (TM are transmembrane 
helices, g2 and g4 marks the attached glycans, β1-14 indicates β-strands, and SS1-5 represents 
disulfide bonds.
44
 
Later in 2012, Hattori et al. successfully co-crystallized the zfP2X4 receptor in its open state bound 
to ATP at a 2.8 Å resolution which confirmed the location of the ATP binding sites. The residues in 
the zfP2X4 receptor are located at the base of the head region of the receptor, near the predicted 
ATP binding pocket.
56 
In the ATP-bound open-channel structure (Figure 1.8, A) the positively 
charged amino acid residues K70, K72, K316, N296, and R298 (zfP2X4 numbering) could directly 
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coordinate the binding of the ATP. The α-phosphate group is indirectly coordinate by K193. This 
interaction occurs through the solvent of crystallization (glycerol), which may be changed by water 
molecules under physiological conditions (Figure 1.8, B). The adenine moiety of ATP is 
coordinated by T189, L191, and I232 residues, while the ribose ring is recognized by L217. The 
different structural domains such as hydrophobic and positively charged amino acid residues are 
able to surround the bound ATP molecule.
47
 
 
Figure 1.8. A) One ATP molecule which is bound to the trimeric structure of zfP2X4 receptor 
(lateral view). B) The ATP-binding site (close-up view). Red sphere indicates the oxygen of the 
glycerol (solvent). Hydrogen bonding is indicated by black dash lines. Due to the subunit of the 
receptor being similar to a leaping dolphin, the domains are named the upper body and head domain 
(chain A), and left flipper, lower body and dorsal fin (chain B).
47
 
Ion permeability 
Conformational change between the subunits of the zfP2X4 receptor, which induced in response to 
the binding of ATP to the extracellular domain, causes a movement of the TM domains and permits 
cation influx via the receptor pore. Two pathways were suggested for passage of the ions from the 
extracellular solution to the transmembrane ion channel. One of the possible pathways of the ion 
passage is through an area on top of the TM domains. The opening approximately 8 Å in diameter 
could be big enough to allow the passage of cations such as Na
+
, K
+
 and Ca
+2
 to the channel. 
Another possibility is that the ions access the TM domains through two vestibules rich in acidic 
Introduction 
 
- 13 - 
 
residues. Even though in the apo, closed-state structure of the zP2X4 receptor, which shows that it is 
too narrow (~2.3 Å) for hydrated ions to pass through, it is thought that when the agonist binds to 
the channel, it will expand these constrictions permitting ions to pass through.
44 
 
Facts about the P2X4 crystal structure 
(1) The crystal structure of zfP2X4 receptor has provided a major advance in the understanding of 
the molecular architecture of the P2X receptors. 
(2) Compared to other trimeric receptor with each subunit containing two TM domains such as the 
acid sensing ion channel (ASIC), there is a similarity in pore architecture and the aqueous 
vestibules.
48 
 
(3) Extracellular movements following ATP binding were identified through the comparison 
between apo and ATP-bound states.
40
 
(4)  The ATP-bound structure at 2.8 Å resolution identifies a previously unseen ATP-binding motif 
and an open pore conformation. 
1.1.4.2.1.2. P2X3 receptor crystal structure
49
 
The first crystal structure of the human P2X3 receptor was discovered in an apo/resting, agonist-
bound/open-pore, agonist-bound/desensitized and antagonist-bound closed states. The ion channel 
pore in the open state structure is stabilized by an intracellular motif named “cytoplasmic cap” 
which forms a phospholipid-lined gate for egress of water molecules and ions. The apo/resting state 
is stabilized by the competitive antagonists TNP-ATP and A-317491. The apo structure of the 
hP2X3 receptor as a more complete transmembrane domain than that of the P2X receptor. It has 
different residues defining the pore constriction, and it has a Mg
2+ 
ion bound in the head domain.  
The extracellular domains and binding pockets of both, the desensitized and the open states of the 
hP2X3 are similar. There are big differences in the transmembrane domains and at the gates. Both 
hP2X3 structures (open state and desensitized state) have transmembrane domains with sufficient 
length to cross a lipid bilayer, and the desensitized state structure has a pore architecture that was 
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not previously observed for any P2X structure. The TM domains of the zfP2X4 structure are short 
and uncomplete compared to the TM domains for the hP2X3 structure. 
The cytoplasmic cap anchors the TMs to allow a change in helical axis in TM2 once the channel 
opened. The cytoplasmic cap undergoes a folding-unfolding transition during channel gating and its 
stability sets the rate of receptor desensitization. In the closed state, when ATP binds, the signal is 
transferred and the channels are open. After some time of ATP binding, the signal is not able to be 
transferred even in the presence of ATP. This state is observed with the P2X3 receptor which is 
characterized by a fast-desensitizing state. In contrast, the P2X4 receptor is slowly desensitizing. In 
the fast-desensitizing state, the P2X receptors possess a relatively unstable cap domain, while the 
slowly and incompletely desensitizing receptors having a more stable cap domain. 
The orthosteric ligand-binding site 
The binding pocket for the ATP-bound, open state, the TNP-ATP bound, closed state, and the A-
317491-bound, closed state of hP2X3 have been characterized (Figure 1.9).The open state structure 
has ATP in the ligand-binding pocket and an open pore, while the desensitized state structure has 
ATP in the pocket but a closed pore. The orthosteric ligands bind in a cleft at an interface between 
two protomers. ATP binding residues make interactions with TNP-ATP and A-317491, notably 
R281, N279, and K65 and T172 (for TNP-ATP) (see Figure 1.10). 
 
Figure 1.9. Structure of ATP, TNP-ATP and A-317491.
37
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Figure 1.10. The orthosteric ligand-binding site.
49  
Pore-lining surface 
The pore radius is a function of distance for the open, apo, and the desensitized state. The 
extracellular boundary of the gate referred to the amino acid residues I323 and T330, respectively. 
I323, which considered as the first site of the gate was constructed, and T330 which defines the 
narrowest region of the pore in the open state. In the desensitized state the pore size and diameter 
were changed (see Figure 1.11).  
 
Figure 1.11. The hP2X3 pore-lining surface in the open, apo and desensitized states.
49
 
Comparison between hP2X3 and zfP2X4 structures emphasizes the longer transmembrane domains 
and the cytoplasmic domain of hP2X3. In the antagonist-bound state, the competitive antagonists 
TNP-ATP and A-317491 occupy the orthosteric ligand-binding pocket, and the ion channel pore is 
closed which is identical to the apo/resting state. 
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1.1.4.2.1.3. P2X7 crystal structure  
Five diverse structures known to be antagonists for P2X7 receptor have been co-crystalized namely, 
A7400003, A804598, AZ10606120, GW791343, and JNJ47965567 (Figure 1.12)
50,51,52,53,54 
using x-
ray crystallographic techniques, which showed that these compounds bind in the same binding 
pocket. Among these five antagonists, three of them namely A740003, A804598, and JNJ47965567 
previously have been identified as competitive inhibitors. However, based on the released crystal 
structures they are predicted as allosteric antagonists. Based on structures diversity,
 
confirmation 
changes of the lower body domain region were occurred. This possibly inhibits indirectly the ATP 
binding pocket through these allosteric modifications.
55
  
 
Figure 1.12. Structures of A7400003, AZ10606120, A804598, GW791343, and JNJ47965567. 
Allosteric binding pocket 
The drug-binding pocket is surrounded by 13 residues which are hydrophobic in nature. Based on 
the crystal structure information, the known binding pocket is hydrophobic involving F95, F103, 
M105, F293, and V312 (Figure 1.13). Compound A804598 is closer to the binding pocket of ATP. 
However, the distances and angles between the side-chains and the drugs cannot be precisely 
evaluated because the resolution of the crystal structure was very low ~ 3.4 Å (Figure 1.13).
55
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Figure 1.13. The allosteric binding pocket.
55
 
In the closed state, the turret was interrupting, the left flipper goes outside down direction, the dorsal 
fin goes up, and the head body goes down. In the open state the turret has to be slightly moved while 
the antagonists stopping the turret to move inside (Figure 1.14).  
 
Figure 1.14. Activation and inhibition mechanisms of the P2X7 receptor.
55
 
In the beginning the P2X crystal structures were co-crystalized with apo and ATP and later it was 
with orthosteric inhibitors and furthers it was extended to allosteric inhibitors. 
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1.1.5. P2X1, P2X2 and P2X4 receptors 
1.1.5.1. P2X1 receptor subtype 
P2X1 receptors are widely distributed in smooth muscle cells and platelets, which regulate smooth 
muscle contractility and prothrombotic functions. P2X1 is similar to the P2X3 receptor in terms of 
agonist and kinetic properties. However, β,γ-MeATP displays higher potency for P2X1 than for 
P2X3.
56
 
1.1.5.2. P2X1 receptor antagonists 
Many P2X1 antagonists have been developed with limitation to increase potency and selectivity, but 
their drug-likeness is low. Several suramin derivatives were identified with extremely high potency 
and selectivity for P2X1 receptors. 4,4',4'',4'''-[Carbonyl-bis-(imino-5,1,3-benzenetriyl-bis-
(carbonylimino))]tetrakis-1,3-benzene disulfonic acid (NF 449), a potent purinergic receptor 
antagonist was found to be highly selective for P2X1 (>3,000-fold more potent than suramin at the 
rat P2X1 receptor).
57
 Certain suramin derivative show a relatively high affinity for P2X1 receptors: 
8,8’-[carbonyl-bis-(imino-3,1-phen-ylenecarbonylimino)]bis-1,3,5-naphthalene-trisulfonic acid 
(NF023) was also identified as a competitive P2X antagonist with IC50 values of 0.21 and 0.24 μM 
on rat and human P2X1, respectively. P2X3 receptors have an intermediate sensitivity with IC50 
values of 8.5 and 28.9 μM on rat and human, respectively, while it is less potent at the P2X2 subtype 
(IC50> 50 μM), and inactive on P2X4 receptors.
58 
Another suramin derivative with nanomolar 
inhibitory potency at the P2X1 receptor is 8,8’-[carbonyl-bis-(imino-4,1-phenylenecarbonylimino-
4,1-pheylene-carbonyl-imino)]bis-1,3,5 naphthalene trisulfonic acid (NF279), which showed 
antagonistic activity for P2X1 with an IC50 of 0.050 μM. Other P2X1 antagonists are derivatives of 
pyridoxal-5'-phosphate and the 6-azophenyl-2',4'-disulfonate derivative (PPADS), such as 
MRS2220, which blocks P2X1 at about 10 μM with no effect on P2X2 or P2X4 receptors or hP2Y2, 
hP2Y4, or rP2Y6 receptors.
59 
However, none of the previously described antagonists can be 
considered as an ideal starting point for drug optimization.
56
 
RO-0437626 (RO-1), a benzimidazole-2-carboxamide derivative is the only non-acidic small 
molecule P2X1 antagonist with drug-like properties. RO-1 was discovered through high-throughput 
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screening (HTS) of optimized dipeptide library, which were originally synthesized as potential renin 
inhibitors, but were shown to be inactive. It showed moderate potency on human P2X1 with an IC50 
of 3 μM, and it was the first P2X1 receptor antagonist proven to be > 30-fold selective over other 
homomeric and heteromeric human P2X receptors (P2X2, P2X3, and P2X2/3, IC50 > 100 μM).
60 
Previously described antagonists are illustrated in Figure 1.15.  
 
Figure 1.15. Structures of suramin-derived P2X1 antagonists NF449, NF023, NF279, RO-1, and 
PPADS-derived MRS2220. 
1.1.5.3. P2X2 receptor subtype 
P2X2 receptors (P2X2R) are distributed within the peripheral and central nervous systems, and on 
many non-neuronal cell types, where they play a role in ATP-mediated sensory transmission and 
modulation of synaptic function. Also, P2X2R may possess extended functions in the organization 
of many central nervous system (CNS) processes, such as memory and learning, motor function, 
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autonomic coordination, and sensory integration. They are similar to P2X4 and P2X5 in agonist 
activity and slow desensitization kinetics.
56
 
P2X2R are established as homomers or heteromers with other receptors. P2X2 subunits may form 
heteromeric channels in combination with two different partners (P2X3 or P2X6). The P2X2/6 
heteromer is composed of two P2X2 monomers and one P2X6 monomer, while the heteromeric 
P2X2/3 formed by one P2X2 and two P2X3 monomers.
61
 
The P2X2 receptor activity can by modulated allosterically by transition metals. The most potent 
metal is copper (Cu
2+
) which triggered a 25-fold potentiation of the ATP-gated currents. For 
comparison, zinc (Zn
2+
), nickel and mercury need 10-fold higher concentration while palladium, 
cobalt need 12-fold and cadmium needs only 3-fold higher concentrations. Platinum was inactive. 
The authors concluded after replacing nine alanines with histidines in the extracellular domain of the 
rat P2X2 receptor that His120, His192, His213 and His245 are residues forming the allosteric metal 
binding site of the P2X2 receptor. These four mutant histidines and His319 were specifically 
important for the coordination of (Cu
2+
), but not (Zn
2+
).
62
 
1.1.5.4. P2X2 receptor antagonists 
Nicardipine is a calcium channel blocker which belongs to the dihydropyridine class. It showed 
antagonistic activity on recombinant rat P2X2 receptor with an IC50 value of 25 μM.
63
 In 2011, Baqi 
et al. published a series of optimized anthraquinone derivatives related to RB-2, which yielded 
disodium 1-amino-4-[3-(4,6-dichloro[1,3,5]triazine-2-ylamino)-4-sulfophenylamino]-9,10-dioxo-
9,10-dihydroanthracene-2-sulfonate (PSB-1011) and sodium 1-amino-4-[3-(4,6-
dichloro[1,3,5]triazine-2-ylamino)phenylamino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate 
(PSB-10211) with IC50 of 0.079 µM and 0.086 µM, respectively as the first potent and selective 
competitive rat P2X2 receptor antagonists (see Figure 1.16).
64 
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Figure 1.16. Structures of P2X2 receptors antagonists PSB-1011, PSB-10211, and nicardipine. 
1.1.5.5. P2X4 receptor subtype 
Between the P2X receptors, the P2X4 subtype is prominently distributed through the central and 
peripheral nervous system including epithelia, smooth muscle cells of the bladder, gastrointestinal 
tract, kidneys, lungs, uterus, and arteries, uterine endometrium, fat cells, liver, heart, pancreas and 
activated microglia.
56,65
 
The activation of spinal microglia as a consequence of damage and inflammation in the spinal cord 
after injury of peripheral nerves leads to an up regulation of P2X4 receptor expression. Stimulation 
by endogenous ATP results in the formation of brain-derived neurotrophic factor (BDNF).
66 
Therefore, P2X4 receptors are novel targets for the treatment of chronic neuropathic pain.
67  
1.1.5.6. P2X4 receptor antagonists 
One of the first selective antagonists of the P2X4 receptor which has been described in literature is 
the benzodiazepine derivative 5-BDBD (5-(3-bromophenyl)-1,3-dihydro-2H-benzofuro[3,2-e]-1,4-
diazepin-2-one). 5-BDBD is moderately potent with an IC50 value of 1.6 μM in human embryonic 
kidney (HEK)-293 cells expressing human P2X4 receptor.
68
 In 2016, Abdelrahman et al. 
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demonstrated that 5-BDBD is a non-competitive antagonist since it does not block [
35
S] ATPγS 
binding. This indicates that it binds allosterically.
69
 
Clinically used antidepressant drugs were investigated for their inhibitory effects on human and rat 
P2X4 receptor. Among these, paroxetine showed inhibition of ATP-mediated calcium influx in 
1321N1 astrocytoma cells expressing the P2X4 receptors with an IC50 of 2.45 μM on human and 
1.87 μM on rat receptors. An antiallodynic effect was seen after intrathecal administration of 
paroxetine. The authors claimed that the antinociceptive activity of paroxetine as well as other 
antidepressants used for the therapy of neuropathic pain could be induced at least partially through 
inhibition of P2X4 receptors.
70
 Radioligand binding assays illustrated that paroxetine is 
characterized as an allosteric antagonist, because it was unable to displace [
35S]ATPγS from its 
binding site at the human P2X4 receptor.
69
 
Amitriptyline, a tricyclic antidepressant was approved to treat neuropathic pain in humans, but its 
anti-hyperalgesic mechanism is still unknown. Amitriptyline’s inhibitory effect was tested on rat, 
mouse, and human P2X receptors (P2X2, P2X4, and P2X7). Amitriptyline showed only moderate 
activity on rat and mouse P2X4 receptor and no activity was found on human P2X4, P2X7 and rat 
P2X2 receptors. In conclusion, P2X4 receptor blockade is not considered as a contributing factor to 
amitriptyline’s efficacy against neuropathic pain.71 
Recently, Hernandez-Olmos et al. reported a series of N-substituted phenoxazine derivatives as 
potent and selective allosteric P2X4 antagonists. Of these derivatives, N-
(benzyloxycarbonyl)phenoxazine (PSB-12054) is a very potent antagonist on human P2X4 with an 
IC50 of 0.189 μM and it has a high selectivity for human P2X4 of over 30-fold as compared to 
human P2X1, P2X2, P2X3, and P2X7 receptors. In contrast to PSB-12054, the sulfonamide 
derivative, N-(p-methylphenylsulfonyl)phenoxazine (PSB-12062) showed lower potency, but was 
more water-soluble. Interestingly, it has a similar potency in all three species: human, rat and mouse 
P2X4 receptors with IC50 values of 1.38, 0.928 and 1.76 μM, respectively. PSB-12062 showed at 
least a 35-fold selectivity toward P2X4 versus P2X1, P2X2, P2X3, and P2X7 receptors.
72
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More recently, a newly developed series of carbamazepine derivatives was synthesized by Tian et 
al. and the compounds were evaluated as potential P2X4 receptor antagonists. N,N-Diisopropyl-5H-
dibenz[b,f]azepine-5-carboxamide was found to be the most potent compound among this series on 
the human P2X4 receptor with an IC50 value of 3.44 μM, but with lower potency on rat and mouse 
P2X4 receptors. The compound showed to be fairly selective towards human P2X2 and P2X7 
receptors, but no selectivity versus P2X1 and P2X3 receptors was observed.
73
 
In 2015, Ase et al. published a new P2X4 receptor-selective phenylurea derived antagonist 1-(2,6-
dibromo-4-isopropyl-phenyl)-3-(3-pyridyl)urea (BX430). The compound was identified through an 
high-throughput screening (HTS) assay and exhibited a non-competitive allosteric mechanism of 
P2X4 inhibition. BX430 potently inhibited the human P2X4 receptor with an IC50 value of 0.54 μM 
and effectively antagonized the zebrafish P2X4 receptor but showed little or no effect on the rat and 
mouse P2X4 orthologues. BX430 is selective for the human P2X4 receptor being ≥ 10-fold more 
potent than at P2X1, P2X2, P2X3 and 100-fold more potent than P2X7 receptors.
74
 
Another successful novel and selective P2X4 antagonist is NP-1815-PX, (5-[3-(5-thioxo-4H-
[1,2,4]oxadiazol-3-yl)phenyl]-1H-naphtho[1,2-b][1,4]diazepine-2,4(3H,5H)-dione) which has been 
identified as a potent inhibitor of the human P2X4 receptor with an IC50 of 0.26 µM. NP-1815-PX 
has a high selectivity for the P2X4 receptor compared to other P2XR subtypes. Administration of 
intrathecal dose of NP-1815-PX produced an antiallodynic effect in a mouse chronic pain model 
induced by herpes virus without affecting acute nociceptive pain sensitivity.
75
 All the structures of 
the pervious described compounds are presented in Figure 1.1.17. 
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Figure 1.17. Structures and potencies of the P2X4 antagonists 5-BDBD, paroxetine, amitriptyline, 
PSB-12054, PSB-12062, N,N-diisopropylcarbamazepine, BX430, and NP-1815-PX. 
1.1.5.7. The P2X5 receptor subtype 
In 1996, the cDNA of P2X5 subunit was isolated from rat sympathetic ganglia, and heart.
76 
Compared to the other P2X receptor subtypes, the expression of P2X5 receptors is limited. 
However, it is expressed in areas such as epithelial cells of the nasal mucosa and may be related to 
cell differentiation, especially in the skin and skeletal muscles.
56
 
P2X5 subunits can probably form heteromeric receptors with P2X1, P2X2, and P2X4 subunits.
34 
P2X subunits can form hetero-multimers, which are unique from homomeric timers. For example, 
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hetero-oligomeric P2X1/5 is generated as an association of P2X1 and P2X5 subunits. The resulting 
hybrid channels display the pharmacological properties of P2X1, and the kinetics of P2X5 receptors. 
The current of P2X1/5 receptor is characterized by a slow desensitization. The agonist α,β-
methylene-adenosine 5'-triphosphate (α,β-meATP) displayed with an EC50 value of 1.1 µM, and the 
antagonist TNP-ATP showed an IC50 value of 0.064 µM which is not observed either with P2X1 or 
P2X5 alone.
77
 
In the plasma membrane, P2X5 subunits can also interact with the P2X2 subunits forming 
heteromeric receptors with various stoichiometry. It is important to note that the formed P2X2/5 
receptors resulted in phosphatidylserine exposure, membrane blebbing, and pore dilatation. 
Previously, it was thought that these features were related to the P2X7 receptor only. P2X5 subunits 
can also form heteromeric receptors with P2X1, P2X2, and P2X4 subunits.
34
 
It was reported by Kotnis et al. that most humans only express a non-functional isoform of the P2X5 
receptor. The non-functional isoform arises from the human P2X5 gene having a single-nucleotide 
polymorphism (SNP) at the 3´ splice of exon 10, which is important for the second transmembrane 
domain. Therefore, the physiological roles of the P2X5 receptor in humans are difficult to assess.
78
 
1.1.5.8. The P2X6 receptor subtype 
The P2X6 receptor is expressed throughout the central nervous system (CNS). Homomeric P2X6 
channels are formed only after glycosylation. They can be activated by α,β-MeATP and blocked by 
TNP-ATP. This receptor can easily form heteromeric channels with P2X2 and/or P2X4 and the 
functional properties of the new heteromer closely resemble those of the P2X2 and P2X4 
receptors.
56
 
Among the P2X receptors, the P2X6 receptor is the only subtype found to be upregulated selectively 
during chronic heart failure (CHF). Based on this finding, novel drugs targeting the P2X6 receptor 
might be used for treating chronic heart failure through the effect on the tumor necrosis factor alpha 
(TNFα).79 
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1.1.5.9. The P2X7 receptor subtype 
The P2X7 receptor (P2X7R) formerly known as P2Z
80
 has an important role in inflammation and 
immunity
 
as indicated by recent studies of P2X7R-knockout (KO) mice.
81 
The P2X7R has a 
potential role in regulating survival of cells depending on the extracellular concentrations of ATP. 
The P2X7R is highly expressed in immune cells such as macrophages and monocytes. It is involved 
in the potentiation of the release of pro-inflammatory cytokines including IL-1β and IL-18 from 
macrophages and microglia.
82 
P2X7R might be drug targets for the treatment of a number of 
diseases including pain, neurodegeneration, and inflammatory diseases such as rheumatoid arthritis 
and osteoarthritis.
83
 
1.1.5.10. P2X7 receptor antagonists  
Many P2X7 antagonists have been identified with a steady increase since the first patent appeared in 
1999. However, no P2X7 antagonist has reached the market yet, even if two compounds made it to 
clinical trials. The AstraZeneca compound AZD9056, was in phase II clinical trials for several 
inflammatory indications i.e. rheumatoid arthritis, osteoarthritis, chronic obstructive pulmonary 
disease, and inflammatory bowel disease. Another clinical trial has been performed by Pfizer. 
Compound CE-224535 that was indicated for rheumatoid arthritis with twice 500 mg as a daily 
dose. Due to the lack of efficacy this compound was terminated for osteoarthritic knee pain.
84 
unfortunately, both compounds failed to give a clear benefits for the patients.
37
  
1-[N,O-Bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazine, an 
isoquinolinesulfonamide, KN-62, which is a selective antagonist of Ca
2+
/calmodulin-dependent 
protein kinase II (CaMKII), was the first small molecule to be identified as a P2X7 antagonist. The 
compound antagonizes the human P2X7R with an IC50 value of 0.100 μM, while no inhibitory 
activity on the rat P2X7R was observed.
85,86 
Another potent, selective antagonist is A-740003, which 
competitively antagonizes P2X7 receptor with IC50 values of 0.018 μM on rat P2X7 and 0.040 μM 
on human P2X7 receptors. A-740003 is selective for P2X7 over different subtypes of P2X and P2Y 
receptors up to concentrations of 100 μM. The compound showed notable reduction of nociception 
in animal models.
87
 Several benzamide derivatives were reported which showed a significant 
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biological effect as inhibitors of the P2X7 receptor with promising results in brain penetration.
88
 
 
The previously stated antagonists of the P2X7 receptor are presented in Figure 1.18. 
 
Figure 1.18. Structures of the P2X7 receptor antagonists AZDF9056, CE-224,535, KN-62, A-
740003, and two benzamide derivatives. 
1.1.6. The P2X3 receptor subtype 
In 1995, rat dorsal root ganglion (DRG) sensory neurons were used for cloning the cDNA of the 
P2X3 receptor.
89 
The P2X3 receptor exists as a homotrimeric channel, but it can also form 
heteromeric trimers consisting two P2X3 and one P2X2 unit resulting in the P2X2/3 receptor.
90,91
 
Among all P2X receptor subtypes, P2X3 is the only receptor which is expressed in a subset of 
sensory neurons.  
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1.1.6.1. Distribution of P2X3 receptors 
The P2X3 subunit shows a restricted distribution in a subset of sensory neurons including the 
trigeminal, dorsal root, and inferior ganglion of the vagus nerve. Recently, it was demonstrated to be 
also expressed in nucleus tractus solatarius and other brain regions. However, the P2X3 receptor is 
absent from smooth muscle, sympathetic, and enteric neurons.
42
 
Due to the restricted tissue distribution in small to medium C- and Aδ-fiber primary afferent 
neurons, P2X3 receptors have been suggested to be involved in pain-sensing.
92 
Indeed, animal 
studied revealed that P2X3 knockout animals or P2X3 siRNA- or antisense-treated animals have 
greatly diminished pain-related behaviors in both inflammatory and neuropathic pain models.
93 
Moreover, administration of the P2X3 receptor-selective agonist α,β-methylene ATP to the hind 
paws of rats resulted in exacerbating nociceptive behaviors.
94
 
The homomeric P2X3 receptor showed rapid desensitization property (<100 ms) upon prolonged 
exposure to the physiological agonist ATP, followed by a long regeneration period. On the contrary, 
the heteromeric P2X2/3 receptor shares the pharmacological profile (α,β-meATP sensitivity) of the 
homomeric P2X3 receptor and the slow desensitization kinetics of the P2X2 homomer and 
potentially represents a naturally occurring form of the receptor that is involved in pain 
perception.
95,96 
1.1.6.2. Screening of P2X3 receptors 
The fast desensitizing of the P2X3 receptor makes the screening by a calcium imaging assay very 
difficult. The exchange of amino acids, namely P-19, V-21, and I-22, which are located in the 
cytoplasmic loop before the transmembrane domain for the corresponding amino acids of the P2X2 
receptor slowed the desensitization process. Also, it was discovered that replacement of the amino 
acid serine in position 15 of the native rat P2X3 by valine or an other hydrophobic residue showed 
the strongest effect to slow down the P2X3 receptor desensitization to the level of that of the P2X2 
receptor. It was found that the S
15
V-rP2X3 mutant allowed the screening of compounds since the 
signal became detectable.
97 
In the human P2X3 receptor using the same mutation could also result in 
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a reliable alternative for its characterization. Recently, the stable transfection the corresponding 
construct into 1321N1 astrocytoma cells was successfully achieved by Dr. Aliaa Abdelrahman. 
1.1.6.3. P2X3 receptor antagonists 
One of the common antagonists is 2',3'-O-(2,4,6-trinitrophenyl)adenosine 5'-triphosphate (TNP-
ATP), an ATP-derivative. It was the only reported dual P2X3/P2X2/3 antagonist but with limitation 
of its use to in vitro experiments due to its nucleotide nature.
90
 
A number of P2X3R antagonists have been developed which are potent, selective and drug-like. 
These were described in few publications and in several patents. A potent and selective P2X3 
P2X2/3R antagonist is the suramin-derived 4,4',4'',4'''-(carbonylbis-(imino-5,1,3- benzenetriylbis-
(carbonylimino)))tetrakisbenzenesulfonic acid (NF110), which inhibits P2X3 receptors with low 
nanomolar potency (Figure 1.19).
98
 
Homomeric P2X3 and heteromeric P2X2/3 receptors are predominantly present in the pathways of 
pain signal transmission peripherally and centrally. The first step for the validation of these 
receptors as chronic pain targets (inflammatory and neuropathic) was the discovery of A-317491, 
which considered the first non-nucleotide antagonist. It was used to demonstrate the reduction of 
hyperalgesia and allodynia in a chronic pain animal model.
99,100
 
A-31749 was synthesized at Abbott Laboratories, and has a high affinity with Ki values in the low 
nanomolar range at human and rat P2X3 and P2X2/3 receptors. Moreover, it is very selective versus 
other P2 receptors, neurotransmitter receptors, ion channels, and enzymes (IC50> 10 μM). 
Furthermore, it binds to the ATP site and is considered as a competitive antagonist like the 
nucleotide-based antagonist TNP-ATP, which showed a high affinity for P2X1 receptors as well but, 
more than 100-fold selectivity for P2X3 and P2X2/3 receptors when it was compared to other P2X 
receptor subtypes. The (S)-configurated derivative was potent in a chronic pain animal model, while 
the (R)-enantiomer designated A-317344 was completely inactive.
100,101
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MK3901,
102,103
 a compound which is a substituted arylamide derivative (SAAs) with a potency in 
the low nanomolar range, is a selective CNS-penetrant P2X3 antagonist. MK3901 showed 
promising results in models of chronic inflammatory and neuropathic pain (see Figure 1.19).
 
 
Figure 1.19. Structures and inhibitory potencies of the P2X3 antagonists NF110, A-317491 and 
MK-3901. 
In an effort to discover novel P2X3 or P2X2/3 receptor antagonists with suitable physicochemical 
and pharmacokinetic properties required for a viable drug candidate, the Roche compound library 
was subjected to high-throughput screening (HTS), and many hits were obtained. AF-001, a 
confirmed HTS hit compound with a diaminopyrimidine structure, which had been developed at 
Hoffmann-La-Roche (Basel) in the early 1970s to investigate the structure-activity relationships of 
trimethoprim, a bacterial dihydrofolate reductase (DHFR) inhibitor. AF-001, was used as a starting 
point for the development of P2X3 receptor antagonists. It showed an IC50 value of 1.2 μM. 
However, the drug trimethoprim itself was completely inactive at 10 μM.103 Structures of 
trimethoprim and AF-001 are shown in Figure 1.20. 
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Optimization of the diaminopyrimidine series  
 
The optimization strategy of the hit structure focused on three main points:  
(1) The small alkyl side-chain: R= propyl, t-butyl, or methoxy abolished the activity. However, 
isopropyl substitution led to RO-3 which was 10-fold more potent than AF-001. (2) The linker: 
reduction of the conformational flexibility by replacing the methylene bridge with an oxygen. (3) 
The addition of different groups at the 4- and 5- position of the aryl ring to enhance potency and 
metabolic stability. 
The extensive chemical optimization yielded many active and promising analogues. Interestingly, 
AF-353 (RO-4), an iodoanisole derivative, was obtained which is a potent and selective P2X3 
antagonist with the proper pharmacokinetic profile. The combination of high selectivity for P2X3 
and P2X2/3, antagonistic potency, and adequate pharmacokinetic properties made this compound an 
excellent tool for in vivo studies in animal models. AF-353 (RO-4), is a small drug-like molecule for 
the potential treatment of pain-related disorders.
104
 Another potent and polar antagonist AF-906 
(RO-51), which showed an inhibitory potency in the low nanomolar range at both human P2X3 and 
P2X2/3 receptors (see Figure 1.20).
37
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Figure 1.20. Structures and inhibitory potencies of P2X3 antagonists, trimethoprim, AF-001,RO-3, 
RO-4, RO-51, RO-85 and AF-219 (Gefapixant).  
RO-85, 1-methyl-3-phenyl-1H-thieno[2,3-c]pyrazole-5-carboxylic acid [(R)-2-(4-acetyl-piperazin-1-
yl)-1-methyl-ethyl]amide, is a thienopyrazole derivative. RO-85 was identified as a potent 
antagonist on rat and human P2X3 receptors (Figure 1.20).
105
 RO-85 has a good selectivity profile 
for the P2X3 receptor, not only over heteromeric P2X2/3 receptors but also versus the other P2X 
members.
106
 RO-85 possesses acceptable pharmacokinetic features including metabolic stability, 
plasma protein binding, and inhibition of CYP450 isozymes. The compound showed good oral 
bioavailability when administrated orally to rats. The combination of potency, selectivity and 
pharmacokinetic profile may allow exploration of its therapeutic potential as P2X3 receptor 
antagonist in vivo studies.
105
 
AF-219, an aryloxy-diaminopyrimidine, is an orally active small molecule antagonist of the P2X3 
receptor with an IC50 of ~ 0.030 μM on recombinant human P2X3 homotrimers and 0.100-0.250 μM 
on human P2X2/3 heterotrimeric receptors. It inhibits P2X3 receptors through a non-competitive 
mechanism. AF-219, showed excellent pharmacokinetic and pharmacodynamic properties and has 
recently been evaluated in clinical phase II studies for the treatment of osteoarthritic joint pain, 
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interstitial cystitis/bladder pain syndrome, and asthma/chronic cough. A study in patients with 
chronic refractory cough has been completed and was positive.
107
 In 2015, AF-219 was reported by 
Abdulqawi et al. as a promising new class of antitussive drugs which supports the role of P2X3 
receptors in mediation of cough neuronal hypersensitivity (Figure 1.20).
108
 
The physiological heptapeptide spinorphin (Figure 1.21), is a highly potent non-competitive 
antagonist of the human P2X3 receptor expressed in Xenopus oocytes. It was reported as the first 
peptide which selectively antagonizes the P2X3 receptor with an IC50 value of 8.3 pM. The 
compound showed selectivity for the human P2X3 receptor versus mouse P2X1 and human P2X7 
receptors. Honda et al. demonstrated antinociceptive and anti-inflammatory activity for spinorphin. 
However, there are no published data till now on its drug-like features.
109,110 
 
Figure 1.21. Structure of spinorphin. 
Two active series of allosteric antagonists derived from either 4-oxo-quinazoline central ring or thia-
triaza-tricyclic core were discovered in the HTS of compounds collection obtained from Gedeon 
Richter Plc, Budapest-Hungary. Interestingly, compound I with 4-oxo-quinazoline central ring 
showed an IC50 value of 0.005 µM which is considered as one of the most potent P2X3 receptor 
antagonist has been recently published in the literature till now.
111
 Among the reported compounds 
bearing thia-triaza-tricyclic core, (S)-3-(2,5-dimethoxyphenethyl)-N,N-dimethyl-4-oxo-3,4,5,6,7,8-
hexahydrobenzo[4,5]thieno[2,3-d]pyrimidine-7-carboxamide (II) was potentially suggested as a 
Introduction 
 
- 34 - 
 
candidate for in vivo testing. The chiral pure (-) (S) enantiomer IIa, showed markedly more activity, 
greater than 30 times in comparison to its stereo-isomer (+) (R) IIb (IC50= 0.021 µM, 0.668 µM, 
respectively).
112
 
A novel class of compounds related to pyrrolinone nucleus has been developed and identified as 
P2X3 receptor antagonists. This class was discovered by Japanese group through a HTS and many 
potent derivatives were obtained. Isoxazole derivative (III) has been described as a potent 
antagonist with IC50= 0.025 µM. It is highly selective, no inhibitory effect over 41 receptors and 17 
enzymes tested at 10 μM (data not shown). In addition, the analgesic activity of the compound was 
evaluated (ED50= 2.6 mg/kg) suggesting that it may be useful as analgesic drug (Figure 1.22).
113
  
 
Figure 1.22. Structures and inhibitory potencies of 4-oxo-quinazoline derivative, thia-triaza-tricycle 
derivatives, and pyrrolinone derivative. 
1.1.7. P2X receptors and pain 
Pain is as an unpleasant sensory and emotional experience evoked by noxious stimuli, inflammation, 
or tissue damage.
114 
Pain can be classed into nociceptive (physiological) pain, inflammatory pain 
and neuropathic pain (Figure 1.23).
115
 Nociceptive pain is defined as a response which has 
developed normally to a noxious stimulus with negligible tissue injury in case of low-intensity, in 
which medical care is not needed. Noxious stimulus with high-intensity, such as thermal, 
mechanical or chemical stimulation, lead to activation of specialized sensory neurons mediated by 
high-threshold unmyelinated (C and Aδ) afferents that transfer signals into nociceptive pathways of 
the CNS to produce pain.
116
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Inflammatory pain is defined as a response to injured tissues and/or inflammatory conditions such as 
surgery, infection and burns or diseases like arthritis. Primary hyperalgesia is an exaggerated pain 
which is produced at the site of injury as a result of low-intensity stimulus through activation of 
high-threshold (C and Aδ) afferents (peripheral nociceptors). Allodynia, can be generated by either 
central sensitization of the dorsal horn of the spinal cord with low-threshold (Aß) afferents or 
prolonged responses of high-threshold (C and Aδ) afferents produced by mild painful stimulus with 
high-intensity.
117,115
 
Neuropathic pain is a major health problem that affects the quality of life, and it is very difficult to 
treat.
118,119
 Injury of the nervous system, trauma, diabetes or infection may lead to painful states 
even with light touching.
120
 The generation of this kind of pain involves both the CNS and the 
peripheral nervous system (PNS).
139
 It is characterized by an unusual response to stimuli (noxious 
and non-noxious).
115 
 
Figure 1.23. Types of pain and sensory processing after peripheral nerve injury.
115
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ATP acting via P2 receptors plays an important role in the changing (modulation or altering) of the 
sensitivity of nociceptive pain which follows the injury of tissues. Several P2X receptor subtypes, 
especially P2X3, P2X2/3, P2X4, and P2X7 play a crucial role in pain sensation/transmission as well 
as the development of neuropathic pain.
121,122,
 ATP acting at different purinoceptors directly on 
neurons in the case of P2X3, P2X2/3 receptors or indirectly through interactions of neural-glial cells 
in the case of P2X4 and P2X7 receptors is involved.
121 
 
Medicines available for the management of pain include
123
 
(1) Opioids such as (morphine and fentanyl), 
(2) nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin, ibuprofen, celecoxib and 
rofecoxib. 
(3) Analgesic adjuvant agents such as tricyclic antidepressants (paroxetine and amitriptyline), local 
anesthetics (e.g. lidocaine), and certain anticonvulsant agents (carbamazepine). 
All of these classes of compounds have therapeutic usefulness in different states of pain. However, 
they have many disadvantages in the clinical use.  
The drawbacks of the compounds clinically used for pain management are listed below. 
(1) Tolerance, dependence, respiratory depression, and sedation are major problems with opioids. 
(2) Gastrointestinal disturbances, increasing of the bleeding tendency and low efficacy in severe 
pain are major drawbacks for NSAIDs. 
(3) CNS and cardiovascular side effects are major problems for analgesic adjuvant agents. 
In the present study we have focused on two different classes of compounds that have been 
identified as P2X receptor antagonists in a screening approach. 
1.2. Anthraquinone (AQ) derivatives 
Anthraquinones (AQs) also referred to as anthracenediones, are related to the quinone family which 
is widely distributed in nature as constituents of plants (aloe latex, rhubarb, and senna), 
microorganisms (fungi and lichens), some insects, and several marine species.
124 
At least 79 AQ 
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derivatives have been demonstrated to be occurring naturally such as emodin, cascarin, physcion, 
and rhein.
125
  
They are polycyclic aromatic compounds, and the parent compound is anthracene, which is formed 
of three fused phenyl rings (Figure 1.24). The parent structure of 9,10-anthracenedione, also called 
9,10-dioxoanthracene is made up of tricyclic ring systems in which the central one contains two 
opposing carbonyl groups at positions 9 and 10.
126
  
AQ was synthesized via oxidation of anthracene either with chromic acid or nitric acid (Laurent 
1840, and Fritzsche 1868, respectively). However, the compound was of little interest until Graebe 
and Liebermann in 1868 prepared alizarin (Figure 1.24) from anthracene and elucidated the relation 
between anthracene, anthraquinone, and alizarin. From that time till today, the study of AQ 
chemistry started to catch the attention of scientists to develop new derivatives related to the AQ 
scaffold with different pharmacological properties.
127,128,129,130
 
 
Figure 1.24. Chemical structures of anthracene, anthraquinone, and alizarin. 
1.2.1. Anthraquinone derivatives and their applications  
AQs and their derivatives constitute a large class with around 700 molecules that were described. 
Nowadays, their chemical diversity and biological activities are of great interest for industries in 
many fields such as dyes and pharmaceuticals.
131
 AQs and their derivatives are incorporated in a 
variety of natural and synthetic products which received a great deal of attention.
132
 
Besides their extensive use since decades for the dyeing of natural and synthetic textiles
133,134
, AQs 
are of importance for various other applications. They are used in imaging devices, and some AQs 
are approved for use as colorants in cosmetics, and foods.
126,135,136
 A number of natural and synthetic 
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AQs have shown a wide range of pharmacological activities including antitumor
137
, antiviral
138
, 
antifungal
139
, anti-inflammatory
140
, laxative
141,142
, antiplatelet
143,144,145
, and neuroprotective 
effects.
146
 Several AQ drugs are on the market; moreover AQs represent important pharmacological 
and biochemical tool compounds. 
Anthraquinones that are found in plants such as senna, frangula, aloe, cascara, and rhubarb, have 
been known for their laxative properties for a long time. They have been used in the treatment of 
constipation, which affects around 14% of the adult population worldwide.
147
 Due to side effects 
observed in vitro and in animal studies, the anthranoid laxatives are not recommended for long-term 
use anymore. However, the use of these anthranoid laxatives for short time is generally safe.
142
 
The anticancer activity of AQs was discovered in the mid-1950s.
148
 Emodin (1,3,8-trihydroxy-6-
methylanthraquinone) is a naturally occurring AQ derivative which is distributed widely in Chinese 
herbs such as Rheum palmatum, Polygonum cuspidatum and Polygonum multiflorum. It has been 
known and used for more than 2000 years in Chinese medicine and is still used in some herbal 
preparations. Emodin has a wide range of pharmacological applications such as hepatoprotective, 
anti-inflammatory, antioxidant and antimicrobial activities. However, there is a limitation to its use, 
not only does it is possess a poor oral bioavailability in rat, but it also triggers hepatotoxicity, kidney 
toxicity and reproductive toxicity resulting from prolonged use in high doses.
149
 
Emodin demonstrated anti-cancer activity through inhibition of tumor cell-growth, proliferation, 
induction of apoptosis, and prevention of metastasis. Many derivatives related to emodin were 
synthesized and evaluated for their cytotoxic and cytostatic activity; a lot of them were stronger than 
emodin itself. Among this set of compounds, 4-(N-cyclohexylamino)emodin showed promising 
results, which revealed it as a potential anti-tumor drug (Figure 1.25).
150 
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Figure 1.25. (A) The chemical structure of emodine (R= H) and 4-(N-cyclohexylamino)emodin (R 
= n-cyclohexylamino). (B) Chemical structure of the anthracyclines daunorubicin (R= H) and 
doxorubicin (R= OH). (C) Chemical structure of the anthracenediones ametantrone (R= H) and 
mitoxantrone (R= OH).
150
 
Daunomycin was originally discovered as a secondary metabolite from Streptomyces peucetius in an 
Italian soil sample. Daunomycin, an anthracycline antibiotic was isolated as a glycoside, formed by 
an anthracenedione-containing chromophore, which is typically linked to an aminosugar by a 
glycosidic bond. At the same time, an identical compound was characterized by a French group and 
named rubidomycin, now termed daunorubicin.
151,152,153 
Daunorubicin was demonstrated to have 
potent antitumor activity in humans.
154 
Daunorubicin (Daunoblastin
®
) and mitoxantrone 
(Onkotrone
®
), are structurally related. They have strong cytostatic activity against tumor-cell growth 
via inhibition of topoisomerase II or intercalation into DNA, and DNA strand scission via free 
radical generation.
155
 
Ametantrone was reported by Cheng et al. It showed a good activity against P-388 leukemia in 
mice.
153 
Mitoxantrone, an anti-neoplastic agent was modified from the parent 1,4-dehydroxy 
analogue, ametantrone, and it was proposed to modulate the therapeutic profile of anthracyclines.
156
 
Mitoxantrone has been applied in the treatment of lymphoma, leukemia, prostate and breast cancer. 
In 1987, the drug was approved by the food and drug administration (FDA) for the treatment of 
acute myeloid leukemia (AML). It inhibits the activity of topoisomerase II.
153 
In 1996, it was given 
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FDA approval for symptomatic hormone-refractory prostate cancer treatment.
157
 After 4 years, it 
was also approved for the treatment of multiple sclerosis
158
 (Figure 1.25). 
Beside emodine, the other major rhubarb anthraquinone is rhein (Figure 1.26), which possesses 
protective effects on acute kidney injury (AKI). Rhein can effectively inhibit the progression of 
endotoxemia-linked AKI with a mechanism akin to the one of its anti-inflammatory action, through 
suppressing the activity of pro-inflammatory cytokines.
159
 
Diacerein (Figure 1.26), also known as Diacetylrhein, is a prodrug which is formally derived from 
rhein by acetylation of two hydroxyl groups. Diacerein, is a commercially available drug, used for 
the treatment of joint diseases such as osteoarthritis of the hips. Its mechanism is different from the 
ones of the existing NSAIDs.
160 
Interestingly, diacerein prevented autoimmune diabetes 
development in a model of nonobese diabetic mice through the suppression of leukocytes’ 
chemotactic activity to the pancreatic islets.
125
 
 
Danthron (Dantron
®
), also referred to as chrysazin, is a derivative which was developed from 
anthraquinone (Figure 1.26). It has been prescribed as a stimulant laxative in some countries. It was 
approved for the U.S. market as a laxative until 1999, since then the U.S. FDA ordered the 
withdrawal of products containing danthron because of the risk of carcinogenesis.
161 
However, in the 
United Kingdom, the drug is still allowed but only for the management of constipation in patients 
with advanced cancer.
162  
 
Figure 1.26. Structures of rhein, diacerein, and danthron. 
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Reactive Blue-2 (RB-2) (Figure 1.27), a textile dye, which consists of the chromophore 
anthraquinone linked to mono-chlorotriazine ring.
163 
Previously, such dyes were commonly used in 
the textile industry. Later they became important as ligands in the purification of enzymes and 
biopolymers. Since the 1970s these dyes have also been utilized as tools in drug research due to 
their antagonistic properties at P2-receptors.
164
  
 
Figure 1.27. Chemical structure of Reactive Blue-2 (RB-2), a mixture of the meta- and para- 
sulfonate (35:65). 
Due to their importance as drug molecules, a library of AQ derivatives, structurally related to RB-2 
has been synthesized and their potencies were tested at a variety of purinergic targets, all of which 
are characterized by a nucleotide binding site.
165,166,167,168,64,169,170 
Many of the synthesized AQ 
derivatives bearing a sulfonate group at the 2-position. Since their synthesis starts with the sodium 
salt of bromaminic acid. However, the effects of other substituents in the AQ 2-position are largely 
unknown due to the difficulties in preparing the desired compounds. For instance, the method 
described by Hagen et al. for the introduction of a carboxylate group via oxidation of 2-
methylanthraquinone required harsh reaction conditions using nitric acid in the presence of 
nitrobenzene and elevated temperatures of the reaction mixture to 200 
°
C.
171
 Therefore, the number 
of anthraquinone derivatives bearing different substituents at the 2-position are small and only very 
few of them were described in few patents.
172
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In our group, a series of anthraquinone derivatives, structurally related to reactive blue 2, was 
previously synthesized and tested for their antagonistic activity on P2Y12 receptors. Of those 
derivatives PSB-0739 and PSB-0702 (Figure 1.28) were the most active ones with Ki values of 
0.025 μM and 0.021 μM respectively.145 PSB-0801 bearing a 2-methyl group did not affect the 
response to 2-methylthio-ADP, which was used to activate the P2Y12 receptor.
173
 The two active 
compounds represent promising lead structures for the development of new antiplatelet drugs.
145 
 
Figure 1.28. Structures anthraquinone derivatives: PSB-0739, PSB-0702, and PSB-0801. 
1.3. Microwave chemistry  
Chemistry using microwaves has received considerable attention and is very useful for thermal 
reactions.
174 
The synthesis of various organic compounds was successfully realized using microwave 
irradiation as non-traditional energy source. This concept has become widely accepted as shown by 
increasing numbers of publications. Microwaves are between the radio and infrared frequencies of 
the electromagnetic spectrum. Because the radiation wavelength is large, no ionization or bond 
breaking is observed.
175 
In contrast to conventional heating methods, microwave irradiation 
produces both thermal effects and selective absorption by polar substances.
176
 
1.3.1. Microwave-assisted organic synthesis (MAOS) 
Microwave-assisted organic synthesis can be used as an alternative energy source for many 
reactions instead of classical heating methods. The reactions performed under microwave conditions 
show significant enhancement in their rate, and also high chemical yields. Medicinal chemistry 
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communities apply MAOS especially in cases where speed of the reactions is of considerable 
value.
177
 
The advantages of microwave-assisted organic synthesis (MAOS)
 
include:
178,176
 
(1) Mild conditions which allow comprehensive control of the reactions.  
(2) Reproducibility: high reaction yields can be easily obtained. 
(3) Effectiveness: reaction times become shorter. 
(4) Useful for reactions which cannot be achieved using conventional heating, for example the 
synthesis of drugs with short half-life (for example, isotopically labelled ones). 
(5) Microwave effect might help to keep the efficacy of the catalysts. 
(6) Assistance in building up combinatorial libraries and rapid parallel synthesis as well. 
(7) Safety concerns: microwave can be used safely (suitable engineering achievable). 
(8) Automatic emergency control can be applied if necessary. 
1.4. Ullmann reaction 
The Ullmann reaction refers to the synthesis of diaryls through condensation of aryl halides and 
copper.
179
 While, the term ‘Ullmann condensation reaction’ describes the synthesis of aryl -amine, -
ether or -thioether from the reaction between an aryl halide with an amine, phenol or thiophenol, 
respectively.
180
 These reactions are mediated by copper (stoichiometric or catalytic). The previous 
nomenclature is now commonly accepted which depends on the chemical nature of nucleophilic 
entity (Scheme 1.1).
181
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Scheme 1.1. Schematic representation of Ullmann reaction and Ullmann condensation.  
1.5. Goldberg condensation reaction 
The synthesis of a new C(aryl)-N bond through condensation between amides and aryl halides 
catalyzed by copper (Scheme 1.2).
182
  
 
Scheme 1.2. Schematic representation of Goldberg condensation reaction. 
Ullmann-type reactions usually require harsh conditions, e.g. high reaction temperature, long 
reaction time and high concentrations of the catalysts were needed. However, modification to 
conventional Ullmann reaction has recently applied aiming to overcome these drawbacks.
183
 
Modified Ullmann reactions are characterized by milder reaction conditions, which facilitate the use 
of copper-catalyzed reactions.
181
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1.6. Triphenylmethanes 
Triarylmethanes (TRAMs) constitute a valuable class of compounds which have an importance in 
medicinal chemistry.
 
TRAMs can have a wide range of pharmacological activities including 
laxative, antitumor, antiviral, antifungal, anti-inflammatory, antituberculosis, antioxidant and anti-
diabetic effects.
184,185,186,187,188 Furthermore, some TRAMs are applied as dyes,189 even as food 
colorants.
190
 The chemical structures of selected TRAMs and their activities are presented in Figure 
1.29. 
 
Figure 1.29. Representative examples of biologically active triarylmethane derivatives. 
The drug bisacodyl is structurally related to the triphenylmethane derivatives with similarity to 
phenolphthalein. It is used as a laxative drug throughout the world for the treatment of 
constipation.
191
 The hydrolyzed diphenol, bis-(p-hydroxyphenyl)-pyridyl-2-methane, termed BHPM 
(Figure 1.30), is the active metabolite of bisacodyl and responsible for the intestinal stimulating 
effect through direct action on the colon.
192
 Bisacodyl is known as a non-toxic drug in humans. 
Moreover, it may have potential as anti-cancer agent in combination with other chemotherapeutic 
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drugs. It is considered as the first known compound which is targeting glioblastoma tumor stem-like 
cells.
193
 
Development of new drugs is considered to be not an easy task and is associated with a lot of 
challenges. Among the promising ways to generate drugs is finding new clinical indications or 
pharmacological targets for already existing drugs that have been approved by the FDA. This is 
referred to as drug repurposing.
194
 
Screening of 440 approved drugs for their inhibitory potency has been done in our group by Dr. 
Claudia Spanier at different P2X receptor subtypes aimed to find new lead structures which could be 
used for the development of selective agonists and antagonists. Bisacodyl has been identified as a 
potent antagonist of the P2X3 receptor. Based on this scaffold, a small library of nine compounds 
was synthesized by M. Sc. The-Hung Vu. The most potent P2X3 antagonist was BHPM.
195
 
 
Figure 1.30. Structure of bisacodyl and its active metabolite BHPM.
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3 2. Research objectives 
3.1 2.1. Anthraquinone derivatives 
Many of the synthesized anthraquinone (AQ) derivatives, which have been developed as selective 
and potent antagonists for different P2 receptors as well as ectonucleotidase inhibitors contain a 
sulfonate group (SO3
-
) at the 2-position. The AQ derivatives RB-2 and Acid Blue 25 (AB-25) 
served as lead structures (Figure 2.1). The negative charge on the sulfonate group renders the 
molecules highly polar and prevents oral bioavailability. Therefore, we aimed in this study to 
improve the physicochemical properties of the molecules by replacing the sulfonate group with 
other substituents such as a methyl group. The effect of other substituents has not been well 
investigated due to difficulties and limitations in preparing the desired compounds.
172 
 
 
Figure 2.1. Structures of RB-2 and AB-25, lead structures for the development of ligands for 
purinergic targets.
172
 
It is important to mention that the method previously used for synthesizing AQ derivatives with 
acidic moieties at the 2-position, namely the Ullmann condensation
165
 of 4-bromo-AQ derivatives 
with solid amines, was not successful for the preparation of AQ derivatives having a methyl 
group at the 2-position. The goal of the present study was to develop a synthetic access to such 
target compounds. This would require exploration and optimization of reaction conditions for a 
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model compound to establish the optimum conditions for the reaction. This method could later be 
used to synthesize 1-amino-4-(aryl)alkylamino-2-methylanthraquinone derivatives as depicted in 
the Figure 2.2. The new method may also be applied to the synthesis of other AQ derivative 
bearing different substituents at the 2-position. 
 
Figure 2.2. 1-Amino-4-(aryl)alkylamino-2-methylanthraquinone derivatives. 
Additionally, this study aims to (i) evaluate the synthesized anthraquinone derivatives on 
different targets, and (ii) to investigate the structure-activity relationships (SARs) of the 
synthesized anthraquinone derivatives to obtain information regarding the 2-position of the AQ 
core structure.  
3.2 2.2. Bisacodyl-derived compounds 
Sir James Black, a Nobel Laureate of 1988 in Physiology and Medicine stated that “The most 
fruitful basis for the discovery of a new drug is to start with an old drug”. Millions of people are 
suffering from different kinds of pain like acute, chronic, and neuropathic pain.
196 
Neuropathic 
pain can develop due to surgical nerve injury, trauma, diabetes or infection.
120 While many 
medications are currently approved for the management of acute pain, unfortunately none of 
these drugs is sufficiently effective in the treatment of chronic, neuropathic pain. 
From a long time, the role of ATP in sensory functions has been well established before its 
discovery as an extracellular neurotransmitter. Purinergic receptors regulate ATP modulatory 
functions in the sensory pathways. ATP can activate many primary afferent neurons, especially 
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C-fibers through P2X3 receptors. P2X3 receptors expressed by dorsal root ganglionic (DRG) 
neurons may have key roles in the inflammatory cascade and in the development of neuropathic 
pain.
197
 The extensive activation of such receptors is believed to be involved in many chronic 
conditions including neuropathic pain and migraine. Since these conditions are frequently 
resistant to treatment, new molecules targeting P2X3 receptors may be useful to achieve pain 
control.
198  
While targeting of P2X3 receptors already has a long historical background, it has only recently 
become obvious that it will probably have a promising future. However, there are still only very 
few P2X3 antagonists known which possess suitable properties for brain penetration. 
One of our goals in this study was to develop potent, selective P2X3 receptor antagonists, which 
may be further developed to have properties for peroral application and potential for brain 
penetration. Based on the identification of bisacodyl as a potent P2X3 receptor antagonist which 
was reported in a study conducted by our group, we sought to further characterize the structure-
activity relationships of bisacodyl by synthesizing a variety of derivatives. The proposed 
modifications are depicted in Figure 2.3.  
 
Figure 2.3. General proposed modifications for the drug bisacodyl. 
This study might lead to more potent P2X3 receptor antagonist that may - in contrast to bisacodyl 
- display systemic effects, and in particular penetrate into the central nervous system (CNS). 
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4 3. Results and Discussion 
4.1 3.1. Anthraquinone derivatives 
3.1.1. Synthesis of 1-amino-4-(aryl)alkylamino-2-methylanthraquinone derivatives 
The synthesis of aryl(alkyl)amino-2-methylanthraquinone derivatives was implemented by the 
Ullmann coupling reaction using two different synthetic protocols (conventional heating protocol 
or microwave heating protocol) starting with commercially available 1-amino-4-bromo-2-
methylanthracene-9,10-dione (2-methyl-AQ, 1) which was condensed with different liquid or 
solid amines (Scheme 3.1). According to the physical nature of the amine used, the coupling 
method was selected. For liquid amines, the Ullmann coupling was performed using the 
conventional heating protocol (solvent-free reaction). For solid amine reactions in which a 
solvent was needed, the Ullmann coupling was done using a microwave heating protocol which 
will be discussed later in more detail. 
 
Scheme 3.1. General scheme for Ullmann reaction of 1-amino-4-bromo-2-methylanthracene-
9,10-dione with amines.  
3.1.2. Condensation with liquid amines using solvent-free Ullmann reaction  
The solvent-free method described by Ukponmwan et al.
199
 was previously employed by Malik et 
al. for condensation of 1-amino-2,4-dibromoanthracene-9,10-dione (26) with aniline to give 1-
amino-2-bromo-4-phenylaminoanthraquinone (27) (Scheme 3.2). Though the reaction time was 1 
h and it produced a high yield (85%), it must be considered that the method required 25 equiv. of 
aniline used as a reagent and solvent, which is not favorable.
200
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Scheme 3.2. Synthesis of 1-amino-2-bromo-4-phenylaminoanthraquinone using the method of 
Ukponmwan et al.
199
 
The synthesis of the targeted 2-methylanthraquinone derivatives was conducted using solvent- 
free reaction conditions according to the procedure described by Harris et al.
201 
This method was 
also used by Baqi et al. for the condensation of 2-methyl-AQ (1) with aniline.
 
The reaction was 
performed using 15 equiv. of aniline in the presence of potassium acetate and copper(I) acetate 
(10 mol%) under an argon atmosphere at 110 
°
C, affording 1-amino-2-methyl-4-
(phenylamino)anthracene-9,10-dione (2) in a good yield of 64%.
202 
This method was optimized 
with respect to the aniline amount. The condensation of 2-methyl-AQ (1) was finally conducted 
using three equivalents of aniline (3, 6, or 10). However, with lower concentrations, additional 
side-products were formed. The AQ dimers 28 and 29, which were obtained as new side-
products, (Figure 3.1) could be identified by liquid chromatography-mass spectroscopy (LC-MS) 
analysis. Thus, an aniline excess of 15 equiv. was fixed for subsequent condensation reactions to 
avoid dimerization reactions. This phenomenon may occur because of the electron-donating 
effect of the 2-methyl group causing the 1-amino group of the anthraquinone derivative to be 
relatively nucleophilic in nature.
200
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Figure 3.1. Proposed structures of side-products (dimerized anthraquinones).
200
 
3.1.3. General synthetic procedure (I) used for anthraquinone derivatives 2-17 
The method of Baqi et al. will be used for the condensation of other amines which are liquid in 
nature as outlined in Scheme 3.3.
202 
 
Scheme 3.3. Ullmann reaction of 1-amino-4-bromo-2-methylanthracene-9,10-dione with amines 
using a conventional heating method.
202
 
The solvent-free method was successfully applied for the preparation of the AQs 2-17 (Table 
3.1). The reactions progressed smoothly with variable rates and yields.  
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Table 3.1. Reaction times, HRMS, UV absorption, melting points, yields, and purity of the 
synthesized anthraquinone derivatives 2-17 obtained from liquid amines
a
  
 
 
 
 
Cmpd R' 
Reaction 
time 
(h:min) 
HRMS (g/mol)
b
 
m/z: [M+H]
+
 max 
(nm) 
m.p. 
(
°
C) 
Yield 
%
c
 
Purity 
(%)
d
 
Calcd. Found 
Structure A 
2 H 01:50 329.1264 329.1265 570, 608 251-253 76 96 
3 2-C2H5 13:00 357.1598 357.1583 608 178-180 58 96 
4 3-C2H5 01:50 357.1598 357.1582 606 229-230 82 98 
5 4-C2H5 00:30 357.1598 357.1573 608 230-232 74 96 
6 2-CH3 2:30 343.1441 343.1421 606 207-209 44 95 
7 2-Cl 77:00 363.0895 363.0860 602 188-189 21 95 
8 3-Cl 18:00 363.0895 363.0832 566, 606 280-281 66 97 
9 4-Cl 18:00 363.0895 363.0841 604 293-294 72 98 
10 2-OCH3 02:40 359.1390 359.1377 602 170-172 66 96 
11 3-OCH3 02:30 359.1390 359.1385 570, 608 231-233 78 95 
12 4-OCH3 02:00 359.1390 359.1372 574, 608 217-219 49 97 
13 
see structure 
above 
01:50 343.1441 343.1431 610 215-216 51 97 
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Cmpd R' 
Reaction 
time 
(h:min) 
HRMS (g/mol)
b
 
m/z: [M+H]
+
 max 
(nm) 
m.p. 
(
°
C) 
Yield 
%
c
 
Purity 
(%)
d
 
Calcd. Found 
 
Structure B 
14 2-Cl 18:00 391.1208 391.1192 568, 610 225-226 56 97 
15 3-Cl 01:20 391.1208 391.1191 610 192-194 55 98 
16 4-Cl 02:00 391.1208 391.1195 610 224-225 69 96 
17 3-F 01:15 375.1503 375.1494 568, 610 257-258 70 97 
a
Reaction conditions: 2-methyl-AQ, amine (15 equiv.), potassium acetate (2.25 equiv.), copper(I) 
acetate (10 mol%), 110 
°
C, argon. 
b
HRMS recorded on a micrOTOF-Q, HPLC coupled-mass 
spectrometer (Bruker). 
c
Isolated yield. 
d
Purity determined by LC-MS coupled to a diode array 
UV detector (220-700 nm). 
Compound 2 was previously synthesized under solvent-free conditions. Condensation of 2-
methyl-AQ 1 was carried out using 15 equiv. of aniline in the presence of potassium acetate and 
copper(I) acetate (10 mol%) at 110 
°
C afforded compound 2 after 300 min with 64% yield.
202 
It is 
noteworthy that when copper(II) acetate (10 mol%) was utilized instead of the copper(I) acetate 
(10 mol%), the reaction became faster (110 min) with much higher yield (76%). 
Reactions were completed smoothly within 30-150 min for ethyl- or methyl-substituted aniline 
derivatives (5, 4 and 6) with one exception: ortho-ethyl derivative 3 imposed a negative effect on 
the reaction rate which proceeded to completion within 13 h. This may be explained in part by 
steric hindrance due to the ortho-ethyl substituent.  
Although the isolated yields were good in case of ortho-methyl substitution (44%), the outcome 
was much better for the ortho-, meta- and para-ethyl substitutions with 58%, 82%, and 74%, 
respectively. The formation of a copper complex with the nucleophile (amine) prior to activation 
of the aryl halide (4-bromo-AQ derivatives) has been proposed for Ullmann condensation 
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reactions.
200
 Thus, coordination of o-ethylaniline to the copper catalyst may result in hindrance of 
the subsequent coordination of the 4-bromo-AQ derivative.
181
 
The same procedure was applied to the condensation of 1 with ortho-, meta- and para-chloro-
substituted aniline derivatives (7, 8 and 9, Table 3.1). A low yield was obtained in case of the 
ortho-chloro substitution, while relatively high yields were obtained for meta- and para-chloro 
substituents (21%, 66% and 72%, respectively). The reactions were progressed at a slower rate 
than in the case of non-substituted aniline, requiring 77 h (7) and 18 h (8 and 9) to completion, 
compared to only 110 min required for the synthesis of 1-amino-2-methyl-4-
(phenylamino)anthracene-9,10-dione (2). This may be due to the electron-withdrawing effect of 
the chlorine atom, which deactivates the aromatic ring and reduces the nucleophilicity of the 
amine. Moreover, steric hindrance imposed by the size of the chlorine atom in case of an ortho-
chloro substituent may provide a probable explanation for the long reaction time (77 h). 
In contrast to the chloro substitutions, the presence of an ortho-, meta- or para-methoxy residue 
on the aniline had a similar effect as the non-substituted aniline, affording products 10, 11 and 12 
within 160, 150, 120 min respectively. This is potentially due to the electron-donating effect of 
methoxy group, which activates the aromatic ring and increases the nucleophilicity of the amine. 
The reaction of 3-chlorophenethylamine, 4-chlorophenethylamine or 3-fluorophenethylamine 
with 2-methyl-AQ proceeded equally as that with aniline, and products 15, 16 and 17 were 
obtained within 80 min, 120 min and 75 min, respectively. The reaction of 2-
chlorophenethylamine required 18 h to be completed. 
In conclusion, the applied solvent-free procedure provided the targeted products 2-17 in good to 
excellent yields (44-82%), with the exception of 1-amino-4-(2-chlorophenylamino)-2-
methylanthraquinone (7), which was the only product obtained in low yield (21 %). A major side-
reaction was the reductive debromination of 2-methyl-AQ. Product 7 was difficult to isolate from 
the debromo-AQ side-product (30, Scheme 3.4) requiring multiple purification runs by column 
chromatography, and therefore resulted in a reduced isolated yield. 
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Scheme 3.4. Formation of the debromo-AQ derivative as a side-product of the Ullmann 
amination reaction of 2-methyl-AQ. 
3.1.4. Optimization of the reaction conditions for 1-amino-4-bromo-2-methylanthraquinone 
derivatives  
3.1.4.1. Condensation with solid amines 
The solvent-free method was successful to obtain the target compounds 2-17, however a major 
problem with this kind of reaction procedure is its limitation to liquid amines or to solid amines 
with low melting point (e.g. 1-naphthylamine).
200
 Condensation with solid amines with a high 
melting point necessitated the use of a solvent as a reaction medium. In the present study we 
focused on the optimization of the reaction conditions for 2-methylanthraquinone derivatives. 
3.1.5. Optimization of the reaction conditions for some 2-substituted anthraquinone 
derivatives  
Recently, Malik et al. developed methods for the synthesis of bromaminic acid analogues bearing 
different substituents at the 2-position of the anthraquinone moiety. The reaction started with the 
synthesis of 2-hydroxymethylanthraquinone from 1-aminoanthraquinone followed by conversion 
to its corresponding carbaldehyde, carboxylic acid, and nitrile derivatives. The latter was then 
converted to its bioisostere tetrazole.
202
  
Baqi et al. reported a modification of the Ullmann coupling reaction. Cu
0
 was used as a catalyst 
in aqueous phosphate buffer (pH 6-7) under microwave irradiation which afforded a series of 
anthraquinone derivatives structurally related to RB-2. The anthraquinone derivatives bearing an 
acidic functionality at the 2-position were easily accessible through this method. Successful 
examples of this method were PSB-0739, which is bearing a sulfonate group at the 2-position, 
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and PSB-0702, which bears a carboxylic group at the same position. Reactions of bromaminic 
acid (sodium 1-amino-4-bromoanthraquinone-2-sulfonic acid) or 1-amino-4-
bromoanthraquinone-2-carboxylic acid with different amines are shown in Scheme 3.5.
165,166  
 
Scheme 3.5. Synthetic procedure for anthraquinone derivatives with acidic groups at the 2-
position.
165,166
 
The previously described synthetic procedure, which has been proven as an efficient method for 
obtaining anthraquinone derivatives bearing acidic groups at the 2-position was applied for non-
acidic functionalities such as 2-methylanthraquinone derivatives, starting with 1-amino-4-bromo-
2-methylanthraquinone (0.1 and 0.2 mmol) yielding 31 or PSB-0801. The reaction was carried 
out using 2-amino- 5-fluorobenzoic acid (0.2 mmol) in the case of 31 and 4-
aminodiphenylamine-2-sulfonic acid (0.4 mmol) in the case of PSB-0801, in the presence of a 
buffer solution of Na2HPO4 (pH 9.6, 4.5 mL) and NaH2PO4 (pH 4.2, 0.5 mL) and finely 
powdered elemental copper (0.002-0.003 g, 5-10 mol%), under microwave irradiation (100 W, 
120 
°
C), see Scheme 3.6. The reactions were completed within 5 min, affording 1-amino-4-(2-
carboxy-4-fluorophenylamino)-2-methylanthracene-9,10-dione (31) and 1-amino-2-methyl-4-(4-
phenylamino-3-sulfophenylamino)anthracene-9,10-dione (PSB-0801). The yield of both 
compounds was low (21%).
166,203  
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Scheme 3.6. Synthetic procedure for anthraquinone derivatives with non-acidic functional groups 
at the 2-position of the anthraquinone core. 
3.1.5.1. Optimization of the reaction conditions for 1-amino-2,4-dibromoanthraquinone (26) 
In previous work, our laboratory sought the optimal reaction conditions for different 2-substituted 
AQ derivatives. Several systematic trials were conducted with the goal to optimize the reaction 
conditions for non-acidic functionalities at the 2-position of the AQ scaffold using MW heating. 
Initially, the method of Baqi et al.
166,165 
was applied for the condensation of 2-bromo-AQ (26) 
with 4-aminodiphenylamine-2-sulfonic acid. However, only less than 5% of the product was 
obtained (entry I, Scheme 3.7). Different solvents including non-polar (toluene, diglyme), 
slightly polar (1,4-dioxane, dichloromethane, and tetrahydrofuran (THF)), polar aprotic (e.g. N,N-
dimethylformamide (DMF), acetonitrile, dimethylsulfoxide (DMSO), and N-methyl-2-
pyrrolidone (NMP)) and polar protic ones (water, ethanol, 2-ethoxyethanol, isopropanol, t-
butanol and 1-pentanol) were tried. Isopropanol and 1-pentanol were found to be superior 
solvents resulting in product 32 with yields of 34% and 40%, respectively (entry II and III, 
Scheme 3.7). It is worth mentioning that the highest conversion rate of 2-bromo-AQ (26) was 
achieved with 1-pentanol (87%). Besides, different reactions were performed using different 
catalysts including copper (0) and copper(II) acetate. As a result of investigating a variety of 
conditions, it was concluded that 1-pentanol as a solvent and copper(II) acetate as a catalyst were 
critical components for the synthesis of various compounds by reaction of 2-bromo-AQ (26) with 
different solid amines.
200  
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Scheme 3.7. Synthetic procedure for 2-bromoanthraquinone derivative 32 using different 
reaction conditions.
200
  
3.1.5.2. Optimization of the reaction conditions for 1-amino-2-methylanthraquinone (1) 
Since the optimum reaction conditions for 2-bromo-AQ were 1-pentanol (4 mL), potassium 
acetate (5 equiv.), and copper(II) acetate, (5 mol%), we tried the same conditions for 2-methyl-
AQ (1) with solid amines. The condensation of 1 (0.1 or 0.25 equiv.) with 4-
aminodiphenylamine-2-sulfonic acid (0.3 or 0.75 equiv.) only afforded less than 20% of PSB-
0801 (Scheme 3.8). No improvement in the yield was achieved under the conditions summarized 
in Scheme 3.8 in comparison to the previous conditions applied for acidic anthraquinones 
summarized in Scheme 3.6.  
 
Scheme 3.8. Synthetic procedure for PSB-0801 using the optimized conditions for 2-
bromoanthraquinone derivatives. 
When 1-pentanol was tested with other solid amines such as 2-aminobenzoic acid (anthranilic 
acid) under the previous microwave (MW) conditions (Scheme 3.9), it afforded only 35% of 
product 18 (entry 1, Table 3.2). The reaction stopped after 60 min and no further progress was 
Results and Discussion 
- 60 - 
 
observed after that time. The produced yield was very low compared to > 90% yield achieved 
with the corresponding 2-bromo- and the 2-cyano-AQ derivatives.
200
 Interestingly, when 
isopropanol was used as a solvent, the time needed for maximum conversion was doubled while 
the yield also increased to 64% (entry 2, Table 3.2). 
 
Scheme 3.9. Synthetic procedure for the synthesis of compound 18 using different solvents.  
According to the result of LC-MS, the condensation between compound 1 and 1-pentanol or 
isopropanol was also observed. While the reaction in case of 1-pentanol resulted in 6% of the 
condensed product 33 with 10% remaining starting material, the condensed product 34 was 5% 
and the unreacted starting material was 24% when the reaction was performed in isopropanol 
(Figure 3.2).  
 
Figure 3.2. Condensation products resulting from 1-pentanol and isopropanol. 
Condensation of 2-methyl-AQ with anthranilic acid in 1-pentanol took 60 min. In case of 
isopropanol, the reaction stopped after 130 min and the conversion process was incomplete. 
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Table 3.2. Reactions using 1-pentanol or isopropanol as solvents 
Entry Solvent 
Reaction time 
(min) 
Yield% 
Compound 
18 
2-methyl-AQ 
(1) 
Alkoxy side-
products 
1 1-pentanol 60 35 10 6
a
 
2 isopropanol 130 64 24 5
b
 
a
Compound 33,
 
1-amino-2-methyl-4-(pentyloxy)anthracene-9,10-dione and 
b
compound 34, 1-
amino-4-isopropoxy-2-methylanthracene-9,10-dione. 
Comparing both solvents, isopropanol showed a much better yield than 1-pentanol, however it 
was still not satisfactory. Thus, we decided to use other solvents such as ethanol or mixtures of 
ethanol and water. 
4.1.1.1.1 3.1.5.2.1. Optimization of the reaction conditions using ethanol as a solvent 
Reaction of 2-methyl-AQ (1) with anthranilic acid in ethanol was completed within 95 min, after 
which no further improvement of the produced yield was observed. The yield of the target 
compound was 80%, and 7% of condensation product with ethanol as a side product was 
obtained. When water (12.5% v/v) was added to ethanol, the reaction time had to be extended for 
an extra 35 minutes to achieve almost the same yield of the target compound without having any 
condensation with ethanol. At the same reaction time, this observation was also noticed with 25% 
v/v water with negligible change in the yield. But in the case of 50% v/v water, the yield was 
significantly decreased to 27%. A higher percentage of 2-methyl-AQ (1) was obtained using 
water/ethanol 50% v/v, and the lowest yield was obtained in water/ethanol 12.5% v/v. Therefore, 
we concluded that water addition prevents the condensation of the 2-methyl-AQ (1) with ethanol, 
but it affects the yield in a negative manner (Table 3.3).  
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Table 3.3. Reactions using ethanol and water/ethanol mixtures as solvents 
*1-Amino-4-ethoxy-2-methylanthracene-9,10-dione (35, Figure 3.3). 
Upon using ethanol alone as a solvent, the reaction proceeded in a straightforward way compared 
to 1-pentanol or isopropanol. The yield was also doubled when compared to 1-pentanol, and 
increased by 15% when compared to isopropanol. These results show that the presence of water 
may act negatively on the yield and the more water is in the reaction medium, the lower is the 
yield.  
To further investigate the impact of solvents on the reaction, we tried several solvents without 
changing the reaction conditions. In this context, the reaction mixture consisted of 2-methyl-AQ 
(1, 0.1 mmol), anthranilic acid (0.3 mmol, 3 equiv.), potassium acetate (5 equiv.), and copper(II) 
acetate (5 mol%) in addition to various solvents (4 mL).  
3.5.2.1.2. Use of ethyleneglycol as a solvent  
Condensation of 2-methyl-AQ with anthranilic acid in ethyleneglycol as a solvent (entry 1, Table 
3.4) resulted in a reduction of the yield (43%) when compared to ethanol. The ethyleneglycol-
condensed side-product (36, Figure 3.3) was obtained in 7% yield, while the debromo derivative 
30 was the main contaminant amounting to 10%. The reaction was completed within 95 min 
(Table 3.4). 
 
Entry Solvent 
Reaction time 
(min) 
Yield% 
Compound
18 
2-methyl-AQ 
(1) 
Ethoxy side-
product* 
1 ethanol 95 80 13 7 
2 
water /ethanol 
(12.5% v/v) 
130 76 - - 
3 
water /ethanol 
(25% v/v) 
130 71 7 - 
4 
water /ethanol 
(50% v/v) 
130 27 46 - 
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3.5.2.1.3. Use of methanol as a solvent  
When methanol was used as a solvent (entry 2, Table 3.4), the reaction time was 15 minutes 
longer than in case of ethanol (110 min). The yield of the desired product 18 jumped to 90%. The 
methoxy-condensed side-product, 1-amino-4-methoxy-2-methylanthracene-9,10-dione 
(compound 37, Figure 3.3), was formed in 8% yield. When phosphate buffer, which was 
previously used for substituted anthraquinones with acidic groups at the 2-position, was added to 
methanol (12.5% v/v, 0.5 mL), the yield was decreased to 17% (entry 3, Table 3.4). This 
indicates that the phosphate buffer is not efficient for compounds with non-acidic substituents at 
the 2-position. 
Table 3.4. Reactions using ethyleneglycol, methanol and phosphate buffer/methanol as solvents 
 
Entry 
 
Solvent 
 
Reaction time 
(min) 
Yield% 
Compound 
18 
2-methyl-AQ 
(1) 
Alkoxy side-
products 
1 ethyleneglycol 95 44 - 7
a
 
2 methanol 110 90 2 8 
3 
phosphate buffer 
/methanol (12.5% v/v) 
110 17 79 - 
a
1-Amino-4-(2-hydroxyethoxy)-2-methylanthracene-9,10-dione (compound 36, Figure 3.3). 
According to the result of LC-MS, the condensation between compound 1 and ethanol, 
ethyleneglycol or methanol was also observed (Figure 3.3).  
 
Figure 3.3. Condensation products resulting from ethanol, ethyleneglycol, and methanol.  
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In conclusion, different solvents were employed to select the most proper one for reactions of 
solid amines. Upon changing 1-pentanol to isopropanol the yield was improved to 64 %, but the 
conversion was still incomplete. A further improved yield (80%) was observed when ethanol 
served as a solvent. When the polarity of the medium was increased by using a mixture of water 
and ethanol, this was not favorable, and the yield decreased with increasing water concentration, 
with only 27% yield in 50% aqueous ethanol. However, an excellent yield of 90% was obtained 
in methanol, while the yield dropped to 44 % and 17% in case of ethyleneglycol, or a mixture of 
phosphate buffer and methanol (12.5% v/v), respectively (Figure 3.4). 
 
 
Figure 3.4. Optimization of the reaction of 1-amino-4-bromo-2-methylanthraquinone (1) with 
anthranilic acid with regard to the solvent. Reaction conditions: 2-methyl-AQ (1, 0.1 mmol.), 
anthranilic acid (3 equiv.), potassium acetate (5 equiv.), copper(II) acetate (5 mol%), 4 mL of 
solvent, 95 
°
C, microwave 80 W.  
Since methanol was one of the solvents under trial which produced a high yield, it was selected 
for further reactions. The condensation reaction conditions are depicted in Scheme 3.10.  
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Scheme 3.10. Synthetic procedure for compound 18 using methanol as a solvent. 
3.1.6. Optimization of the reaction conditions using methanol as a solvent 
3.1.6.1. Effect of concentration  
To our surprise when the reaction was conducted using a higher amount (0.25 mmol) of 2-
methyl-AQ (1) than initially used during the optimization process (0.1 mmol, entry 1, Table 3.5), 
the yield dropped to 64% and the unreacted components were 8% (entry 2, Table 3.5), while the 
main side-product was the debrominated product 30.  
Table 3.5. Optimization using methanol as a solvent with a higher concentration of 2-methyl-
AQ
a
.  
Entry 
Amount of 2-
methyl-AQ 
(1) (mmol) 
Solvent 
(4 mL) 
Reaction time 
(min) 
Yield%
b
 
Compound 
18 
2-methyl-
AQ (1) 
Methoxy 
side-product 
1 0.1 
methanol 110 
90 2 8 
2 0.25 64 8 8 
a
Reaction conditions: 2-methyl-AQ (1, 0.1 or 0.25 mmol.), anthranilic acid (0.3 or 0.75 mmol, 3 
equiv.), potassium acetate (5 equiv.), copper(II) acetate (5 mol%), 95 
°
C microwave 80 W. 
b
Yield% according to the result of LCMS. 
Based on these findings, we preferred to keep 0.1 mmol as a standard amount for further 
reactions.  
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3.1.6.2. Effect of the catalyst 
To investigate the effect of the catalyst on the reaction, we employed different copper catalysts. 
The reaction of 2-methyl-AQ with anthranilic acid using copper(II) acetate monohydrate (5 
mol%) instead of copper(II) acetate resulted in a significant reduction in the yield from 90% to 40 
% which may indicate that the presence of water in the crystal was detrimental for the reaction 
(entry 2, Table 3.6). As previously described, elemental copper (copper(0)) was advantageous for 
Ullmann condensation reactions of AQs bearing acidic functional groups at the 2-position. Thus, 
we conducted the reactions with different concentrations of copper(0). Upon shifting to elemental 
copper (5 mol%) instead of copper(II) acetate monohydrate, the yield unfavorably dropped to 
80% without any improvement in reaction time (80 min). When the concentration of copper(0) 
was increased to 10 mol%, there was a further drop in the yield (63%) with the same reaction 
time (entries 3 and 4, Table 3.6).  
We had expected that copper(0) might improve the reaction rate, so we conducted the reaction 
using a combination of copper(0) and copper(II) acetate (5 mol% each). Indeed the reaction rate 
slightly improved compared to copper(II) acetate alone (entry 5, Table 3.6). To our surprise, 
using a mixture of copper(II) acetate monohydrate and copper(0) (5 mol% each) significantly 
improved both the yield (93%) and the reaction time (60 min) (entry 6, Table 3.6) when 
compared to copper(II) acetate monohydrate alone.  
Since the addition of copper (0) significantly improved the reaction outcome, we carried out 
multiple reactions using higher concentrations of copper (0) (10% or 15%). While the reaction 
time markedly improved as expected (45 min, and 25 min), the yields were reduced (64 % and 61 
%, respectively) (entries 7 and 8, Table 3.6).  
Table 3.6. Optimization of the reaction of 2-methyl-AQ (1) with anthranilic acid
 
with regard to 
the catalyst
a
 
Entry Catalyst (5 mol%)
b
 Time (min) Isolated Yield (%) 
1 Cu(OAc)2 110 90 
2 Cu(OAc)2·H2O 110 40 
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Entry Catalyst (5 mol%)
b
 Time (min) Isolated Yield (%) 
3 Cu
0
 80 80 
4 Cu
0c
 80 63 
5 Cu(OAc)2/Cu
0
 80 70 
6 Cu(OAc)2·H2O/Cu
0
 60 93 
7 Cu(OAc)2·H2O/Cu
0d
 45 64 
8 Cu(OAc)2·H2O/Cu
0e
 25 61 
a
Reaction conditions: 2-methyl-AQ (1, 0.1 mmol), anthranilic acid (3 equiv.), potassium acetate 
(5 equiv.), 4 mL of methanol, 95 
°
C, microwave 80 W. 
b
In case of using a mixture, 5 mol % of 
each component was employed. 
c
10 mol%, 
d
10 mol% each. 
e
15 mol% each. 
Till now, the mechanism of Ullmann-type reactions has not been fully understood.
204,205 
In 
general, the progress or inhibition of the reactions mediated by copper is influenced by many 
parameters such as reaction medium which may explain the variability of reaction rates.
200,206
 In 
the present study, different attempts were made towards the optimization of the reaction 
conditions. The solvent played a fundamental effect on the reaction rate and yield which is 
supported by our results. Polar protic solvents, namely ethanol and methanol, were favorable for 
condensation of 2-methyl-AQ (1) with different amines. These findings could be explained by the 
fact that solvents having free hydroxyl group may also act as ligands. The study by Tuong, Arai 
and Hida has reported a series of mechanistic investigations on Ullmann condensations of 
haloanthraquinones with variable chemical structures such as amines, ligands and catalysts. The 
authors concluded that the reaction was enhanced by the presence of free hydroxyl-containing 
compounds such as alcohols. The free hydroxyl group of the alcohol can form a complex with the 
catalyst which shows much higher catalytic activity than the original copper species (Scheme 
3.11).
207,208,209
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Scheme 3.11. Reported alkoxy-Cu
II
 complexes by Arai et al.
208 
X= Cu counter anion e.g. halide. 
There is a strong correlation between the lipophilicity of the AQ derivatives and the polarity of 
the solvent. Ideally, the more lipophilic the AQ derivative is, the less polar the solvent has to be. 
Since, 2-methyl-AQ (1) is lipophilic, it required solvents such as ethanol and methanol, instead of 
water as was the case of acidic AQ derivatives.
200
  
Among the catalysts applied in the presence of methanol, both copper (0), copper(II) acetate and 
a mixture of copper(0) and copper(II) acetate monohydrate were acceptable (Figure 3.5).   
 
 
Figure 3.5. Effects of different catalysts on the reaction of 2-methyl-AQ (1) in methanol. 
a
10 
mol%, 
b
10 mol% each, and 
c
15 mol% each. 
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3.1.7. General synthetic procedure (II) used for anthraquinone derivatives 18-25 
The optimized reaction conditions for 2-methyl-AQ were methanol (4 mL) as a solvent, 
potassium acetate (5 equiv.), and a mixture of copper(0), and copper(II) acetate monohydrate (5 
mol% each)) as catalysts (Scheme 3.12).  
 
Scheme 3.12. Ullmann reaction of 2-methyl-AQ (1) with amino derivatives using microwave 
heating.  
The above described method was successful for the synthesis of the 2-methyl-substituted AQ 
derivatives 18-25 (Table 3.7). 
Table 3.7. Reaction times, HRMS, UV absorption, melting points, yields, and purity of the 
synthesized anthraquinone derivatives 18-25 obtained from solid amines
a
  
 
Cmpd R' 
Reaction 
time 
(min) 
HRMS (g/mol)
b
 
m/z: [M-H]
-
 max 
(nm) 
m.p. 
(
o
C) 
Yield  
%
c
 
Purity 
(%)
d
 
Calcd Found 
18 2-CO2H 70 371.1037 371.1036 616 >300 93 99 
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19 3-CO2H 55 371.1037 371.1039 608 >300 36 96 
20 4-CO2H 65 371.1037 371.1033 612 >300 40 99 
21 2-CO2H-4-F 70 389.0938 389.0943
e
 612 >300 44 95 
22 
3-SO3H-4-
NHC6H5 
40 500.1280 500.1266
e
 608 >300 42 96 
23 4-NHC6H5 35 n.d.
*
 608 n.d.
*
 48 85 
24 3-OH 70 343,1088 343,1087 616 285-286 43 93 
25 4-OH 45 n.d.
*
 610 225-226 45 91 
a
Reaction conditions: 2-methyl-AQ (1, 0.1 mmol, 1 equiv.), amine (3 equiv.), potassium acetate 
(5 equiv.), copper(II) acetate (5 mol%), 4 mL of methanol, microwave 80 W, 95 
°
C, 
b
HRMS was 
recorded on a micrOTOF-Q, HPLC coupled-mass spectrometer (Bruker). 
c
Isolated yield. 
d
Purity 
was determined by LC-MS coupled to a diode array UV detector (220-700 nm), 
e
m/z: [M+H]
+
. 
n.d.
*
: not determined. 
Regarding the position of the carboxyl group, the reaction with 3-aminobenzoic acid (19) 
requires 55 min until no further progress was observed with marked decrease in the yield 36%. 
However, condensation of 2-methyl-AQ (1) with 4-aminobenzoic acid (20) using the same 
conditions, the reaction time nearly the same compared to compound 18, but the yield was 
dropped 2-fold decrease.  
Introduction of fluorine atom at the para-position (21) had a negative impact on the yield 44% 
compared to compound 18. After 70 min, there is no progress was noticed and the condensation 
side-product was increased instead of compound 21. Compound 22 was previously prepared by 
reaction in phosphate buffer in only 21% yield. 
In conclusion, the new, optimized method provided the targeted products 18-25 in acceptable to 
excellent yields (36-93%).  
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4.2 3.2. Bisacodyl-derived compounds 
Bisacodyl (4,4'-diacetoxy-diphenyl)-(pyridyl-2)-methane is a member of the TRAM family. 
Bisacodyl was identified by our group to be a moderately potent P2X3 receptor antagonist and 
was selected for further characterization.
195
 
3.2.1. Synthesis of bisacodyl  
Bisacodyl is composed of a tricyclic structure, where an ortho-pyridyl ring is attached to a central 
carbon atom in addition to two phenyl residues which bear acetate moieties at the para- positions. 
Bisacodyl was synthesized by acetylation of the precursor bis-(p-hydroxyphenyl)-pyridyl-2-
methane 46 according to literature.
210,211,212 
This precursor can be prepared by two different 
pathways as follows:  
1. Starting with pyridine-2-carboxylic acid (38), which is converted to the corresponding acid 
chloride 39 with thionyl chloride. Compound 39 is subsequently reacted with phenol to give 
pyridine 2-carboxylic acid phenyl ester (phenyl picolinate) 40. Fries rearrangement is the key 
step of this method which allows the transfer of the 2-pyridylacyl group of 40 forming the 
isomers 2-hydroxyphenyl-2-pyridyl-ketone (ortho-, 41) and 4-hydroxyphenyl-2-pyridyl-ketone (-
para, 42) (1 : 2), which can be easily separated by column chromatography on silica gel using 
cyclohexane/ethyl acetate (70 : 30) as eluent system. The reduction of the key intermediate 4-
hydroxyphenyl-2-pyridyl-ketone (para-, 42) results in the formation of the alcohol derivative 
(43), which is then condensed with phenol in the presence of phosphoric acid to afford the key 
precursor 46.
211 
However, there are some limitations associated with the application of this 
method including its being a multi-step synthetic process. 
2. Condensation reaction between 2-pyridinecarboxaldehyde (44) and phenol catalyzed by 
sulfuric acid. The reaction yields the ortho- and para- isomers, namely 2-((4-
hydroxyphenyl)(pyridin-2-yl)methyl)phenol (45) and the key precursor 46. The remarkable 
advantage of this method is the improvement in the production process in addition to being an 
inexpensive pathway for saving resources.
212 
Since the condensation is the most efficient method 
to prepare triarylmethanes, it will be used in the next chapter for the synthesis of derivatives and 
analogs. 
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Bisacodyl was obtained by acetylation of the key precursor 46 with acetic anhydride in the 
presence of 4-dimethylaminopyridine (DMAP) or pyridine (Scheme 3.13).  
 
Scheme 3.13. Synthetic procedures for bisacodyl.
 
3.2.2. Development of P2X3 receptor antagonists
 
Bisacodyl is a moderately potent P2X3 receptor antagonist, which was selected for further 
optimization. The previous analysis of nine bisacodyl derivatives showed that the di-hydroxy 
metabolite was the most potent compound among the synthesized series (work by The-Hung Vu 
and Claudia Spanier). In order to investigate the structure-activity relationships and to elucidate 
the effects of different residues on the activity, a series of bisacodyl derivatives was synthesized 
and evaluated at the human P2X3 receptor for antagonistic activity.  
Following a reported procedure, commercially obtained bisacodyl was subjected to hydrolysis of 
the di-acetyl ester groups using a solution of potassium hydroxide/10% aqueous (aq.) ethanol 
affording the bis-phenol derivative 46 in an excellent yield.
213
 It should be noted that this high 
yield cannot be reached when using a mixture of methanol : water (4 : 1) as a solvent instead of 
ethanol : water (1 : 9). The removal of only one-acetyl ester group of bisacodyl can be achieved 
using lithium hydroxide monohydrate as a base in a mixture of tetrahydrofuran (THF) and 
methanol (MeOH) to form the monohydroxyl derivative 47 as described in Scheme 1.14.  
Results and Discussion 
- 73 - 
 
3.2.3. Alkylation of the bis-phenol metabolite of bisacodyl  
The bis-phenol 46 can be converted to aryl ethers through alkylation using alkylating agents in 
the presence of potassium carbonate as a base and dry acetone as a solvent under reflux 
conditions. However, there is a major drawback with using this method due to the long time 
required for completion of the reaction (22 h).
214
 In most cases the mono-alkylated compounds 
were required, and this method may not be ideal for the preparation of such compounds.  
In the present study, bis-phenol 46 was subjected to alkylation using different alkylating agents in 
the presence of sodium hydride (NaH) as a base, in N,N-dimethylformamide (DMF) as a 
solvent.
213
 All reactions proceeded smoothly, starting at 0 
°
C and allowing the reaction mixtures 
to warm up to room temperature. Reactions were completed within 1-4 h affording a series of 
derivatives with different substituents at the 4,4'-positions (48-66) in moderate to high yields 
(Scheme 1.14 and Table 3.8).  
 
Scheme 1.14. Synthesis of compounds 46, 47 and 4,4'-substituted derivatives.  
Since it was easy to obtain the bis-phenol 46 on a gram scale, most reactions were conducted 
with 1 mmol. While the reactions involving different alkyl chains (linear, unsaturated, branched, 
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and aromatic) proceeded smoothly without any problem, differences in the rates and yields of the 
reactions were observed (Table 3.8).  
Table 3.8. Reaction times, HRMS, melting points, yields, and purity of the synthesized 
bisacodyl-derived compounds 48-66 obtained by etherification of compound 46
a
 
 
 
Cmpd 
 
R
1
 R
2
 
Reaction 
time 
(h) 
HRMS (g/mol)
b
 
m/z: [M+H]
+
 
 
m.p. 
(
°
C) 
(or ) 
Yield 
%
c
 
Purity 
(%)
d
 
Calcd. Found 
48 H  1 332.1656 332.1657
e
 145-146 31 97 
49 H 
 
1.5 332.1656 332.1682
e
 160-162 44 99 
50 H  2 382.0448 382.0444
e
 155-157 42 96 
51 H  
1 n.d.* n.d.* n.d.* 46 98 
52 H  2 334.1449 334.1454
e
 100-102 43 95 
53 H 
 
3 n.d.* n.d.* 112-114 32 97 
54 H 
 
3 410.1398 410.1415
e
 195-197 13 99 
55 H 
 
1 366.1500 366.1498
e
 160-161 20 98 
56 H 
 
1 380.1656 380.1653 135-136 9 95 
57  2 390.2428 390.2397 (1.5310) 94 95 
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Cmpd R
1
 R
2
 
Reaction 
time 
(h) 
HRMS (g/mol)
b
 
m/z: [M+H]
+
 
m.p. 
(
°
C) 
(or ) 
Yield 
%
c
 
Purity 
(%)
d
 
Calcd. Found 
58  4 394.2013 394.1983 (1.5817) 79 96 
59 
 
2 450.1911 450.1871 75-77 77 95 
60 
 
3 410.2115 410.2085 (1.5940) 66 99 
61 
 
1.5 390.2428 390.2358 (1.4480) 31 96 
62 
 
3 502.3680 502.3701 60-62 55 96 
63 
 
3 546.1911 546.1877 170-172 68 100 
64 
 
2 518.2326 518.2312 122-124 29 99 
65 
 
1 458.2115 458.2079 113-115 39 96 
66 
 
1 486.2428 486.2398 (1.5693) 33 97 
a
Reaction conditions: bis-phenol (46, 1-3 equiv.), sodium hydride (2.2-6.6 equiv.), alkylating 
agent (2.2-6.6 equiv.), 10 mL of N,N-dimethylformamide for each equiv. of 46, 0 
°
C to rt. 
b
HRMS was recorded on a micrOTOF-Q, HPLC coupled-mass spectrometer (Bruker). 
c
Isolated 
yield. 
d
Purity was determined by LC-MS coupled to a diode array UV detector (220-700 nm), 
e
m/z: [M-H]
-
. n.d.
*
: not determined. ( ): Refractive index.  
Moreover, we aimed to replace the bromine atom on the side chain of compound 50. Thus the 
morpholine derivative 67 was synthesized through reaction of compound 50 with morpholine in 
the presence of potassium carbonate as a base in acetonitrile at 60 
°
C as shown in Scheme 
3.15.
215
 Compounds 50 and 55 were subjected to further alkylation as described in Scheme 3.15 
affording the di-alkylated derivatives 68 and 69, with two different alkyl groups in an acceptable 
yields (see Table 3.9).  
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Scheme 3.15. Synthesis of the morpholine derivative 67 and di-alkylated derivatives 68 and 69.  
Table 3.9. Reaction times, HRMS, melting points, yields, and purity of the synthesized 
derivatives 67-69  
 
 
Cmpd 
 
R
1
 R
2
 
Reaction 
time 
(h) 
HRMS (g/mol) 
m/z: [M+H]
+
 
 
m.p. 
(
o
C) 
(or ) 
Yield 
(%) 
Purity 
(%) 
Calcd. Found 
67 
 
H 13 389.1871 389.1886
a
 140-142 54 99 
68   
2 440.1220 440.1167 
Semi-
solid 
28 97 
69 
  
1 406.1802 406.1791 (1.5431) 41 95 
a
[M-H]
-
. ( ): Refractive index. 
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3.2.4. Preparation of a triarylcarbinol derivative 
We aimed to study the structure-activity relationships of the hit structure 46 to determine which 
position would be critical for the enhancement of the activity. Therefore, the hydrogen atom 
attached to the central carbon atom in the hit structure 46 was replaced by a hydroxyl group to 
form the corresponding carbinol derivative. This was conducted by reaction of the commercial 4-
methoxyphenylmagnesium bromide with ethyl 2-picolinate under an argon atmosphere followed 
by quenching the reaction with aqueous ammonium chloride (NH4Cl).
216 
Subsequently, the 
carbinol derivative 71 was reacted with the alkylating agent 1-bromopropane (Scheme 3.16. 
Pathway A) to afford the corresponding propyl derivative 72 in a good isolated yield (64%) 
(Table 3.10). 
The pyrido[1,2-a]indole derivative 73 (Pathway B), which constitutes the cyclized form of 
carbinol 71, was obtained by an adapted procedure reported by Karthikeyan et al.
217  
The reaction 
was carried out in a pressure tube in the presence of formic acid at 120 
°
C and compound 73 was 
obtained in an excellent yield of 93% (Table 3.10). The corresponding hydroxy derivative 74 
was synthesized through O-demethylation of the cyclized pyrido[1,2-a]indole 73, by boron 
tribromide to afford product 74 in 50% yield (Scheme 3.16, Table 3.10). 
 
Scheme 3.16. Synthetic pathways to compounds 71-74. 
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3.2.4.1. Confirmation of structures  
The structures of the synthesized carbinol 71 and its propyl derivative 72 were confirmed by 
1
H 
and 
13
C NMR spectroscopy (Figure 3.6). However, the molecular ion peak was not detected by 
(LC/ESI-MS) since both structures were not ionized during measurement under positive or 
negative mode.  
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Figure 3.6. Comparison of the three 
1
H NMR spectra for structures 46, 71 and 72. 
1
H NMR 
spectral data were collected on a Brucker Avance NMR spectrometer at 600 MHz in case of 
compound 46 and at 500 MHz in case of compounds 71 and 72. DMSO-d6 was used as a solvent. 
Based on the NMR spectra, we can conclude that the carbinol derivative 71 was formed (signal at 
5.40 ppm in case of compound 46 and 6.28 for 71). The formation of the propyl derivative 72 
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was confirmed by the presence of signals for the propyl group in the aliphatic region instead of 
the alcoholic hydroxyl group of the carbinol derivative.  
Table 3.11. Reaction times, melting points, and yields of the synthesized derivatives 71-74  
 
Cmpd R Reaction time (h) m.p. (
°
C) Yield % 
Structure A 
71 H 3 88-89 37 
72 propyl 1 100-102 64 
Structure B 
73 CH3 6 156-158 93 
74 H 12 94-96 50 
3.2.4.2. Plausible mechanism for the formation of 3-methoxy-10-(4-methoxyphenyl)-
pyrido[1,2-a]indole (73) 
The aza-Nazarov-type cyclized product was successfully obtained through intramolecular C-H 
amination mediated by formic acid, and the mechanism may be proposed as follows.
217
 The 
carbinol derivative 71 is converted into its protonated form in the acidic medium (formic acid) 
affording intermediate A. Subsequently the tertiary carbocation B is formed when a water 
molecule is dissociated. At 120 
°
C, this carbocation is subjected to an electrocyclic ring closure 
reaction which leads to the formation of intermediate C. Then, deprotonation and re-
aromatization takes place and the desired cyclized derivative 73 is formed (Scheme 3.17).  
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Scheme 3.17. Proposed mechanism for the intramolecular reaction producing pyrido[1,2-a]indole 
73.
217
 
In the beginning we focused on the derivatives with disubstituted hydroxyl groups at the 4- and 
4'-positions. Then, we tried to determine the effect of the lacking of both hydroxyl groups on the 
activity 75. We also tried to replace the hydroxyl groups with electro-negative fluorine atoms 76. 
While we showed that substitution in the 4- and 4'-positions is advantageous, we also aimed to 
study substitution of the 3,3'-positions. We aimed to introduce electro-negative atoms beside the 
hydroxyl groups, namely a small fluorine atom (77) or a larger iodine atom (78). Among the 
different approaches for the preparation of such compounds
 
we used a procedure which is 
outlined in Scheme 3.18 Condensation reaction of 2-pyridinecarboxaldehyde with different 
moieties (fluorobenzene, 2-fluorophenol and 2-iodophenol) was performed in the presence of 
concentrated sulfuric acid at 0 
°
C.
218
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Scheme 3.18. Synthetic pathway for obtaining compounds 75-78. 
Replacement of the hydroxyl groups of compound 78 with methoxy residues for (78a) was 
conducted using the same procedure which had been used for alkylation of bis-phenol (Table 
3.12). 
Table 3.12. Reaction times, HRMS, melting points, yields, and purity of the synthesized 
derivatives 75-78a  
 
 
Cmpd 
 
R
1
 R
2
 
Reaction 
time 
(h) 
HRMS (g/mol) 
m/z: [M-H]
-
 
 
m.p. 
(
o
C) 
 
Yield 
(%) 
Purity 
(%) 
Calcd. Found 
75 H 13 246.1277 246.1275
a
 62-64 61 96 
76 F 13 282.1089 282.1083
a
 n.d.* 25 97 
77 OH F 9 312.0842 312.085 246-248 60 97 
78 OH I 14 527.8963 527.8960 186-187 24 97 
78a OCH3 I 0.5 555.9276 555.9265 68-70 83 98 
a
[M+H]
+
. n.d.
*
: not determined. 
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The next part of this study was dedicated to the simplification of structure 46. We specifically 
aimed to remove or replace the pyridine ring by other substituents while maintaining the other 
features (two aryl rings) and to accordingly assess its importance for the activity.  
To achieve that, direct alkylation was performed on compound 79 with 1-bromopropane or 1-
bromobutane in the presence of sodium hydride as a base in DMF, thereby producing the propyl 
and butyl derivatives 80 and 81. Similarly, the treatment of compounds 82 and 84 with 1-
bromopropane generated the propyl derivatives 83 and 85 (Scheme 3.19).
219
  
 
Scheme 3.19. Synthesis of the alkylated derivatives 80, 81, 83 and 85. 
The synthetic strategy to obtain compounds 89 and 90 relied mainly on the alkylation of the key 
intermediates 87 and 88, as described in Scheme 3.20. The 3,6-dihydroxy-9H-xanthen-9-one 
(xanthone scaffold) containing two hydroxyl groups (87) was generated in a pressure tube 
through dehydration of commercially available 2,2',4,4'-tetrahydroxybenzophenone 86. The 
reaction was only accomplished under high pressure and elevated temperature. Temperature is 
the key element in this dehydration reaction. In fact, the high temperature is necessary to 
evaporate the water by generating steam. The latter creates the pressure essential to produce the 
xanthone compounds.
220,221 
The higher the temperature, the greater the pressure and the faster the 
reaction will proceed. 
In the second step, compound 87 was subjected to reduction using borane-tetrahydrofuran 
complex (1.0 M in THF). The reaction proceeded smoothly at room temperature under argon 
affording 9H-xanthene-3,6-diol (88) in an excellent yield (Scheme 3.20, Table 3.13).
222 
Then, the 
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propyl side chains were introduced on the two hydroxyl groups in the presence of potassium 
carbonate as a base in solvents such as acetone or acetonitrile, to give compounds 89 and 90 
(Scheme 3.20).
223
  
 
Scheme 3.20. Synthesis of xanthone and xanthene derivatives 89 and 90. 
Table 3.13. Reaction times, HRMS, melting points, yields, and purity of the synthesized 
derivatives 80, 81, 83, 85 and 87-90.  
 
Cmpd R X 
Reaction 
time 
(h) 
HRMS (g/mol)
a
 
m/z: [M+H]
+
 
m.p. 
(
°
C) 
(or ) 
Yield 
%
b
 
Purity 
(%)
c
 
Calcd. Found 
Structure A 
80  CH2 4 285.1849 285.1853 (1.534) 35 95 
81  CH2 3 313.2162 313.2158 46-48 64 99 
83  C(CH3)2 4 313.2162 313.2165 (1.3282) 75 98 
85 See structure above 3 n.d.* (1.4480) 52 n.d.* 
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Cmpd R X 
 
Reaction 
time 
(h) 
HRMS (g/mol)
a
 
m/z: [M+H]
+
  
m.p. 
(
°
C) 
(or ) 
Yield 
%
b
 
Purity 
(%)
c
 
Calcd. Found 
Structure B 
87 -H C=O 16 227.0350 227.0374
d
 > 300 66 99 
88 -H CH2 5 213.0557 213.0577
 d
 215-217 95 95 
89  C=O 16 313.1434 313.1439 115-117 35 99 
90  CH2 15 299.1642 299.1648 83-84 27 94 
a
HRMS was recorded on a micrOTOF-Q mass spectrometer (Bruker) coupled with an HPLC 
instrument. 
b
Isolated yield. 
c
Purity was determined by LC-MS coupled to UV detector , 
d
m/z: [M-
H]
-
. n.d.*: not determined. ( ): Refractive index. 
3.2.5. Miscellaneous modifications 
3.2.5.1. Synthesis of N
4
-(4-methoxyphenyl)2,4,6-triamino-pyrimidine 
The protocols reported for the synthesis of arylaminopyrimidines seem to be quite similar.
224 
 
Elena et al. reported a convenient synthetic procedure to generate the pyrimidine derivatives. We 
used the same strategy to synthesize the title compound. N
4
-substituted pyrimidine derivative 91 
prepared from 6-chloro-2,4-pyrimidinediamine by a nucleophilic aromatic substitution with para-
methoxyaniline in the presence of N,N-diisopropylethylamine (DIPEA) as a base using dioxane 
as a solvent as outlined in Scheme 3.21.
225
 The purification of the product was relatively difficult 
due to poor separation on silica gel, even when different eluent systems were utilized. Thus, the 
compound required multiple purification procedures using flash chromatography. This may 
explain the low isolated yield (26%). 
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Scheme 3.21. Synthesis of N
4
-(4-methoxyphenyl)pyrimidine-2,4,6-triamine 
3.2.5.2. Synthesis of diindolylmethane derivatives 
Indole-containing compounds are privileged structures in medicinal chemistry
226
 endowed with 
many biological activities such as anti-inflammatory, cytotoxic, antitumour, antiviral, and 
antimicrobial effects. Indole is an important precursor which is widely used in the synthesis of 
many drugs, such as indomethacin (Figure 3.7). Diindolylmethanes (DIMs), are composed of 
two indole molecules and display a wide spectrum of pharmacological activities including 
antibacterial (Figure 3.7) and antioxidant activities in addition to being inducers of apoptosis in 
human cancer cells.
227,228  
 
Figure 3.7. Chemical structures of indomethacin and nitrofuryl-diindolylmethane. 
For these reasons, we sought to replace the phenol scaffolds of 46 with indole moieties as shown 
in Scheme 3.22. Several studies including that reported by Kobayashi et al. demonstrated that 
surfactants besides Lewis and Brønsted acid catalysis showed positive impact on the formation of 
the carbon-carbon bond in water. However, many reports suggested the de-activation of Lewis 
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acid catalysts by the nitrogen atom of indole.
229
 In the present study, condensation of 5-
methoxyindole and 2-pyridinecarbaldhyde (44) was done using sodium dodecylsulfate (SDS) as a 
surfactant in aqueous medium to give the key intermediate diindolylmethane 92 in a good 
yield.
230
 The major advantage of this approach is the use of a green chemistry procedure, in 
which toxic catalysts and solvents can be avoided. The target compound 93 was prepared in a 
very good yield through deprotection of the two methoxy groups using boron tribromide in 
dichloromethane, as outlined in Scheme 3.22.  
 
Scheme 3.22. Synthesis of diindolylmethanes 92 and 93. SDS: sodium dodecylsulfate 
Oxadiazole moieties were shown to constitute bioisosteres of urea in the development of β3 
adrenergic receptor agonists.
231
 They were also demonstrated as bioisosteres for esters and 
amides. 1,2,4-Oxadiazole-containing molecules are an important class of compounds which 
possess a wide range of pharmacological applications. Some oxadiazole derivatives are classified 
as potent antitumor agents, coronary artery dilators, anthelmintic and muscle relaxants,
232 and 
some oxadiazole derivatives were shown to display antitussive, antiallergic, anti-inflammatory, 
antiplatelet activity in vitro, while others were active as glycogen phosphorylase (GP) 
inhibitors.
233
 The 1,2,4-oxadiazole ring was selected for its key role in many pharmacologically 
active compounds. Thus, we aimed to synthesize compounds containing the oxadiazole moiety.  
3.2.5.3. Synthesis of 5,5'-(4-(benzyloxy)-1,3-phenylene)-bis-(3-ethyl-1,2,4-oxadiazole) (99) 
As outlined in Scheme 3.23, the synthesis of compound 95 was done by treatment of the 
commercially available methyl 3-formyl-4-hydroxybenzoate 94 with the alkylating agent 
dimethyl sulfate in the presence of potassium carbonate as a base using acetonitrile as a solvent. 
The reaction was performed under reflux and was completed after 2 h affording the 
corresponding methoxy derivative in 88% yield.
223
 In the next step, the replacement of the ester 
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and aldehyde groups by 1,2,4-oxadiazole rings (97) was achieved through the reaction of 
propionamidoxime (96) with compound 95.
234 
Propionamidoxime
235
 was synthesized through 
reaction of propionitrile with hydroxylamine (Scheme 3.23). 
4.2.1.1.1 3.2.5.3.1. Deprotection of the methoxy group of compound 97 
Many deprotecting agents have been demonstrated as efficient tools for removal of methoxy 
groups to access the corresponding hydroxyl groups. This includes aluminum chloride, lithium 
chloride and boron tribromide.
236,237,238 In our study, we tried the O-demethylation of compound 
97 using boron tribromide in dichloromethane under an argon atmosphere. The reaction started at 
0 
°
C which then reached room temperature. The corresponding hydroxyl derivative 98 was 
obtained in a good isolated yield without use of any complicated purification procedures. Then, 
alkylation of the hydroxyl group was performed using benzyl bromide as an alkylating agent and 
sodium hydride as a base in DMF, and the desired product 99 was obtained in a good yield 
(Scheme 3.23).  
 
Scheme 3.23. Synthesis of 5,5'-(4-(benzyloxy)-1,3-phenylene)-bis-(3-ethyl-1,2,4-oxadiazole) 
(99). 
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4.2.1.1.2 3.2.5.3.2. Proposed mechanism of the formation of the bis-oxadiazole 
Synthesis of bis-oxadiazoles can be achieved in two consecutive steps utilizing a base to catalyze 
the reaction between the propionamidoxime and the carbonyl-containing compound. The 
cyclization (intramolecular reaction) of the intermediate A was achieved at elevated temperature, 
a process known as thermal cyclization (Scheme 3.24).
239
  
 
Scheme 3.24. Proposed mechanism of the formation of the bis-oxadiazole.
239
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5 3.3. Pharmacological evaluation 
5.1 3.3.1. Anthraquinone (AQ) derivatives 
3.3.1.1. Biological evaluation of anthraquinone derivatives (previous results)  
Our group has previously studied a number of AQ derivatives as antagonists of different P2 
purine receptors. A series of AQ derivatives, structurally related to Reactive Blue 2 (RB-2) and 
Acid Blue 25 (AB-25) have been synthesized and tested for their antagonistic activity on 
different P2Y receptors, e.g. P2Y12. Some of these derivatives were bearing a sulfonate group at 
the 2-position, e.g. PSB-0739, while others bear a carboxylic acid group, e.g. PSB-0702 (Figure 
1.28). These two derivatives have shown the best affinity for the P2Y12 receptor so far with Ki 
values of 0.025 μM and 0.021 μM, respectively.145 
Because of the success of these compounds, a library of AQ derivatives was synthesized in order 
to develop potent anthraquinones (AQs) for other target receptors. The activity of AQs has been 
studied at several P2Y receptor subtypes. PSB-16133, sodium 1-amino-4-[4-(2,4-
dimethylphenylthio)phenylamino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate, was found to 
be a potent antagonist at the human P2Y4 receptor with an IC50= 0.233 μM. Compound 100 
showed a lower potency (IC50= 1.70 μM) that was completely abolished when the 2-sulfonate 
group was replaced with a methyl group (102). In comparison to compound 101 bearing a 
sulfonate at the 2-position, which was inactive at 100 μM, there was no improvement in the 
activity upon replacement of the acidic group with a methyl residue (31) (Table 3.14).
240
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Table 3.14. Inhibitory potencies of selected AQ derivatives on the human P2Y4 receptor
240
 
 
compd R
1
 R
2
 R
3
 
IC50 ± SEM (μM)
a
 (or 
% inhibition at 
indicated 
concentration) 
Structure A 
PSB-16133 H H 
 
0.233 ± 0.079 
100 H OMe H 1.70 ± 0.28 
101 CO2H H F >100 (17%)
b
 
Structure B 
102 H OMe H >30 (38%)
c
 
31 CO2H H F ≈100 (57%)
b
 
a
Potency to inhibit calcium mobilization induced by receptor activation with UTP in 1321N1 
astrocytoma cells stably transfected with the human P2Y4 receptor. 
b
Percent inhibition at 100 
μM. cPercent inhibition at 30 μM.240 
3.3.1.2. Potency of newly synthesized AQ derivatives on the human P2Y4 receptor 
The AQ derivatives synthesized as part of this project were assessed for antagonistic potency on 
the human P2Y4 receptor in Ca
2+ 
mobilization assays using stably transfected 1321N1 
astrocytoma cells. A monoclonal human P2Y4 cell line was created and Ca
2+
 measurements on 
the P2Y4 receptor were performed by Dr. Muhammad Rafehi according to a previously published 
procedure.
240 
Poor solubility of the compounds in aqueous buffer was noted during the screening 
Results and Discussion 
- 92 - 
 
process due to the lipophilicity of the derivatives. To overcome this challenge and to avoid 
precipitation during the assay, all compounds were screened at a micromolar concentration level. 
Unfortunately, all of the synthesized AQ derivatives having a methyl group at the 2-position were 
found inactive when the screening was conducted at 1 μM. Thus it appears that the acidic 
function in this position is required for the activity. Based on a homology model previously 
established by our group, it seems that the lack of the sulfonate group at the 2-position is 
responsible for the loss of the activity of these 2-methyl-AQ derivatives. We believe that the 
acidic functionality is essential for strong electrostatic and hydrogen bonding interactions with 
amino acids Lys179 and Arg272 of the human P2Y4 receptor.
240
 
AQs may also be antagonists at P2X receptor subtypes. A series of AQ derivatives structurally 
related to RB-2 yielded PSB-1011 and PSB-10211 as P2X2 antagonists with IC50 values of 0.079 
µM, and 0.086 µM, respectively. These two derivatives represented the first potent and selective 
competitive P2X2 receptor antagonists. Based on the success of these compounds, we aimed to 
find superior potent and selective AQ derivatives with enhanced potency for other P2X 
receptors.
64
  
3.3.1.3. Potency on the human P2X3 receptor 
A monoclonal human P2X3 cell line was created and Ca
2+
 measurements on P2X3 were done by 
Dr. Aliaa Abdelrahman. P2X3 receptor blockade was determined by measuring agonist-mediated 
increases in cytosolic Ca
2+
 concentration. 
The synthesized 1-amino-2-methyl-4-substituted AQ derivatives were investigated for their 
activity on the human P2X3 receptor using Ca
2+ 
mobilization assay. In Figure 3.8, examples of 
concentration-inhibition curves of the two active AQ derivatives 6 and 22 are depicted. 
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Figure 3.8. Concentration-inhibition curves of the two active AQ derivatives 6 and 22 on the 
human P2X3 receptor. IC50 values (μM): 6, 7.46 ± 1.25; 22, 3.07 ± 1.14. 
All AQ derivatives bearing a methyl group at the 2-postion were inactive at the P2X3 receptor at 
10 µM except for compounds 6 and 22 (Table 3.15). Compound 23 was found inactive although 
it shows the same pattern of rings as 22 but without the sulfonate group at the C-3' position in 
ring D. Electrostatic interactions are likely to be generated between the negatively charged 
sulfonate group and positively charged amino acids of the P2X3 receptor. Interestingly, 
compound 6 (IC50= 7.46 µM) which was anticipated to completely lose the activity as a result of 
lacking E ring was found active with only 2-fold lower potency when compared to compound 22. 
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Table 3.15. Potencies of AQ derivatives on the human P2X3 receptor 
 
Cmpd R' 
IC50 ± SEM [µM] 
(% Inhibition at 10 µM) 
Cmpd R' 
IC50 ± SEM [µM] 
(% Inhibition at 10 µM) 
2 H >10 (16 ± 7) 
18 2-CO2H >10 (20 ± 8) 
19 3-CO2H >10 (32 ± 2) 
 
3 2-C2H5 >10 (22 ± 4) 20 4-CO2H >>10 (10 ± 5)  
4 3-C2H5 >10 (1 ± 3) 21 
2-CO2H- 
4-F 
>10 (21 ± 9) 
 
5 4-C2H5 >10 (23 ± 4) 22 
3-SO3H- 
4-NHC6H5 
3.07 ± 1.14 
6 2-CH3 7.46 ± 1.25 23 4-NHC6H5 >10 (25 ± 11)  
7 2-Cl >10 (30 ± 5) 24 3-OH >>10 (-3 ± 8)  
8 3-Cl >10 (5 ± 5)  Structure B 
9 4-Cl >10 (17 ± 7) 14 2-Cl 
 
>>10 (13 ±2) 
 
10 2-OCH3 ≥10 (51 ± 9) 15 3-Cl 
 
>>10 (2 ± 3) 
 
11 3-OCH3 n.d.* 16 4-Cl 
 
>10 (18 ± 18) 
 
12 4-OCH3 >10 (14 ± 3) 
17 3-F 
 
>>10 (3 ± 1) 
 13 
see structure 
above 
>>10 (2 ± 2) 
n.d.* not determined  
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In conclusion, a small library of 22 AQ derivatives bearing a methyl group at the 2-position were 
evaluated for their inhibitory activity on the human P2X3 receptor. Compound 22 having an 
ABCDE ring system with a sulfonate group at the C-3' position in ring D showed a promising 
result. Moreover, the small compound 6 displayed some P2X3-inhibitory activity. Our results 
indicate that the AQ derivatives may have different binding modes depending on the substitution 
patterns. 
Possible approaches for enhancing the activity of AQ derivatives on the human P2X3 receptor. 
(1) Synthesis of analogues of compound 22 with variations of substituents on ring D while 
keeping the acidic functionality (SO3H or COOH) in addition to having NH as a linker, or 
replacing the NH linker by oxygen or sulfur.  
(2) Introduction of substituents to ring E to determine the optimal residue which may enhance the 
activity (Figure 3.9). 
 
Figure 3.9. Proposed modifications of AQ 22 for potential enhancement of the inhibitory activity 
at the human P2X3 receptor. 
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5.2 3.3.2. Bisacodyl-derived compounds  
3.3.2.1. Biological evaluation of the synthesized bisacodyl-derived compounds 
The bisacodyl-related compounds synthesized in the present study were investigated for their 
inhibitory potency on the P2X3 receptor. Initially, the compounds were screened at four different 
concentrations (0.01 μM, 0.10 μM, 1 μM, and 10 μM). Compounds which showed an inhibition 
of ≥ 50% at 10 μM were further characterized and concentration-inhibition curves were generated 
from which IC50 values could be determined. The results of the synthesized compounds will be 
discussed, however for comparison purposes, examples of other bisacodyl derivatives or 
compounds from the literature will be included. 
3.3.2.1.1. Inhibitory potency of bisacodyl-derived compounds on the human P2X3 receptor 
and study of structure-activity relationships  
The synthesized bisacodyl-derived compounds were biologically evaluated on the human P2X3 
receptor. The evaluation of the hit compound and all the derivatives were done using calcium 
mobilization assays in transfected 1321N1 astrocytoma cell lines. Examples of concentration-
inhibition curves of the most potent bisacodyl-derived compounds are depicted in Figure 3.10. 
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Figure 3.10. Concentration-inhibition curves of selected bisacodyl-derived compounds on the 
human P2X3 receptor. IC50 values (μM): 46, 0.421 ± 0.196; 81, 0.493 ± 0.115; 69, 0.645 ± 0.144; 
and 89, 0.121 ± 0.012. 
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The evaluation was aimed to investigate the effects of substituents at different positions on the 
inhibitory activity of compounds at the P2X3 receptor. Our studies demonstrated that bisacodyl 
was identified as a potent antagonist on the human P2X3 receptor with an IC50 value of 1.59 µM. 
Interestingly, the hydrolyzed product, diphenol 46, which was obtained via removal of the di-
acetyl residues, was found to be more active with an IC50 value of 0.421 μM. This compound was 
chosen as a lead structure. We were interested to test the effects of other substituents in place of 
the di-hydroxyl groups at the 4,4'-positions on the activity. Thus, a total of 22 derivatives were 
obtained via etherification of the phenolic hydroxyl groups with either aliphatic or aromatic 
residues (different lengths, linear, unsaturated, or branched chains). On the other hand, we were 
interested in testing the effect of modifying the position of the hydroxyl groups and of 
simplification of the hit structure on the inhibitory activity at P2X3 receptors. The analysis of the 
structure-activity relationships of the synthesized derivatives of these series could give more 
insights in possible interactions between bisacodyl-derived ligands and the P2X3 receptor. Table 
3.16 and Table 3.17 list the IC50 values of selected derivatives. 
Table 3.16. Inhibitory potency of symmetrical bisacodyl derivatives on the human P2X3 receptor 
 
Cmpd R 
IC50 ± SEM (µM) 
(% inhibition at 10 
µM) 
Cmpd R 
IC50 ± SEM (µM) 
(% inhibition at 10 
µM) 
Bisacodyl COCH3 
1.59 ± 1.37 
(79 ± 3)* 
46 H 
0.421 ± 0.196 
(81 ± 6)* 
58  ≥10 (46 ± 5) 49  
1.08 ± 0.22 
(58 ± 2)* 
62  
>10 (32 ± 23) 63 
 
>10 (19 ± 8) 
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Cmpd R 
IC50 ± SEM (µM) 
(% inhibition at 10 
µM) 
Cmpd R 
IC50 ± SEM (µM) 
(% inhibition at 10 
µM) 
57  
2.72 ± 0.53 
(71 ± 15)* 
64 
 
>>10 (20 ± 20) 
59 
 
2.48 ± 0.67 
(92 ± 2)* 
65 
 
>10 (37 ± 8) 
60 
 
1.65 ± 0.55 
(63 ± 3)* 
66 
 
>10 (44 ± 5) 
*Maximal inhibition observed.  
3.3.2.1.2. Effects of symmetrical substitution of the bisacodyl-derived drug 46 on the 
inhibitory activity 
Symmetrical substitution of the di-hydroxyl groups either with aliphatic residues, methoxyethyl 
58, octyl 62, or with aromatic residues, e.g. para-methoxybenzoyl 63, para-methoxybenzyl 64, 
benzyl 65, or phenethyl 66 abolished the activity (Table 3.16). The symmetric benzyl derivative 
65 showed only 37% inhibition when tested at 10 μM. The introduction of a methoxy group in 
the para-position of the benzyl moiety (64) increased the lipophilicity of the compound but had 
no impact on the inhibitory activity. No enhancement of the activity was observed when the 
length of the carbon chain between the phenyl ring and the oxygen atom was increased to two 
methylene units (66) instead of one (65). This observation indicates that the symmetric 
substitution with bulky residues on both sides completely abolishes the activity.  
In order to investigate the impact of aliphatic side chains on the inhibitory activity, many 
derivatives with various residues were prepared. Previously, the effect of aliphatic substitutions 
had been limited to the methoxy, ethoxy and propoxy derivatives which were synthesized in our 
group by M. Sc. The-Hung Vu. The preliminary results revealed that the elongation of the 
attached aliphatic side chains did not improve the affinity towards the P2X3 receptor as 
compared to the hydrolyzed diphenol 46. However, it was shown by our group that the di-
substituted propoxy derivative is more potent than the ethoxy derivative which is also more 
potent than the methoxy derivative. To have a broader picture about the elongation of this carbon 
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chain, we additionally synthesized the butyl and octyl derivatives. We also modified the carbon 
chains to branched and unsaturated ones.  
The introduction of symmetrical aliphatic chains with different residues led, as shown in Table 
3.16, to a lower activity compared to the hydrolyzed diphenol compound 46. For instance, the 
butyl derivative 57 and the sec-butyl derivative 49, showed almost identical IC50 values of 2.72 
and 1.08 µM, respectively. The symmetrical 2-pentyne derivative 60 was found to be almost 4-
fold less potent than the hydrolyzed diphenol 46. No improvement in the potency was observed 
upon introducing the symmetrical ethyl acetate residues in compound 59, resulting in an IC50 
value of 2.48 µM. 
Comparing the biological activity of bisacodyl derivatives with different substituents, it was 
noticed that the introduction of symmetrical substitutions with aromatic moieties at the 4,4'-
positions completely abolished the activity, whereas symmetrical substitutions with aliphatic 
moieties at the same positions were tolerated, but less favorable as compared to the lead structure 
46. A long aliphatic residue such as an octyl chain completely abolished the activity. 
5.2.1.1.1 3.3.2.1.3 Effects of asymmetrical substitutions of leads structure 46 on the inhibitory 
activity 
Compound 47 that was obtained by cleavage of only one acetyl group of bisacodyl showed only 
46% inhibition of ATP-induced P2X3 activation when screened at 10 μM. A surprising finding 
was that when one hydroxyl group of 46 was substituted with an aliphatic residue e.g. butan-1-ol 
(52), the activity was completely lost (Table 3.17). The asymmetric butyl derivative 48 was 
found to be slightly less active than its symmetric analog 57. In contrast, the asymmetric octyl 
derivative 53 showed an increase in the inhibitory activity in comparison to the symmetric octyl 
derivative 62. The presence of a long side chain such as an octyl residue leads to an increase in 
the lipophilicity and positively effects on the activity. Replacement of bromine in the asymmetric 
derivative 50 by a morpholine moiety led to an increase in the bulkiness in the case of 67, which 
may explain the slight increase in potency. The combination of a bromine containing side chain 
with a sec-butyl moiety, in the case of 68, resulted in an insignificant, 2-fold increase in the 
activity with an IC50 value of 1.69 μM compared to 50. 
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The antagonistic potency of asymmetric benzyl-containing derivative 55 was demonstrated with 
an IC50 value of 3.70 μM, while the presence of two benzyl residues in 65 led to no inhibitory 
activity when screened at 10 μM. The activity was dramatically increased to the nanomolar range 
when the hydroxyl group of 55 was substituted with a propragyl residue (69), resulting in a more 
than 5-fold potency increase with an IC50= of 0.645 μM as compared to 55. In comparison to 55, 
the asymmetric para-methoxybenzoyl derivative 54 led to a slight increase in potency with an 
IC50 of 1.17 μM, while the symmetric compound 63 did not show any potency when tested at 10 
μM. Compound 56 differs from 55 by the presence of one methylene group more in the bridge 
between the phenyl ring and the oxygen atom. This difference increased the lipophilicity and led 
to a 2-fold insignificant increase in potency. These results suggest that combination between a 
propargyl residue in (69) and a phenethyl group of (in 56) may enhance the inhibitory potency to 
the low nanomolar range. However, it has to be noted that the inhibition, especially by the more 
lipophilic compounds, was only partial (see Figure 3.10). 
Table 3.17. Inhibitory potency of some bisacodyl derivatives with asymmetrical substitution on 
the human P2X3 receptor  
 
Cmpd R
1
 R
2
 
IC50 ± SEM (µM) 
(% inhibition at 10 
µM) 
Cmpd R
1
 R
2
 
IC50 ± SEM (µM) 
(% inhibition at 10 
µM) 
47 H -COCH3 >10 (46 ± 3) 52 H  >10 (35 ± 10) 
50 H  
3.35 ± 1.01 
(86 ± 4)* 
68  
 
1.69 ± 0.35 
(81 ± 5)* 
67 H 
 
2.26 ± 1.07 
(75 ± 7)* 
54 H 
 
1.17 ± 0.58 
(76 ± 8)* 
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Cmpd R
1
 R
2
 
IC50 ± SEM (µM) 
(% inhibition at 10 
µM) 
Cmpd R
1
 R
2
 
IC50 ± SEM (µM) 
(% inhibition at 10 
µM) 
51 H 
 
3.97 ± 0.72 
(81 ± 5)* 
55 H 
 
3.70 ± 1.12 
(64 ± 6)* 
48 H  
3.66 ± 0.98 
(101 ± 4)* 
56 H 
 
1.47 ± 0.30 
(92 ± 3)* 
53 H 
 
1.58 ± 0.44 
(85 ± 4)* 
69 
  
0.645 ±0.144 
(64 ± 3)* 
*Maximal inhibition observed.  
These findings demonstrate that the inhibitory activity associated with symmetrical and 
unsymmetrical substitution by aliphatic side chains is not satisfactory. The symmetrical 
substitution with aromatic side chains led to complete loss of activity, while the combination of 
different residues in unsymmetrically substituted compounds retained some inhibitory activity. It 
can be concluded that the most potent compounds among the bisacodyl derivatives are 46 and 69 
with IC50 values of 0.421 and 0.645 μM, respectively. The binding mode of 69 may be as 
follows: The propargyl residue may interact through hydrophobic interactions. The second 
residue may interact through π-π interactions. Both interactions probably increase the inhibitory 
activity. On the other hand, the hydrolyzed diphenol 46 may display a different binding mode. 
In order to elucidate the impact of the position of the residues, several modifications were carried 
out. For example, as seen in Table 3.18, we completely removed the hydroxyl functionalities in 
75 or introduced fluorine atoms instead of the hydroxyl groups in 76. We also combined fluorine 
and hydroxyl groups in 77 or replaced the fluorine atoms by other halogen atoms such as iodine 
in 78. In addition, we also alkylated the hydroxyl groups of 78 resulting in 78a. 
The importance of the hydroxyl groups at the 4,4'-positions of hit structure 46 was evaluated 
either by their removal in case of compound 75 or by replacing them with fluorine atoms (76). 
The activity in both cases dropped by 13-fold as compared to the hit structure 46. The 
combination of fluorine atoms with hydroxyl groups was not tolerated in the case of 77. When 
the fluorine atom was replaced with another bigger halogen atom such as iodine, the activity was 
restored 78. In contrast, replacing the hydroxyl groups of compound 78 with methoxy residues in 
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78a, increased the lipophilicity of the phenyl rings but had a negative impact on the inhibitory 
activity (Table 3.18).  
Table 3.18. Inhibitory potencies of selected bisacodyl-derived compounds 75-78a on the human 
P2X3 
 
 
 
Cmpd R
1
 R
2
 
IC50 ± SEM (µM) 
(% inhibition at 10 
µM) 
Cmpd R
1
 R
2
 
IC50 ± SEM (µM) 
(% inhibition at 10 
µM) 
75 H 
5.67 ± 0.68 
(68 ± 4)* 
78 -OH I 
1.63 ± 0.21 
(98 ± 3)* 
76 F H 
5.83 ± 1.25 
(64 ± 8)* 
78a -OCH3 
 
I 
 
>>10 (5 ± 12) 
77 OH F >10 (32 ± 7)  
*Maximal inhibition observed. 
As a next step, we investigated the effects of substituents at the central carbon atom (Table 3.19, 
structure A). The introduction of a hydroxyl group resulted in a loss of the inhibitory potency 
(71) in comparison with the same structure without the alcoholic functionality, which had been 
previously synthesized by M.Sc. The-Hung Vu and was tested on rat P2X3 receptor with an IC50 
value of 7.55 µM (I, Table 3.19).
195 In contrast, the alkylation of the alcoholic hydroxyl group 
with a propyl residue in compound 72 unexpectedly led to an increase in activity yielding an IC50 
value of 1.62 µM. There might be species differences between rat and human P2X3 receptors and 
the direct comparison may be not be accurate, since previous studies were performed at the rat 
P2X3 receptor but we can conclude that the propyl ether substitution at that position might be 
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profitable. Concerning the alcoholic functionality, the removal of this hydroxyl group via 
cyclization (73) abolished activity. Methyl ether 73 was less potent than bisphenol (74, Table 
3.19, structure B).  
Table 3.19. Inhibitory potencies of carbinol derivative 71, its propyl derivative 72, cyclized form 
of carbinol 73 and its hydroxylated derivative 74 
  
Cmpd R 
IC50 ± SEM (µM) 
(% inhibition at 10 
µM) 
Cmpd R
1
 
IC50 ± SEM (µM) 
(% inhibition at 10 
µM) 
Structure A Structure B  
71 H ≥10 (44 ± 7) 73 CH3 
 
≥10 (52 ± 7) 
 
72  
1.62 ± 0.61 
(75 ± 8)* 
74 H 
4.53 ± 1.13 
(78 ± 13)* 
*Maximal inhibition observed.  
There seems to be a negative effect due to by the presence of an alcoholic hydroxyl group instead 
of a hydrogen atom on the central carbon. We noticed an improvement upon replacing it with a 
propyl ether group. 
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3.3.2.1.4. Effects of simplification of the lead structure (46)  
5.2.1.1.2 3.3.2.1.4.1. Replacement or removal of the pyridine ring  
Replacement of the pyridine ring by a phenol moiety in case of the commercially available 
compound 103 (tris-(4-hydroxyphenyl)methane) resulted in a loss of the activity. The attempt to 
completely remove the pyridine ring in (79), resulted in a 3-fold decrease in the activity 
compared to the compound with the pyridine ring (46). Introduction of propyl ether residues 
instead of the di-hydroxyl groups of 79 (80, Table 3.20) had no change in the activity compared 
to compound 79. Surprisingly, the introduction of a hydrophobic butyl group in case of 81, which 
increases the lipophilicity, had a positive impact on the inhibitory activity with a 5-fold increase 
in the potency, resulting in an IC50 value of 0.493 µM in comparison with (57, Table 3.16, IC50= 
2.72 µM). This compound is equipotent to 46 (IC50= 0.421 µM). 
Initially, we were aiming to form the xanthone scaffold in order to see the effect of the 
molecule’s planarity on its activity. Commercially available compound 104 was completely 
inactive. Unfortunately, the xanthone compound 87 did not show any significant activity, with 
only 22% inhibition at 10 µM. We then removed the carbonyl group by reduction, thus obtaining 
the xanthene compound 88. However, the activity of the compound was not determined because 
the compound interfered with the dye used for biological testing. Interestingly, changing the 
hydroxyl groups of xanthene 88 with propyl residues 90, had no pronounced effect on the 
inhibitory activity. Surprisingly, the propyl derivative of the xanthone (89) was found to be the 
most potent compound of the present series, with an IC50 value of 0.121 µM on the human P2X3 
receptor. The presence of a carbonyl group on the xanthone resulted in a higher potency (34-fold) 
in comparison to 90. Compound 89 was found to be 3-fold more potent than the hit compound 
46. This result demonstrates that the pyridine ring can be replaced by a carbonyl group in the 
presence of hydrophobic groups such as propyl which may interact through hydrophobic 
interactions. 
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Table 3.20. Inhibitory potencies of selected compounds related to bisacodyl on the human P2X3 
receptor 
*Maximal inhibition observed.  
3.3.2.1.5. Miscellaneous modifications  
The diaminopyrimidine class of compounds comprises a lot of potent P2X3 antagonists such as 
Gefapixant (II, Table 3.21), which has been evaluated in a phase II clinical trial and the result 
was positive in patients with chronic refractory cough. In our case, the introduction of a 
diaminopyrimidine moiety (91) did not result in any inhibitory activity. The positions of the 
amino groups may be inadequate.  
  
Cmpd R 
IC50 ± SEM (µM) 
(% inhibition at 
10 µM) 
Cmpd R
1
 X 
IC50 ± SEM (µM) 
(% inhibition at 
10 µM) 
103 
See structure 
above 
>>10 (10 ± 5) 104 
See structure 
above 
 >>10 (-13 ± 4) 
Structure A Structure B 
79 H 
1.26 ± 0.11 
(75 ± 8)* 
87 H COCH2 >>10 (22 ± 12) 
80  
1.10 ± 0.36 
(73 ± 3)* 
88 H CH2 
Interferes with the 
experiment 
81  
0.493 ± 0.115 
(71 ± 9)* 
89  COCH2 
0.121 ± 0.012 
(74 ± 6)* 
 90  CH2 
4.11 ± 0.87 
(92 ± 4)* 
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Then, we tried to explore structures with an indole moiety. Replacement of the bis-phenol 
moieties by symmetrical 5-methoxy indoles (92) or the corresponding hydroxyl derivative (93, 
Table 3.21, structure A), had a negative impact on the inhibitory activity.  
We decided to explore structures with bis-oxadiazole moieties on the phenyl ring. Compound 97 
and 98 were inactive at 10 µM. The introduction of a benzyl group in 99 showed a slight increase 
in the potency with an IC50 value in the micromolar range (Table 3.21, structure B). 
Table 3.21. Inhibitory potencies of compounds 91-93 and compounds 97-99 
 
Cmpd R 
IC50 ± SEM (µM) 
(% inhibition at 10 
µM) 
Cmpd R 
IC50 ± SEM (µM) 
(% inhibition at 10 µM) 
Structure A Structure B 
91 
See structure 
above 
>>10 (12 ± 7) 97 CH3 >10 (37 ± 10) 
92 CH3 >>10 (27 ± 7) 98 H >10 (21± 3) 
93 H >>10 (21 ± 9) 99 
 
5.44 ± 1.12 
(96 ± 5)* 
*Maximal inhibition observed.  
For further confirmation of our data, different concentrations of bisacodyl, compounds 46, 81 and 
89 were tested for inhibition of ATP-induced calcium influx in 1321N1 astrocytoma cells stably 
transfected with the human P2X3 receptor. We found that all compound attenuated ATP-induced 
calcium influx in a dose-dependent manner. Notably, higher concentrations of compounds 81 and 
89 almost completely inhibited ATP-induced calcium influx (Figure 3.11). 
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Figure 3.11. Concentration-inhibition curves of the most potent bisacodyl-derived compounds on 
the human P2X3 receptor.  
Detailed structure-activity relationships of selected bisacodyl-derived compounds are 
summarized in Figure 3.12 and Figure 3.13. These findings might help in the development of 
new potent and selective compounds for the human P2X3 receptor to fully understand their 
structure-activity relationships. 
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Figure 3.12. Structure-activity relationships of selected bisacodyl-derived compounds (46, 48-56, 
57-66, 71 and 72) on the human P2X3 receptor. 
 
Figure 3.13. Structure-activity relationships of selected bisacodyl-derived compounds (80, 81, 
and 87-90) on the human P2X3 receptor. 
3.3.2.2. Pharmacophore model 
In order to understand and rationalize important structural features of human P2X3 receptor 
antagonists, we generated a pharmacophore model based on a very potent compound which 
possesses a 4-oxo-quinazoline as a central ring, namely N-(4-(3-(2,5-dimethoxyphenethyl)-4-
oxo-3,4-dihydroquinazolin-6-yl)-3-methoxyphenyl)acetamide showing an IC50 value of 0.005 
µM (Figure 3.14). The pharmacophore model may rationalize the observed structure-activity 
relationships between the potent antagonist and the newly synthesized molecules described in the 
previous section. Furthermore, the model possibly helps to design new potent compounds. 
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3.3.2.2.1. Pharmacophore model features 
The pharmacophore model revealed two hydrophobic pockets, one constituted by the phenyl ring 
which is attached to the quinazoline moiety at the 6-position (F1), and the other hydrophobic 
pocket is represented by the phenyl ring of the quinazolin-4-one moiety (F2). The latter feature 
has to be an aromatic ring. Additionally, a hydrogen bond acceptor, the nitrogen atom (N
1
) of the 
quinazolin-4-one scaffold (F3), was identified as an important pharmacophore feature. The 
pharmacophore features identified from the potent antagonist are shown in Figure 3.14. 
 
Figure 3.14. The pharmacophore features of a very potent P2X3 receptor antagonist described in 
literature.
111
  
In comparison, our lead compound 46 possesses two hydrophobic pockets and two hydroxyl 
groups (Figure 3.15). Among these two hydroxyl groups, only one hydroxyl group acts as a 
hydrogen bond acceptor, which is definitely needed, but the requirement of the second one was 
not confirmed. Based on the pharmacophore model, one of the two hydroxyl groups may be 
matching feature F3. 
To further rationalize the results identified for the synthesized compounds, we mapped these data 
obtained from the pharmacophore model with the determined biological activities. If the hydroxyl 
groups were substituted with shorter chains such as butyl (57, IC50= 2.72 µM) significantly 
decreases the activity, and a longer chain such as octyl (62, IC50 >10 µM) or para-methoybenzyl 
(64, IC50 >>10 µM) abolishes the activity (Table 3.16). However, it was found that substitutions 
with longer length are acceptable and the compounds were active. For example, in compounds 53 
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and 54 one of the hydroxyl groups is substituted with octy1 or para-methoybenzoyl moieties, 
respectively, and the activity was slightly decreased with IC50 values of 1.58 µM and 1.17 µM, 
respectively (Table 3.17). This shows that one of the hydroxyl groups of compound 46 may be 
comparable with the N
1
 of the quinazolin-4-one ring of the potent antagonist and confirms that 
there is a need of a hydrogen bond acceptor at this position. Furthermore, substitution of the 
hydroxyl groups with shorter chains on one side and large hydrophobic groups on the other side 
is also tolerated. For example, compound 69 with propargyl and benzyl substitutions showed an 
IC50 value of 0.645 µM (Table 3.17). 
 
Figure 3.15. The pharmacophore features of compound 46. 
The analysis of the pharmacophore model showed that there is no feature matching with the 
pyridine ring of compound 46. There is no need for that pyridine to keep the activity. This was 
confirmed with compound 89, in which the pyridine ring is replaced with a carbonyl group 
leading to improved activity by 3-fold in comparison to lead structure 46 with an IC50 value of 
0.121 µM for 89. The alignment of the features F1-F3 with compound 89 is shown in Figure 
3.16. However, this has to be confirmed with additional molecules to be synthesized and tested.  
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Figure 3.16. The pharmacophore features of compound 89. 
Finally, we compared the structural features of the potent quinazoline antagonist (Figure 3.14) 
with the best synthesized compound 89 as shown in Figure 3.17. This further confirms that one 
of the hydroxyl groups may be replaced with a shorter alkoxy chain and substituting the pyridine 
ring with a carbonyl group leads to improvement of the activity.  
 
Figure 3.17. Comparison of the potent P2X3 antagonist, a 4-quinozaline derivative (blue) and 
compound 89 (green) showing the pharmacophore model features F1-F3. 
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A summary of the main findings and of the principal issues and suggestions which have arisen in 
this discussion are provided in Figure 3.18. Based on the pharmacophore modelling results, 
bisacodyl core is suggested to have better interactions with the P2X3 receptor. 
 
Figure 3.18. Structure-activity relationships of bisacodyl-derived compounds on the human 
P2X3 receptor. 
Outlook 
Following the pharmacophore model, the synthesis of derivatives of compound 89 with various 
substitutions introducing hydrophobic groups only on one side(on one phenolic group), might 
further improve potency (Figure 3.19). 
The compounds’ selectivity versus the different P2X receptor subtypes will have to be 
determined in future studies. 
 
Figure 3.19. Proposed hydrophobic groups for potential enhancement of P2X3 receptor-blocking 
activity.
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6 4. Summary  
P2X3 receptors are ligand-gated ion channels activated by extracellular ATP. Their activation is 
associated with the pro-nociceptive effects of ATP. P2X3 receptor antagonists are promising 
drugs for the treatment of inflammatory pain. This project has focused on the synthesis of novel 
classes of P2X3 receptor antagonists. 
6.1 4.1. Anthraquinone derivatives  
4.1.1. Synthesis and optimization of 1-amino-4-(aryl)alkylamino-2-methylanthraquinone 
derivatives 
Anthraquinone (AQ) derivatives related to Reactive Blue 2 have previously been described to 
block P2Y as well as P2X receptors. An acidic group in the 2-position (sulfonate or bioisoster) 
was found to be essential for interaction with P2Y receptors, but was expected to potentially be 
less important for inhibition P2X receptors. In order to study AQ derivatives with a non-acidic 
group in the 2-position, we had to optimize the reaction conditions of the Ullmann coupling 
reactions employed to prepare the desired 4-aryl-, alkyl- or arylalkyl-aminouracil derivatives 
(Scheme 4.1). 
Ullmann condensation reactions had previously been successfully applied for amines which are 
liquid in nature (Scheme 4.1, A). In the present study the reaction conditions for employing solid 
amines were carefully optimized. While 1-pentanol was established as the best solvent for AQs 
bearing a bromine atom at the 2-position, methanol was found as the optimal solvent for 
condensation of solid amines with the 2-methyl-substituted AQ derivative, 1-amino-4-bromo-2-
methylanthraquinone (1). It was also suitable for reactions of 2-hydroxymethyl-AQ derivatives 
with the addition of a small percentage of water (2.5% v/v) to initiate the reaction. The use of a 
mixture of copper(0), and copper(II) acetate monohydrate as a catalyst was required for 2-
methyl-substituted AQ derivatives (Scheme 4.1, B). This mixture of catalysts was also superior 
to copper(II) acetate alone which had previously been used in case of 2-bromo- and 2-
hydroxymethyl-AQ derivatives. Our results show that copper-catalyzed reactions are highly 
variable depending on the AQ derivative present in the medium. Yields (21-82% in case of the 
solvent-free synthetic procedure) and reaction rates (30 min to 77 h) in case of the solvent-free 
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synthetic procedure) were highly variable. They also depended on the catalysts and the nature of 
the employed amines. 
 
Scheme 4.1. General scheme for successful Ullmann coupling reactions of 1-amino-4-bromo-2-
methylanthracene-9,10-dione with amines. 
4.1.2. Biological evaluation of the synthesized anthraquinone derivatives 
A series of 24 1-amino-4-(aryl)alkylamino-2-methylanthraquinone derivatives has been 
synthesized and fully characterized, 18 of these being novel derivatives not previously described 
in literature. The synthesized derivatives were biologically assessed on the human P2X3 receptor 
as well as other P2 receptor subtypes.  
While at P2Y receptors the sulfonate group at the 2-position was essential for activity, this was 
not the case for the P2X3 receptor. Compound 22 was the most potent P2X3 antagonist of the 
present series with an IC50 value of 3.07 µM (see Figure 4.1). Interestingly, compound 6 (IC50= 
7.46 µM) which lacks ring E and is not acidic at all anymore was found to display an only 2-fold 
lower potency compared to compound 22 (Figure 4.1). 
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Figure 4.1. Structures of selected anthraquinone derivatives which act as antagonists at the 
human P2X3 receptor. 
Thus, anthraquinone derivatives bearing an uncharged group such as methyl at the 2-position, 
which showed no activity on P2Y receptors, represent new lead structures for optimization as 
P2X3 receptor antagonists. 
6.2 4.2. Bisacodyl-derived compounds 
4.2.1. Synthesis of Bisacodyl-derived compounds 
The prodrug bisacodyl, which is employed as a laxative therapeutic, and its pharmacologically 
active metabolite bis-(p-hydroxyphenyl)pyridyl-2-methane (46), were recently found in our 
laboratory to block P2X3 receptors. The laxative drug 46 was found to be significantly more 
potent than its prodrug bisacodyl. In the present study, structure-activity relationships were 
extensively explored by synthesizing derivatives and analogs of 46.  
To this end the prodrug bisacodyl was hydrolyzed to obtain the bis-phenol 46, which was 
subsequently alkylated to obtain a variety of mono- (48-56) and di- (57-66) alkylated derivatives. 
Some of the mono-alkylated compounds were further alkylated to obtain unsymmetrically 
substituted compounds (67-69). In order to study the role of the phenolic OH groups they were 
replaced by bioisosteric fluorine atoms, which can, however, not act as hydrogen bond donors in 
contrast to hydroxy groups (76). 
Moreover, we prepared related hydroxylated triphenylmethane derivative (71). Finally, we 
simplified the structure of 46 by removing the pyridine ring (80, 81, and 83) or by replacing it by 
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a carbonyl function (87 and 89) while maintaining the other features (two phenol rings) (Scheme 
4.2).  
 
Scheme 4.2. Synthetic scheme for some bisacodyl-derived compounds. 
4.2.2. Inhibitory potency of bisacodyl derivatives on the human P2X3 receptor and study of 
structure-activity relationships 
The synthesized bisacodyl derivatives and analogs were investigated as P2X3 receptor 
antagonists by measuring their potency to inhibit ATP-induced calcium influx in 1321N1 
astrocytoma cells stably transfected with the human P2X3 receptor (Figure 4.2). A total of 56 
compounds were synthesized and tested for biological activity, 36 of which are novel 
compounds. The prodrug bisacodyl exhibited P2X3-antagonistic potency with an IC50 value of 
1.59 μM at the human receptor. The biologically active laxative drug 46 that is formed from 
bisacodyl by ester hydrolysis is significantly more potent than the prodrug with an IC50 value of 
0.421 μM at the human P2X3 receptor. An even higher potency had been determined for the rat 
P2X3 receptor (IC50= 0.0194 μM).
195
 Deletion of the pyridine ring led to potent compounds (81 
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and 89). Compound 81 had an IC50 value of 0.493 μM and was nearly equipotent to the lead 
structure 46. The cyclized analog 89, a dibenzo-pyranone derivative was found to be the most 
potent P2X3 receptor antagonist of the present series with an IC50 value of 0.121 μM at the 
human receptor, being 3-fold more potent than the lead structure 46 (see Figure 4.2 and Figure 
4.3).  
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Figure 4.2. Inhibitory potencies of selected bisacodyl-derived compounds 
The structures of most potent compounds within this series are shown in Figure 4.3. 
 
Figure 4.3. Structures of the most potent bisacodyl-derived P2X3 receptor antagonists. 
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In conclusion, the synthesis and structure-activity relationship analysis of bisacodyl-derived 
compounds resulted in potent – presumably allosteric - antagonists for the human P2X3 receptor. 
A pharmacophore model was subsequently developed which provides a basis for further 
improvement. These new P2X3 receptor antagonists represent a promising class of novel 
therapeutics for inflammatory diseases. 
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7 5. Experimental part 
7.1 5.1. General considerations 
All commercially available materials were obtained from different sources (ABCR, Alfa Aesar, 
Acros, Merck, Grüssing, Sigma Aldrich, and Fluka, Germany) and TCI (Belgium) and used as 
received unless otherwise revealed. Solvents used for both extraction and purification purposes 
were of technical grade and some of them were subjected to additional distillation before use.  
Reactions were controlled by thin layer chromatography (TLC) performed on pre-coated 
aluminum-packed silica gel 60 sheets with fluorescent indicator UV254 or pre-coated aluminum-
packed sheets RP silica gel C18 with fluorescent indicator UV254 (Merck, Darmstadt, Germany). 
Silica gel 60 (0.040-0.063 mm, Merck) was used for column chromatography. Flash 
chromatography was performed on a Büchi apparatus using silica gel RP-18 (Macherey-Nagel, 
Germany) or silica gel 60 (0.060-0.200 mm, Acros).  
Compounds were visualized under UV light (254 nm), but the colored compounds were visible at 
daylight. All melting points determined by on a Büchi-545 melting point apparatus were 
uncorrected.
 
Refractive index ( ) was measured on refractometer, Carl Zeiss, Germany. 
Microwave (MW) experiments were conducted with a CEM Focused
TM
 Microwave Synthesis 
type Discover apparatus in 10 mL sealed reaction tubes. Lyophilization of compounds was done 
using a freeze dryer (CHRIST ALPHA 1-4 LSC). 
Mass spectra of isolated compounds were determined on an API 2000 (Applied Biosystems) 
mass spectrometer (turbo ion spray ion source) coupled with an Agilent 1100 HPLC system 
(Agilent, Böblingen, Germany). The following procedure was used: the sample was dissolved at 
a concentration of 1.0 mg/mL in methanol, acetonitrile, water, or a mixture of two of them. 
Sample solution (8 µL) was injected into the HPLC column (Macherey-Nagel EC50/2Nucleodur 
C18 Gravity 3 µm). HPLC was started with 90% water : 10% methanol (containing 2mM 
ammonium acetate). After 1 min, the gradient immediately started at a flow rate of 300 µL/min to 
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reach 100% methanol in 9 min followed by washing with 100% methanol for another 10 min. 
The ultra violet (UV) absorption was detected at 190 to 900 nm using a diode array detector 
(DAD). The purity of the compounds was determined at 200-700 nm and proved to be ≥ 95% 
(except 23-25 and 90).  
1
H- and 
13
C-NMR spectral data were performed at room temperature on either a Bruker AV-500 
MHz spectrometer (
1
H), and 126 MHz (
13
C) or on a Bruker AV-600 MHz spectrometer (
1
H), and 
151 MHz (
13
C). Sample measurement of pure compounds was done using chloroform-d, DMSO-
d6, or acetone-d6, as solvents. Data were expressed as chemical shifts (δ) in parts per million 
(ppm) related to residual deuterated solvent, i.e. chloroform, (
1
H: δ 7.26; 13C: 77.36); DMSO, 
(
1
H: δ 2.49; 13C: 39.7); methanol, (1H: δ3.31, 4.87; 13C: 49.00) and tetramethylsilane (TMS) used 
as internal standard on the δ scale. 1H coupling constants J were given in Hz and multiplicities of 
the spin were given as s (singlet), d (doublet), t (triplet), q (quartet), dd (doublet of doublets), td 
(triplet of doublets), m (multiplet), br (broad) and qt (quartet of triplet). 
High-resolution mass spectral (HRMS) data were recorded on a Q-TOF micro mass spectrometer 
(Bruker) with electrospray ionization (ESI)-source and coupled with an HPLC Dionex Ultimate 
3000 system (Thermo Scientific). The temperature of the HPLC column (Macherey-Nagel 
EC50/2 Nucleodur C18 Gravity 3 µm) was 25 
°
C, and a flow rate of 0.3 mL/min was applied. 
Then, 1 µL of a 0.6 mg/mL from the sample solution in acetonitrile was injected into the 
previously described column and HPLC separation was started with 10% acetonitrile and 90% 
water containing 2 mM ammonium acetate. After 1 min, the gradient was started reaching 100% 
acetonitrile within 9 min and then flushed with the same concentration for another 5 min. With 
these conditions, positive or negative full scan MS were observed from 50-1000 m/z.  
7.2 5.2. Pharmacological Assays 
5.2.1. Evaluating the pharmacological actions of the compounds at human P2Y4 receptors  
The whole set of experiments were conducted by Dr. Muhammad Rafehi (Pharmaceutical 
Institute, University of Bonn) on P2Y4-R-expressing 1321N1 human brain astrocytma cells. Prior 
to the assays, the 1321N1 human astrocytoma cells were transfected with a plasmid encoding the 
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sequence for the human P2Y4 receptors according to the procedure described previously
241
 and 
monoclones selected. The cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) 
completed with 10% fetal calf serum (FCS), 1% of a penicillin/streptomycin, and 200 µg/mL of 
Geneticin in T175 culture flasks (175 cm
2
 surface area). The DMEM and other supplements were 
provided by Invitrogen (Life Technologies GmbH, Darmstadt, Germany). The cells were then 
incubated at 37 
°
C in 10% CO2 humidified air. Cells were maintained in the exponential growth 
phase throughout the experiment and closely monitored for any potential mycoplasma 
contamination. 
Calcium-mobilization assay. This assay was done as previously reported.
72
 Briefly, the DMEM 
medium was removed and cells were gently rinsed with sterile phosphate-buffered saline (PBS) 
and detached by trypsin/ EDTA (0.05%/ 0.6 mM) solution. The cells were then re-suspended in 
complete DMEM and cultured into sterile flat bottom 96-well polystyrene coated microplates 
(Corning
®
 3340) at concentration of 50,000 cells/ well then incubated at 37 
°
C in 10% CO2 
humidified air for 24 hours till cells become adherent to the wells. The compounds were then 
tested for their inhibitory activity on the P2Y4 receptor -mediated intracellular calcium 
mobilization using a FlexStation 3
®
 plate reader (Molecular Devices GmbH, Biberach an der 
Riss, Germany). Briefly, the adherent cells were loaded with fluo-4 acetoxymethyl ester (Life 
Technologies GmbH, Darmstadt, Germany) for 60 minutes. The excess dye was removed and 
Hank’s balanced salt solution (HBSS) buffer was added to the cells. The cells were pre-incubated 
with the test compound for 30 min and the physiological ligand uridine 5’-triphosphate was 
injected at a final concentration of 500 nM, which corresponds to its EC80 at a final volume of 
200 µl per well. The produced fluorescence was measured at 525 nm following excitation at 488 
nm. Each experiment was conducted in triplicates using 2 independent sets. The IC50 values were 
calculated by non-linear regression equation using GraphPad Prism
®
 5.0 software (San Diego, 
CA, USA).
242
 Experiments were performed by Dr. Muhammad Rafehi. 
5.2.2. Measurement of Ca
2+
 in transfected 1321N1 astrocytoma cells  
A monoclonal human P2X3 cell line was created and Ca
2+
 measurements on P2X3 were done in 
our group. Human P2X3 receptor function was determined on the basis of agonist-mediated 
increases in cytosolic Ca
2+
 concentration. The calcium 5 assay kit was used as an indicator of the 
relative levels of intracellular Ca
2+
 in a 96-well format using a fluorescence imaging plate reader 
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(Novostar, BMG, Germany). Cells were grown to confluence in 96-well black-walled tissue 
culture plates and loaded calcium 5 dye in Hank’s balanced salt solution (HBSS, containing 10 
mM HEPES, pH 7.3) for 1 h at 37 
°
C. Compound solutions were prepared in DMSO depending. 
The final DMSO concentration in the assays did not exceed 0.5%. Fluorescence intensity was 
measured at 510 nm for 30 s at 0.4 s intervals. Buffer or test compounds were injected 
sequentially into separate wells using the automatic pipetting device. At least three independent 
experiments were performed in duplicate. Antagonists were added 30 min before the addition of 
agonists (agonist concentration ~ EC80). The assays were performed in a final volume of 200 µl. 
Compounds were tested at 7-8 different concentrations spanning three orders of magnitude of 
concentrations. Experiments were performed by Dr. Aliaa Abdelrahman. 
7.3 5.3. Pharmacophore modelling 
Based on the conformations for each compound, LigandScout 4.1 was used to construct possible 
pharmacophore models.
243
 For this, approximately 200 conformations were generated by iCon 
with the best settings option for compounds belong to the training set.
244
 Ten pharmacophore 
models were generated with different scores using LigandScout4.1 package which showed 
different feature patterns and pharmacophore-fit values of each compound. The pharmacophore 
model with the highest score was considered as the best model. In a shared feature 
pharmacophore model generation, LigandScout generates pharmacophore models from the 
chemical functionalities of the training compounds and aligns the molecules according to their 
pharmacophores.
245
 The features present in all the training molecules are further considered for 
model building. The shared pharmacophore features are created and assembled together 
comprising the final pharmacophore model to get the best alignment. These pharmacophore 
models contain only the chemical features present in all the training molecules. The number of 
frequent chemical features decreases by increasing the number of the training molecules, 
particularly when diverse structures are used. In our current study with the known P2X3 
antagonists and newly synthesized compounds, we started with a large number of training sets 
and finally find the best model with two molecules. The shared feature pharmacophore 
generation uses these values to determine which molecules should be considered when building 
the pharmacophore space and which molecules should map to all or some of the features in the 
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final pharmacophores.
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 We would like to thank Inte:Ligand GmbH for providing the evaluation 
license of LigandScout 4.1. This study was performed by Dr. Vigneshwaran Namasivayam. 
7.4 5.4. Chemistry of anthraquinone derivatives 
5.4.1. General synthetic procedure (I) used for anthraquinone derivatives (2-17) 
To a mixture consisting of 1-amino-4-bromo-2-methylanthracene-9,10-dione (1, 1 equiv.) and 
copper(I) acetate (10 mol%) in the presence of potassium acetate (2.25 equiv.) the corresponding 
amine (15 equiv.) was added. The reaction mixture was heated at 110 
°
C under an argon 
atmosphere, and the progress of the reaction was controlled by TLC. The formed mixture was 
then allowed to cool to room temperature and work-up was done according to procedure A or B 
as described below. 
Work-up procedure A. Using a vacuum pump, the obtained blue precipitate after addition of 1-
5 mL of ethanol was filtered off, washed successively with ethanol, 0.1 M HCl, and water (ca. 5-
25 mL each) and then dried at 70 
°
C in an oven overnight. Purification of the crude product was 
done using column chromatography on silica gel providing the desired products in high purities. 
For some compounds, the latter step of column chromatography was repeated 2-3 times to gain a 
purity of ≥ 95% as determined by LCMS. 
Work-up procedure B. The reaction mixture was dissolved in ca. 30-50 mL dichloromethane, 
and then washed with ca. 20 mL of conc. HCl whereby a color change from blue to violet was 
clearly observed. Extraction was done using dichloromethane and water (ca. 75-100 mL each), 
upon which the still remaining amine was transferred to the aqueous layer whereas the blue color 
containing the product was transferred to the organic layer. The acid addition and extraction 
process were repeated until the amine was completely transferred into the aqueous layer (as 
monitored by TLC). The organic layers obtained were washed with 30 mL of brine, dried over 
anhydrous MgSO4 and then evaporated under reduced pressure. Column chromatography of the 
crude product on silica gel provided the products in high purities. For some compounds, the 
previous step of column chromatography was repeated 2-3 times to achieve purity of ≥ 95% as 
determined by LCMS. 
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5.4.2. Characterization of 1-amino-4-(aryl)alkylamino-2-methylanthraquinone derivatives 
(2-17) 
1-Amino-2-methyl-4-(phenylamino)anthracene-9,10-dione (2)
64
 
The compound was synthesized according to general 
procedure (I). 1-Amino-4-bromo-2-methylanthracene-9,10-
dione (1) (316.2 mg, 1 mmol, 1 equiv.), copper(I) acetate (13.2 
mg, 10 mol%), potassium acetate (220.5 mg, 2.25 mmol, 2.25 
equiv.) and aniline (1.4 mL, 1400 mg, 15 mmol, 15 equiv.). 
Reaction time: 110 min. Work up procedure A. Purification 
was done by column chromatography on silica gel using cyclohexane/dichloromethane (10:90). 
Appearance: blue powder. Yield: 248 mg (76%); m.p. 251-253 
°
C. Solubility: The compound is 
soluble in acetone, chloroform and DMSO, but insoluble in water. Analytical data: 
1
H-NMR 
(DMSO-d6, 500 MHz) δ (ppm) = 2.26 (s, 3H, CH3); 7.18 (t, J = 7.34 Hz, 1H, 4'-H); 7.31 (d, J = 
7.79 Hz, 2H, 2'-H, 6'-H); 7.41-7.43 (m, 2H, 3'-H, 5'-H); 7.44 (s, 1H, 3-H); 7.81-7.84 (m, 2H, 6-H, 
7-H); 8.25-8.28 (m, 2H, 5-H, 8-H); 12.25 (s, 1H, 4-NH); (1-NH2 not detectable). 
13
C-NMR 
(DMSO, 126 MHz) δ (ppm) = 18.67 (-CH3), 108.07, 109.61 (C-4a, C-9a), 123.17, 124.41, 
124.50 (C-3), 125.99, 126.12 (C-5, C-8), 129.81, 132.81(C-6), 133.01 (C-7), 133.95, 134.10 (C-
8a, C-10a), 137.53 (C-2), 139.38, 142.00 (C-4), 147.21 (C-1), 181.95, 182.02 (C-9, C-10). Purity 
by HPLC-UV (254 nm) ESI-MS: 96%. HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd. for C21H17N2O2 
329.1264, Found 329.1265. 
1-Amino-4-((2-ethylphenyl)amino)-2-methylanthracene-9,10-dione (3) 
The compound was synthesized according to general 
procedure (I). 1-Amino-4-bromo-2-methylanthracene-9,10-
dione (1) (316.2 mg, 1 mmol, 1 equiv.), copper(I) acetate (13.2 
mg, 10 mol%), potassium acetate (220.5 mg, 2.25 mmol, 2.5 
equiv.) and 2-ethylaniline (1.8 mL, 1818 mg, 15 mmol, 15 
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equiv.). Reaction time: 13 h. Work up procedure A. Purification was done by column 
chromatography on silica gel using cyclohexane/dichloromethane (50:50). Appearance: blue 
powder. Yield: 208 mg (58%); m.p. 178-180 
°
C. Solubility: The compound is soluble in acetone, 
dichloromethane and DMSO, but insoluble in water. Analytical data: 
1
H-NMR (Chloroform-d, 
500 MHz) δ (ppm) = 1.25 (t, J = 7.50 Hz, 3H, -CH2-CH3); 2.27 (s, 3H, CH3); 2.72 (q, J = 7.49 
Hz, 2H, -CH2-CH3); 7.11 (s, 1H, 3-H); 7.22 (d, J = 7.77 Hz, 1H, 3'-H); 7.26 (m, 2H, 4'-H, 5'-H); 
7.35 (d, J = 7.27 Hz, 1H, 6'-H); 7.70-7.75 (m, 2H, 6-H, 7-H); 8.34-8.37 (m, 2H, 5-H, 8-H); 12.05 
(s, 1H, 4-NH); (1-NH2 not detectable). 
13
C-NMR (CDCl3, 126 MHz) δ (ppm) = 14.55 (-CH2-
CH3), 18.39 (-CH3), 24.83 (-CH2-CH3), 110.09, 111.55 (C-4a, C-9a), 124.32,125.87, 125.93 (C-
3), 126.25, 129.30, 126.45 (C-5, C-8), 126.65, 129.52, 132.46 (C-6, C-7), 134.17, 134.61 (C-8a, 
C-10a), 136.19 (C-2), 137.14, 139.63, 142.99 (C-4), 144.96 (C-1), 183.01, 184.32 (C-9, C-10). 
Purity by HPLC-UV (220-700 nm): 96%. HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd. for 
C23H21N2O2 357.1598, Found 357.1583. 
1-Amino-4-((3-ethylphenyl)amino)-2-methylanthracene-9,10-dione (4) 
The compound was synthesized according to general 
procedure (I). 1-Amino-4-bromo-2-methylanthracene-
9,10-dione (1) (316.2 mg, 1 mmol, 1 equiv.), copper(I) 
acetate (13.2 mg, 10 mol%), potassium acetate (220.5 
mg, 2.25 mmol, 2.25 equiv.) and 3-ethylaniline (1.8 
mL, 1818 mg, 15 mmol, 15 equiv.). Reaction time: 
110 min. Work up procedure A. Purification was done by column chromatography on silica gel 
using cyclohexane/dichloromethane (50:50). Appearance: blue powder. Yield: 293 mg (82%); 
m.p. 229-230 
°
C. Solubility: The compound is soluble in acetone, dichloromethane and DMSO, 
but insoluble in water. Analytical data: 
1
H-NMR (DMSO-d6, 500 MHz) δ (ppm) = 1.21 (t, J = 
7.57 Hz, 3H, -CH2-CH3); 2.25 (s, 3H, CH3); 2.63 (q, J = 7.58 Hz, 2H, -CH2-CH3); 7.03 (d, J = 
7.54 Hz, 1H, 2'-H); 7.10-7.16 (m, 2H, 4'-H, 5'-H); 7.32 (d, J = 7.66 Hz, 1H, 6'-H); 7.44 (s, 1H, 3-
H); 7.80-7.84 (m, 2H, 6-H, 7-H); 8.25-8.28 (m, 2H, 5-H, 8-H); 12.26 (s, 1H, 4-NH); (1-NH2 not 
detectable). 
13
C-NMR (DMSO, 126 MHz) δ (ppm) = 15.49 (-CH2-CH3), 18.23 (-CH3), 28.17 (-
CH2-CH3), 108.04, 109.47 (C-4a, C-9a), 120.47, 122.64, 124.03 (C-3), 124.60, 125.97, 126.11 
(C-5, C-8), 129.63, 132.78, 132.96 (C-6, C-7), 133.97, 134.10 (C-8a, C-10a), 137.50 (C-2), 
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139.29, 142.16, 145.68 (C-4), 147.18 (C-1), 181.82, 181.98 (C-9, C-10). Purity by HPLC-UV 
(220-650 nm): 98%. HRMS (ESI-TOF) m/z: [M+H]
+
 Calcd. for C23H21N2O2 357.1598, Found 
357.1582. 
1-Amino-4-((4-ethylphenyl)amino)-2-methylanthracene-9,10-dione (5) 
The compound was synthesized according to general 
procedure (I). 1-Amino-4-bromo-2-methylanthracene-
9,10-dione (1) (316.2 mg, 1 mmol, 1 equiv.), copper(I) 
acetate (13.2 mg, 10 mol%), potassium acetate (220.5 
mg, 2.25 mmol, 2.25 equiv.) and 4-ethylaniline (1.8 mL, 
1818 mg, 15 mmol, 15 equiv.). Reaction time: 30 min. 
Work up procedure A. Purification was done by 
column chromatography on silica gel using cyclohexane/dichloromethane (30:70). Appearance: 
blue powder. Yield: 262 mg (74%); m.p. 230-232 
°
C. Solubility: The compound is soluble in 
acetone, dichloromethane and DMSO, but insoluble in water. Analytical data: 
1
H-NMR 
(Chloroform-d, 600 MHz) δ (ppm) = 1.28 (t, J = 7.62 Hz, 3H, -CH2-CH3); 2.23 (s, 3H, CH3); 
2.68 (q, J = 7.62 Hz, 2H, -CH2-CH3); 7.18 (d, J = 8.28 Hz, 2H, 2'-H, 6'-H); 7.23 (d, J = 8.21 Hz, 
2H, 3'-H, 5'-H); 7.36 (s, 1H, 3-H); 7.70-7.73 (m, 2H, 6-H, 7-H); 8.33-8.35 (m, 2H, 5-H, 8-H); 
12.14 (s, 1H, 4-NH); (1-NH2 not detectable). 
13
C-NMR (CDCl3, 151 MHz) δ (ppm) = 15.54 (-
CH2-CH3), 18.21 (-CH3), 28.36 (-CH2-CH3),110,23 110.33 (C-4a, C-9a), 124.27, 124.56, 126.18 
(C-3), 126.36, 128.86 (C-5, C-8), 132.49, 132.34 (C-6, C-7), 134.39, 134.69 (C-8a, C-10a), 
135.31 (C-2), 137.23, 140.84, 143.68 (C-4), 145.23 (C-1), 182.87, 183.95 (C-9, C-10). Purity by 
HPLC-UV (220-700 nm): 96%. HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd. for C23H21N2O2 
357.1598, Found 357.1573. 
1-Amino-2-methyl-4-(o-tolylamino)anthracene-9,10-dione (6) 
The compound was synthesized according to general 
procedure (I). 1-Amino-4-bromo-2-methylanthracene-
9,10-dione (1) (316.2 mg, 1 mmol, 1 equiv.), copper(I) 
acetate (13.2 mg, 10 mol%), potassium acetate (220.5 mg, 
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2.25 mmol, 2.5 equiv.) and o-toluidine (1.6 mL, 1607 mg, 15 mmol, 15 equiv.). Reaction time: 
150 min. Work up procedure A. Purification was done by column chromatography on silica gel 
using cyclohexane/dichloromethane (20:80). Appearance: blue powder. Yield: 150 mg (44%); 
m.p. 207-209 
°
C. Solubility: The compound is soluble in acetone, ethanol and DMSO, but 
insoluble in water. Analytical data: 
1
H-NMR (Chloroform-d, 600 MHz) δ (ppm) = 2.20 (s, 
3H, 2-CH3); 2.33 (s, 3H, 2'-CH3); 7.10-7.14 (m, 2H, 3'-H, 6'-H); 7.21-7.25 (m, 2H, 4'-H, 5'-H); 
7.29 (d, J = 7.48 Hz, 3-H); 7.69-7.71 (m, 2H, 6-H, 7-H); 8.33-8.35 (m, 2H, 5-H, 8-H); 12.02 (s, 
1H, 4-NH); (1-NH2 not detectable). 
13
C-NMR (CDCl3, 151 MHz) δ (ppm) = 18.18 (2-CH3, 2′-
CH3), 110.14, 110.31 (C-4a, C-9a), 124.47 (C-3), 125.24, 125.35, 126.18, 126.37, 126.67 (C-5, 
C-8),131.18 (C-2), 132.37, 132.48 (C-8a, C-10a), 134.43, 134.68 (C-6, C-7), 135.43, 138.24, 
143.99 (C-4), 150.52 (C-1), 183.04, 182.98 (C-9, C-10). Purity by HPLC-UV (220-700 nm): 
95%. HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd. for C22H19N2O2 343.1441, Found 343.1421. 
1-Amino-4-((2-chlorophenyl)amino)-2-methylanthracene-9,10-dione (7) 
The compound was synthesized according to general procedure 
(I). 1-Amino-4-bromo-2-methylanthracene-9,10-dione (1) 
(316.2 mg, 1 mmol, 1 equiv.), copper(I) acetate (13.2 mg, 10 
mol%), potassium acetate (220.5 mg, 2.25 mmol, 2.25 equiv.) 
and 2-chloroaniline (1.6 mL, 1913 mg, 15 mmol, 15 equiv.). 
Reaction time: 77 h. Work up procedure A. Purification was 
done by column chromatography on silica gel using 
cyclohexane/dichloromethane (30:70) and then purified by HPLC. Appearance: blue powder. 
Yield: 83 mg (21%); m.p. 188-189 
°
C. Solubility: The compound is soluble in acetone, 
dichloromethane, DMSO, but insoluble in water. Analytical data: 
1
H-NMR (DMSO-d6, 500 
MHz) δ (ppm) = 2.26 (s, 3H, CH3); 7.15-7.19 (m, 7.73 Hz, 1H, 4'-H); 7.39 (s, 1H, 3-H); 7.37 
(dd, J = 1.27, 7.94 Hz, 1H, 6'-H); 7.52 (dd, J = 1.50, 8.15 Hz, 1H, 5'-H ); 7.60 (dd, J = 1.49, 8.10 
Hz, 1H, 3'-H); 7.81-7.87 (m, 2H, 6-H, 7-H); 8.25-8.28 (m, 2H, 5-H, 8-H); 12.16 (s, 1H, 4-NH); 
(1-NH2 not detectable). 
13
C-NMR (DMSO, 126 MHz) δ (ppm) = 18.60 (-CH3), 108.28, 110.93 
(C-4a, C-9a),123.72 (C-3), 124.79, 125.15, 126.13 (C-5), 126.16 (C-8), 128.28, 130.34,132.69 
(C6), 132.95 (C7), 133.34, 134.76 (C-8a, C-10a), 134.12 (C-2), 136.81, 137.30, 140.34 (C-4), 
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147.42 (C-1), 182.27, 182.83 (C-9, C-10). Purity by HPLC-UV (254 nm): 95%. HRMS (ESI-
TOF) m/z: [M+H]
+ 
Calcd. for C21H16ClN2O2 363.0895, Found 363.0860. 
 
 
1-Amino-4-((3-chlorophenyl)amino)-2-methylanthracene-9,10-dione (8) 
The compound was synthesized according to general 
procedure (I). 1-Amino-4-bromo-2-methylanthracene-9,10-
dione (1) (316.2 mg, 1 mmol, 1 equiv.), copper(I) acetate (13.2 
mg, 10 mol%), potassium acetate (220.5 mg, 2.25 mmol, 2.25 
equiv.) and 3-chloroaniline (1.6 mL, 1913 mg, 15 mmol, 15 
equiv.). Reaction time: 18 h. Work up procedure A. 
Purification was done by column chromatography on silica gel 
using cyclohexane/dichloromethane (30:70). Appearance: blue powder. Yield: 240 mg (66%); 
m.p. 280-281 
°
C. Solubility: The compound is soluble in acetone, dichloromethane and DMSO, 
but insoluble in water. Analytical data: 
1
H-NMR (DMSO-d6, 500 MHz) δ (ppm) = 2.28 (s, 3H, 
CH3); 7.17-7.19 (m, 1H, 5'-H); 7.27 (dd, J = 2.07, 7.95 Hz, 1H, 2'-H); 7.37 (t, J = 2.14 Hz, 1H, 6'-
H); 7.41 (t, J = 8.03 Hz, 1H, 4'-H); 7.48 (s, 1H, 3-H); 7.83-7.86 (m, 2H, 6-H, 7-H); 8.24-8.28 (m, 
2H, 5-H, 8-H); 12.03 (s, 1H, 4-NH); (1-NH2 not detectable). 
13
C-NMR (DMSO-d6, 126 MHz) δ 
(ppm) = 18.62 (-CH3), 108.24, 110.54 (C-4a, C-9a), 121.06, 122.12, 123.66 (C-3), 124.97, 
126.06, 126.17 (C-5, C-8), 131.24, 132.96 (C-2), 133.30, 133.80 (C-8a, C-10a), 134.09, 134.11, 
(C-6, C-7), 137.38, 140.64, 141.52 (C-4), 147.52 (C-1), 182.25, 182.60 (C-9, C-10). Purity by 
HPLC-UV (200-650 nm): 97%. HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd. for C21H16ClN2O2 
363.0895, Found 363.0832. 
1-Amino-4-((4-chlorophenyl)amino)-2-
methylanthracene-9,10-dione (9) 
The compound was synthesized according to general 
procedure (I). 1-Amino-4-bromo-2-methylanthracene-
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9,10-dione (1) (316.2 mg, 1 mmol, 1 equiv.), copper(I) acetate (13.2 mg, 10 mol%), potassium 
acetate (220.5 mg, 2.25 mmol, 2.25 equiv.) and 4-chloroaniline (1.6 mL, 1913 mg, 15 mmol, 15 
equiv.). Reaction time: 18 h. Work up procedure A. Purification was done by column 
chromatography on silica gel using cyclohexane/dichloromethane (30:70). Appearance: blue 
powder. Yield: 260 mg (72%); m.p. 293-294 
°
C. Solubility: The compound is soluble in acetone, 
dichloromethane and DMSO, but insoluble in water. Analytical data: 
1
H-NMR (DMSO-d6, 500 
MHz) δ (ppm) = 2.30 (s, 3H, CH3); 7.32-7.34 (m, 2H, 2'-H, 6'-H); 7.44-7.47 (m, 3H, 3'-H, 5'-H, 
3-H); 7.80-7.85 (m, 2H, 6-H, 7-H); 8.24-8.27 (m, 2H, 5-H, 8-H); 12.15 (s, 1H, 4-NH); (1-NH2 
not detectable). 
13
C-NMR (DMSO-d6, 126 MHz) δ (ppm) = 18.62 (-CH3), 108.24, 110.54 (C-
4a, C-9a), 124.57 (C-3), 124.62, 127.96, 129.63, 126.02 (C-5), 126.15 (C-8), 132.85, 132.89 (C-
8a, C-10a), 133.18 (C-2), 133.85, 134.10 (C-6, C-7), 137.51, 138.61, 141.29 (C-4), 147.33 (C-1), 
182.14, 182.30 (C-9, C-10). Purity by HPLC-UV (220-650 nm): 98%. HRMS (ESI-TOF) m/z: 
[M+H]
+ 
Calcd. for C21H16ClN2O2 363.0895, Found 363.0841. 
1-Amino-4-((2-methoxyphenyl)amino)-2-methylanthracene-9,10-dione (10) 
The compound was synthesized according to general 
procedure (I). 1-Amino-4-bromo-2-methylanthracene-9,10-
dione (1) (316.2 mg, 1 mmol, 1 equiv.), copper(I) acetate 
(13.2 mg, 10 mol%), potassium acetate (220.5 mg, 2.25 
mmol, 2.25 equiv.) and 2-methoxyaniline (1.7 mL, 1847 
mg, 15 mmol, 15 equiv.). Reaction time: 160 min. Work 
up procedure A. Purification was done by column 
chromatography on silica gel using cyclohexane/dichloromethane (10:90). Appearance: blue 
powder. Yield: 235 mg (66%); m.p. 170-172 
°
C. Solubility: The compound is soluble in acetone, 
dichloromethane and DMSO, but insoluble in water. Analytical data: 
1
H-NMR (Chloroform-d, 
600 MHz) δ (ppm) = 2.24 (s, 3H, CH3); 3.91 (s, 3H, -OCH3); 6.97 (dd, J = 1.34, 7.60 Hz, 1H, 6'-
H); 6.99-7.00 (m, 1H, 5'-H); 7.12-7.15 (m, 1H, 4'-H); 7.33 (dd, J = 1.58, 7.69 Hz, 1H, 3'-H); 7.39 
(s, 1H, 3-H); 7.69-7.73 (m, 2H, 6-H, 7-H); 8.33-8.37 (m, 2H, 5-H, 8-H); 11.97 (s, 1H, 4-NH); (1-
NH2 not detectable). 
13
C-NMR (CDCl3, 151 MHz) δ (ppm) = 18.30 (-CH3), 55.79 (-OCH3), 
110.81, 111.06 (C-4a, C-9a), 111.51, 120.59, 123.26 (C-3), 124.84, 124.92, 126.28, 126.33 (C-5, 
C-8), 128.75 (C-2), 132.38, 132.56 (C-6, C-7), 134.27, 134.66 (C-8a, C-10a); 135.14, 142.76, 
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144.67 (C-4), 152.49 (C-1), 183.03, 184.12 (C-9, C-10). Purity by HPLC-UV (220-400 nm): 
96%. HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd. for C22H19N2O3 359.1390, Found 359.1377. 
 
 
1-Amino-4-((3-methoxyphenyl)amino)-2-methylanthracene-9,10-dione (11)
240
 
The compound was synthesized according to general 
procedure (I). 1-Amino-4-bromo-2-
methylanthracene-9,10-dione (1) (316.2 mg, 1 mmol, 
1 equiv.), copper(I) acetate (13.2 mg, 10 mol%), 
potassium acetate (220.5 mg, 2.25 mmol, 2.5 equiv.) 
and 3-methoxyaniline (1.7 mL, 1847 mg, 15 mmol, 
15 equiv.). Reaction time: 150 min. Work up 
procedure A. Purification was done by column chromatography on silica gel using 
cyclohexane/dichloromethane (25:75). Appearance: blue powder. Yield: 281 mg (78%); m.p. 
231-233 
°
C. Solubility: The compound is soluble in acetone, dichloromethane and DMSO, but 
insoluble in water. Analytical data: 
1
H-NMR (Chloroform-d, 500 MHz) δ (ppm) = 2.26 (s, 
3H, CH3); 3.78 (s, 3H, -OCH3); 6.75 (d, J = 8.10 Hz, 1H, 2'-H); 6.86-6.89 (m, 2H, 4'-H, 6'-H); 
7.32 (t, J = 7.97 Hz, 1H, 5'-H); 7.48 (s, 1H, 3-H); 7.81-7.83 (m, 2H, 6-H, 7-H); 8.24-8.27 (m, 2H, 
5-H, 8-H); 12.19 (s, 1H, 4-NH); (1-NH2 not detectable). 
13
C-NMR (CDCl3, 126 MHz) δ (ppm) 
= 18.64 (-CH3), 55.33 (-OCH3), 108.07, 108.51 (C-4a, C-9a), 109.76, 110.23, 115.19, 124.83 (C-
3), 125.98, 126.10 (C-5, C-8), 130.48 (C-2), 132.80, 133.02 (C-6, C-7), 133.91, 134.09 (C-8a, C-
10a), 137.42, 140.68, 141.77, 147.22 (C-4), 160.50 (C-1), 182.00, 182.02 (C-9, C-10). Purity by 
HPLC-UV (200-650 nm): 95%. HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd. for C22H19N2O3 
359.1390, Found 359.1385. 
1-Amino-4-((4-methoxyphenyl)amino)-2-methylanthracene-9,10-dione (12) 
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The compound was synthesized according to general 
procedure (I). 1-Amino-4-bromo-2-methylanthracene-
9,10-dione (1) (316.2 mg, 1 mmol, 1 equiv.), copper(I) 
acetate (13.2 mg, 10 mol%), potassium acetate (220.5 mg, 
2.25 mmol, 2.25 equiv.) and 4-methoxyaniline(1.7 mL, 
1847 mg, 15 mmol, 15 equiv.). Reaction time: 120 min. 
Work up procedure B. Purification was done by column 
chromatography on silica gel using cyclohexane/dichloromethane (15:85). Appearance: blue 
powder. Yield: 175 mg (49%); m.p. 217-219 
°
C. Solubility: The compound is soluble in acetone, 
dichloromethane and DMSO, but insoluble in water. Analytical data: 
1
H-NMR (Chloroform-d, 
600 MHz) δ (ppm) = 2.24 (s, 3H, CH3); 3.85 (s, 3H, -OCH3); 6.95 (d, J = 8.93 Hz, 2H, 3'-H, 5'-
H); 7.19 (d, J = 8.88 Hz, 3H, 2'-H, 6'-H, 3-H); 7.69-7.73 (m, 2H, 6-H, 7-H); 8.34-8.35 (m, 2H, 5-
H, 8-H); 12.06 (s, 1H, 4-NH); (1-NH2 not detectable). 
13
C-NMR (CDCl3, 151 MHz) δ (ppm) = 
18.24 (-CH3), 55.73 (-OCH3), 109.78, 110.43 (C-4a, C-9a), 114.77, 124.27 (C-3), 126.13, 132.25, 
126.35, 126.47 (C-5, C-8), 132.28, 132.36 (C-6, C-7), 132.50 (C-2), 134.34, 134.56 (C-8a, C-
10a), 134.56, 135.58, 144.65 (C-4), 157.25 (C-1), 182.69, 183.97 (C-9, C-10). Purity by HPLC-
UV (220-700 nm): 97%.HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd. for C22H19N2O3 359.1390, 
Found 359.1372. 
1-Amino-4-(benzylamino)-2-methylanthracene-9,10-dione (13) 
The compound was synthesized according to general 
procedure (I). 1-Amino-4-bromo-2-methylanthracene-
9,10-dione (1) (316.2 mg, 1 mmol, 1 equiv.), copper(I) 
acetate (13.2 mg, 10 mol%), potassium acetate (220.5 mg, 
2.25 mmol, 2.5 equiv.) and phenylmethanamine (1.6 mL, 
1607 mg, 15 mmol, 15 equiv.). Reaction time: 110 min. 
Work up procedure B. Purification was done by column 
chromatography on silica gel using cyclohexane/dichloromethane (10:90). Appearance: blue 
powder. Yield: 175 mg (51%); m.p. 215-216 
°
C. Solubility: The compound is soluble in acetone, 
dichloromethane and DMSO, but insoluble in water. Analytical data: 
1
H-NMR (Chloroform-d, 
600 MHz) δ (ppm) = 2.29 (s, 3H, CH3); 4.61 (s, 2H, 4-NHCH2-); 7.10 (s, 1H, 3-H); 7.28-7.40 
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(m, 5H, 2'-H, 3'-H ,4'-H, 5'-H, 6'-H); 7.68-7.73 (m, 2H, 6-H, 7-H); 8.26-8.32 (m, 2H, 5-H, 8-H); 
(1-NH2 not detectable). 
13
C-NMR (CDCl3, 151 MHz) δ (ppm) = 18.69 (CH3), 48.11 (-CH2-), 
111.11, 111.39 (C-4a, C-9a), 123.86, 126.27, 126.45, 127.48, 127.72, 128.88 (C-5, C-8), 130.93 
(C-3), 132.63, 132.80 (C-6, C-7), 134.07, 134.41 (C-8a, C-10a), 136.27 (C-2), 137.28, 143.72 (C-
4), 144.07 (C-1), 183.21, 184.34 (C-9, C-10). Purity by HPLC-UV (220-650 nm): 97%. HRMS 
(ESI-TOF) m/z: [M+H]
+ 
Calcd. for C22H19N2O2 343.1441, Found 343.1431. 
 
  
1-Amino-4-((2-chlorophenethyl)amino)-2-methylanthracene-9,10-dione (14) 
The compound was synthesized according to general 
procedure (I). 1-Amino-4-bromo-2-methylanthracene-
9,10-dione (1) (316.2 mg, 1 mmol, 1 equiv.), copper(I) 
acetate (13.2 mg, 10 mol%), potassium acetate (220.5 mg, 
2.25 mmol, 2.25 equiv.) and 2-(2-
chlorophenyl)ethanamine (2 mL, 2334 mg, 15 mmol, 15 
equiv.). Reaction time: 18 h. Work up procedure A. 
Purification was done by column chromatography on silica gel using ethyl acetate/cyclohexane 
(30:70). Appearance: blue powder. Yield: 220 mg (56%); m.p. 225-226 
°
C. Solubility: The 
compound is soluble in acetone, soluble in DMSO and ethanol, but insoluble in water. Analytical 
data: 
1
H-NMR (DMSO-d6, 500 MHz) δ (ppm) = 2.31 (s, 3H, CH3); 3.11 (t, J = 7.32 Hz, 2H, -
NHCH2-CH2-Ph); 3.71 (m, 2H, -NHCH2-CH2-Ph); 7.28-7.32 (m, 2H, 3'-H, 4'-H); 7.35 (s, 1H, 3-
H); 7.46-7.49 (m, 2H, 5'-H, 6'-H); 7.78-7.81 (m, 2H, 6-H, 7-H); 8.24-8.27 (m, 2H, 5-H, 8-H); 
10.87 (s, 1H, 4-NH); (1-NH2 not detectable). 
13
C-NMR (DMSO, 126 MHz) δ (ppm) = 19.38 (-
CH3), 35.73 (-CH2-CH2-), 44.77 (-CH2-CH2-), 108.08, 108.81 (C-4a, C-9a), 123.97, 126.49, 
126.69 (C-3), 128.21, 129.30, 130.14 (C-5, C-8), 132.25, 132.99, 133.24 (C-6, C-7), 134.06, 
134.69 (C-8a, C-10a), 135.08 (C-2), 137.19, 138.77, 146.68 (C-4), 147.00 (C-1), 180.97, 182.52 
(C-9, C-10). Purity by HPLC-UV (200-700 nm): 97%. HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd. 
for C23H20ClN2O2 391.1208, Found 391.1192. 
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1-Amino-4-((3-chlorophenethyl)amino)-2methylanthracene-9,10-dione (15) 
The compound was synthesized according to general 
procedure (I). 1-Amino-4-bromo-2-methylanthracene-
9,10-dione (1) (316.2 mg, 1 mmol, 1 equiv.), copper(I) 
acetate (13.2 mg, 10 mol%), potassium acetate (220.5 
mg, 2.25 mmol, 2.25 equiv.) and 2-(3-
chlorophenyl)ethanamine (2 mL, 2334 mg, 15 mmol, 15 
equiv.). Reaction time: 80 min. Work up procedure A. 
Purification was done by column chromatography on silica gel using 
cyclohexane/dichloromethane (10:90). Appearance: blue powder. Yield: 215 mg (55%); m.p. 
192-194 
°
C. Solubility: The compound is soluble in acetone, dichloromethane and DMSO, but 
insoluble in water. Analytical data: 
1
H-NMR (Chloroform-d, 600 MHz) δ (ppm) = 2.25 (s, 
3H, CH3); 3.02 (t, J = 7.11 Hz, 2H, -NHCH2-CH2-Ph); 3.57 (t, J = 7.15 Hz, 2H, -NHCH2-CH2-
Ph); 6.96 (s, 1H, 2'-H); 7.16 (d, J = 7.02 Hz, 1H, 6'-H); 7.21 (m, 1H, 5'-H); 7.24 (d, J = 5.06 Hz, 
1H, 4'-H); 7.26 (s, 1H, 3-H); 7.67-7.71 (m, 2H, 6-H, 7-H); 8.29-8.32 (m, 2H, 5-H, 8-H), (4-NH 
and 1-NH2 not detectable). 
13
C-NMR (CDCl3, 151 MHz) δ (ppm) = 18.46 (CH3), 35.73 (-CH2-
CH2-), 44.77 (-CH2-CH2-), 109.68, 110.54 (C-4a, C-9a), 122.72, 126.09, 126.28 (C-3), 126.86, 
127.08, 128.87 (C-5, C-8), 129.89, 132.18, 132.46 (C-6, C-7), 134.19, 134.41 (C-8a, C-10a), 
134.68 (C-2), 135.93, 140.74, 144.38 (C-4), 145.15 (C-1), 182.50, 184.01 (C-9, C-10). Purity by 
HPLC-UV (200-650 nm): 98%. HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd. for C23H20ClN2O2 
391.1208, Found 391.1191.  
1-Amino-4-((4-chlorophenethyl)amino)-2-methylanthracene-9,10-dione (16) 
The compound was synthesized according to 
general procedure (I). 1-Amino-4-bromo-2-
methylanthracene-9,10-dione (1) (316.2 mg, 1 
mmol, 1 equiv.), copper(I) acetate (13.2 mg, 10 
mol%), potassium acetate (220.5 mg, 2.25 mmol, 
2.25 equiv.) and 2-(4-chlorophenyl)ethanamine (2 
mL, 2334 mg, 15 mmol, 15 equiv.). Reaction 
time: 120 min. Work up procedure A. Purification was done by column chromatography on 
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silica gel using ethyl acetate/cyclohexane (30:70). Appearance: blue powder. Yield: 271 mg 
(69%); m.p. 224-225 
°
C. Solubility: The compound is soluble in acetone, dichloromethane and 
DMSO, but insoluble in water. Analytical data: 
1
H-NMR (Chloroform-d, 600 MHz) δ (ppm) 
= 2.29 (s, 3H, CH3); 2.96 (t, J = 7.13 Hz, 2H, -NHCH2-CH2-Ph); 3.67 (q, J = 6.73 Hz, 2H, 
NHCH2-CH2-Ph); 7.30 (s, 1H, 3-H); 7.36 (m, 4H, 2'-H, 3'-H, 5'-H, 6'-H); 7.29 (d, J = 7.89 Hz, 
2H, 3'-H, 5'-H); 7.74-7.78 (m, 2H, 6-H, 7-H); 8.19-8.24 (m, 2H, 5-H, 8-H); 10.82 (s, 1H, 4-NH); 
(1-NH2 not detectable). 
13
C-NMR (DMSO, 126 MHz) δ (ppm) = 18.55 (CH3), 34.81 (-CH2-
CH2-), 43.46 (-CH2-CH2-), 107.15, 108.01 (C-4a, C-9a), 123.31; 125.72, 125.90 (C-3), 128.37, 
130.85 (C-5, C-8), 131.09, 132.16 (C-6, C-7), 132.43, 133.92 (C-8a, C-10a), 134.34 (C-2), 
138.03, 138.23, 145.92 (C-4); 146.30 (C-1), 180.11, 181.72 (C-9, C-10). Purity by HPLC-UV 
(200-650 nm): 96%. HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd. for C23H20ClN2O2 391.1208, Found 
391.1195.  
1-Amino-4-((3-fluorophenethyl)amino)-2-methylanthracene-9,10-dione (17) 
The compound was synthesized according to general 
procedure (I). 1-Amino-4-bromo-2-methylanthracene-
9,10-dione (1) (316.2 mg, 1 mmol), copper(I) acetate 
(13.2 mg, 10 mol%), potassium acetate (220.5 mg, 2.25 
mmol, 2.25 equiv.) and 2-(3-fluorophenyl)ethanamine 
(2 mL, 2100 mg, 15 mmol, 15 equiv.). Reaction time: 
75 min. Work up procedure A. Purification was done by column chromatography on silica gel 
using cyclohexane/dichloromethane (10:90). Appearance: blue powder. Yield: 260 mg (70%); 
m.p. 257-258 
°
C. Solubility: The compound is soluble in acetone, dichloromethane and DMSO, 
but insoluble in water. Analytical data: 
1
H-NMR (Chloroform-d, 600 MHz) δ (ppm) = 2.32 (s, 
3H, CH3); 3.11 (t, J = 7.36 Hz, 2H, -NHCH2-CH2-Ph); 3.62 (t, J = 7.39 Hz, 2H, -NHCH2-CH2-
Ph); 6.94-6.97 (m, 1H, 5'-H); 7.00 (d, J = 9.63 Hz, 1H, 2'-H); 7.09 (d, J = 7.48 Hz, 1H, 6'-H); 
7.16 (s, 1H, 3-H); 7.29-7.31 (m, 1H, 4'-H); 7.71-7.72 (m, 2H, 6-H, 7-H); 8.27-8.32 (m, 2H, 5-H, 
8-H); (1-NH2 not detectable). 
13
C-NMR (CDCl3, 151 MHz) δ (ppm) = 18.50 (CH3), 35.35 (-
CH2-CH2-), 45.98 (-CH2-CH2-), 113.65, 113.79 (C-4a, C-9a), 115.61, 115.75, 124.58 (C-3), 
126.28, 128.44 (C-5, C-8), 130.18, 130.23, 132.71, 132.76 (C-6, C-7), 134.14, 134.33 (C-8a, C-
10a), 135.93 (C-2), 140.78, 140.82, 162.19 (C-4), 163.82 (C-1), 183.19, 184.17 (C-9, C-10). 
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Purity by HPLC-UV (200-650 nm): 97%. HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd. for 
C23H20FN2O2 375.1503, Found 375.1494.  
5.4.3. General synthetic procedure (II) used for anthraquinone derivatives (18-25) 
1-Amino-4-bromo-2-methylanthracene-9,10-dione (1), a mixture of copper metal and copper(II) 
acetate monohydrate (5 mol% each) as a catalyst, potassium acetate (5 equiv.), the appropriate 
amine derivative (1.5 or 3 equiv.), and 3.0-4.0 mL of the solvent (methanol, 2.5% v/v) were 
placed into a 10 mL microwave vial equipped with a magnetic stirrer. The reaction mixture vial 
was capped and irradiated in a microwave oven using different conditions until complete reaction 
(as monitored by TLC). The vessel was then allowed to cool to room temperature, the formed 
mixture was dissolved in water (ca. 250 mL) and the aqueous mixture was extracted with 
dichloromethane (3 × 150 mL) until the organic layer became colorless. In cases where a portion 
of the product was dissolved in dichloromethane layer, the combined organic layers were washed 
with 0.1 N NaOH solution until the pH reached ca. 7.5-8. The previous basic washing step was 
repeated until the transfer of the product to the aqueous layer was completed. Using the rotary 
evaporator, the volume of the combined aqueous extracts was then reduced to approximately 20-
100 mL; based on the solubility of each compound in water. After that, purification of the 
solution was achieved by either using normal column chromatography on silica gel or flash 
column chromatography on reversed-phase C-18 material using a gradient of acetone in water at 
concentrations of (5%, 20%, 40%, 60%, and up to 100%) as needed. The collected blue fractions 
containing the product were concentrated in order to reduce the volume of water and remove 
acetone. Finally, the remaining water was removed by lyophilization on a freeze dryer, and the 
desired products were afforded as blue solids. 
5.4.4. Characterization of 1-amino-4-(aryl)alkylamino-2-methylanthraquinone derivatives 
(18-25) 
1-Amino-4-(2-carboxyphenylamino)-2-methylanthracene-9,10-dione (18) 
The compound was synthesized according to general procedure 
(II). 1-Amino-4-bromo-2-methylanthracene-9,10-dione (1) (79 
mg, 0.25 mmol, 1 equiv.), copper(II) acetate monohydrate (2.5 
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mg, 5 mol%), copper metal (ca. 0.8 mg, 5 mol%), potassium acetate (122.5 mg, 1.25 mmol, 5 
equiv.), 2-aminobenzoic acid (103 mg, 0.75 mmol, 3 equiv.), methanol (2.5% v/v, 4.0 mL), MW 
condition: 80 W, 95 
°
C; pressure up to 10 bar. Reaction time: 70 min. Work up. Purification 
was done by flash column chromatography on reversed-phase C18 material using gradient of 
acetone in water 5%, 10%, 20%, then 40%). Appearance: blue powder. Yield: 87 mg (93%); 
m.p. > 300 
°
C. Solubility: The compound is soluble in acetone, ethanol, DMSO and water. 
Analytical data: 
1
H-NMR (DMSO-d6, 500 MHz) δ (ppm) = 2.21 (s, 3H, CH3); 7.02-7.05 (m, 
1H, 4'-H or 5'-H); 7.35 (d, J = 8.11 Hz, 1H, 6'-H); 7.43-7.46 (m, 1H, 4'-H or 5'-H); 7.56 (s, 1H, 3-
H); 7.79-7.85 (m, 2H, 6-H, 7-H); 7.92 (d, J = 7.77 Hz, 1H, 3'-H); 8.20-8.26 (m, 2H, 5-H, 8-H); 
12.43 (s, 1H, 4-NH); (1-NH2 not detectable). 
13
C-NMR (DMSO, 126 MHz) δ (ppm) = 18.59 (-
CH3); 108.95, 112.42 (C-4a, C-9a), 119.86 , 120.95 (C-3), 125.87, 126.26(C-5), 126.96 (C-8), 
128.64, 131.30, 132.55(C-6), 132.60 (C-7), 134.04, 134.38 (C-8a, C-10a), 135.19, 139.15,140.03 
(C-4), 147.33 (C-1),170.24 (-COOH), 180.54, 182.42 (C-9, C-10). Purity by HPLC-UV (200-
700 nm): 99%. HRMS (ESI-TOF) m/z: [M-H]
- 
Calcd. for C22H15N2O4 371.1037, Found 
371.1036. 
1-Amino-4-(3-carboxyphenylamino)-2-methylanthracene-9,10-dione (19) 
The compound was synthesized according to general 
procedure (II). 1-Amino-4-bromo-2-methylanthracene-
9,10-dione (1) (79 mg, 0.25 mmol, 1 equiv.), copper(II) 
acetate monohydrate (2.5 mg, 5 mol%), copper metal (ca. 
0.8 mg, 5 mol %), potassium acetate (122.5 mg, 1.25 
mmol, 5 equiv.), 3-aminobenzoic acid (103 mg, 0.75 
mmol, 3 equiv.), methanol (2.5% v/v, 4.0 mL), MW 
condition: 80 W, 95 
°
C; pressure up to 9.2 bar. Reaction time: 55 min. Work up. Purification 
was done by flash column chromatography on reversed-phase C-18 material using gradient of 
acetone in water 5%, 10%, 20%, then 40%). Appearance: blue powder. Yield: 40 mg (36%); 
m.p. > 300 
°
C. Solubility: The compound is soluble in acetone, ethanol, DMSO and water. 
Analytical data: 
1
H-NMR (DMSO-d6, 500 MHz) δ (ppm) = 2.25 (s, 3H, CH3); 7.22-7.24 (m, 
1H, 5'-H); 7.32 (d, J = 7.62 Hz, 1H, 2'-H); 7.39 (s, 1H, 3-H); 7.69 (d, J = 7.52 Hz, 1H, 4'-H); 7.74 
(d, J = 2.11 Hz, 1H, 6'-H); 7.81-7.83 (m, 2H, 6-H, 7-H); 8.25-8.29 (m, 2H, 5-H, 8-H); 12.32 (s, 
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1H, 4-NH); (1-NH2 not detectable). 
13
C-NMR (DMSO, 126 MHz) δ (ppm) = 18.77 (-CH3), 
108.00, 109.14 (C-4a, C-9a),123.44, 124.17, 124.51(C-3), 125.55; 126.00(C-5), 126.09 (C-8), 
128.44, 132.74(C-6), 132.86 (C-7), 134.06, 134.12 (C-8a, C-10a), 137.51 (C-2), 138.09, 142.78, 
143.28 (C-4), 147.11 (C-1),168.33 (-COOH), 181.60, 181.93 (C-9, C-10). Purity by HPLC-UV 
(220-650 nm): 96%. HRMS (ESI-TOF) m/z: [M-H]
- 
Calcd. for C22H15N2O4 371.1037, Found 
371.1039. 
 
 
 
1-Amino-4-(4-carboxyphenylamino)-2-methylanthracene-9,10-dione (20) 
The compound was synthesized according to general 
procedure (II). 1-Amino-4-bromo-2-methylanthracene-
9,10-dione (1) (79 mg, 0.25 mmol, 1 equiv.), copper(II) 
acetate monohydrate (2.5 mg, 5 mol%), copper metal (ca. 
0.8 mg, 5 mol%), potassium acetate (122.5 mg, 1.25 
mmol, 5 equiv.), 4-aminobenzoic acid (103 mg, 0.75 
mmol, 3 equiv.), methanol (2.5% v/v, 4.0 mL), MW 
condition: 80 W, 95 
°
C; pressure up to 9.2 bar. Reaction time: 65 min. Work up. Purification 
was done by flash column chromatography on reversed-phase C18 material using gradient of 
acetone in water 5%, 10%, 20%, then 40%). Appearance: blue powder. Yield: 45 mg (40%); 
m.p. > 300 
°
C. Solubility: The compound is soluble in acetone, ethanol, DMSO and water. 
Analytical data: 
1
H-NMR (DMSO-d6, 600 MHz) δ (ppm) = 2.29 (s, 3H, CH3); 7.36 (d, J = 8.15 
Hz, 2H, 2'-H, 6'-H); 7.63 (s, 1H, 3-H); 7.82-7.86 (m, 2H, 6-H, 7-H); 7.93 (d, J = 8.11 Hz, 2H, 3'-
H, 5'-H); 8.23-8.27 (m, 2H, 5-H, 8-H); 12.07 (s, 1H, 4-NH); (1-NH2 not detectable). 
13
C-NMR 
(DMSO, 126 MHz) δ (ppm) = 18.93 (-CH3), 108.75, 112.08 (C-4a, C-9a), 120.78, 125.97 (C-3), 
126.46, 126.53 (C-5, C-8), 131.55, 133.36 (C-6), 133.79 (C-7), 134.07, 134.42 (C-8a, C-10a), 
137.46 (C-2), 139.62, 148.06 (C-1), 167.37 (-COOH), 181.32, 182.21 (C-9, C-10). Purity by 
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HPLC-UV (200-700 nm): 99%. HRMS (ESI-TOF) m/z: [M-H]
- 
Calcd. for C22H15N2O4 
371.1037, Found 371.1033. 
1-Amino-4-(2-carboxy-4-fluorophenylamino)-2-methylanthracene-9,10-dione (21)
240
 
The compound was synthesized according to general 
procedure (II). 1-Amino-4-bromo-2-methylanthracene-9,10-
dione (1) (79 mg, 0.25 mmol, 1 equiv.), copper(II) acetate 
monohydrate (2.5 mg, 5 mol%), copper metal (ca. 0.8 mg, 5 
mol%), potassium acetate (122.5 mg, 1.25 mmol, 5 equiv.), 
2-amino-5-fluorobenzoic acid (116 mg, 0.75 mmol, 3 
equiv.), methanol (2.5% v/v, 4.0 mL), MW condition: 75 W, 
95 
°
C; pressure up to 9.5 bar. Reaction time: 70 min. Work up. Purification was done by column 
chromatography on normal silica gel using methanol/dichloromethane (20:80), followed by flash 
column chromatography on reversed phase silica gel using a gradient of acetone in water (5%, 
20%, then 40%). Appearance: blue powder. Yield: 52 mg (44%); m.p. > 300 
°
C. Solubility: The 
compound is soluble in water, acetone and DMSO, but insoluble in dichloromethane. Analytical 
data: 
1
H-NMR (DMSO-d6, 500 MHz) δ (ppm) = 2.25 (s, 3H, CH3); 7.05 (s, 1H, 3'-H); 7.21-7.23 
(m, 1H, 4'-H); 7.47 (s, 1H, 3-H); 7.57 (d, J = 4.56 Hz, 1H, 5'-H); 7.79 (d, J = 5.99 Hz, 2H, 6-H, 
7-H); 8.22-8.24 (m, 2H, 5-H, 8-H); (4-NH or 1-NH2 not detectable). 
13
C-NMR (DMSO, 126 
MHz) δ (ppm) = 18.77 (-CH3), 108.87, 112.22 (C-4a, C-9a), 122.00, 123.20 (C-3), 125.96, 
126.54(C-5), 126.57 (C-8),132.62, 132.74 (C-6, C-7), 134.03, 134.19 (C-8a, C-10a), 135.52 (C-
2), 139.47 (C-4), 147.24 (C-1),169.19 (-COOH), 182.42, 184.88 (C-9, C-10). Purity by HPLC-
UV (220-700 nm): 95%. HRMS (ESI-TOF) m/z: [M-H]
- 
Calcd. for C22H14FN2O 389.0938, 
Found 389.0943. 
1-Amino-2-methyl-4-(4-phenylamino-3–sulfophenylamino)anthracene-9,10-dione (22)64 
The compound was synthesized according to general 
procedure (II). 1-Amino-4-bromo-2-
methylanthracene-9,10-dione (1) (79 mg, 0.25 mmol, 
1 equiv.), copper(II) acetate monohydrate (2.5 mg, 5 
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mol %), copper metal (ca. 0.8 mg, 5 mol%), potassium acetate (122.5 mg, 1.25 mmol, 5 equiv.), 
4-aminodiphenylamine-2-sulfonic Acid (99 mg, 0.375 mmol, 1.5 equiv.), methanol (2.5% v/v, 
4.0 mL), MW condition: 80 W, 93 
°
C; pressure 8 bar. Reaction time: 40 min. Work up. 
Purification was done by flash column chromatography on reversed-phase C18 material using 
gradient of acetone in water 5%, 10%, 20%, then 40%). Appearance: blue powder. Yield: 63 mg 
(42%); m.p. > 300 
°
C. Solubility: The compound is soluble in acetone, water and DMSO, but 
insoluble in dichloromethane. Analytical data: 
1
H-NMR (DMSO-d6, 600 MHz) δ (ppm) = 2.25 
(s, 3H, CH3); 6.91 (t, J = 7.32 Hz, 1H, 4''-H); 7.11 (d, J = 7.90 Hz, 2H, 2''-H, 6''-H); 7.17 (dd, J = 
2.74, 8.53 Hz, 1H, 6'-H); 7.28 (d, J = 6.26 Hz, 2H, 3''-H, 5''-H); 7.30 (s, 1H, 3-H); 7.33 (d, J = 
8.52 Hz, 1H, 5'-H); 7.51 (d, J = 2.71 Hz, 1H, 2'-H); 7.80-7.83 (m, 2H, 6-H, 7-H); 8.26-8.28 (m, 
2H, 5-H, 8-H); 8.51 (s, 1H, 3-H); 12.27 (s, 1H, 4-NH); (1-NH2 not detectable). 
13
C-NMR 
(DMSO, 151 MHz) δ (ppm) = 18.82(-CH3), 116.01, 118.34(C-4a, C-9a), 121.07, 124.00 (C-3), 
124.36, 126.06, 126.17, 126.33, 126.38, 129.58, 132.79 (C-6), 132.83 (C-7), 134.09, 134.16 (C-
8a, C-10a), 135.06 (C-2), 137.80 (C-4), 143.05, 143.76, 147.09 (C-1), 150.89, 164.16, 168.89, 
181.28 (C-9), 181.93 (C-10). Purity by HPLC-UV (220-650 nm): 96%. HRMS (ESI-TOF) m/z: 
[M+H]
+ 
Calcd. for C27H22N3O5S 500.1280, Found 500.1266.  
1-Amino-2-methyl-4-(4-(phenylamino)phenylamino)anthracene-9,10-dione (23) 
The compound was synthesized according to 
general procedure (II). 1-Amino-4-bromo-2-
methylanthracene-9,10-dione (1) (79 mg, 0.25 
mmol, 1 equiv.), copper(II) acetate monohydrate 
(2.5 mg, 5 mol %), copper metal (ca. 0.8 mg, 5 
mol%), potassium acetate (122.5 mg, 1.25 mmol, 
5 equiv.), 4-aminodiphenylamine (69 mg, 0.375 
mmol, 1.5 equiv.), methanol (2.5% v/v, 4.0 mL), 
MW condition: 80 W, 93 
°
C; pressure up to 9.4 bar. Reaction time: 35 min. Work up. 
Purification was done by column chromatography on normal silica gel using 
methanol/dichloromethane (5:95). Appearance: blue powder. Yield: 50 mg (48%). Solubility: 
The compound is soluble in acetone, dichloromethane and DMSO, but insoluble in water. 
Analytical data: 
1
H-NMR (DMSO-d6, 600 MHz) δ (ppm) = 2.26 (s, 3H, CH3); 6.87 (t, J = 7.30 
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Hz, 1H, 2'-H or 6'-H); 7.06 (d, J = 7.82 Hz, 2H, 3'-H, 5'-H); 7.18 (dd, J = 2.52, 8.64 Hz, 1H, 2'-H 
or 6'-H); 7.25 (dd, J = 7.27, 8.56 Hz, 2H, 3''-H, 5''-H); 7.30 (d, J = 8.75 Hz, 1H, 4''-H); 7.36 (s, 
1H, 2''-H or 6''-H); 7.41 (d, J = 2.46 Hz, 1H, 2''-H or 6''-H); 7.68 (s, 1H, 3-H); 7.81-7.83 (m, 2H, 
6-H, 7-H); 8.25-8.28 (m, 2H, 5-H, 8-H); 12.12 (s, 1H, 4-NH); (1-NH2 not detectable). 
13
C-NMR 
(DMSO, 151 MHz) δ (ppm) = 18.65 (-CH3), 107.98, 109.32 (C-4a, C-9a), 117.91, 120.28, 
120.56, 123.68 (C-3), 124.38, 124.48, 125.30, 125.95 (C-5), 126.11 (C-8), 129.20, 132.77 (C-6), 
132.94 (C-7), 133.19 (C-8a), 133.94 (C-10a), 134.08 (C-2), 137.22 (C-4), 137.62, 142.51, 
143.41, 147.16 (C-1), 181.70, 181.95 (C-9, C-10). Purity by HPLC-UV (220-700 nm): 85%. 
 
 
 
1-Amino-4(3-hydroxyphenylamino)-2-methylanthracene-9,10-dione (24) 
The compound was synthesized according to general 
procedure (II). 1-Amino-4-bromo-2-methylanthracene-
9,10-dione (1) (79 mg, 0.25 mmol, 1 equiv.), copper(II) 
acetate monohydrate (2.5 mg, 5 mol %), copper metal 
(ca. 0.8 mg, 5 mol%), potassium acetate (122.5 mg, 
1.25 mmol, 5 equiv.), 3-aminophenol (58 mg, 0.375 
mmol, 1.5 equiv.), methanol (2.5% v/v, 4.0 mL). MW 
condition: 80 W, 95 
°
C; pressure up to 9. Reaction time: 70 min. Work up. Purification was 
done by column chromatography on normal silica gel using ethyl acetate/cyclohexane (30:70). 
Appearance: blue powder. Yield: 37 mg (43%); m.p. 285-286 
°
C. Solubility: The compound is 
soluble in dichloromethane, acetone and DMSO, but insoluble in water. Analytical data: 
 1
H-
NMR (DMSO-d6, 500 MHz) δ (ppm) = 2.26 (s, 3H, -CH3); 6.59 (dd, J = 1.98, 8.29 Hz, 1H, 2'-
H); 6.68 (t, J = 2.22 Hz, 1H, 4'-H); 6.72 (dd, J = 1.98, 7.64 Hz, 1H, 6'-H); 7.20 (t, J = 8.01 Hz, 
1H, 5'-H); 7.46 (s, 1H, 3-H); 7.80-7.84 (m, 2H, 6-H, 7-H); 8.24-8.28 (m, 2H, 5-H, 8-H); 9.57 (s, 
1H, 3'-OH); 12.18 (s, 1H, 4-NH); (1-NH2 not detectable). 
13
C-NMR (DMSO, 126 MHz) δ 
(ppm) = 18.68 (-CH3), 108.02, 109.54 (C-4a, C-9a), 109.82, 111.72, 113.79, 124.83 (C-3), 
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125.98 (C-5), 126.09 (C-8), 130.50, 132.78 (C-6), 132.97 (C-7), 133.94, 134.08 (C-8a, C-10a), 
137.39, 140.41 (C-4), 142.02 (C-2), 147.15 (C-1), 158.59, 181.86 (C-9), 181.98 (C-10). Purity by 
HPLC-UV (200-700 nm): 93%. HRMS (ESI-TOF) m/z: [M-H]
- 
Calcd. for C21H15N2O3 
343,1088, Found 343,1087.  
1-Amino-4(4-hydroxyphenylamino)-2-methylanthracene-9,10-dione (25) 
The compound was synthesized according to general 
procedure (II). 1-Amino-4-bromo-2-methylanthracene-
9,10-dione (1) (79 mg, 0.25 mmol, 1 equiv.), copper(II) 
acetate monohydrate (2.5 mg, 5 mol%), copper metal (ca. 
0.8 mg, 5 mol%), potassium acetate (122.5 mg, 1.25 
mmol, 5 equiv.), 4-aminophenol (58 mg, 0.375 mmol, 
1.5 equiv.), methanol (2.5% v/v, 4.0 mL), MW 
condition: 75 W, 95 
°
C; pressure up to 9.5 bar. Reaction time: 45 min. Work up. Purification 
was done by column chromatography on normal silica gel using methanol/dichloromethane 
(5:95), followed by ethyl acetate/cyclohexane (30:70). Appearance: blue powder. Yield: 39 mg 
(45%); m.p. 225-226 
°
C. Solubility: The compound is soluble in dichloromethane, acetone and 
DMSO, but insoluble in water. Analytical data: 
1
H-NMR (DMSO-d6, 500 MHz) δ (ppm) = 
2.22 (s, 3H, -CH3); 6.84 (d, J= 8.65 Hz, 2H, 3'-H, 5'-H); 7.12 (d, J = 8.70 Hz, 2H, 2'-H, 6'-H); 
7.21 (s, 1H, 3-H), 7.79-7.82 (m, 2H, 6-H, 7-H); 8.24-8.28 (m, 2H, 5-H, 8-H); 9.49 (s, 1H, -OH); 
12.22 (s, 1H, 4-NH); (1-NH2 not detectable). 
13
C-NMR (DMSO, 126 MHz) δ (ppm) = 18.70 (-
CH3), 107.84, 108.24 (C-4a, C-9a), 116.35, 124.16 (C-3), 125.89, 126.08 (C-5), 126.30 (C-8), 
130.03, 132.67, 134.11, 137.72, 144.20 (C-2), 146.90 (C-1), 155.30, 181.00 (C-9), 181.78 (C-10). 
Purity by HPLC-UV (200-700 nm): 91%. 
7.5 5.5. Chemistry of bisacodyl-derived compounds 
Bisacodyl (4,4'-diacetoxy-diphenyl)-(pyridyl-2)-methane which is a commercially available drug, 
was either subjected to complete hydrolysis of the di-acetyl ester groups affording the diphenol 
derivative (46), or the removal of one acetyl group formed the monohydroxylated derivative (47).  
Bis-(p-hydroxyphenyl)pyridyl-2-methane (46) 
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According to the reported procedure, a suspension of 
(pyridin-2-ylmethylene)bis-(4,1-phenylene) diacetate (5 g, 
13.84 mmol) in 55 mL of a solution of KOH containing 
10% of EtOH was stirred overnight at rt. After the 
completion of the reaction, the volatile solvent was 
removed and the solid residue was dissolved in EtOAc 
(100 mL). The mixture was treated with dilute aqueous HCl solution (2 M) until a pH value of 1-
2 was reached, then treated with a saturated aqueous solution of Na2CO3 until the pH turned to 
ca. 8-9. The collected organic extracts were successively washed with brine (3 × 50 mL), three 
more times with water and then dried over MgSO4. The residue after solvent removal was 
purified using column chromatography on silica gel using ethyl acetate/dichloromethane (25:75) 
to yield the title compound. Reaction time: 15 h. Appearance: white powder. Yield: 3.5 g 
(93%); m.p. 258-260 
°
C. Solubility: The compound is soluble in acetone, ethyl acetate and 
methanol, but insoluble in water. Analytical data: 
1
H-NMR (DMSO-d6, 600 MHz) δ (ppm) = 
5.40 (s, 1H, -CH); 6.66 (d, J = 8.52 Hz, 4H, 3-H, 3'-H, 5-H, 5'-H); 6.94 (d, J = 8.53 Hz, 4H, 2-H, 
2'-H, 6-H, 6'-H); 7.15 (d, J = 7.86 Hz, 1H, 3-Hpy);7.18 (dd, J = 5.15, 6.97 Hz, 1H, 4-Hpy); 7.67 
(td, J = 1.87, 7.68 Hz, 1H, 5-Hpy); 8.48 (d, J = 4.03 Hz, 1H, 6-HPy); 9.23 (br s, 2H, -OH). 
13
C-
NMR (DMSO, 151 MHz) δ (ppm) = 56.95(-CH), 115.07, 121.43 (5-CPy), 123.42 (3-CPy), 
129.97, 133.94, 136.64(4-CPy), 149.126 (6-CPy), 155.75, 163.74. LC-MS: (m/z): positive mode 
278 [M]
+
. Purity by HPLC-UV (220-400 nm)-ESI-MS: 98%. HRMS (ESI-TOF) m/z: [M-H]
-
 
Calcd. for C18H14NO2 276.1030, Found 276.1056.  
4-((4-Hydroxyphenyl)(pyridin-2-yl)methyl)phenyl acetate (47) 
The title compound was prepared according to the 
method reported by Marie et al. with some 
modifications. (Pyridin-2-ylmethylene)bis-(4,1-
phenylene) diacetate (1000 mg, 2.76 mmol; 1 equiv.) 
was suspended in a 30 mL mixture of (THF : MeOH 
14 : 1). The mixture was treated LiOH·H2O (150.5 
mg, 3.59 mmol; 1.3 equiv.) in water (15 mL). After complete addition, the mixture was stirred at 
rt and the reaction was controlled by TLC. The solid residue obtained after evaporation of 
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solvents using a vacuum pump was diluted with water (50 mL). The aqueous mixture was 
extracted using EtOAc (3 × 50 mL), and then the organic layers were washed with brine (2 × 15 
mL) and dried over anhydrous Na2SO4. Purification was done using column chromatography on 
silica gel using ethyl acetate/dichloromethane (5:95) to afford the pure product (47). Reaction 
time: 45 min. Appearance: white powder. Yield: 500 mg (57%); m.p. 150-152 
°
C. Solubility: 
The compound is freely soluble in acetone, methanol and dichloromethane, but insoluble in 
water. Analytical data: 
1
H-NMR (DMSO-d6, 600 MHz) δ (ppm) = 2.23 (s, 3H, -CH3); 5.55 (s, 
1H, -CH); 6.68 (d, J = 8.58 Hz, 2H, 3-HArOH, 5-HArOH); 7.00 (d, J = 3.13 Hz, 2H, 3-HAr, 5-HAr); 
7.02 (d, J = 3.22 Hz, 2H, 2-HAr, 6-HAr); 7.19 (d, J = 8.61 Hz, 2H, 2-HArOH, 6-HArOH); 7.21-7.23 
(m, 2H, 3-HPy, 4-HPy); 7.71 (td, J = 1.91, 7.70 Hz, 1H, 5-HPy); 8.51-8.52 (m, 1H, 6-HPy); 9.26 (s, 
1H, -OH). 
13
C-NMR (DMSO, 151 MHz) δ (ppm) = 20.98 (-CH3), 56.85 (-CH), 115.24, 121.56 
(5-CPy), 121.71, 123.64 (3-CPy), 130.02, 130.06, 133.26, 136.88 (4-CPy), 141.28, 148.86 (6-CPy), 
149.29, 155.98, 162.95, 169.39 (-COOCH3). LC-MS: (m/z): positive mode 319.9 [M]
+
. Purity by 
HPLC-UV (220-400 nm)-ESI-MS: 97%. HRMS (ESI-TOF) m/z: [M-H]
-
 Calcd. for 
C20H16NO3 318.1136, Found 318.1148. 
5.5.1. General synthetic procedure (III) (48-66, 68, 69, 72, 78a, 80, 81, 83, 85, and 99) 
The phenolic (46, 50, 55, 79, 82, 78, and 98) or alcoholic (71 and 84) starting material (1 equiv.) 
was dissolved in DMF (5 mL), then the mixture thus obtained was cooled down to 0 
°
C, followed 
by the addition of NaH (60% in paraffin oil, 1.1 equiv. for each OH group) portionwise over 10 
min. After stirring for an additional 30-45 min at the same temperature, the corresponding 
alkylating agent (1.1 equiv. for each OH group) was added dropwise. The reaction mixture was 
allowed to reach rt and was controlled by TLC. After the reaction was completed, the mixture 
was poured onto ice and extracted with EtOAc (3 × 25 mL). The organic layers were washed 
with brine (2 × 15 mL), dried over MgSO4 and concentrated. Purification was done using column 
chromatography to give the pure compounds (48-66 in case of starting material 46; 68 in case of 
starting material 55; 80 and 81 in case of starting material 79; 83 in case of starting material 82; 
78a in case of starting material 78; 99 in case of starting material 98; 72 in case of starting 
material 71; and 85 in case of starting material 84), some compounds needed further re-
crystallization. 
Experimental Part 
- 145 - 
 
5.5.2. Characterization of the bisacodyl-derived compounds 
5.5.2.1. 4-((4-Butoxyphenyl)(pyridin-2-yl)methyl)phenol (48) 
The compound was synthesized according to 
general procedure (III). Compound 46 (200 
mg, 0.72 mmol, 1 equiv.), NaH (60% in 
paraffin oil, 63 mg, 1.6 mmol, 2.2 equiv.) and 
1-bromobutane (0.15 mL, 219 mg, 1.6 mmol, 
2.2 equiv.). Reaction time: 1 h. Work up. 
Purification was done by column 
chromatography on silica gel using ethyl acetate/dichloromethane (5:95). Appearance: beige 
powder. Yield: 75 mg (31%); m.p. 145-146 
°
C. Solubility: The compound is freely soluble in 
acetone, methanol and ethyl acetate, but insoluble in water. Analytical data: 
1
H-NMR (DMSO-
d6, 600 MHz) δ (ppm) = 0.90 (t, J = 7.39 Hz, 3H, -OCH2-CH2-CH2-CH3); 1.37-1.43 (m, -OCH2-
CH2-CH2-CH3); 1.63-1.67 (m, 2H, -OCH2-CH2-CH2-CH3); 3.90 (t, J = 6.50 Hz, 2H, -OCH2-CH2-
CH2-CH3); 5.45 (s, 1H, -CH); 6.65 (d, J = 8.54 Hz, 2H, 3-HArOH, 5-HArOH); 6.81 (d, J = 8.71 Hz, 
2H, 3-HAr, 5-HAr); 6.95 (d, J = 8.53 Hz, 2H, 2-HArOH, 6-HArOH); 7.05 (d, J = 8.65 Hz, 2H, 2-HAr, 
6-HAr); 7.16 (d, J = 7.84 Hz, 1H, 3-HPy); 7.19 (dd, J = 4.89, 7.43 Hz, 1H, 4-HPy); 7.69 (td, J = 
1.87, 7.63 Hz, 1H, 5-HPy); 8.49 (d, J = 4.60 Hz, 1H, 6-HPy); 9.21 (s, 1H, -OH). 
13
C-NMR 
(DMSO, 151 MHz) δ (ppm) = 13.82 (-OCH2-CH2-CH2-CH3), 18.88 (-OCH2-CH2-CH2-CH3), 
30.90(-OCH2-CH2-CH2-CH3), 56.80 (-CH), 67.15 (-OCH2-CH2-CH2-CH3), 114.20, 115.09, 
121.50 (5-CPy), 123.47 (3-CPy), 129.97, 130.01, 133.76, 135.60, 136.70 (4-CPy), 149.17 (6-CPy), 
155.78, 157.13, 163.49. LC-MS: (m/z): positive mode 333.9 [M]
+
. Purity by HPLC-UV (220-
400 nm)-ESI-MS: 97%. HRMS (ESI-TOF) m/z: [M-H]
- 
Calcd. for C22H22NO2 332.1656, Found 
332.1657. 
5.5.2.2. 4-((4-(Sec-butoxy)phenyl)(pyridin-2-yl)methyl)phenol (49)  
The compound was synthesized according to general 
procedure (III). Compound 46 (1200 mg, 4.32 
mmol, 1 equiv.), NaH (60% in paraffin oil, 380 mg, 
9.5 mmol, 2.2 equiv.) and 2-bromobutane (1 mL, 
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1302 mg, 9.5 mmol, 2.2 equiv.). Reaction time: 1.5 h. Work up. Purification was done by 
column chromatography on silica gel using ethyl acetate/dichloromethane (20:80), followed by 
crystallization with diethyl ether. Appearance: white powder. Yield: 640 mg (44%); m.p. 160-
162 
°
C. Solubility: The compound is soluble in acetone and methanol, but insoluble in water. 
Analytical data: 
1
H-NMR (DMSO-d6, 600 MHz) δ (ppm) = 0.88 (t, J = 7.43 Hz, 3H, -
CH(CH3)-CH2-CH3); 1.16-1.18 (m, 3H, -CH(CH3)-CH2-CH3); 1.49-1.63 (m, 2H, -CH(CH3)-CH2-
CH3); 4.26-4.31 (m, J = 6.02 Hz, 1H, -CH(CH3)-CH2-CH3); 5.44 (s, 1H, -CH); 6.66 (d, J = 8.53 
Hz, 2H, 3-HArOH, 5-HArOH); 6.80 (d, J = 8.67 Hz, 2H, 3-HAr, 5-HAr); 6.96 (d, J = 8.59 Hz, 2H, 2-
HArOH, 6-HArOH); 7.04 (d, J = 8.62 Hz, 2H, 2-HAr, 6-HAr); 7.17-7.20 (m, 2H, 3-HPy, 4-HPy); 7.69 
(td, J = 1.89, 7.65 Hz, 1H, 5-HPy); 8.49-8.50 (m, 1H, 6-HPy); 9.21 (s, 1H, -OH). 
13
C-NMR 
(DMSO, 151 MHz) δ (ppm) = 9.71 (-CH-(CH3)-CH2-CH3), 19.26 (-CH-(CH3)-CH2-CH3), 28.74 
(-CH-(CH3)-CH2-CH3), 56.83 (-CH), 74.15 (-CH-(CH3)-CH2-CH3), 115.10, 115.35, 121.51 (5-
CPy), 123.48 (3-CPy), 129.98, 130.08, 133.77, 135.49, 136.71 (4-CPy), 149.18 (6-CPy), 155.79, 
156.21, 163.51. LC-MS: (m/z): positive mode 333.9 [M]
+
. Purity by HPLC-UV (220-400 nm)-
ESI-MS: 99%. HRMS (ESI-TOF) m/z: [M-H]
- 
Calcd. for C22H22NO2 332.1656, Found 
332.1682. 
5.5.2.3. 4-((4-(2-Bromoethoxy)phenyl)(pyridin-2-yl)methyl)phenol (50)  
The compound was synthesized according to 
general procedure (III). Compound 46 (400 mg, 
1.44 mmol, 1 equiv.), NaH (60% in paraffin oil, 127 
mg, 3.2 mmol, 2.2 equiv.) and 1,2-dibromoethane 
(0.2 mL, 413 mg, 3.2 mmol, 2.2 equiv.). Reaction 
time: 2 h. Work up. Purification was done by 
column chromatography on silica gel using ethyl acetate/dichloromethane (5:95), followed by 
crystallization with ethyl acetate/cyclohexane (20:80). Appearance: yellow powder. Yield: 231 
mg (42%); m.p. 155-157 
°
C. Solubility: The compound is soluble in acetone and methanol, but 
insoluble in water. Analytical data: 
1
H-NMR (DMSO-d6, 600 MHz) δ (ppm) = 3.76 (t, J = 6.00 
Hz, 2H, -OCH2-CH2-Br); 4.26 (t, J = 6.00 Hz, 2H, -OCH2-CH2-Br); 5.47 (s, 1H, -CH); 6.66 (d, J 
= 8.52 Hz, 2H, 3-HArOH, 5-HArOH); 6.86 (d, J = 8.68 Hz, 2H, 3-HAr, 5-HAr); 6.96 (d, J = 8.49 Hz, 
2H, 2-HArOH, 6-HArOH); 7.08 (d, J = 8.63 Hz, 2H, 2-HAr, 6-HAr); 7.17-7.20 (m, 2H, 3-HPy, 4-HPy); 
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7.69 (td, J = 1.92, 7.70 Hz, 1H, 5-HPy); 8.49 (d, J = 3.86 Hz, 1H, 6-HPy); 9.22 (s, 1H, -OH). 
13
C-
NMR (DMSO, 151 MHz) δ (ppm) = 31.66 (-OCH2-CH2-Br), 56.78 (-CH), 67.87 (-OCH2-CH2-
Br), 114.47, 115.13, 121.56 (5-CPy), 123.51 (3-CPy), 129.99, 130.16, 133.69, 136.37 (4-CPy), 
136.75, 149.20 (6-CPy), 155.82, 156.38, 163.40. LC-MS: (m/z): positive mode 383.9 [M]
+
. Purity 
by HPLC-UV (220-400 nm)-ESI-MS: 96%. HRMS (ESI-TOF) m/z: [M-H]
- 
Calcd. for 
C20H17BrNO2 382.0448, Found 382.0444. 
 
 
 
 
5.5.2.4. Ethyl 2-(4-((4-hydroxyphenyl)(pyridin-2-yl)methyl)phenoxy)acetate (51) 
The compound was synthesized according to 
general procedure (III). Compound 46 (100 mg, 
0.36 mmol, 1 equiv.), NaH (60% in paraffin oil, 
16 mg, 0.396 mmol, 1.1 equiv.) and ethyl 
bromoacetate (0.04 mL, 66 mg, 0.396 mmol, 1.1 
equiv.). Reaction time: 1 h. Work up. 
Purification was done by column chromatography 
on silica gel using ethyl acetate/dichloromethane (10:90). Appearance: colorless oil. Yield: 60 
mg (46%). Solubility: The compound is miscible with acetone and methanol, but immiscible 
with water. Analytical data: 
1
H-NMR (DMSO-d6, 500 MHz) δ (ppm) = 1.19 (t, J = 7.11 Hz, 
3H, -OCH2-CH3); 4.14 (q, J = 7.09 Hz, 2H, OCH2-CH3); 4.70 (s, 2H, -OCH2-CO); 5.46 (s, 1H, 
CH); 6.66 (d, J = 8.52 Hz, 2H, 3-HArOH, 5-HArOH); 6.82 (d, J = 8.74 Hz, 2H, 3-HAr, 5-HAr); 6.96 
(d, J = 8.53 Hz, 2H, 2-HArOH, 6-HArOH); 7.07 (d, J = 8.70 Hz, 2H, 2-HAr, 6-HAr); 7.17-7.20 (m, 
2H, 3-HPy, 4-HPy); 7.69 (td, J = 1.90, 7.70 Hz, 1H, 5-HPy); 8.49-8,50 (m, 1H, 6-HPy); 9.22 (s, 1H, 
OH). 
13
C-NMR (DMSO, 126 MHz) δ (ppm) = 14.18 (-CH3), 56.77 (-CH), 60.74 (-CH2-CH3), 
64.84 (-OCH2), 114.34, 115.14, 121.56 (5-CPy), 123.51 (3-CPy), 129.98, 130.06, 133.66, 136.55 
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(4-CPy), 136.75, 149.21 (6-CPy), 155.83, 156.09, 163.36, 168.91 (CO). LC-MS: (m/z): positive 
mode 364 [M]
+
. Purity by HPLC-UV (220-400 nm)-ESI-MS: 98%. 
5.5.2.6. 4-((4-(3-Hydroxypropoxy)phenyl)(pyridin-2-yl)methyl)phenol (52) 
The compound was synthesized according to 
general procedure (III). Compound 46 (800 mg, 
2.9 mmol, 1 equiv.), NaH (60% in paraffin oil, 
256 mg, 6.4 mmol, 2.2 equiv.) and 3-bromo-1-
propanol (0.58 mL, 890 mg, 6.4 mmol, 2.2 
equiv.). Reaction time: 2 h. Work up. 
Purification was done by column chromatography on silica gel using ethyl 
acetate/dichloromethane (20:80). Appearance: yellow powder. Yield: 420 mg (43%); m.p. 100-
102 
°
C. Solubility: The compound is soluble in acetoneand methanol, but insoluble in water. 
Analytical data: 
1
H-NMR (DMSO-d6, 500 MHz) δ (ppm) = 1.79-1.84 (m, 2H, -OCH2-CH2-
CH2-OH); 3.50-3.54 (m, 2H, -OCH2-CH2-CH2-OH); 3.97 (t, J = 6.38 Hz, 2H, -OCH2-CH2-CH2-
OH); 4.48 (t, J = 5.15 Hz, 1H, -OCH2-CH2-CH2-OH); 5.45 (s, 1H, -CH); 6.66 (d, J = 8.54 Hz, 
2H, 3-HArOH, 5-HArOH); 6.82 (d, J = 8.67 Hz, 2H, 3-HAr, 5-HAr); 6.95 (d, J = 8.46 Hz, 2H, 2-
HArOH, 6-HArOH); 7.05 (d, J = 8.58 Hz, 2H, 2-HAr, 6-HAr); 7.15-7.20 (m, 2H, 3-HPy, 4-HPy); 7.69 
(td, J = 1.87, 7.66 Hz, 1H, 5-HPy); 8.49-8.50 (m, 1H, 6-HPy); 9.19 (s, 1H, -OH). 
13
C-NMR 
(DMSO, 126 MHz) δ (ppm) = 32.30 (-OCH2-CH2-CH2-OH), 56.81 (-CH), 57.47 (-OCH2-CH2-
CH2-OH), 64.63 (-OCH2-CH2-CH2-OH), 114.22, 115.09, 121.49 (5-CPy), 123.46 (3-CPy), 129.96, 
130.01, 133.77, 135.62, 136.68 (4-CPy), 149.16 (6-CPy), 155.77, 157.13, 163.50. LC-MS: (m/z): 
positive mode 335.9 [M]
+
. Purity by HPLC-UV (220-400 nm)-ESI-MS: 95%. HRMS (ESI-
TOF) m/z: [M-H]
- 
Calcd. for C21H20NO3 334.1449, Found 334.1454. 
5.5.2.7. 4-((4-(Octyloxy)phenyl)(pyridin-2-yl)methyl)phenol (53) 
The compound was synthesized 
according to general procedure 
(III). Compound 46 (400 mg, 1.44 
mmol, 1 equiv.), NaH (60% in 
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paraffin oil, 127 mg, 3.2 mmol, 2.2 equiv.) and 1-bromooctane (0.4 mL, 425 mg, 3.2 mmol, 2.2 
equiv.). Reaction time: 3 h. Work up. Purification was done by column chromatography on 
silica gel using ethyl acetate/dichloromethane (20:80). Appearance: white powder. Yield: 178 
mg (32%); m.p. 112-114 
°
C. Solubility: The compound is soluble in acetone and methanol, but 
insoluble in water. Analytical data: 
1
H-NMR (DMSO-d6, 600 MHz) δ (ppm) = 0.84 (t, J = 6.87 
Hz, 3H, -OCH2-(CH2)5-CH2-CH3); 1.24-1.30 (m, 8H, -OCH2-CH2-CH2-(CH2)4-CH3); 1.34-1.39 
(m, -OCH2-CH2-CH2-(CH2)4-CH3); 1.63-1.68 (m, -OCH2-CH2-CH2-(CH2)4-CH3); 3.88 (t, J = 
6.47 Hz, 2H, -OCH2-CH2-CH2-(CH2)4-CH3); 5.45 (s, 1H, -CH); 6.65 (d, J = 8.51 Hz, 2H, 3-
HArOH, 5-HArOH); 6.81 (d, J = 8.66 Hz, 2H, 3-HAr, 5-HAr); 6.95 (d, J = 8.55 Hz, 2H, 2-HArOH, 6-
HArOH); 7.04 (d, J = 8.68 Hz, 2H, 2-HAr, 6-HAr); 7.16-7.20 (m, 2H, 3-HPy, 4-HPy); 7.69 (td, J = 
1.86, 7.68 Hz, 1H, 5-HPy); 8.48-8.49 (m, 1H, 6-HPy); 9.21 (s, 1H, -OH). 
13
C-NMR (DMSO, 151 
MHz) δ (ppm) = 14.09 (-OCH2-(CH2)5-CH2-CH3), 22.21 (-OCH2-(CH2)5-CH2-CH3), 25.68, 
28.79, 28.85, 28.86, 31.37 (-OCH2-CH2-CH2-(CH2)4-CH3), 56.81 (-CH), 67.46 (-OCH2-(CH2)5-
CH2-CH3), 114.21, 115.10, 121.51 (5-CPy), 123.47 (3-CPy), 129.97, 130.02, 130.02, 133.77, 
135.60, 136.70 (4-CPy), 149.18 (6-CPy), 155.78, 157.14, 163.50. LC-MS: (m/z): positive mode 
390.4 [M]
+
. Purity by HPLC-UV (254 nm)-ESI-MS: 97%. 
5.5.2.8. 4-((4-Hydroxyphenyl)(pyridin-2-yl)methyl)phenyl 4-methoxybenzoate (54) 
 The compound was synthesized according 
to general procedure (III). Compound 46 
(400 mg, 1.44 mmol, 1 equiv.), NaH (60% 
in paraffin oil, 127 mg, 3.2 mmol, 2.2 
equiv.) and 4-methoxybenzoyl chloride (0.4 
mL, 546 mg, 3.2 mmol, 2.2 equiv.). 
Reaction time: 3 h. Work up. Purification 
was done by column chromatography on 
silica gel using ethyl acetate/dichloromethane (2:98). Appearance: beige powder. Yield: 165 mg 
(13%); m.p. 195-197 
°
C. Solubility: The compound is soluble in acetone and dichloromethane, 
but insoluble in water. Analytical data: 
1
H-NMR (DMSO-d6, 600 MHz) δ (ppm) = 3.85 (s, 3H, 
-OCH3); 5.59 (s, 1H, -CH); 6.70 (d, J = 8.53 Hz, 2H, 3-HArOH, 5-HArOH); 7.03 (d, J = 8.51 Hz, 2H, 
2-HArOH, 6-HArOH); 7.10 (d, J = 8.87 Hz, 2H, 2H, 3-HArOMe, 5-HArOMe); 7.15 (d, J = 8.56 Hz, 2H, 
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2-HAr, 6-HAr); 7.21-7.25 (m, 4H, 3-HAr, 5-HAr, 3-HPy, 4-HPy); 7.73 (td, J = 1.84, 7.69 Hz, 1H, 5-
HPy); 8.05 (d, J = 8.87 Hz, 2H, 2-HArOMe, 6-HArOMe); 8.52-8.54 (m, 1H, 6-HPy); 9.27 (s, 1H, -OH). 
13
C-NMR (DMSO, 151 MHz) δ (ppm) = 55.78 (-OCH3), 56.85 (-CH), 114.41, 115.23, 121.14 
(5-CPy), 121.69, 123.64 (3-CPy), 130.06, 132.09, 133.27, 136.87 (4-CPy), 141.35, 149.04 (6-CPy), 
149.29, 155.96, 162.95, 163.85 (-CO), 164.37. LC-MS: (m/z): positive mode 412.2 [M]
+
. Purity 
by HPLC-UV (220-400 nm)-ESI-MS: 99%. HRMS (ESI-TOF) m/z: [M-H]
- 
Calcd. for 
C26H20NO4 410.1398, Found 410.1415. 
 
 
 
5.5.2.9. 4-((4-(Benzyloxy)phenyl)(pyridin-2-yl)methyl)phenol (55) 
The compound was synthesized according to 
general procedure (III). Compound 46 (800 
mg, 2.9 mmol, 1 equiv.), NaH (60% in paraffin 
oil, 256 mg, 6.4 mmol, 2.2 equiv.) and benzhyl 
bromide (0.76 mL, 1095 mg, 6.4 mmol, 2.2 
equiv.). Reaction time: 1 h. Work up. 
Purification was done by column 
chromatography on silica gel using ethyl 
acetate/dichloromethane (8:92). Appearance: yellow powder. Yield: 420 mg (20%); m.p. 160-
161 
°
C. Solubility: The compound is soluble in acetoneand methanol, but insoluble in water. 
Analytical data: 
1
H-NMR (DMSO-d6, 600 MHz) δ (ppm) = 5.04 (s, 2H, -CH2); 5.46 (s, 1H, -
CH); 6.66 (d, J = 8.58 Hz, 2H, 3-HArOH, 5-HArOH); 6.91 (d, J = 8.76 Hz, 2H, 2-HAr, 6-HAr); 6.96 
(d, J = 8.53 Hz, 2H, 2-HArOH, 6-HArOH); 7.07 (d, J = 8.68 Hz, 2H, 3-HAr, 5-HAr); 7.16-7.20 (m, 
2H, 3-HPy, 4-HPy); 7.30 (m, 1H, 4-HPh); 7.36 (m, J = 7.52 Hz, 2H, 3-HPh, 5-HPh); 7.41 (d, J = 7.37 
Hz, 2H, 2-HPh, 6-HPh); 7.69 (td, J = 1.87, 7.68 Hz, 1H, 5-HPy); 8.49-8.50 (m, 1H, 6-HPy); 9.22 (s, 
1H, -OH). 
13
C-NMR (DMSO, 151 MHz) δ (ppm) = 56.81 (-CH), 69.33 (-CH2), 114.59, 115.13, 
121.54 (5-CPy), 123.50 (3-CPy), 127.78, 127.92, 128.56, 130.00, 130.08, 133.74, 136.04 (4-CPy), 
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136.74, 137.34, 149.20 (6-CPy), 155.82, 156.84, 163.46. LC-MS: (m/z): positive mode 368.1 
[M]
+
. Purity by HPLC-UV (220-400 nm)-ESI-MS: 97%. HRMS (ESI-TOF) m/z: [M-H]
- 
Calcd. 
for C25H20NO2 366.1500, Found 366.1498. 
5.5.2.10. 4-((4-Phenethoxyphenyl)(pyridin-2-yl)methyl)phenol (56) 
The compound was synthesized according to 
general procedure (III). Compound 46 (1200 
mg, 4.32 mmol, 1 equiv.), NaH (60% in paraffin 
oil, 380 mg, 9.5 mmol, 2.2 equiv.) and (2-
bromoethyl)benzene (0.3 mL, 407 mg, 9.5 
mmol, 2.2 equiv.). Reaction time: 1 h. Work 
up. Purification was done by column 
chromatography on silica gel using ethyl acetate/dichloromethane (20:80). Appearance: white 
powder. Yield: 155 mg (9%); m.p. 135-136 
°
C. Solubility: The compound is soluble in acetone 
and methanol, but insoluble in water. Analytical data: 
1
H-NMR (DMSO-d6, 600 MHz) δ (ppm) 
= 2.99 (t, J = 6.84 Hz, 2H, -OCH2-CH2-Ph); 4.12 (t, J = 6.85 Hz, 2H, -OCH2-CH2-Ph); 5.45 (s, 
1H, -CH); 6.66 (d, J = 8.60 Hz, 2H, 3-HArOH, 5-HArOH); 6.83 (d, J = 8.79 Hz, 2H, 3-HAr, 5-HAr); 
6.95 (d, J = 8.50 Hz, 2H, 2-HArOH, 6-HArOH); 7.05 (d, J = 8.70 Hz, 2H, 2-HAr, 6-HAr); 7.16 (d, J = 
7.86 Hz, 1H, CHPh); 7.17-7.21 (m, 2H, 3-HPy, 4-HPy); 7.27-7.31 (m, 4H, CHPh); 7.68 (td, J = 1.88, 
7.67 Hz, 1H, 5-HPy); 8.48-8.50 (m, 1H, 6-HPy); 9.21 (s, 1H, -OH). 
13
C-NMR (DMSO, 151 MHz) 
δ (ppm) = 35.43 (-OCH2-CH2-Ph), 57.12 (-CH), 68.53 (-OCH2-CH2-Ph), 114.59, 115.43, 121.83 
(5-CPy), 123.80 (3-CPy), 126.69, 128.74, 129.37, 130.30, 130.39, 134.07, 136.13 (4-CPy), 137.02, 
138.87, 149.50 (6-CPy), 156.12, 157.19, 163.80. LC-MS: (m/z): positive mode 382.2 [M]
+
. Purity 
by HPLC-UV (220-400 nm)-ESI-MS: 95%. HRMS (ESI-TOF) m/z: [M-H]
- 
Calcd. for 
C26H22NO2 380.1656, Found 380.1653. 
5.5.2.11. Bis-(p-butoxyphenyl)pyridyl-2-methane (57) 
The compound was synthesized 
according to general procedure (III). 
Compound 46 (434 mg, 1.56 mmol, 1 
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equiv.), NaH (60% in paraffin oil, 137 mg, 3.4 mmol, 2.2 equiv.) and1-bromobutane (0.4 mL, 
466 mg, 3.4 mmol, 2.2 equiv.). Reaction time: 2 h. Work up. Purification was done by column 
chromatography on silica gel using ethyl acetate/dichloromethane (2:98). Appearance: yellow 
oil. Yield: 574 (94%). Solubility: The compound is miscible with acetone, methanol and ethyl 
acetate, but immiscible with water. Analytical data: 
1
H-NMR (DMSO-d6, 600 MHz) δ (ppm) = 
0.90 (t, J = 7.43 Hz, 6H, 2(-OCH2-CH2-CH2-CH3)); 137-1.43 (m, 2(-OCH2-CH2-CH2-CH3)); 
1.62-1.67 (m, 2(-OCH2-CH2-CH2-CH3)); 3.90 (t, J = 6.46 Hz, 4H, 2(-OCH2-CH2-CH2-CH3)); 
5.51 (s, 1H, -CH); 6.82 (d, J = 8.70 Hz, 4H, 3-H, 3'-H, 5-H, 5'-H); 7.06 (d, J = 8.63 Hz, 4H, 2-H, 
2'-H, 6-H, 6'-H); 7.18-7.21 (m, 2H, 3-HPy, 4-HPy); 7.69 (td, J = 1.89, 7.68 Hz, 1H, 5-HPy); 8.50 (d, 
J = 5.49 Hz, 1H, 6-HPy). 
13
C-NMR (DMSO, 151 MHz) δ (ppm) = 13.80 (-OCH2-CH2-CH2-
CH3), 18.87 (-OCH2-CH2-CH2-CH3), 30.90 (-OCH2-CH2-CH2-CH3), 56.67(-CH), 67.15 (-OCH2-
CH2-CH2-CH3), 114.23, 121.56 (5-CPy), 123.51 (3-CPy), 130.01, 135.40, 136.74, 149.21 (6-CPy), 
157.18, 163.26. LC-MS: (m/z): positive mode 390.1 [M]
+
. Purity by HPLC-UV (220-400 nm)-
ESI-MS: 95%. HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd. for C26H32NO2 390.2428, Found 
390.2397. 
5.5.2.12. Bis-(p-(2-methoxyethoxy)phenyl)pyridyl-2-methane (58) 
The compound was synthesized 
according to general procedure 
(III).Compound 46 (400 mg, 1.44 
mmol, 1 equiv.), NaH (60% in paraffin 
oil, 127 mg, 3.2 mmol, 2.2 equiv.) and 
1-bromo-2-methoxyethane (0.2 mL, 
306 mg, 3.2 mmol, 2.2 equiv.). 
Reaction time: 4 h. Work up. Purification was done by column chromatography on silica gel 
using ethyl acetate/dichloromethane (2:98). Appearance: yellow oil. Yield: 447 mg (79%). 
Solubility: The compound is miscible with acetone and methanol, but immiscible with water. 
Analytical data: 
1
H-NMR (DMSO-d6, 600 MHz) δ (ppm) = 3.28 (s, 6H, 2(-OCH3)); 3.61-3.62. 
(m, 4H, 2(-OCH2-CH2-OCH3)); 4.02-4.03 (m, 4H, 2(-OCH2-CH2-OCH3)); 5.52 (s, 1H, -CH); 
6.84 (d, J = 8.74 Hz, 4H, 3-H, 3'-H, 5-H, 5'-H); 7.07 (d, J = 8.71 Hz, 4H, 2-H, 2'-H, 6-H, 6'-H); 
7.18-7.21 (m, 2H, 3-HPy,4-HPy); 7.70 (td, J = 1.88, 7.66 Hz, 1H, 5HPy); 8.50-8.51 (m, 1H, 6-HPy). 
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13
C-NMR (DMSO, 151 MHz) δ (ppm) = 56.63 (-CH), 58.29 (-OCH2-CH2-OCH3), 66.96 (-
OCH2-CH2-OCH3), 70.54 (-OCH2-CH2-OCH3), 114.29, 121.61 (5-CPy), 123.55 (3-CPy), 130.06, 
135.63, 136.79 (4-CPy), 149.25 (6-CPy), 156.99, 163.21. LC-MS: (m/z): positive mode 394.2 
[M]
+
. Purity by HPLC-UV (220-400 nm)-ESI-MS: 96%. HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd. for C24H28NO4 394.2013, Found 394.1983. 
 
 
 
5.5.2.13. Diethyl 2,2'-(4,4'-(pyridin-2-ylmethylene)-bis-(4,1-phenylene))-bis-(oxy)diacetate 
(59)
214
 
The compound was synthesized 
according to general procedure 
(III). Compound 46 (1200 mg, 
4.32 mmol, 1 equiv.), NaH (60% 
in paraffin oil, 380 mg, 9.5 mmol, 
2.2 equiv.) and ethyl bromoacetate 
(1.1 mL, 1587 mg, 9.5 mmol, 2.2 
equiv.). Reaction time: 2 h. Work up. Purification was done by column chromatography on 
silica gel using ethyl acetate/dichloromethane (2:98). Appearance: light brown powder. Yield: 
1490 mg (77%); m.p. 75-77 
°
C. Solubility: The compound is soluble in acetone and ethyl 
acetate, but insoluble in water. Analytical data: 
1
H-NMR (DMSO-d6, 600 MHz) δ (ppm) = 
1.19 (t, J = 7.09 Hz, 6H, 2(-CH2-CH3)); 4.14 (q, J = 7.10 Hz, 4H, 2(-CH2-CH3)); 4.70 (s, 4H, 2(-
OCH2)); 5.54 (s, 1H, -CH); 6.83 (d, J = 8.77 Hz, 4H, 3-H, 3'-H, 5-H, 5'-H); 7.09 (d, J = 8.72 Hz, 
4H, 2-H, 2'-H, 6-H, 6'-H); 7.20-7.22 (m, 2H, 3-HPy, 4-HPy); 7.71 (td, J = 1.88, 7.70 Hz, 1H, 5-
HPy); 8.50-8.51 (m, 1H, 6-HPy). 
13
C-NMR (DMSO, 151 MHz) δ (ppm) = 14.19 (-CH3), 56.53 (-
CH), 60.74 (-CH2-CH3), 64.81 (-OCH2), 114.40, 121.69(5-CPy), 123.60 (3-CPy), 130.07, 136.21 
(4-CPy), 136.89, 149.26 (6-CPy), 156.16, 168.89 (CO). LC-MS: (m/z): positive mode 450 [M]
+
. 
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Purity by HPLC-UV (220-400 nm)-ESI-MS: 95%. HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd. for 
C26H28NO6 450.1911, Found 450.1871. 
5.5.2.14. Bis-(p-(pent-2-yn-1-yloxy)phenyl)pyridyl-2-methane (60) 
The compound was synthesized 
according to general procedure (III). 
Compound 46 (800 mg, 2.9 mmol, 1 
equiv.), NaH (60% in paraffin oil, 256 
mg, 6.4 mmol, 2.2 equiv.) and 1-bromo-
2-pentyne (0.76 mL, 953.8 mg, 6.4 
mmol, 2.2 equiv.). Reaction time: 3 h. Work up. Purification was done by column 
chromatography on silica gel using ethyl acetate/dichloromethane (3:97). Appearance: dark 
yellow oil. Yield: 750 mg (66%). Solubility: The compound is miscible with acetone and 
methanol, but immiscible with water. Analytical data: 
1
H-NMR (DMSO-d6, 600 MHz) δ 
(ppm) = 1.03 (t, J = 7.48 Hz, 6H, 2(-CH2-CH3)); 2.19 (qt, J = 2.10, 7.48 Hz, 4H, 2(-CH2-CH3)); 
4.68 (t, J = 2.21 Hz, 4H, 2(-CH2-C)); 5.53 (s, 1H, -CH); 6.87 (d, J = 8.71 Hz, 4H, 3-H, 3'-H, 5-H, 
5'-H); 7.10 (d, J = 8.68 Hz, 4H, 2-H, 2'-H, 6-H, 6'-H); 7.20-7.21 (m, 2H, 3-HPy, 4-HPy); 7.70 (td, J 
= 1.86, 7.69 Hz, 1H, 5-HPy); 8.50-8.51 (m, 1H, 6-HPy). 
13
C-NMR (DMSO, 151 MHz) δ (ppm) = 
11.83, 13.66, 56.01, 56.63, 75.20, 89.04, 114.62, 121.65 (5-CPy), 123.57 (3-CPy), 130.00, 136.03, 
136.82 (4-CPy), 149.26 (6-CPy), 156.01, 163.06. LC-MS: (m/z): positive mode 410.4 [M]
+
. Purity 
by HPLC-UV (220-400 nm)-ESI-MS: 99%. HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd. for 
C28H28NO2 410.2115, Found 410.2085. 
5.5.2.15. Bis-(p-(sec-butoxy)phenyl)pyridyl-2-methane (61) 
The compound was synthesized according to 
5.5.2.2. Reaction time: 1.5 h. Work up. 
Purification was done by column 
chromatography on silica gel using ethyl 
acetate/dichloromethane (2:98). Appearance: 
yellow oil. Yield: 520 mg (31%). Solubility: 
The compound is miscible with acetone and methanol, but immiscible with water. Analytical 
Experimental Part 
- 155 - 
 
data: 
1
H-NMR (DMSO-d6, 600 MHz) δ (ppm) = 0.88 (t, J = 7.43 Hz, 6H, 2(-CH-(CH3)-CH2-
CH3)); 1.18 (d, J = 6.04 Hz, 6H, 2(-CH-(CH3)-CH2-CH3)); 1.49-1.64 (m, 4H, 2(-CH-(CH3)-CH2-
CH3)); 4.27-4.30 (m, 2H, 2(-CH-(CH3)-CH2-CH3)); 5.49 (s, 1H, -CH); 6.81 (d, J = 8.75 Hz, 4H, 
3-H, 3'-H, 5-H, 5'-H); 7.06 (d, J = 8.65 Hz, 4H, 2-H, 2'-H, 6-H, 6'-H); 7.19-7.21 (m, 2H, 3-HPy, 4-
HPy); 7.70 (td, J = 1.87, 7.68 Hz, 1H, 5-HPy); 8.50-8.51 (m, 1H, 6-HPy). 
13
C-NMR (DMSO, 151 
MHz) δ (ppm) = 9.69 (-CH-(CH3)-CH2-CH3), 19.24 (-CH-(CH3)-CH2-CH3), 28.73 (-CH-(CH3)-
CH2-CH3), 56.69 (-CH), 74.15 (-CH-(CH3)-CH2-CH3), 115.39, 121.57 (5-CPy), 123.53 (3-CPy), 
130.08, 135.29, 136.77 (4-CPy), 149.22 (6-CPy), 156.27, 163.28. LC-MS: (m/z): positive mode 
390 [M]
+
. Purity by HPLC-UV (220-400 nm)-ESI-MS: 96%. HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd. for C26H32NO2 390.2428, Found 390.2358. 
 
5.5.2.16. Bis-(p-(octyloxy)phenyl)pyridyl-2-methane (62) 
The compound was 
synthesized 
according to 
5.5.2.7. Reaction 
time: 3 h. Work 
up. Purification 
was done by column chromatography on silica gel using ethyl acetate/dichloromethane (1:99). 
Appearance: yellow oil. Yield: 400 mg (55%). Solubility: The compound is soluble in acetone 
and dichloromethane, but insoluble in water. Analytical data: 
1
H-NMR (DMSO-d6, 500 MHz) 
δ (ppm) = 0.83-0.85 (m, 6H, 2(-OCH2-(CH2)5-CH2-CH3)); 1.24-1.30 (m, 16H, 2(-OCH2-CH2-
CH2-(CH2)4-CH3)); 1.34-1.40 (m, 4H, 2(-OCH2-CH2-CH2-(CH2)4-CH3)); 1.63-1.69 (m, 4H, 2(-
OCH2-CH2-CH2-(CH2)4-CH3)); 3.89 (t, J = 6.50 Hz, 4H, 2(-OCH2-CH2-CH2-(CH2)4-CH3)); 5.50 
(s, 1H, -CH); 6.81 (d, J = 8.70 Hz, 4H, 3-H, 3'-H, 5-H, 5'-H); 7.06 (d, J = 8.25 Hz, 4H, 2-H, 2'-H, 
6-H, 6'-H); 7.17-7.21 (m, 2H, 3-HPy, 4-HPy); 7.69 (td, J = 1.89, 7.68 Hz, 1H, 5-HPy); 8.49-8.50 
(m, 1H, 6-HPy). 
13
C-NMR (DMSO, 151 MHz) δ (ppm) = 14.05 (-OCH2-(CH2)5-CH2-CH3), 
22.18 (-OCH2-(CH2)5-CH2-CH3), 25.65, 28.76, 28.83, 28.84, 31.34 (-OCH2-CH2-CH2-(CH2)4-
CH3), 56.69 (-CH), 67.47 (-OCH2-(CH2)5-CH2-CH3), 114.25, 121.55 (5-CPy), 123.49 (3-CPy), 
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130.00, 135.40, 136.72 (4-CPy), 149.20 (6-CPy), 157.18, 163.26. LC-MS: (m/z): positive mode 
502.3 [M]
+
. Purity by HPLC-UV (220-400 nm)-ESI-MS: 96%. HRMS (ESI-TOF) m/z: 
[M+H]
+ 
Calcd. for C34H48NO 502.3680, Found 502.3701. 
5.5.2.17. (Pyridin-2-ylmethylene)-bis-(4,1-phenylene)-bis-(4-methoxybenzoate) (63) 
The compound was 
synthesized according to 
5.5.2.8. Reaction time: 3 
h. Work up. Purification 
was done by column 
chromatography on silica 
gel using ethyl 
acetate/petroleum ether (15:85), followed by crystallization with diethyl ether. Appearance: 
white powder. Yield: 267 mg (68%); m.p. 170-172 
°
C. Solubility: The compound is soluble in 
acetone and dichloromethane, but insoluble in water. Analytical data: 
1
H-NMR (DMSO-d6, 600 
MHz) δ (ppm) = 3.86 (s, 6H, 2(-OCH3)); 5.79 (s, 1H, -CH); 7.11 (d, J = 8.89 Hz, 4H, 3-HArOMe, 
3'-HArOMe, 5-HArOMe, 5'-HArOMe); 7.20 (d, J = 8.61 Hz, 4H, 2-H, 2'-H, 6-H, 6'-H); 7.27 (m, 1H, 3-
HPy); 7.32-7.34 (m, 5H, 3-HAr, 3'-HAr, 5-HAr, 5'-HAr, 4-HPy); 7.77 (td, J = 1.86, 7.69 Hz, 1H, 5-
HPy); 8.06 (d, J = 8.90 Hz, 4H, 2-HArOMe, 2'-HArOMe, 6-HArOMe, 6'-HArOMe); 8.58-8.59 (m, J = 0.91, 
1.82, 4.78 Hz, 1H, 6-HPy). 
13
C-NMR (DMSO, 151 MHz) δ (ppm) = 55.77 (-OCH3), 56.73 (-
CH), 114.41, 121.10 (5-CPy), 121.89, 121.96, 123.86 (3-CPy), 130.14, 132.09, 137.09 (4-CPy), 
140.64, 149.26 (6-CPy), 149.46, 162.20, 163.86 (-CO), 164.34. LC-MS: (m/z): positive mode 
546.2 [M]
+
. Purity by HPLC-UV (220-400 nm)-ESI-MS: 100%. HRMS (ESI-TOF) m/z: 
[M+H]
+ 
Calcd. for C34H28NO6 546.1911, Found 546.1877. 
5.5.2.18. Bis-(p-((4-methoxybenzyl)oxy)phenyl)pyridyl-2-methane (64) 
The compound was 
synthesized according to 
general procedure (III). 
Compound 46 (800 mg, 
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2.9 mmol, 1 equiv.), NaH (60% in paraffin oil, 256 mg, 6.4 mmol, 2.2 equiv.) and 4-
methoxybenzyl chloride (0.9 mL, 1002 mg, 6.4 mmol, 2.2 equiv.). Reaction time: 2 h. Work up. 
Purification was done by column chromatography on silica gel using ethyl 
acetate/dichloromethane (1:99). Appearance: white powder. Yield: 440 mg (29%); m.p. 122-
124 
°
C. Solubility: The compound is soluble in acetone and methanol, but insoluble in water. 
Analytical data: 
1
H-NMR (DMSO-d6, 600 MHz) δ (ppm) = 3.73 (s, 6H, 2(-OCH3)); 4.95 (s, 
4H, 2(-CH2)); 5.52 (s, 1H, -CH); 6.90 (d, J = 8.79 Hz, 4H, 3-HArOMe, 3'-HArOMe, 5-HArOMe, 5'-
HArOMe); 6.92 (d, J = 8.70 Hz, 4H, 2-H, 2'-H, 6-H, 6'-H); 7.07 (d, J = 8.71 Hz, 4H, 2-HArOMe, 2'-
HArOMe, 6-HArOMe, 6'-HArOMe); 7.18-7.21 (m, 2H, 3-HPy, 4-HPy); 7.34 (d, J = 8.66 Hz, 4H, 3-HAr, 
3'-HAr, 5-HAr, 5'-HAr); 7.70 (td, J = 1.86, 7.68 Hz, 1H, 5-HPy); 8.50-8.51 (m, 1H, 6-HPy). 
13
C-
NMR (DMSO, 151 MHz) δ (ppm) = 55.22 (-OCH3), 56.65 (-CH), 69.06 (-CH2), 113.93, 
114.62, 121.59 (5-CPy), 123.53 (3-CPy), 129.15, 129.54, 130.02, 135.66, 136.78 (4-CPy), 149.24 
(6-CPy), 156.92, 159.08, 163.18. LC-MS: (m/z): positive mode 518.3 [M]
+
. Purity by HPLC-UV 
(254 nm)-ESI-MS: 99%. HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd. for C34H32NO4 518.2326, 
Found 518.2312. 
5.5.2.19. Bis-(p-(benzyloxy)phenyl)pyridyl-2-methane (65) 
The compound was synthesized 
according to 5.5.2.9. Reaction time: 1 h. 
Work up. Purification was done by 
column chromatography on silica gel 
using ethyl acetate/dichloromethane 
(2:98), followed by crystallization with 
diethyl ether. Appearance: white 
powder. Yield: 517 mg (39%); m.p. 113-115 
°
C. Solubility: The compound is soluble in acetone 
and methanol, but insoluble in water. Analytical data: 
1
H-NMR (DMSO-d6, 500 MHz) δ (ppm) 
= 5.52 (s, 4H, 2(-CH2)); 5.52 (s, 1H, -CH); 6.92 (d, J = 8.68 Hz, 4H, 3-HAr, 3'-HAr, 5-HAr, 5'-HAr); 
7.09 (d, J = 8.61 Hz, 4H, 2-HAr, 2'-HAr, 6-HAr, 6'-HAr); 7.19-7.21 (m, 2H, 3-HPy, 4-HPy); 7.29-7.32 
(m, 2H, 4-HPh, 4'-HPh); 7.35-7.38 (m, J = 7.52 Hz, 4H, 2-HPh, 2'-HPh, 6-HPh, 6'-HPh); 7.41 (d, J = 
6.96 Hz, 4H, 3-HPh, 3'-HPh, 5-HPh, 5'-HPh); 7.70 (td, J = 1.87, 7.68 Hz, 1H, 5-HPy); 8.50-8.51 (m, 
1H, 6-HPy). 
13
C-NMR (DMSO, 151 MHz) δ (ppm) = 56.64 (-CH), 69.32 (-CH2), 114.62, 121.58 
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(5-CPy), 123.52 (3-CPy), 127.73, 127.88, 128.52, 130.04, 135.77, 136.77 (4-CPy), 137.29, 149.22 
(6-CPy), 156.88, 163.12. LC-MS: (m/z): positive mode 458.3 [M]
+
. Purity by HPLC-UV (220-
400 nm)-ESI-MS: 96%. HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd. for C32H28NO2 458.2115, 
Found 458.2079. 
 
 
 
 
5.5.2.20. Bis-(p-phenethoxyphenyl)pyridyl-2-methane (66) 
The compound was synthesized 
according to 5.5.2.10. Reaction 
time: 1 h. Work up. Purification 
was done by column 
chromatography on silica gel using 
ethyl acetate/dichloromethane 
(3:97). Appearance: colorless oil. 
Yield: 700 mg (33%). Solubility: The compound is miscible with acetone and methanol, but 
immiscible with water. Analytical data: 
1
H-NMR (Methanol-d4, 600 MHz) δ (ppm) = 3.08 (t, 
J = 6.85 Hz, 4H, 2(-OCH2-CH2-Ph)); 4.19 (t, J = 6.87 Hz, 4H, 2((-OCH2-CH2-Ph)); 5.60 (s, 1H, -
CH); 6.87 (d, J = 8.71 Hz, 4H, 3-H, 3'-H, 5-H, 5'-H); 7.02 (d, J = 8.72 Hz, 4H, 2-H, 2'-H, 6-H, 6'-
H); 7.16 (d, J = 7.92 Hz, 1H, CHPh); 7.22-7.24 (m, 2H, 3-HPy, 4-HPy); 7.28-7.35 (m, 9H, CHPh); 
7.78 (td, J = 1.84, 7.74 Hz, 1H, 5-HPy); 8.48 (d, J = 4.30 Hz, 1H, 6-HPy). 
13
C-NMR (151 MHz, 
MeOD) δ (ppm) = 37.06 (-OCH2-CH2-Ph), 58.90 (-CH), 70.18 (-OCH2-CH2-Ph), 115.83, 123.33 
(5-CPy), 125.73 (3-CPy), 127.66, 129.70, 130.31, 131.61, 136.54 (4-CPy), 138.94, 140.17, 149.93 
(6-CPy), 159.31, 165.36. LC-MS: (m/z): positive mode 486.3 [M]
+
. Purity by HPLC-UV (220-
400 nm)-ESI-MS: 97%. HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd. for C34H32NO2 486.2428, 
Found 486.2398. 
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5.5.2.21. 4-((4-(2-Morpholinoethoxy)phenyl)(pyridin-2-yl)methyl)phenol (67) 
The compound was synthesized from 
compound 50 (192 mg, 0.5 mmol, 1 equiv.), 
anhydrous K2CO3 (138 mg, 1 mmol, 2 equiv.), 
morpholine (0.09 mL, 1mmol, 1 equiv.) and 
acetonitrile (20 mL) at 60 
°
C. Reaction time: 13 
h. Work up. Purification was done by column 
chromatography on silica gel using ethyl acetate/petroleum ether (30:70). Appearance: beige 
powder. Yield: 105 mg (54%); m.p. 140-142 
°
C. Solubility: The compound is soluble in acetone 
and methanol, but insoluble in water. Analytical data: 
1
H-NMR (DMSO-d6, 500 MHz) δ (ppm) 
= 2.43-2.45 (m, 4H, -N(CH2)2-(CH2)2-O); 2.65 (t, J = 5.75 Hz, 2H, -OCH2-CH2N-); 3.54-3.56 (m, 
4H, -N(CH2)2-(CH2)2-O); 4.02 (t, J = 5.75 Hz, 2H, -OCH2-CH2N-); 5.45 (s, 1H, -CH); 6.66 (d, J 
= 8.58 Hz, 2H, 3-HArOH, 5-HArOH); 6.83 (d, J = 8.75 Hz, 2H, 3-HArOH, 5-HAr); 6.95 (d, J = 8.64 
Hz, 2H, 2-HArOH, 6-HArOH); 7.06 (d, J = 8.78 Hz, 2H, 2-HAr, 6-HAr); 7.16-7.20 (m, 2H, 3-HPy, 4-
HPy); 7.69 (td, J = 1.88, 7.69 Hz, 1H, 5-HPy); 8.48-8.50 (m, 1H, 6-HPy); 9.19 (s, 1H, -OH). 
13
C-
NMR (DMSO, 126 MHz) δ (ppm) = 26.47 (-OCH2-CH2N-), 53.74 (-N(CH2)2-(CH2)2-O), 56.79 
(-CH), 57.17 (-OCH2-CH2N-), 65.41, 66.30 (-N(CH2)2-(CH2)2-O), 114.27, 115.08, 121.48(5-CPy), 
123.45(3-CPy), 129.94, 130.01, 133.73, 135.79, 136.67(4-CPy), 149.15(6-CPy), 155.77, 156.89, 
163.45. LC-MS: (m/z): positive mode 391.2 [M]
+
. Purity by HPLC-UV (220-400 nm)-ESI-MS: 
99%. HRMS (ESI-TOF) m/z: [M-H]
- 
Calcd. for C24H25N2O3 389.1871, Found 389.1886.  
5.5.2.22. 2-((4-(2-Bromoethoxy)phenyl)(4-(sec-butoxy)phenyl)methyl)pyridine (68)  
The compound was synthesized according to 
general procedure (III). Compound 50 (400 
mg, 1.2 mmol, 1 equiv.), NaH (60% in 
paraffin oil, 52 mg, 1.3 mmol, 1.1 equiv.) and 
1,2-dibromoethane (0.1 mL, 244 mg, 1.3 
mmol 1.1 equiv.). Reaction time: 2 h. Work 
up. Purification was done by column chromatography on silica gel using ethyl 
acetate/dichloromethane (5:95). Appearance: light brown oil. Yield: 150 mg (28%). Solubility: 
The compound is soluble in acetone and methanol, but insoluble in water. Analytical data: 
1
H-
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NMR (Methanol-d4, 600 MHz) δ (ppm) = 0.99 (t, J = 7.45 Hz, 3H, (-CH(CH3)-CH2-CH3)); 
1.27 (d, J = 6.05 Hz, 3H, (-CH(CH3)-CH2-CH3)); 1.59-1.76 (m, 2H, (-CH(CH3)-CH2-CH3)); 3.69 
(t, J = 5.77 Hz, 2H, -OCH2-CH2Br); 4.30 (t, J = 5.78 Hz, 2H, -OCH2-CH2Br); 4.34 (q, J = 6.03 
Hz, 1H, -CH(CH3)-CH2-CH3); 5.61 (s, 1H, -CH); 6.86 (d, J = 8.72 Hz, 2H, 3-H, 5-H), 6.90 (d, J 
= 8.74 Hz, 2H, 3'-H, 5'-H); 7.02 (d, J = 8.64 Hz, 2H, 2-H, 6-H); 7.06 (d, J = 8.63 Hz, 2H, 2'-H, 
6'-H); 7.17 (d, J = 7.93 Hz, 1H, 3-HPy); 7.29 (ddd, J = 1.14, 4.94, 7.55 Hz, 1H, 4-HPy); 7.77 (td, J 
= 1.85, 7.73 Hz, 1H, 5-HPy); 8.49 (d, J = 4.09 Hz, 1H, 6-HPy). 
13
C-NMR (MeOD, 151 MHz) δ 
(ppm) = 10.36(-CH(CH3)-CH2-CH3)), 19.90(-CH(CH3)-CH2-CH3)), 30.55 (-OCH2-CH2Br), 
30.82(-CH(CH3)-CH2-CH3)), 58.89 (-CH), 69.63 (-OCH2-CH2Br), 76.37 (-CH(CH3)-CH2-CH3)), 
116.01, 117.15, 123.34 (5-CPy), 125.70 (3-CPy), 131.63, 131.73, 136.22 (4-CPy), 137.20, 138.94, 
149.96 (6-CPy), 158.59, 158.72, 165.25. LC-MS: (m/z): positive mode 440.1 [M]
+
. Purity by 
HPLC-UV (220-400 nm)-ESI-MS: 97%. HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd. for 
C24H27BrNO2 440.1220, Found 440.1167. 
5.5.2.23. 2-((4-(Benzyloxy)phenyl)(4-(prop-2-ynyloxy)phenyl)methyl)pyridine (69) 
The compound was synthesized according 
to general procedure (III). Compound 55 
(100 mg, 0.27 mmol, 1 equiv.), NaH (60% 
in paraffin oil, 12 mg, 0.297 mmol, 1.1 
equiv.) and propargyl bromide (0.03 mL, 
35 mg, 0.297 mmol, 1.1 equiv.). Reaction 
time: 1 h. Work up. Purification was 
done by column chromatography on silica gel using ethyl acetate/dichloromethane (1:99). 
Appearance: brown oil. Yield: 30 mg (41%). Solubility: The compound is miscible with acetone 
and methanol, but immiscible with water. Analytical data: 
1
H-NMR (DMSO-d6, 600 MHz) δ 
(ppm) = 3.51 (t, J = 2.38 Hz, 1H, -CH2Ph); 4.73 (d, J = 2.40 Hz, 2H, -CH2-C); 5.04 (s, 2H, -CH); 
5.54 (s, 1H, -CH); 6.89 (d, J = 8.75 Hz, 2H); 6.92 (d, J = 8.74 Hz, 2H); 7.09-7.11 (m, 4H); 7.19-
7.21 (m, 2H); 7.30 (t, J = 7.28 Hz, 1H); 7.37 (t, J = 7.53 Hz, 2H); 7.41 (d, J = 7.21 Hz, 2H); 7.70 
(td, J = 1.91, 7.70 Hz, 1H, 5-HPy); 8.50-8.51 (m, 1H, 6-HPy). 
13
C-NMR (DMSO, 151 MHz) δ 
(ppm) = 55.48, 56.61 (-CH), 69.31, 78.24, 79.49, 114.63, 114.66, 121.62 (5-CPy), 123.55 (3-CPy), 
127.75, 127.90, 128.53, 130.02, 130.06, 135.70, 136.30(4-CPy), 136.81, 137.29, 149.25(6-CPy), 
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155.72, 156.90, 163.06. LC-MS: (m/z): positive mode 406.3 [M]
+
. Purity by HPLC-UV (254 
nm)-ESI-MS: 95%.HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd. for C28H24NO2 406.1802, Found 
406.1791. 
5.5.3. General synthetic procedure (IV)
 
 
An ice-cooled suspension of the corresponding methoxy derivatives (1 equiv.) in dry DCM (15 
mL) and a solution of BBr3 in DCM (1M, 3.5 equiv.) was added dropwise. The mixture obtained 
was allowed to warm up to reach rt and stirred vigorously overnight. The resulting mixture was 
poured over a cold saturated aqueous solution NaHCO3 and then extracted with EtOAc (2 × 25 
mL), dried over MgSO4, filtered, and concentrated in vacuum. The residue was chromatographed 
over column of silica gel to afford the corresponding pure products. 
5.5.4. Characterization of compounds 71-74 
5.5.4.1. Bis-(p-methoxyphenyl)(pyridin-2-yl)methanol (71)
 
 
To an oven-dried 100 mL two-necked flask, ethyl 
2-picolinate (0.7 mL, 756 mg, 5 mmol, 1 equiv.) 
was suspended in dry THF (20 mL) and then 
cooled using ice bath to 0 
°
C. 4-
Methoxyphenylmagnesium bromide solution (0.25 
M in THF, 40 mL, 2113 mg, 2 equiv.) in dry THF 
(30 mL) was added dropwise using a dropping 
funnel and the resulting mixture was further stirred for 3 h at the same temperature under argon 
atmosphere. The reaction was quenched with saturated NH4Cl solution (20 mL), and then 
extracted with ethyl acetate (3 × 50 mL) and the white precipitate which formed was stirred with 
ethyl acetate (2 × 15 ml). The organic extracts were combined, washed with brine (2 × 50 mL), 
dried over anhydrous MgSO4, filtered and then concentrated in rotary evaporator till dryness. 
After the solvent was evaporated, purification of the crude material carried out with flash column 
chromatography using ethyl acetate/petroleum ether (25:75) to afford the pure product. 
Appearance: yellowish powder. Yield: 600 mg (37%); m.p. 88-89 
°
C. Solubility: The 
compound is soluble in acetone and methanol, but insoluble in water. Analytical data: 
1
H-NMR 
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(DMSO-d6, 500 MHz) δ (ppm) = 3.71 (s, 6H, 2(-OCH3); 6.28 (s, 1H, -OH); 6.81 (d, J = 8.88 
Hz, 4H, 3-H, 3'-H, 5-H, 5'-H); 7.13 (d, J = 8.84 Hz, 4H, 2-H, 2'-H, 6-H, 6'-H); 7.24 (ddd, J = 
1.14, 4.80, 7.48 Hz, 1H); 7.54 (dt, J = 1.06, 7.96 Hz, 1H); 7.77 (ddd, J = 1.85, 7.50, 7.98 Hz, 
1H); 8.49-8.50 (m, 1H, 6-HPy). 
13
C-NMR (DMSO, 126 MHz) δ (ppm) = 55.14 (-OCH3), 80.08, 
112.87, 121.47 (5-CPy), 121.91 (3-CPy), 129.11, 136.61 (4-CPy), 139.56, 147.84 (6-CPy), 158.03, 
165.46. 
 
 
 
5.5.4.2. 2-(Bis-(p-methoxyphenyl)(propoxy)methyl)pyridine (72) 
The compound was synthesized according to 
general procedure (III). Compound 71 (160 mg, 
0.52 mmol, 1 equiv.), NaH (60% in paraffin oil, 23 
mg, 0.57 mmol, 1.1 equiv.) and 1-bromopropane 
(0.02 mL, 33 mg, 0.57 mmol, 1.1 equiv.). 
Reaction time: 1 h. Work up. Purification was 
done by column chromatography on silica gel 
using ethyl acetate/petroleum ether (7:93). Appearance: pale yellow solid. Yield: 120 mg (64%); 
m.p. 100-102 
°
C. Solubility: The compound is soluble in acetone, ethyl acetate and methanol, but 
insoluble in water. Analytical data: 
1
H-NMR (DMSO-d6, 500 MHz) δ (ppm)
 
= 0.88 (t, J = 7.40 
Hz, 3H, -OCH2-CH2-CH3); 1.53-1.60 (m, 2H, -OCH2-CH2-CH3); 2.96 (t, J = 6.61 Hz, 2H, -
OCH2-CH2-CH3); 3.72 (s, 6H, 2(-OCH3); 6.84 (d, J = 8.90 Hz, 4H, 3-H, 3'-H, 5-H, 5'-H); 7.19 
(m, 1H); 7.22 (d, J = 8.95 Hz, 4H, 2-H, 2'-H, 6-H, 6'-H); 7.70 (dt, J = 1.09, 8.03 Hz, 1H); 7.75-
7.79 (m, J = 1.89, 7.42, 8.04 Hz, 1H); 8.46-8.48 (m, 1H, 6-HPy).
 13
C-NMR (DMSO, 126 MHz) δ 
(ppm) = 10.89 (-OCH2-CH2-CH3), 22.92 (-OCH2-CH2-CH3), 55.12 (-OCH3), 64.97 (-OCH2-
CH2-CH3), 85.67, 112.95, 120.80 (5-CPy), 121.69 (3-CPy), 130.09, 135.66, 136.70 (4-CPy), 148.45 
(6-CPy), 158.11, 164.30. 
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5.5.4.3. 3-Methoxy-10-(4-methoxyphenyl)pyrido[1,2-a]indole (73)
 
 
The above compound was synthesized using an 
adapted reported procedure. Bis(4-
methoxyphenyl)(pyridin-2-yl)methanol (71) (230 mg, 
0.71 mmol, 1 equiv.) was placed in pressure tube and 
formic acid (3 mL) was added, then the mixture was 
heated at 120 
o
C. After cooling, neutralization of the 
remaining formic acid was accomplished with a saturated aqueous solution of NaHCO3. The 
aqueous mixture was extracted with EtOAc (3 × 50 mL) and the combined organic layers were 
washed with brine (2 × 25 mL), dried over Na2SO4, filtered and then concentrated under vacuum. 
The pure compound was obtained after purification by column chromatography using ethyl 
acetate/petroleum ether (5:95) then crystallized with diethyl ether. Reaction time: 6 h. 
Appearance: pale yellow solid. Yield: 200 mg (93%); m.p. 156-158 
°
C. Solubility: The 
compound is soluble in acetone and ethyl acetate, but in soluble in water. Analytical data: 
1
H-
NMR (DMSO-d6, 600 MHz) δ (ppm)
 
= 3.81 (s, 3H); 3.89 (s, 3H); 6.56 (t, J = 6.24 Hz, 1H); 
6.88-6.90 (m, 1H); 7.04-7.08 (m, 3H); 7.52 (d, J = 8.65 Hz, 2H); 7.56 (d, J = 9.34 Hz, 1H); 7.75 
(d, J = 8.84 Hz, 1H); 7.83 (d, J = 2.26 Hz, 1H); 8.76 (d, J = 7.17 Hz, 1H). 
13
C-NMR (DMSO, 
151 MHz) δ (ppm) = 55.28, 55.80, 94.25, 104.43, 108.26, 114.46, 114.67, 117.61, 119.51, 
121.33, 121.98, 125.40, 127.11, 129.58, 129.62, 131.39, 154.95, 157.44. 
5.5.4.4. 10-(4-Hydroxyphenyl)pyrido[1,2-a]indol-3-ol (74) 
The compound was synthesized according to general 
procedure (IV). Compound 73 (190 mg, 0.62 mmol, 1 
equiv.) and BBr3 in DCM (1M, 2.17 mL, 2.17 mmol, 3.5 
equiv.). Reaction time: 12 h. Work up. Purification was 
done by flash column chromatography on silica gel using 
ethyl acetate/dichloromethane (5:95). Appearance: 
greenish solid. Yield: 85 mg (50%); m.p. 94-96 
°
C. Solubility: The compound is soluble in 
acetone and ethyl acetate, but insoluble in water. Analytical data:
 1
H-NMR (DMSO-d6, 500 
MHz) δ (ppm) = 6.46 (m, 1H); 6.80 (ddd, J = 1.07, 6.22, 9.35 Hz, 1H); 6.89 (d, J = 2.01 Hz, 
1H); 6.91 (d, J = 2.03 Hz, 1H); 6.95 (dd, J = 2.14, 8.72 Hz, 1H); 7.38 (d, J = 2.05 Hz, 1H); 7.39 
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(d, J = 2.02 Hz, 1H); 7.47 (d, J = 2.09 Hz, 1H); 7.50 (dt, J = 1.19, 9.27 Hz, 1H); 7.66 (d, J = 8.72 
Hz, 1H); 8.52 (d, J = 7.23 Hz, 1H); 9.34 (s, 2H). 
13
C-NMR (DMSO, 151 MHz) δ (ppm) = 
95.95, 104.81, 107.88, 114.60, 115.95, 117.72, 119.48, 120.67, 121.31, 125.15, 125.53, 129.57, 
129.86, 130.79, 152.53, 155.47. 
5.5.5. General synthetic procedure (V) (75-78)
 
 
To a mixture of the starting material (5.8 equiv.) and sulfuric acid (8.7 equiv.) which cooled in an 
ice bath to 0 
°
C, 2-pyridinecarboxaldehyde (1 equiv.) was added via syringe dropwise over 10 
min. The solution was allowed to reach room temperature (rt) and stirred overnight. The mixture 
was then poured onto crushed ice and extracted with EtOAc (50 mL). The aqueous layer 
containing the insoluble residue was neutralized with saturated solution of NaHCO3 and was then 
extracted two times with 25 mL of EtOAc each. The combined EtOAc layers were washed with 
brine (2 × 25 mL), dried over anhydrous Na2SO4, filtered and then concentrated under vacuum. 
The residual mixture was purified by column chromatography to afford the desired compounds. 
5.5.5.1. 2-Benzhydrylpyridine (75)
184
 
The compound was synthesized according to general procedure 
(V). 2-Pyridinecarboxaldehyde (0.2 mL, 214 mg, 2 mmol, 1 
equiv.) and benzene (1 mL, 877 mg, 11.6 mmol, 5.8 equiv.) in 
sulfuric acid (0.93 mL, 1706.4 mg, 17.4 mmol, 8.7 equiv.). 
Reaction time: 13 h. Work up. Purification was done by 
column chromatography on silica gel using ethyl 
acetate/dichloromethane (5:95). Appearance: pale yellow 
powder. Yield: 300 mg (61%); m.p. 62-64 
°
C. Solubility: The compound is soluble in acetone, 
ethyl acetate and methanol, but insoluble in water. Analytical data: 
1
H-NMR (DMSO-d6, 500 
MHz) δ (ppm) = 5.67 (s, 1H, -CH); 7.18-7.24 (m, 8H, CHPh); 7.27-7.30 (m, 4H, 2CHPh, 3-HPy, 
4-HPy); 7.72 (td, J = 1.51, 7.37 Hz, 1H, 5-HPy); 8.52-8.54 (m, 1H, 6-HPy). 
13
C-NMR (DMSO, 
126 MHz) δ (ppm) = 58.21 (-CH), 121.74 (5-CPy), 123.73 (3-CPy), 126.37, 128.35, 129.15, 
136.83 (4-CPy), 143.13, 149.29 (6-CPy), 162.51. LC-MS: (m/z): positive mode 245.9 [M]
+
. Purity 
by HPLC-UV (220-400 nm)-ESI-MS: 96%. HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd. for 
C18H16N 246.1277, Found 246.1275. 
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5.5.5.2. 2-(Bis-(p-fluorophenyl)methyl)pyridine (76) 
The compound was synthesized according to general procedure 
(V). 2-Pyridinecarboxaldehyde (0.2 mL, 214 mg, 2 mmol, 1 
equiv.) and fluorobenzene (1.1 mL, 1114.8 mg, 11.6 mmol, 5.8 
equiv.) in sulfuric acid (0.93 mL, 1706.4 mg, 17.4 mmol, 8.7 
equiv.). Reaction time: 13 h. Work up. Purification was done 
by column chromatography on silica gel using ethyl 
acetate/petroleum ether (15:85). Appearance: colorless oil. Yield: 140 mg (25%). Solubility: 
The compound is miscible with acetone, ethyl acetate and methanol, but immiscible with water. 
1
H-NMR (DMSO-d6, 500 MHz) δ (ppm) = 5.71 (s, 1H, -CH); 7.09-7.13 (m, 4H, CHPh); 7.22-
7.28 (m, 6H, 4CHPh, 3-HPy, 4-HPy); 7.74 (td, J = 1.89, 7.68 Hz, 1H, 5-HPy); 8.53-8.55 (m, 1H, 6-
HPy). 
13
C-NMR (DMSO, 126 MHz) δ (ppm) = 56.18 (-CH), 115.03, 115.20, 121.92 (5-CPy), 
123.76 (3-CPy), 130.84, 130.90, 137.07 (4-CPy), 139.25, 139.27, 149.41 (6-CPy), 159.95, 161.88, 
162.10. LC-MS: (m/z): positive mode 282 [M]
+
. Purity by HPLC-UV (220-400 nm)-ESI-MS: 
97%. HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd. for C18H14F2N 282.1089, Found 282.1083. 
5.5.5.3. 4,4'-(Pyridin-2-ylmethylene)-bis-(2-fluorophenol) (77) 
The compound was synthesized according to general 
procedure (V). 2-Pyridinecarboxaldehyde (0.2 mL, 214 mg, 
2 mmol, 1 equiv.) and 2-fluorophenol (1 mL, 1300.4 mg, 
11.6 mmol, 5.8 equiv.) in sulfuric acid (0.93 mL, 1706.4 
mg, 17.4 mmol, 8.7 equiv.). Reaction time: 9 h. Work up. 
The purification was done by column chromatography on 
silica gel using ethyl acetate/dichloromethane (5:95). 
Appearance: yellow powder. Yield: 370 mg (60%); m.p. 246-248 
°
C. Solubility: The compound 
is soluble in acetone and methanol, but insoluble in water. Analytical data: 
1
H-NMR (DMSO-
d6, 500 MHz) δ (ppm) = 5.46 (s, 1H,-CH); 6.79 (dd, J = 2.08, 8.39 Hz, 2H, 5-H, 4'-H); 6.84-6.87 
(m, 2H, 3-H, 5'-H); 6.92 (dd, J = 2.07, 12.64 Hz, 2H, 6-H, 6'-H); 7.20-7.23 (m, 2H, 3-HPy, 4-HPy); 
7.71 (td, J = 1.88, 7.67 Hz, 1H, 5-HPy); 8.5-8.53 (m, 1H, 6-HPy); 9.66 (br s, 2H, -OH). 
13
C-NMR 
(DMSO, 126 MHz) δ (ppm) = 55.92(-CH), 116.41, 116.56, 117.61, 117.63, 121.81(5-CPy), 
123.59(3-CPy), 125.00, 125.03, 134.62, 134.66, 136.95(4-CPy), 143.26, 143.36, 149.32(6-CPy), 
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149.85, 151.77, 162.45. LC-MS: (m/z): positive mode 314 [M]
+
. Purity by HPLC-UV (254 
nm)-ESI-MS: 97%. HRMS (ESI-TOF) m/z: [M-H]
- 
Calcd. for C18H12F2NO2 312.0842, Found 
312.0859. 
 
 
 
 
5.5.5.4. 4,4'-(Pyridin-2-ylmethylene)bis(2-iodophenol) (78) 
The compound was synthesized according to general procedure 
(V). 2-Pyridinecarboxaldehyde (0.2 mL, 214 mg, 2 mmol, 1 
equiv.) and 2-iodoophenol (2552.1 mg, 11.6 mmol, 5.8 equiv.) 
in sulfuric acid (0.93 mL, 1706.4 mg, 17.4 mmol, 8.7 equiv.) 
and DCM (5 mL). Reaction time: 14 h. Work up. The 
purification was done by column chromatography on silica gel 
using ethyl acetate/dichloromethane (5:95). Appearance: white 
powder. Yield: 250 mg (24%); m.p. 186-187 
°
C. Solubility: The compound is soluble in acetone, 
ethyl acetate, dichloromethane and methanol, but insoluble in water. Analytical data: 
1
H-NMR 
(DMSO-d6, 500 MHz) δ (ppm) = 5.43 (s, 1H, -CH); 6.79 (d, J = 8.35 Hz, 2H; 3-H; 3'-H); 7.01 
(dd, J = 2.23, 8.38 Hz, 2H, 5-H; 5'-H); 7.21-7.23 (m, 2H, 3-HPy, 4-HPy); 7.46 (d, J = 2.21 Hz, 2H, 
6-H; 6'-H); 7.72 (td, J = 1.89, 7.65 Hz, 1H, 5-HPy); 8.51-8.53 (m, 1H, 6-HPy). 
13
C-NMR 
(DMSO, 126 MHz) δ (ppm) = 84.46 (-CH), 114.87, 121.77 (5-CPy), 123.59 (3-CPy), 130.11, 
135.92, 136.97 (4-CPy), 138.87, 149.32 (6-CPy), 155.16, 162.44. LC-MS: (m/z): positive mode 
529.9 [M]
+
. Purity by HPLC-UV (220-400 nm)-ESI-MS: 97%. HRMS (ESI-TOF) m/z: [M-H]
-
 
Calcd. for C18H12I2NO2 527.8963, Found 527.8960. 
5.5.5.5. 2-(Bis(3-iodo-4-methoxyphenyl)methyl)pyridine (78a) 
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The compound was synthesized according to general 
procedure (III). Compound 78 (132 mg, 0.25 mmol), 
NaH (60% in paraffin oil, 22 mg, 0.55 mmol, 2.2 equiv.) 
and iodomethane (0.03 mL, 78 mg, 0.55 mmol, 2.2 
equiv.). Reaction time: 30 min. Work up. Purification 
was done by column chromatography on silica gel using 
ethyl acetate/dichloromethane (7:93). Appearance: 
white powder. Yield: 115 mg (83%); m.p. 68-70 
°
C. Solubility: The compound is soluble in 
acetone, dichloromethane and methanol, but insoluble in water. Analytical data: 
1
H-NMR 
(DMSO-d6, 500 MHz) δ (ppm) = 3.77 (s, 6H, 2-OCH3); 5.56 (s, 1H, -CH); 6.93 (d, J = 8.53 Hz, 
2H, 3-H; 3'-H); 7.19 (dd, J = 2.21, 8.50 Hz, 2H, 5-H; 5'-H); 7.22-7.27 (m, 2H, 3-HPy, 4-HPy ); 
7.59 (d, J = 2.20 Hz, 2H, 6-H; 6'-H); 7.74 (td, J = 1.90, 7.70 Hz, 1H, 5-HPy); 8.54-8.55 (m, 1H, 6-
HPy). 
13
C-NMR (DMSO, 126 MHz) δ (ppm) = 54.85 (-OCH3), 56.49 (-CH), 86.01, 111.57, 
121.93 (5-CPy), 123.73 (3-CPy), 130.29, 137.11 (4-CPy), 137.41, 139.16, 149.43 (6-CPy), 156.43, 
162.02. LC-MS: (m/z): positive mode 557.8 [M]
+
. Purity by HPLC-UV (220-400 nm)-ESI-MS: 
98%. HRMS (ESI-TOF) m/z: [M-H]
- 
Calcd. for C20H16I2NO2 555.9276, Found 555.9265. 
5.5.6. Characterization of the synthesized derivatives (80, 81, 83, 85, 87 and 88) 
5.5.6.1. Bis-(p-propoxyphenyl)methane (80) 
The compound was synthesized 
according to general procedure (III). 
4,4'-methylenediphenol (79) (600 mg, 
3 mmol, 1 equiv.), NaH (60% in 
paraffin oil, 264 mg, 6.6 mmol, 2.2 
equiv.) and 1-bromopropane (0.6 mL, 811.8 mg, 6.6 mmol, 2.2 equiv.). Reaction time: 4 h. 
Work up. Purification was done by column chromatography on silica gel using ethyl 
acetate/dichloromethane (2:98). Appearance: yellow oil. Yield: 300 mg (35%). Solubility: The 
compound is miscible with acetone and methanol, but immiscible with water. Analytical data: 
1
H-NMR (DMSO-d6, 600 MHz) δ (ppm) = 0.94 (t, J = 7.40 Hz, 6H, 2(-OCH2-CH2-CH3)); 1.65-
171 (m, 4H, 2(-OCH2-CH2-CH3)); 3.77 (s, 2H, -CH2); 3.85 (t, J = 6.52 Hz, 4H, 2(-OCH2-CH2-
CH3)); 6.81 (d, J = 8.55 Hz, 4H, 3-H, 3'-H, 5-H, 5'-H); 7.07 (d, J = 8.52 Hz, 4H, 2-H, 2'-H, 6-H, 
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6'-H).
13
C-NMR (DMSO, 151 MHz) δ (ppm) = 10.55 (-OCH2-CH2-CH3), 22.22 (-OCH2-CH2-
CH3), 39.50 (-CH2), 69.00 (-OCH2-CH2-CH3), 114.47, 114.67, 129.64, 133.71, 157.04. LC-MS: 
(m/z): positive mode 285 [M]
+
. Purity by HPLC-UV (220-400 nm)-ESI-MS: 95%. HRMS 
(ESI-TOF) m/z: [M+H]
+ 
Calcd. forC19H25O2 285.1849, Found 285.1853. 
5.5.6.2. Bis-(4-butoxyphenyl)methane (81)
247
 
The compound was synthesized 
according to general procedure (III). 
4,4'-methylenediphenol (79) (1200 mg, 
6 mmol, 1 equiv.), NaH (60% in 
paraffin oil, 528 mg, 13.2mmol, 2.2 
equiv.) and 1-bromobutane (1.4 mL, 1808.7 mg, , 13.2 mmol, 2.2 equiv.). Reaction time: 3 h. 
Work up. Purification was done by column chromatography on silica gel using ethyl 
acetate/dichloromethane (3:97), followed by recrystallization from ethyl acetate/cyclohexane 
(20:80). Appearance: yellowish powder. Yield: 1200 mg (64%); m.p. 46-48 
°
C. Solubility: The 
compound is soluble in acetone and methanol, but insoluble in water. Analytical data: 
1
H-NMR 
(DMSO-d6, 600 MHz) δ (ppm) = 0.90 (t, J = 7.41 Hz, 6H, 2(-OCH2-CH2-CH2-CH3)); 1.37-1.43 
(m, 4H, 2(-OCH2-CH2-CH2-CH3)); 1.62-1.67 (m, 4H, 2(-OCH2-CH2-CH2-CH3)); 3.76 (s, 2H, -
CH2); 3.89 (t, J = 6.49 Hz, 4H, 2(-OCH2-CH2-CH2-CH3)); 6.80 (d, J = 8.62 Hz, 4H, 3-H, 3'-H, 5-
H, 5'-H); 7.07 (d, J = 8.60 Hz, 4H, 2-H, 2'-H, 6-H, 6'-H). 
13
C-NMR (DMSO, 151 MHz) δ (ppm) 
= 13.84 (-OCH2-CH2-CH2-CH3), 18.89 (-OCH2-CH2-CH2-CH3), 39.50(-CH2), 67.18(-OCH2-
CH2-CH2-CH3), 114.47, 129.63, 133.71, 157.05. LC-MS: (m/z): positive mode 313.3 [M]
+
. 
Purity by HPLC-UV (220-400 nm)-ESI-MS: 99%. HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd. for 
C21H29O2 313.2162, Found 313.2158. 
5.5.6.3. 2,2-Bis-(p-propoxyphenyl)propane (83) 
The compound was synthesized according 
to general procedure (III). 2,2-Bis-(4-
hydroxyphenyl)propane (82) (685 mg, 3 
mmol, 1 equiv.), NaH (60% in paraffin oil, 
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264 mg, 6.6 mmol, 2.2 equiv.) and 1-bromopropane (0.6 mL, 811.8 mg, , 6.6 mmol, 2.2 equiv.). 
Reaction time: 4 h. Work up. Purification was done by column chromatography on silica gel 
using ethyl acetate/petroleum ether (10:90). Appearance: colorless oil. Yield: 700 mg (75%). 
Solubility: The compound is soluble in acetone and methanol, but insoluble in water. Analytical 
data: 
1
H-NMR (DMSO-d6, 600 MHz) δ (ppm) = 0.95 (t, J = 7.39 Hz, 6H, 2(-OCH2-CH2-CH3); 
1.56 (s, 6H, 2(-CH3)); 1.66-1.71 (m, J = 7.33 Hz, 4H, 2(-OCH2-CH2-CH3); 3.86 (t, J = 6.50 Hz, 
4H, 2(-OCH2-CH2-CH3); 6.79 (d, J = 8.75 Hz, 4H, 3-H, 3'-H, 5-H, 5'-H); 7.07 (d, J = 8.78 Hz, 
4H, 2-H, 2'-H, 6-H, 6'-H). 
13
C-NMR (DMSO, 151 MHz) δ (ppm) = 10.55 (-OCH2-CH2-CH3), 
22.21 (-OCH2-CH2-CH3), 30.87 (-CH3), 41.24 (-CH3), 68.93 (-OCH2-CH2-CH3), 113.89, 127.48, 
142.55, 156.54. LC-MS: (m/z): positive mode 313.2 [M]
+
. Purity by HPLC-UV (220-400 nm)-
ESI-MS: 98%. HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd. for C21H29O2 313.2162, Found 313.2165.  
5.5.6.4. 4,4'-(Propoxymethylene)-bis-(methoxybenzene) (85) 
The compound was synthesized according to 
general procedure (III). Bis-(4-
methoxyphenyl)methanol (84) (122 mg, 0.5 
mmol, 1 equiv.), NaH (60% in paraffin oil, 22 
mg, 0.55 mmol, 1.1 equiv.) and 1-bromopropane 
(0.05 mL, 68 mg, 0.55 mmol, 2.2 equiv.). 
Reaction time: 3 h. Work up. Purification was done by column chromatography on silica gel 
using ethyl acetate/dichloromethane (2:98). Appearance: colorless oil. Yield: 75 mg (52%). 
Solubility: The compound is soluble in acetone and methanol, but insoluble in water. Analytical 
data: 
1
H-NMR (DMSO-d6, 600 MHz) δ (ppm) = 0.87 (t, J = 7.40 Hz, 3H, -OCH2-CH2-CH3); 
1.51-1.56 (m, 2H, -OCH2-CH2-CH3); 3.28 (t, J = 6.52 Hz, 2H, -OCH2-CH2-CH3); 3.70 (s, 6H, 2(-
OCH3)); 5.28 (s, 1H, -CH); 6.86 (d, J = 8.66 Hz, 4H, 2-H, 2'-H, 6-H, 6'-H); 7.21 (d, J = 8.62 Hz, 
4H, 3-H, 3'-H, 5-H, 5'-H).
13
C-NMR (DMSO, 151 MHz) δ (ppm) = 10.84 (-OCH2-CH2-CH3), 
22.76 (-OCH2-CH2-CH3), 39.27 (-CH), 55.16 (-OCH3), 69.78 (-OCH2-CH2-CH3), 81.66, 113.74, 
127.83, 135.29, 158.43. 
5.5.6.5. 3,6-Dihydroxy-9H-xanthen-9-one (87)
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The synthetic procedure was achieved using a 
miniclave tube (Büchi AG, Uster, Switzerland). 
2,2',4,4' Tetrahydroxybenzophenone (86) (2000 mg, 
8.12 mmol) was treated with water (12 mL) and then 
heated using an oil bath at 150 °C and the pressure 
inside was 3 bar during the reaction time. The vessel 
was cooled to rt, and then the mixture was filtered using a vacuum pump. Pure product was 
obtained after crystallization with acetone : ethanol (2 : 1). Reaction time: 16 h. Appearance: 
light brown powder. Yield: 1200 mg (66%); m.p. > 300 
°
C. Solubility: The compound is soluble 
in acetone and ethyl acetate, but insoluble in water. Analytical data: 
1
H-NMR (DMSO-d6, 500 
MHz) δ (ppm) = 6.81 (s, 2H); 6.85 (d, J = 8.62 Hz, 2H); 7.98 (d, J = 8.69 Hz, 2H); 10.77 (br s, 
2H, -OH). 
13
C-NMR (DMSO, 126 MHz) δ (ppm) = 102.20, 113.77, 114.12, 127.87, 157.59, 
163.47, 174.01 (CO). LC-MS: (m/z): positive mode 229.3 [M]
+
. Purity by HPLC-UV (220-400 
nm)-ESI-MS: 99%. HRMS (ESI-TOF) m/z: [M-H]
- 
Calcd. for C13H7O4 227.0350, Found 
227.0374. 
5.5.6.6. 9H-xanthene-3,6-diol (88) 
The corresponding product 87 (578 mg, 2.5 mmol) was 
suspended in 60 mL of dry THF and borane-
tetrahydrofuran complex (1.0 M in THF) (10 mL) was 
added dropwise. The formed mixture was stirred 
vigorously at rt under argon atmosphere until a clear 
yellow solution was obtained. The excess solution was removed under reduced pressure and the 
sticky suspension was treated with 1.0 N HCl (15 mL) then filtered off. The residual material 
obtained was purified by flash column chromatography using ethyl acetate/dichloromethane 
(10:90) to afford the pure final product. Reaction time: 5 h. Appearance: orange yellow powder. 
Yield: (95%); m.p. 215-217 
°
C. Solubility: The compound is soluble in acetone, ethyl acetate 
and methanol, but insoluble in water. Analytical data: 
1
H-NMR (DMSO-d6, 600 MHz) δ (ppm) 
= 3.77 (s, 2H, -CH2); 6.40 (d, J = 2.38 Hz, 2H); 6.47 (dd, J = 2.44, 8.20 Hz, 2H); 6.98 (d, J = 
8.10 Hz, 2H); 9.41 (br s, 2H, -OH). 
13
C-NMR (DMSO, 151 MHz) δ (ppm) = 25.73 (-CH2), 
102.77, 110.87, 110.97, 129.72, 151.85, 156.94. LC-MS: (m/z): positive mode 215.2 [M]
+
. Purity 
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by HPLC-UV (220-400 nm)-ESI-MS: 95%. HRMS (ESI-TOF) m/z: [M-H]
- 
Calcd. for C13H9O3 
213.0557, Found 213.0577. 
5.5.7. General synthetic procedure (VI) used for the synthesized compounds 89, 90 and 95
 
 
Intermediates 87 and 88 or methyl 3-formyl-4-hydroxybenzoate (94) (1 equiv.) and anhydrous 
K2CO3 (5 equiv.) were suspended in the appropriate solvent (25 mL), the corresponding 
alkylating agent (15 equiv.) was added dropwise via syringe. The reaction mixture was refluxed 
until the starting material was consumed. The reaction mixture was cooled to rt and the solvent 
was removed under reduced pressure. The residue was taken up with water (25 mL) and extracted 
with EtOAc (3 × 50 mL). The combined extracts were washed with brine (2 × 25 mL), dried over 
anhydrous MgSO4, filtered and then concentrated under vacuum. The pure products were 
obtained via purification using column chromatography. 
5.5.7.1. 3,6-Dipropoxy-9H-xanthen-9-one (89) 
The compound was synthesized 
according to general procedure (VI). 
Compound 87 (228.2 mg, 1 mmol, 1 
equiv.), anhydrous K2CO3 (691 mg, 5 
mmol, 5 equiv.), 1-bromopropane 
(1.36 mL, 1884.9 mg, 15 mmol, 15 
equiv.) and acetone (25 mL). 
Reaction time: 16 h. Work up. Purification was done by column chromatography on silica gel 
using ethyl acetate/dichloromethane (2:98). Appearance: white powder. Yield: 110 mg (35%); 
m.p. 115-117 
°
C. Solubility: The compound is soluble in acetone and methanol, but insoluble in 
water. Analytical data: 
1
H-NMR (DMSO-d6, 500 MHz) δ (ppm) = 1.00 (t, J = 7.41 Hz, 6H, 2 
(-OCH2-CH2-CH3)); 1.74-1.81 (m, 4H, 2(-OCH2-CH2-CH3)); 4.10 (t, J = 6.51 Hz, 4H, 2(-OCH2-
CH2-CH3)); 7.02 (dd, J = 2.36, 8.80 Hz, 2H); 7.05 (d, J = 2.33 Hz, 2H); 8.05 (d, J = 8.81 Hz, 
2H). 
13
C-NMR (DMSO, 126 MHz) δ (ppm) = 10.42 (-OCH2-CH2-CH3), 21.93 (-OCH2-CH2-
CH3), 70.04 (-OCH2-CH2-CH3), 101.11, 113.65, 115.00, 127.59, 157.62, 164.10, 174.13 (CO). 
LC-MS: (m/z): positive mode 313.1 [M]
+
. Purity by HPLC-UV (220-400 nm)-ESI-MS: 99%. 
HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd. for C19H21O4 313.1434, Found 313.1439. 
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5.5.7.2. 3,6-Dipropoxy-9H-xanthene (90) 
The compound was synthesized according 
to general procedure (VI). Compound 88 
(53.6 mg, 0.25 mmol, 1 equiv.), anhydrous 
K2CO3 (172.7 mg, 1.25 mmol, 5 equiv.), 1-
bromopropane (0.3 mL, 461.2 mg, 3.75 
mmol, 15 equiv.) and acetonitrile (25 mL). Reaction time: 15 h. Work up. Purification was done 
by column chromatography on silica gel using ethyl acetate/petroleum ether (2:98). Appearance: 
white powder. Yield: 20 mg (27%); m.p. 83-84 
°
C. Solubility: The compound is soluble in 
acetone and methanol, but insoluble in water. Analytical data: 
1
H-NMR (DMSO-d6, 500 MHz) 
δ (ppm) = 0.96 (t, J = 7.39 Hz, 6H, 2(-OCH2-CH2-CH3)); 1.69-1.73 (m, 4H, 2(-OCH2-CH2-
CH3)); 3.86 (s, 2H, -CH2); 3.91 (t, J = 6.54 Hz, 4H, 2(-OCH2-CH2-CH3)); 6.59 (d, J = 2.53 Hz, 
2H); 6.63 (d, J = 2.53 Hz, 1H); 6.65 (d, J = 2.53 Hz, 1H); 7.11 (d, J = 8.38 Hz, 2H).
 13
C-NMR 
(DMSO, 126 MHz) δ (ppm) = 10.48 (-OCH2-CH2-CH3), 22.09 (-OCH2-CH2-CH3), 25.67 (-
CH2), 69.26 (-OCH2-CH2-CH3), 101.87, 110.35, 112.38, 114.46, 129.60, 129.80, 151.83, 158.36. 
LC-MS: (m/z): positive mode 299.3 [M]
+
. Purity by HPLC-UV (220-400 nm)-ESI-MS: 94%. 
HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd. for C19H23O3 299.1642, Found 299.1648. 
5.5.8. N
4
-(4-Methoxyphenyl)pyrimidine-2,4,6-triamine (91) 
4-Methoxyaniline (264 mg, 2 mmol, 1 equiv.), was 
added to a suspension of 6-chloro-2,4-
pyrimidinediamine (289 mg, 2 mmol, 1 equiv.) and 
DIPEA (0.4 mL, 284 mg, 2.2 mmol, 1.1 equiv.) in 
dioxane (25 mL). The reaction was refluxed under 
argon atmosphere and the formation of the compound 
was monitored by TLC. After the reaction was completed, the formed mixture was then allowed 
to cool and the solvent was removed using a vacuum pump. The residue was diluted with water 
(50 mL) and extracted with EtOAc (2 × 50 mL). The collected organic layers were washed with 
brine (2 × 25 mL), dried over Na2SO4, filtered and then concentrated to dryness. The residual 
material was purified by flash column chromatography using methanol/dichloromethane (5:95) to 
afford the pure title compound. Reaction time: 24 h. Appearance: light green powder. Yield: 
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120 mg (26%); m.p. 225-227 
°
C. Solubility: The compound is soluble in acetone and ethyl 
acetate, but insoluble in water. Analytical data: 
1
H-NMR (DMSO-d6, 600 MHz) δ (ppm) = 
3.73 (s, 3H,-OCH3); 5.19 (s, 1H, -HPyr); 6.89 (d, J = 8.90 Hz, 2H, 3-H, 5-H); 7.07 (s, 2H, -NH2); 
7.16 (s, 2H, -NH2); 7.35 (d, J = 8.64 Hz, 2H, 4-H, 6-H); 9.30 (s, 1H, -NH). 
13
C-NMR (DMSO, 
151 MHz) δ (ppm) = 55.75 (-OCH3), 74.23, 114.59, 124.51, 132.20, 155.93, 156.37. LC-MS: 
(m/z): positive mode 231.9 [M]
+
. Purity by HPLC-UV (220-400 nm)-ESI-MS: 99%. HRMS 
(ESI-TOF) m/z: [M+H]
+ 
Calcd. for C11H14N5O 232.1193, Found 232.1205. 
 
 
 
5.5.9. 3,3'-(Pyridin-2-ylmethylene)-bis-(5-methoxy-1H-indole) (92)
 
 
The compound was synthesized from 2-
pyridinecarboxaldhyde (0.2 mL, 2 mmol, 1 equiv.), 5-
methoxyindole (588 mg, 4 mmol, 2 equiv.) and 
sodium dodecyl sulfate (231 mg, 0.8 mmol, 0.4 
equiv.) in water (20 mL). Reaction time: 17 h. Work 
up. Purification was done by column chromatography 
on silica gel using ethyl acetate/petroleum ether 
(60:40). Appearance: light brown powder. Yield: 500 (65%); m.p. 118-120 
°
C. Solubility: The 
compound is soluble in acetone and ethyl acetate, but insoluble in water. Analytical data: 
1
H-
NMR (DMSO-d6, 500 MHz) δ (ppm) 
 
= 3.60 (s, 6H, 2(-OCH3)); 5.83 (s, 1H, -CH); 6.68 (dd, J = 
2.47, 8.74 Hz, 2H, 2-H, 2'-H); 6.77 (d, J = 2.51 Hz, 2H, 6-H, 6'-H); 6.93 (d, J = 2.39 Hz, 2H, 4-
H, 4'-H); 7.17 (ddd, J = 1.14, 4.84, 7.43 Hz, 1H, 3-HPy); 7.22 (d, J = 8.73 Hz, 2H, 7-H, 7'-H); 
7.37-7.39 (m, 1H, 4-HPy); 7.67 (td, J = 1.88, 7.64 Hz, 1H, 5-HPy); 8.48-8.50 (m, 1H, 6-HPy); 
10.65 (br s, 2H, 2(-NH)). 
13
C-NMR (DMSO, 126 MHz) δ (ppm) = 42.71 (-CH), 55.37 (-OCH3), 
101.34, 110.75, 112.09, 116.70, 121.27 (5-CPy), 122.61, 124.39 (3-CPy), 127.18, 131.76, 136.45 
(4-CPy), 148.76 (6-CPy), 152.86, 164.20. LC-MS: (m/z): positive mode 384.2 [M]
+
. Purity by 
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HPLC-UV (220-400 nm)-ESI-MS: 98%. HRMS (ESI-TOF) m/z: [M-H]
- 
Calcd. for 
C24H20N3O2 382.1561, Found 382.1574. 
5.5.10. 3,3'-(Pyridin-2-ylmethylene)-bis-(1H-indol-5-ol) (93) 
The compound was synthesized according to general 
procedure (IV). Compound 92 (191 mg, 0.5 mmol, 1 
equiv.) and BBr3 in DCM (1M, 1.8 ml, 1.75 mmol, 3.5 
equiv.). Reaction time: 12 h. Work up. Purification 
was done by column chromatography on silica gel using 
ethyl acetate/petroleum ether (60:40). Appearance: 
brown powder. Yield: 150 mg (85%); m.p. 118-120 
°
C. 
Solubility: The compound is soluble in acetone and ethyl acetate, but insoluble in water. 
Analytical data: 
1
H-NMR (DMSO-d6, 500 MHz) δ (ppm) = 5.65 (s, 1H, -CH); 6.53 (dd, J = 
2.34, 8.60 Hz, 2H, 2-H, 2'-H); 6.61 (d, J = 2.36 Hz, 2H, 6-H, 6'-H); 6.74 (d, J = 2.26 Hz, 2H, 4-
H, 4'-H); 7.11 (d, J = 8.56 Hz, 2H, 7-H, 7'-H); 7.17 (ddd, J = 1.16, 4.86, 7.50 Hz, 1H, 3-HPy); 
7.28-7.30 (m, 1H, 4-HPy); 7.65 (td, J = 1.89, 7.68 Hz, 1H, 5-HPy); 8.43 (s, 2H, 2-(OH)); 8.47-8.48 
(m, 1H, 6-HPy); 10.46 (d, J = 2.49 Hz, 2H, 2-(NH)). 
13
C-NMR (DMSO, 126 MHz) δ (ppm) = 
43.07 (-CH), 103.11, 111.30, 111.75, 116.07, 121.22, 122.43, 124.08, 127.48, 131.14, 136.34, 
148.74, 150.09, 164.18. LC-MS: (m/z): positive mode 356.3 [M]
+
. Purity by HPLC-UV (220-
400 nm)-ESI-MS: 95%. HRMS (ESI-TOF) m/z: [M-H]
- 
Calcd. for C22H16N3O2 354.1248, 
Found 354.1247. 
5.5.11. 5,5'-(4-(Benzy)loxy)-1,3-phenylene)-bis-(3-ethyl-1,2,4-oxadiazole) (99) 
5.5.11.1. Methyl 3-formyl-4-methoxybenzoate (95) 
The compound was synthesized according to general procedure (VI). 
Methyl 3-formyl-4-hydroxybenzoate (94) (900.8 mg, 5 mmol, 1 
equiv.), anhydrous K2CO3 (1382 mg, 10 mmol, 5 equiv.) and dimethyl 
sulfate (7.1 mL, 9460 mg, 75 mmol, 15 equiv.). Reaction time: 2 h. 
Work up. Purification was done by column chromatography on silica 
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gel using ethyl acetate/dichloromethane (2:98). Appearance: white powder. Yield: 850 mg 
(88%). Analytical data: 
1
H-NMR (DMSO-d6, 600 MHz) δ (ppm) = 3.84 (s, 3H, -OCH3); 3.99 
(s, 3H, -COOCH3); 7.35 (d, J = 8.78 Hz, 1H, 2-H); 8.19 (dd, J = 2.37, 8.78 Hz, 1H, 5-H); 8.23 (d, 
J = 2.34 Hz, 1H, 6-H); 10.33 (s, 1H, -CHO). 
13
C-NMR (DMSO, 151 MHz) δ (ppm) = 52.31 (-
COOCH3), 56.73 (-OCH3), 113.38, 122.10, 124.04, 129.38, 136.99, 164.72 (-COOCH3), 165.37, 
188.75 (-CHO). 
5.3.11.2. Propionamidoxime (96)
 
 
A solution of propionitrile (1.7 mL, 1377 mg, 25 mmol) in 
MeOH (45 mL) was brought to reflux. NH2-OH (50% 
hydroxylamine by wt. in water, 0.99 ml, 1073.5 mg, 32.5 
mmol, 1.3 equiv.) was added dropwise over 20 min via 
syringe. The resulting solution was refluxed overnight and 
then allowed to reach rt and evaporated. The residue was 
partially co-evaporated with toluene (3 × 25 mL) under reduced pressure. The desired compound 
was obtained as colorless viscous oil after drying over a high vacuum pump and used without any 
further purification. 
5.5.11.3. 5,5'-(4-Methoxy-1,3-phenylene)-bis-(3-ethyl-1,2,4-oxadiazole) (97)
 
 
Using dean-stark apparatus, methyl 3-formyl-4-
methoxybenzoate (95) (582.6 mg, 3 mmol, 1 equiv.), 
N-hydroxypropanimidamide (96) (528.6 mg, 6 mmol, 
2 equiv.) and anhydrous K2CO3 (829.3 mg, 6 mmol, 2 
equiv.) were suspended in toluene (100 mL).The 
mixture was refluxed at 150 
o
C and was controlled by 
TLC. The mixture was cooled to rt and solvent was 
removed under reduced pressure. Water (50 mL) was added and the mixture was extracted with 
EtOAc (3 × 50 mL). The combined organic layers were washed with brine (2 × 20 mL) and then 
were dried over MgSO4, filtered, and concentrated under vacuum. Purification was done using 
column chromatography on silica gel using ethyl acetate/dichloromethane (5:95) to give the titled 
compound. Reaction time: 48 h. Appearance: white powder. Yield: 250 mg (28%); m.p. 105-
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107 
°
C. Solubility: The compound is soluble in acetone and ethyl acetate, but insoluble in water. 
Analytical data: 
1
H-NMR (DMSO-d6, 600 MHz) δ (ppm) = 1.27-1.31 (m, 6H, 2(-CH2-CH3); 
2.77-2.83 (m, 4H, 2(-CH2-CH3); 4.04 (s, 3H, -OCH3); 7.52 (d, J = 8.91 Hz, 1H); 8.32 (dd, J = 
2.34, 8.84 Hz, 1H); 8.62 (d, J = 2.30 Hz, 1H). 
13
C-NMR (DMSO, 151 MHz) δ (ppm) = 11.33 (-
CH3), 11.40 (-CH3), 19.18 (-CH2-CH3), 19.25 (-CH2-CH3), 57.00 (-OCH3), 113.58, 114.34, 
116.33, 130.77, 133.82, 161.27, 171.40, 172.03, 173.30, 173.73. LC-MS: (m/z): positive mode 
300.9 [M]
+
. Purity by HPLC-UV (220-400 nm)-ESI-MS: 98%. HRMS (ESI-TOF) m/z: 
[M+H]
+ 
Calcd. for C15H17N4O3 301.1295, Found 301.1305. 
 
 
 
 
5.5.11.4. 2,4-Bis-(3-ethyl-1,2,4-oxadiazol-5-yl)phenol (98) 
The compound was synthesized according to general 
procedure (IV). Compound 97 (200 mg, 0.66 mmol, 1 
equiv.) and BBr3 in DCM (1M, 2.3 ml, 2.31 mmol, 3.5 
equiv.). Reaction time: 13 h. Work up. Purification 
was done by column chromatography on silica gel 
using ethyl acetate/dichloromethane (5:95). 
Appearance: white powder. Yield: 130 mg (69%); m.p. 128-130 
°
C. Solubility: The compound 
is soluble in acetone, ethyl acetate and methanol, but insoluble in water. Analytical data: 
1
H-
NMR (DMSO-d6, 500 MHz) δ (ppm) = 1.26-1.31 (m, 6H, 2(-CH2-CH3); 2.75-2.83 (m, 4H, 2(-
CH2-CH3); 7.28 (d, J = 8.74 Hz, 1H); 8.15 (dd, J = 2.33, 8.77 Hz, 1H); 8.57 (d, J = 2.31 Hz, 1H); 
11.59 (s, 1H, -OH). 
13
C-NMR (DMSO, 126 MHz) δ (ppm) = 11.32 (-CH3), 11.35 (-CH3), 19.13 
(-CH2-CH3), 19.23(-CH2-CH3), 111.43, 115.12, 118.73, 130.47, 133.45, 160.82, 171.10, 171.92, 
173.52, 173.93. LC-MS: (m/z): positive mode 286.9 [M]
+
. Purity by HPLC-UV (220-400 nm)-
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ESI-MS: 95%. HRMS (ESI-TOF) m/z: [M-H]
- 
Calcd. for C14H13N4O3 285.0993, Found 
285.1020. 
5.3.11.5. 5,5'-(4-(Benzy)loxy)-1,3-phenylene)-bis-(3-ethyl-1,2,4-oxadiazole) (99) 
 The compound was synthesized according to general 
procedure (III). Compound 98 (100 mg, 0.35 mmol, 1 
equiv.), NaH (60% in paraffin oil, 16 mg, 0.4 mmol, 
1.1 equiv.) and benzyl bromide (0.05 mL, 68 mg, 0.4 
mmol, 1.1 equiv.). Reaction time: 1 h. Work up. The 
purification was done by column chromatography on 
silica gel using ethyl acetate/dichloromethane (5:95). 
Appearance: white powder. Yield: 85 mg (65%); m.p. 
104-105 
°
C. Solubility: The compound is soluble in acetone, dichloromethane and methanol, but 
insoluble in water. Analytical data: 
1
H-NMR (DMSO-d6, 500 MHz) δ (ppm)
 
= 1.27-1.32 (m, 
6H, 2(-CH2-CH3)); 2.76-2.84 (m, 4H, 2(-CH2-CH3)); 5.45 (s, 2H, -OCH2-Ph); 7.35 (m, 1H); 7.41 
(m, 2H); 7.56 (m, 2H); 7.61 (d, J = 8.89 Hz, 1H); 8.31 (dd, J = 2.32, 8.87 Hz, 1H); 8.65 (d, J = 
2.30 Hz, 1H). 
13
C-NMR (DMSO, 126 MHz) δ (ppm) = 11.31 (-CH3), 11.33 (-CH3), 19.18 (-
CH2-CH3), 19.25 (-CH2-CH3), 70.66 (-OCH2-Ph), 113.99, 115.46, 116.60, 127.24, 128.09, 
128.60, 130.83, 133.70, 136.10, 160.21, 171.41, 172.03, 173.27, 173.70. LC-MS: (m/z): positive 
mode 377.3 [M]
+
. Purity by HPLC-UV (220-400 nm)-ESI-MS: 97%. HRMS (ESI-TOF) m/z: 
[M-H]
- 
Calcd. for C21H19N4O3 375,1463, Found 375,1452. 
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8 6. Abbreviation 
Item Abbreviation 
5-BDBD 
(5-(3-Bromophenyl)- 1,3-dihydro-2H-benzofuro[3,2-e]-1,4-diazepin-2-
one) 
A-740003 
N-(1-{[(Cyanoimino)(5-quinolinylamino)methyl]amino}-2,2 
dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide 
AA Amino acid 
AB-25 Acid Blue 25 
ADP   Adenosine 5′-diphosphate 
AMP Adenosine 5′-monophosphate 
AQ Anthraquinone 
aq. Aqeous  
ATP Adenosine 5′-triphosphate 
ATPγS Adenosine 5′-O-(3-thio) triphosphate 
BDNF Brain-derived neurotrophic factor 
BHPM Bis-(p-hydroxyphenyl)-pyridyl-2-methane  
Brine Saturated solution of sodium chloride 
BX430 Dibromo-4-isopropyl-phenyl)-3- (3-pyriudyl)urea 
cDNA Complementary deoxyribonucleic acid 
CNS Central nervous system 
Crysophanol 1,8-Dihydroxy-3-methylanthracenedione 
Danthron 1,8-Dihydroxyanthraquinone 
EC50 molar concentration of agonist that produces 50% of maximal effect 
ECL Extracellular loop 
Emodin 1,3,8-Trihydroxy-6-methylanthraquinone 
Equiv. Equivalent 
FDA Food and Drug Administration 
GABA γ-Aminobutyric acid 
GPCRs    G protein-coupled receptors 
HEK human embryonic kidney cells 
HRMS High-resolution mass spectral   
HTS High-throughput screening 
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Item Abbreviation 
IC Intracellular loop 
IC50 molar concentration of antagonist that produces 50% of maximal effect 
KN-62 
1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]- 
4-phenylpiperazine 
LC-MS liquid chromatography-mass spectroscopy 
LGICs Ligand gated ion channels 
MAOS Microwave-assisted organic synthesis 
MW Microwave 
NP-1815-PX 
(5-[3-(5-Thioxo-4H-[1,2,4]oxadiazol-3-yl)phenyl]-1H-naphtho[1,2-
b][1,4]diazepine-2,4(3H,5H)-dione) 
NSAIDs Nonsteroidal anti-inflammatory drugs 
PPADS Pyridoxal-phosphate-6-azophenyl-2',4'-disulfonate 
PSB-0702 
1-Amino-4-[4-phenylamino-3-carboxyphenylamino]-9,10-dioxo-9,10-
dihydroanthracene-2-sulfonate 
PSB-0739 
1-Amino-4-[4-phenylamino-3-sulfophenylamino]-9,10-dioxo-9,10-
dihydroanthracene-2-sulfonate 
PSB-12054 N-(benzyloxycarbonyl)phenoxazine 
PSB-12062 N-(p-methylphenylsulfonyl)phenoxazine 
Py Pyridine 
RB-2 Reactive Blue-2 
Rhein 4,5-Dihydroxy-9,10-dioxoanthracene-2-carboxylic acid 
RO-85 
1-Methyl-3-phenyl-1H-thieno[2,3-c]pyrazole-5-carboxylic acid [(R)- 2-
(4-acetyl-piperazin-1-yl)-1-methyl-ethyl]-amide 
rt Room temperature  
SARs Structure-activity relationships 
TLC Thin layer chromatography  
TM Transmembrane 
TNP-ATP 2',3'-O-(2,4,6-trinitrophenyl)adenosine 5'-triphosphate 
TRAMs Triarylmethanes  
UDP        Uridine diphosphate 
UTP Uridine -5'- triphosphate 
VGICs Voltage-gated ion channels 
zfP2X4 Zebrafish P2X4 receptor 
 
References 
- 180 - 
 
9 7. References 
(1)  Burnstock, G. Discovery of purinergic signalling, the initial resistance and current 
explosion of interest. Br. J. Pharmacol. 2012, 167, 238–255. 
(2)  Burnstock, G. Introduction: P2 receptors. Curr. Top. Med. Chem. 2004, 4, 793–803. 
(3)  Vergani, A.; Tezza, S.; Fotino, C.; Visner, G.; Pileggi, A.; Chandraker, A.; Fiorina, P. The 
purinergic system in allotransplantation. Am. J. Transplant. 2014, 14, 507–514. 
(4)  Drury, A. N; Szent-Györgyi, A. The physiological activity of adenine compounds with 
especial reference to their action upon the mammalian heart. J. Physiol. 1929, 68, 213–
237. 
(5)  Buchtal, F.; Folokow, B. Close arterial injection of adenosine triphosphate and inorganic 
triphosphate into frog muscle. Acta Physiol. Scand. 1944, 8, 312–316. 
(6)  Holton, B. F. A.; Holton, P. The capillary dilator substances in dry powders of spinal roots; 
a possible role of adenosine triphosphate in chemical transmission from nerve endings. J. 
Physiol. 1954, 126, 124–140. 
(7)  Mary, S.; Medical, H. The liberation of adenosine triphosphate on antidromic stimulation 
of sensory nerves. J. Physiol. 1959, 145, 494–504. 
(8)  Jo, Y.; Schlichter, R. Synaptic corelease of ATP and GABA in cultured spinal neurons. 
Nat. Neurosci. 1999, 2, 241–245. 
(9)  Salgado, A. I.; Cunha, R. A.; Ribeiro, J. A. Facilitation by P2 receptor activation of 
acetylcholine release from rat motor nerve terminals: interaction with presynaptic nicotinic 
receptors. Brain Res. 2000, 877, 245–250. 
(10)  Ergene, E.; Dunbar, J. C.; O’Leary, D. S.; Barraco. R. A. Activation of P2-purinoceptors in 
the nucleus tractus solitarius mediate depressor responses. Neurosci Lett. 1994, 174, 188–
192. 
(11)  Ziganshin, A. U.; Hoyle, C. H. V; Burnstock, G. Ecto-enzymes and metabolism of 
extracellular ATP. Drug Dev. Res. 1994, 32, 134–146. 
References 
- 181 - 
 
(12)  Zimmermann, H.; Mishra, S.; Shukla, V.; Langer, D.; Gampe, K.; Grimm, I.; Delic, J.; 
Braun, N. Ecto-nucleotidases, molecular properties and functional impact. An. R. Acad. 
Nac. Farm. 2007, 73, 537–566. 
(13)  Burnstock, G. Physiology and pathophysiology of purinergic neurotransmission. Physiol. 
Rev. 2007, 87, 659–797. 
(14)  Zeiser, R.; Robson, S. C.; Vaikunthanathan, T.; Dworak, M.; Burnstock, G. Unlocking the 
potential of purinergic signaling in transplantation. Am. J. Transplant. 2016, 16, 2781–
2794. 
(15)  Burnstock, G. Purinergic nerves. Pharmacological Reviews, 1972, 24, 509–581. 
(16)  Burnstock, G. Purinergic receptors. J. Theor. Biol. 1976, 62, 491–503. 
(17)  Abbracchio, M. P.; Burnstock, G. Purinoceptors: are there families of P2X and P2Y 
purinoceptors? Pharmac. Ther. 1994, 64, 445–475. 
(18)  Webb, T. E.; Simon, J.; Krishek, B. J.; Bateson, A. N.; Smart, T. G.; King, B. F.; 
Burnstock, G.; Barnard, E. A. Cloning and functional expression of a brain G-protein-
coupled ATP receptor. Fed. Eur. Biochem. Soc. 1993, 324, 219–225. 
(19)  Brunschweiger, A.; Müller, C. E. P2 receptors activated by uracil nucleotides- an update. 
Curr. Med. Chem. 2006, 13, 289–312. 
(20)  Borrmann, T.; Abdelrahman, A.; Volpini, R.; Lambertucci, C.; Alksnis, E.; Gorzalka, S.; 
Knospe, M.; Schiedel, A. C.; Cristalli, G.; Müller, C. E. Structure-activity relationships of 
adenine and deazaadenine derivatives as ligands for adenine receptors, a new purinergic 
receptor family. J. Med. Chem. 2009, 52, 5974–5989. 
(21)  Bender, E.; Buist, A.; Jurzak, M.; Langlois, X.; Baggerman, G.; Verhasselt, P.; Ercken, 
M.; Guo, H. Q.; Wintmolders, C.; Van den Wyngaert, I.; Van Oers, I.; Schoofs, L.; 
Luyten, W. Characterization of an orphan G protein-coupled receptor localized in the 
dorsal root ganglia reveals adenine as a signaling molecule. Proc. Natl. Acad. Sci. U. S. A. 
2002, 99, 8573–8578. 
(22)  Burnstock, G. Purine and pyrimidine receptors. Cell. Mol. Life Sci. 2007, 64, 1471–1483. 
References 
- 182 - 
 
(23)  Flower, D. R. Modelling G-protein-coupled receptors for drug design. Biochim. Biophys. 
1999, 1422, 207–234. 
(24)  Ferguson, S. S. Evolving concepts in G protein-coupled receptor endocytosis: the role in 
receptor desensitization and signaling. Pharmacol Rev. 2001, 53, 1–24. 
(25)  Marinissen, M. J.; Gutkind, J. S. G-protein-coupled receptors and signaling networks: 
emerging paradigms. Trends Pharmacol. Sci. 2001, 22, 368–376. 
(26)  Santos, R.; Ursu, O.; Gaulton, A.; Bento, A. P.; Donadi, R. S.; Bologa, C. G.; Karlsson, 
A.; Al-Lazikani, B.; Hersey, A.; Oprea, T. I.; Overington, J. P. A comprehensive map of 
molecular drug targets. Nat. Rev. Drug Discov. 2016, 16, 19–34. 
(27)  Abbracchio, M. P.; Burnstock, G.; Boeynaems, J.; Eric, A.; Boyer, J. L.; Kennedy, C.; 
Knight, G. E.; Gachet, C.; Jacobson, K. A.; Weisman, G. A. International union of 
pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from 
molecular mechanisms and pathophysiology to therapy. Pharmacol. Rev. 2012, 58, 281–
341. 
(28)  Burnstock, G.; Williams, M. P2 purinergic receptors: modulation of cell function and 
therapeutic potential. J. Pharmacol. Exp. Ther. 2000, 295, 862–869. 
(29)  King, B. F.; Townsend-Nicholson, A. Nucleotide and nucleoside receptors. Tocris Rev. 
2003, 23, (Published and distributed by Tocris Cookson, Bristol, UK). 
(30)  Dubyak, G. R. Knock-out mice reveal tissue-specific roles of P2Y receptor subtypes in 
different epithelia. Mol. Pharmacol. 2003, 63, 773–776. 
(31)  Burnstock, G. Purinergic signalling and disorders of the central nervous system. Nat. Rev. 
Drug Discov. 2008, 7, 575–590. 
(32)  Bagal, S. K.; Brown, A. D.; Cox, P. J.; Omoto, K.; Owen, R. M.; Pryde, D. C.; Sidders, B.; 
Skerratt, S. E.; Stevens, E. B.; Storer, R. I.; Swain, N. A. Ion channels as therapeutic 
targets: a drug discovery perspective. J. Med. Chem. 2013, 56, 593–624. 
(33)  Lemoine, D.; Jiang, R.; Taly, A.; Chataigneau, T.; Specht, A.; Grutter, T. Ligand-gated ion 
channels: new insights into neurological disorders and ligand recognition. Chem. Rev. 
2012, 112, 6285–6318. 
References 
- 183 - 
 
(34)  Compan, V.; Ulmann, L.; Stelmashenko, O.; Chemin, J.; Rassendren, F. P2X2 and P2X5 
subunits define a new heteromeric receptor with P2X7-like properties. J. Neurosci. 2012, 
32, 4284–4296. 
(35)  Antonio, L. S.; Stewart, A. P.; Varanda, W. A.; Edwardson, J. M. Identification of 
P2X2/P2X4/P2X6 heterotrimeric receptors using atomic force microscopy (AFM) 
imaging. FEBS Lett. 2014, 588, 2125–2128. 
(36)  North, R. A. Molecular physiology of P2X receptors. Physiol. Rev. 2002, 82, 1013–1067. 
(37)  Jacobson, K. A.; Müller, C. E. Medicinal chemistry of adenosine , P2Y and P2X receptors. 
Neuropharmacology 2016, 104, 31–49. 
(38)  Egan, T. M.; Samways, D. S.; Li. Z. Biophysics of P2X receptors. Eur. J. Physiol. 2006, 
452, 501–512. 
(39)  Brake, A. J.; Wagenbach, M. J.; Julius, D. New structural motif for ligand-gated ion 
channels defined by an iontropic ATP receptor. Nature 1994, 371, 519–523. 
(40)  Kaczmarek-Hájek, K.; Lörinczi, É.; Hausmann, R.; Nicke, A. Molecular and functional 
properties of P2X receptors-recent progress and persisting challenges. Purinergic Signal. 
2012, 8, 375–417. 
(41)  Ben, D. D.; Buccioni, M.; Lambertucci, C.; Marucci, G.; Thomas, A.; Volpini, R. 
Purinergic P2X receptors: structural models and analysis of ligand-target interaction. Eur. 
J. Med. Chem. 2015, 89, 561–580. 
(42)  Jacobson, K. A.; Jarvis, M. F.; Williams, M. Purine and pyrimidine (P2) receptors as drug 
targets. J. Med. Chem. 2002, 45, 4057–4093. 
(43)  Jacobson, K. A. P2X and P2Y receptors, Tocris Reviews, 2010, 33, 1-16. 
(44)  Kawate, T.; Michel, J. C.; Birdsong, W. T.; Gouaux, E. Crystal structure of the ATP-gated 
P2X4 ion channel in the closed state. Nature 2009, 460, 592–598. 
(45)  Hattori, M.; Gouaux, E. Molecular mechanism of ATP binding and ion channel activation 
in P2X receptors. Nature 2012, 485, 207–212. 
(46)  Müller, C. E. Emerging structures and ligands for P2X3 and P2X4 receptors–towards 
References 
- 184 - 
 
novel treatments of neuropathic pain. Purinergic Signal. 2010, 6, 145–148. 
(47)  Chataigneau, T.; Lemoine, D.; Grutter, T. Exploring the ATP-binding site of P2X 
receptors. Front. Cell. Neurosci. 2013, 7, 1–12. 
(48)  Gonzales, E. B.; Kawate, T.; Gouaux, E. Pore architecture and ion sites in acid-sensing ion 
channels and P2X receptors. Nature 2009, 460, 599–604. 
(49)  Mansoor, S. E.; Lü, W.; Oosterheert, W.; Shekhar, M.; Tajkhorshid, E.; Gouaux, E. X-ray 
structures define human P2X3 receptor gating cycle and antagonist action. Nature 2016, 
538, 66–71. 
(50)  Brandao-Burch, A.; Key, M. L.; Patel, J. J.; Arnett, T. R.; Orriss, I. R. The P2X7 receptor 
is an important regulator of extracellular ATP levels. Front. Endocrinol. 2012, 3, 1–9. 
(51)  Donnelly-Roberts, D. L.; Namovic, M. T.; Surber, B.; Vaidyanathan, S. X.; Perez-
Medrano, A.; Wang, Y.; Carroll, W. A.; Jarvis, M. F. [3H]A-804598 ([3H]2-cyano-1-
[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist 
radioligand for P2X7 receptors. Neuropharmacology 2009, 56, 223–229. 
(52)  Michel, A. D.; Chambers, L. J.; Walter, D. S. Negative and positive allosteric modulators 
of the P2X7 receptor. Br. J. Pharmacol. 2008, 153, 737–750. 
(53)  Bhattacharya, A.; Wang, Q.; Ao, H.; Shoblock, J. R.; Lord, B.; Aluisio, L.; Fraser, I.; 
Nepomuceno, D.; Neff, R. A.; Welty, N.; Lovenberg, T. W.; Bonaventure, P.; Wickenden, 
A. D.; Letavic, M. A. Pharmacological characterization of a novel centrally permeable 
P2X7 receptor antagonist: JNJ-47965567. Br. J. Pharmacol. 2013, 170, 624–640. 
(54)  Michel, A. D.; Clay, W. C.; Ng, S. W.; Roman, S.; Thompson, K.; Condreay, J. P.; Hall, 
M.; Holbrook, J.; Livermore, D.; Senger, S. Identification of regions of the P2X7 receptor 
that contribute to human and rat species differences in antagonist effects. Br. J. 
Pharmacol. 2008, 155, 738–751. 
(55)  Karasawa, A.; Kawate, T. Structural basis for subtype-specific inhibition of the P2X7 
receptor. Elife 2016, 5, 1–17. 
(56)  Gever, J. R.; Cockayne, D. A.; Dillon, M. P.; Burnstock, G.; Ford, A. P. D. W. 
Pharmacology of P2X channels. Eur. J. Physiol. 2006, 452, 513–537. 
References 
- 185 - 
 
(57)  North, R. A.; Jarvis, M. F. P2X receptors as drug targets. Mol. Pharmacol. 2013, 83, 759–
769. 
(58)  Soto, F.; Lambrecht, G.; Nickel, P.; Stühmer, W.; Busch, A. E. Antagonistic properties of 
the suramin analogue NF023 at heterologously expressed P2X receptors. 
Neuropharmacology 1999, 38, 141–149. 
(59)  Jacobson, K. A.; Kim, Y.; Wildman, S. S.; Mohanram, A.; Harden, T. K.; Boyer, L.; King, 
B. F.; Burnstock, G. A pyridoxine cyclic phosphate and its 6-azoaryl derivative selectively 
potentiate and antagonize activation of P2X1 receptors. J. Med. Chem. 1998, 41, 2201–
2206. 
(60)  Greenhouse, R.; Padilla, F.; Dillon, M. P.; Gever, J. R.; Ford, A. P. D. W. Discovery and 
synthesis of a novel and selective drug-like P2X1 antagonist. Bioorg. Med. Chem. Lett. 
2005, 15, 3292–3295. 
(61)  Hausmann, R.; Bodnar, M.; Woltersdorf, R.; Wang, H.; Fuchs, M.; Messemer, N.; Qin, Y.; 
Günther, J.; Riedel, T.; Grohmann, M.; Nieber, K.; Schmalzing, G.; Rubini, P.; Illes, P. 
ATP binding site mutagenesis reveals different subunit stoichiometry of functional P2X2/3 
and P2X2/6 receptors. J. Bio. Chem. 2012, 287, 13930–13943. 
(62)  Lorca, R. A.; Coddou, C.; Gazitu, M. C.; Bull, P.; Huidobro-toro, J. P. Extracellular 
histidine residues identify common structural determinants in the copper/zinc P2X2 
receptor modulation. J. Neurochem. 2005, 95, 499–512. 
(63)  Jacobson, K. A.; Kim, Y-C.; King, B. F. In search of selective P2 receptor ligands: 
interaction of dihydropyridine derivatives at recombinant rat P2X2 receptors. J. Auton. 
Nerv. Syst. 2015, 81, 152–157. 
(64)  Baqi, Y.; Hausmann, R.; Rosefort, C.; Rettinger, J.; Schmalzing, G.; Müller, C. E. 
Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor. 
J. Med. Chem. 2011, 54, 817–830. 
(65)  Bo, X.; Kim, M.; Nori, S. L.; Schoepfer, R.; Burnstock, G.; North, R. A. Tissue 
distribution of P2X4 receptors studied with an ectodomain antibody. Cell Tissue Res. 
2003, 313, 159–165. 
References 
- 186 - 
 
(66)  Ulmann, L.; Hatcher, J. P.; Hughes, J. P.; Chaumont, S.; Green, P. J.; Conquet, F.; Buell, 
G. N.; Reeve, A. J.; Chessell, I. P.; Rassendren, F. Up-regulation of P2X4 receptors in 
spinal microglia after peripheral nerve injury mediates BDNF release and neuropathic 
pain. J. Neurosci. 2008, 28, 11263–11268. 
(67)  Tsuda, M.; Shigemoto-Mogami, Y.; Koizumi, S.; Mizokoshi, A.; Kohsaka, S.; Salter, M. 
W.; Inoue, K. P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve 
injury. Nature 2003, 424, 778–783. 
(68)  Balázs, B.; Tamás Dankó, T.; Kovács, G.; Köles, L.; Hediger, M. A.; Zsembery, Á. 
Investigation of the inhibitory effects of the benzodiazepine derivative, 5-BDBD on P2X4 
purinergic receptors by two complementary methods. Cell. Physiol. Biochem. 2013, 32, 
11–24. 
(69)  Abdelrahman, A.; Namasivayam, V.; Hinz, S.; Anke, C.; Köse, M.; Burton, M.; El-tayeb, 
A.; Gillard, M.; Ryck, M. De; Müller, C. E. Characterization of P2X4 receptor agonists 
and antagonists by calcium influx and radioligand binding studies. Biochem. Pharmacol. 
2016, 125, 41-54. 
(70)  Nagata, K.; Imai, T.; Yamashita, T.; Tsuda, M.; Tozaki-saitoh, H.; Inoue, K. 
Antidepressants inhibit P2X4 receptor function: a possible involvement in neuropathic 
pain relief. Mol. Pain 2009, 5, 1–12. 
(71)  Sim, J. A.; North, R. A. Amitriptyline does not block the action of ATP at human P2X4 
receptor. Br. J. Pharmacol. 2010, 160, 88–92. 
(72)  Hernandez-olmos, V.; Abdelrahman, A.; El-tayeb, A.; Freudendahl, D.; Weinhausen, S.; 
Müller, C. E. N-substituted phenoxazine and acridone derivatives: structure−activity 
relationships of potent P2X4 receptor antagonists. J. Med. Chem. 2012, 55, 9576–9588. 
(73)  Tian, M.; Abdelrahman, A.; Weinhausen, S.; Hinz, S.; Weyer, S.; Dosa, S.; El-Tayeb, A.; 
Müller, C. E. Carbamazepine derivatives with P2X4 receptor-blocking activity. Bioorganic 
Med. Chem. 2014, 22, 1077–1088. 
(74)  Ase, A. R.; Honson, N. S.; Zaghdane, H.; Pfeifer, T. A.; Séguéla, P. Identification and 
characterization of a selective allosteric antagonist of human P2X4 receptor channels. Mol. 
Pharmacol. 2015, 87, 606–616. 
References 
- 187 - 
 
(75)  Matsumura, Y.; Yamashita, T.; Sasaki, A.; Nakata, E.; Kohno, K. A novel P2X4 receptor-
selective antagonist produces anti-allodynic effect in a mouse model of herpetic pain. Sci. 
Rep. 2016, 1–11. 
(76)  Cello, G.; North, R. A.; Kawashima, E.; Buell, G.; Merlo-pith, E. Cloning of P2X, and 
P2X, receptors and the distribution and properties of an extended family of ATP-gated ion 
channels. J. Neurosci. 1996, 16, 2495–2507. 
(77)  Le, K.; Archambault, V.; Se, P. Functional and biochemical evidence for heteromeric 
ATP-gated channels composed of P2X1 and P2X5 subunits. J. Biol. Chem. 1999, 274, 
15415–15419. 
(78)  Kotnis, S.; Bingham, B.; Vasilyev, D. V; Miller, S. W.; Bai, Y.; Yeola, S.; Chanda, P. K.; 
Bowlby, M. R.; Kaftan, E. J.; Samad, T. A.; Whiteside, G. T. Genetic and functional 
analysis of human P2X5 reveals a distinct pattern of exon 10 polymorphism with 
predominant expression of the nonfunctional receptor isoform. Mol. Pharmacol. 2010, 77, 
953–960. 
(79)  Banfi, C.; Ferrario, S.; Vincenti, O. De; Ceruti, S.; Fumagalli, M.; Mazzola, A.; Ambrosi, 
N. D.; Volontè, C.; Fratto, P.; Vitali, E.; Burnstock, G.; Beltrami, E.; Parolari, A.; Polvani, 
G.; Biglioli, P.; Tremoli, E.; Abbracchio, M. P. P2 receptors in human heart: upregulation 
of P2X6 in patients undergoing heart transplantation , interaction with tnf a and potential 
role in myocardial cell death. J. Mol. Cell. Cardiol. 2005, 39, 929–939. 
(80)  Gargett, C. E.; Wiley, J. S. The isoquinoline derivative KN-62 a potent antagonist of the 
P2Z-receptor of human lymphocytes. Br. J. Pharmacol. 1997, 120, 1483–1490. 
(81)  Arulkumaran, N.; Unwin, R. J.; Tam, F. W. K. A potential therapeutic role for P2X7 
receptor (P2X7R) antagonists in the treatment of inflammatory diseases. Expert Opin. 
Investig. Drugs 2011, 20, 897–915. 
(82)  Ferrari, D.; Pizzirani, C.; Adinolfi, E.; Lemoli, R. M.; Curti, A.; Idzko, M.; Panther, E.; Di 
Virgilio, F. The P2X7 receptor: a key player in IL-1 processing and release. J. Immunol. 
2006, 176, 3877–3883. 
(83)  Romagnoli, R.; Baraldi, P. G.; Cruz-lopez, O.; Lopez-cara, C.; Preti, D.; Borea, P. A.; 
Gessi, S. The P2X7 receptor as a therapeutic target. Expert Opin. Ther. Targets 2008, 12, 
References 
- 188 - 
 
647–662. 
(84)  Guile, S. D.; Alcaraz, L.; Birkinshaw, T. N.; Bowers, K. C.; Ebden, M. R.; Furber, M.; 
Stocks, M. J. Antagonists of the P2X7 receptor. From lead identification to drug 
development. J. Med. Chem. 2009, 52, 3123–3141. 
(85)  Humphreys, B. D.; Virginio, C.; Surprenant, A.; Rice, J.; Dubyak, G. R. Isoquinolines as 
antagonists of the P2X7 nucleotide receptor: high selectivity for the human versus rat 
receptor homologues. Mol. Pharmacol. 1998, 32, 22–32. 
(86)  Donnelly-roberts, D. L.; Namovic, M. T.; Han, P.; Jarvis, M. F. Mammalian P2X7 
receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 
receptors. Br. J. Pharmacol. 2009, 157, 1203–1214. 
(87)  Honore, P.; Donnelly-Roberts, D.; Namovic, M. T.; Hsieh, G.; Zhu, C. Z.; Mikusa, J. P.; 
Hernandez, G.; Zhong, C.; Gauvin, D. M.; Chandran, P.; Harris, R.; Medrano, A. P.; 
Carroll, W.; Marsh, K.; Sullivan, J. P.; Faltynek, C. R.; Jarvis, M. F. A-740003 [N-(1-
{[(cyanoimino)(5-quinolinylamino)methyl]mino}-2,2-dimethylpropyl)-2-(3,4-
dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-
dependently reduces neuropathic. J. Pharmacol. Exp. Ther. 2006, 319, 1376–1385. 
(88)  Wilkinson, S. M.; Gunosewoyo, H.; Barron, M. L.; Boucher, A.; McDonnell, M.; Turner, 
P.; Morrison, D. E.; Bennett, M. R.; McGregor, I. S.; Rendina, L. M.; Kassiou, M. The 
first CNS-active carborane: a novel P2X7 receptor antagonist with antidepressant activity. 
ACS Chem. Neurosci. 2014, 5, 335–339. 
(89)  Chen, C. C.; Akopian, A. N.; Sivilotti, L.; Colquhoun, D.; Burnstock, G.; Wood, J. N. A 
P2X purinoceptor expressed by a subset of sensory neurons. Nature 1995, 377, 428–431. 
(90)  Virginio, C.; Robertson, G.; Surprenant, A.; North, R. A. Trinitrophenyl-substituted 
nucleotides are potent antagonists selective for P2X1, P2X3, and heteromeric P2X2/3 
receptors. Mol. Pharmacol. 1998, 53, 969–973. 
(91)  Dunn, P. M.; Zhong, Y.; Burnstock, G. P2X receptors in peripheral neurons. Prog. 
Neurobiol. 2001, 65, 107–134. 
(92)  Bradbury, E. J.; Burnstock, G.; McMahon, S. B. The expression of P2X3 purinoreceptors 
References 
- 189 - 
 
in sensory neurons: effects of axotomy and glial-derived neurotrophic factor. Mol. Cell. 
Neurosci. 1998, 12, 256–268. 
(93)  Dorn, G.; Patel, S.; Wotherspoon, G.; Hemmings-Mieszczak, M.; Barclay, J.; Natt, F. J.; 
Martin, P.; Bevan, S.; Fox, A.; Ganju, P.; Wishart, W.; Hall, J. siRNA relieves chronic 
neuropathic pain. Nucleic Acids Res. 2004, 32, 1–6. 
(94)  Tsuda, M.; Koizumi, S.; Kita, A.; Shigemoto, Y.; Ueno, S.; Inoue, K. Mechanical 
allodynia caused by intraplantar injection of P2X receptor agonist in rats: involvement of 
heteromeric P2X2/3 receptor signaling in capsaicin-insensitive primary afferent neurons. J. 
Neurosci. 2000, 20, 1–5. 
(95)  Lewis, C.; Neidhart, S.; Holy, C.; North, R. A.; Buell, G.; Surprenant, A. Coexpression of 
P2X2 and P2X3 receptor subunits can account for ATP-gated currents in sensory neurons. 
Nature 1995, 377, 432–435. 
(96)  Burnstock, G. Purine-mediated signalling in pain and visceral perception. Trends 
Pharmacol. Sci. 2001, 22, 182–188. 
(97)  Hausmann, R.; Bahrenberg, G.; Kuhlmann, D.; Schumacher, M.; Braam, U.; Bieler, D.; 
Schlusche, I.; Schmalzing, G. A hydrophobic residue in position 15 of the rP2X3 receptor 
slows desensitization and reveals properties beneficial for pharmacological analysis and 
high-throughput screening. Neuropharmacology 2014, 79, 603–615. 
(98)  Hausmann, R.; Rettinger, J.; Gerevich, Z.; Meis, S.; Kassack, M. U.; Illes, P.; Lambrecht, 
G.; Schmalzing, G. The suramin analog 4,4',4'',4'''-(carbonylbis-(imino-5,1,3-
benzenetriylbis-(carbonylimino)))tetra-kis-benzenesulfonic acid (NF110) potently blocks 
P2X3 receptors: subtype selectivity is determined by location of sulfonic acid groups Mol. 
Pharmacol. 2006, 69, 2058–2067. 
(99)  Ballini, E.; Virginio, C.; Medhurst, S. J.; Summerfield, S. G.; Aldegheri, L. 
Characterization of three diaminopyrimidines as potent and selective antagonists of P2X3 
and P2X2/3 receptors with in vivo efficacy in a pain model. Br. J. Pharmacol. 2011, 163, 
1315–1325. 
(100)  Jarvis, M. F.; Burgard, E. C.; Mcgaraughty, S.; Honore, P.; Lynch, K.; Brennan, T. J.; 
Subieta, A.; Biesen, T. Van; Cartmell, J.; Bianchi, B.; Niforatos, W.; Kage, K.; Yu, H.; 
References 
- 190 - 
 
Mikusa, J.; Wismer, C. T.; Zhu, C. Z.; Chu, K.; Lee, C.; Stewart, A. O.; Polakowski, J.; 
Cox, B. F.; Kowaluk, E.; Williams, M.; Sullivan, J.; Faltynek, C. A-317491, a novel potent 
and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors , reduces chronic 
inflammatory and neuropathic pain in the rat. PNAS 2002, 99, 17179–17184. 
(101)  McGaraughty, S.; Wismer, C. T.; Zhu, C. Z.; Mikusa, J.; Honore, P.; Chu, K. L.; Lee, C.-
H.; Faltynek, C. R.; Jarvis, M. F. Effects of A-317491, a novel and selective P2X3/P2X2 
/3 receptor antagonist, on neuropathic, inflammatory and chemogenic nociception 
following intrathecal and intraplantar administration. Br. J. Pharmacol. 2003, 140, 1381–
1388. 
(102)  Gum, R. J.; Wakefield, B.; Jarvis, M. F. P2X receptor antagonists for pain management : 
examination of binding and physicochemical properties. Purinergic Signal. 2012, 8, 41-56. 
(103)  Ford, A. P. In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and afferent 
sensitization. Purinergic Signal. 2012, 8, 3–26. 
(104)  Gever, J. R.; Soto, R.; Henningsen, R. A.; Martin, R. S.; Hackos, D. H.; Panicker, S.; 
Rubas, W.; Oglesby, I. B.; Dillon, M. P.; Milla, M. E.; Burnstock, G.; Ford, A. P. D. W. 
AF-353 , a novel , potent and orally bioavailable P2X3/ P2X2/3 receptor antagonist. Br. J. 
Pharmacol. 2010, 160, 1387–1398. 
(105)  Brotherton-pleiss, C. E.; Dillon, M. P.; Ford, A. P. D. W.; Gever, J. R.; Carter, D. S.; 
Gleason, S. K.; Lin, C. J.; Moore, A. G.; Thompson, A. W.; Villa, M.; Zhai, Y. Discovery 
and optimization of RO-85, a novel drug-like, potent, and selective P2X3 receptor 
antagonist. Bioorg. Med. Chem. Lett. 2010, 20, 1031–1036. 
(106)  Saul, A.; Hausmann, R.; Kless, A.; Nicke, A. Heteromeric assembly of P2X subunits. 
Front. Cell. Neurosci. 2013, 7, 1–20. 
(107)  Ford, A. P.; Undem, B. J. The therapeutic promise of ATP antagonism at P2X3 receptors 
in respiratory and urological disorders. Front. Cell. Neurosci. 2013, 7, 1–10. 
(108)  Abdulqawi, R.; Dockry, R.; Holt, K.; Layton, G.; Mccarthy, B. G.; Ford, A. P.; Smith, J. 
A. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-
blind, placebo-controlled phase 2 study. Lancet 2015, 385, 1198–1205. 
References 
- 191 - 
 
(109)  Jung, K.; Moon, H. D.; Lee, G. E.; Lim, H.; Park, C.; Kim, Y. Structure-activity 
relationship studies of spinorphin as a potent and selective human P2X3 receptor 
antagonist. J. Med. Chem. 2007, 4543–4547. 
(110)  Yamamoto, Y.; Ono, H.; Ueda, A.; Shimamura, M.; Nishimura, K.; Hazato, T. Spinorphin 
as an endogenous inhibitor of enkephalin-degrading enzymes: roles in pain and 
inflammation. Curr. Protein Pept. Sci. 2002, 3, 587–599. 
(111)  Szántó, G.; Makó, A.; Vágó, I.; Hergert, T.; Bata, I.; Farkas, B.; Kolok, S.; Vastag, M. 
New P2X3 receptor antagonists. Part 2: Identification and SAR of quinazolinones. 
Bioorganic Med. Chem. Lett. 2016, 26, 3905–3912. 
(112)  Szántó, G.; Makó, A.; Bata, I.; Farkas, B.; Kolok, S.; Vastag, M.; Cselenyák, A. New 
P2X3 receptor antagonists. Part 1: Discovery and optimization of tricyclic compounds. 
Bioorganic Med. Chem. Lett. 2016, 26, 3896–3904. 
(113)  Takahashi, F.; Kinoshita, H.; Shimada, S. Pyrrolinone derivatives as a new class of P2X3 
receptor antagonists . Part 1: Initial structure-activity relationship studies of a hit from a 
high throughput. Bioorg. Med. Chem. Lett. 2017. 
(114)  Rajagopal, M. R. Pain-basic considerations. Indian J. Anaesth. 2006, 50, 331-334. 
(115)  Williams, M.; Kowaluk, E. A.; Arneric, S. P. Emerging molecular approaches to pain 
therapy. J. Med. Chem. 1999, 42, 1481-1500. 
(116)  Woolf, C. J.; Ma, Q. Nociceptors-noxious stimulus detectors. Neuron 2007, 55, 353–364. 
(117)  Juhl, G. I.; Jensen, T. S.; Norholt, S. E.; Svensson, P. Central sensitization phenomena 
after third molar surgery: a quantitative sensory testing study. Eur. J. Pain 2008, 12, 116–
127. 
(118)  Toth, C.; Lander, J.; Wiebe, S. The prevalence and impact of chronic pain with 
neuropathic pain symptoms in the general population. Pain Med. 2009, 10, 918–929. 
(119)  Colvin, L. A.; Dougherty, P. M. Peripheral neuropathic pain: signs, symptoms, 
mechanisms, and causes: are they linked? Br. J. Anaesth. 2014, 114, 361–363. 
(120)  Inoue, K. P2 receptors and chronic pain. Purinergic Signal. 2007, 3, 135–144. 
References 
- 192 - 
 
(121)  Donnelly-roberts, D.; Mcgaraughty, S.; Shieh, C.; Honore, P.; Jarvis, M. F. Painful 
purinergic receptors. J. Pharmacol. Exp. Ther. 2008, 324, 409–415. 
(122)  Inoue, K.; Tsuda, M.; Koizumi, S. ATP receptors in pain sensation: involvement of spinal 
microglia and P2X4 receptors. Purinergic Signal. 2005, 1, 95–100. 
(123)  Jarvis, M. F.; Kowaluk, E. A. Pharmacological characterization of P2X3 homomeric and 
heteromeric channels in nociceptive signaling and behavior. Drug Dev. Res. 2001, 52, 
220–231. 
(124)  Pankewitz, F.; Zöllmer, A.; Gräser, Y.; Hilker, M. Anthraquinones as defensive 
compounds in eggs of galerucini leaf beetles: biosynthesis by the beetles? Arch. Insect 
Biochem. Physiol. 2007, 66, 98–108. 
(125)  Chien, S. C.; Wu, Y. C.; Chen, Z. W.; Yang, W. C. Naturally occurring anthraquinones: 
chemistry and therapeutic potential in autoimmune diabetes. Evidence-based Complement. 
Altern. Med. 2015, 2015, 1-13. 
(126)  Caro, Y.; Anamale, L.; Fouillaud, M.; Laurent, P.; Petit, T.; Dufosse, L. Natural 
hydroxyanthraquinoid pigments as potent food grade colorants: an overview. Nat. 
Products Bioprospect. 2012, 2, 174–193. 
(127)  Laurent, A. Ueber verschiedene verbindungen des anthracen’s. Justus Liebigs Ann. Chem. 
1840, 34, 287–296. 
(128)  Graebe, C.; Liebermann, C. Ueber alizarin und anthracen. Berichte der Dtsch. Chem. 
Gesellschaft 1868, 1, 49–51. 
(129)  Russell, W. J. Address to the chemical section. In Chemical News and Journal of 
Industrial Science.; Crookers, W., Ed.; Henry Gillman, Boy court, Ludgate Hill, E.C.: 
London, 1873; pp. 148–153. 
(130)  Phillips, M. The chemistry of anthraquinone. Chem. Rev. 1929, 6, 157–174. 
(131)  Fouillaud, M.; Venkatachalam, M.; Girard-Valenciennes, E.; Caro, Y.; Dufossé, L. 
Anthraquinones and derivatives from marine-derived fungi: structural diversity and 
selected biological activities. Mar. Drugs 2016, 14, 1-64. 
References 
- 193 - 
 
(132)  Yusuf, M.; Shabbir, M.; Mohammad, F. Natural colorants: historical, processing and 
sustainable prospects. Nat. Products Bioprospect. 2017, 7, 123–145. 
(133)  Aspland, J. R. Textile dyeing and coloration; AATCC 1997, 1-410. 
(134)  Zollinger, H. Color chemistry: syntheses, properties, and application of organic dyes and 
pigments; 3
rd
 ed.; VCH Publishers, Inc.: New York, 1991. 
(135)  Pearson, J. C.; Weaver, M. A.; Fleischer, J. C.; King, G. A. Copolymerizable methine and 
anthraquinone compounds and articles containing them. U.S. Patent 8501890 B2, 2013. 
(136)  Motallebi, S.; Maghsoodi, S. Anthraquinone dye-containing material, composition 
including the same, camera including the same, and associated methods. U.S. Patent 
20010149128 A1, 2011. 
(137)  Huang, Q.; Lu, G.; Shen, H. M.; Chung, M. C. M.; Choon, N. O. Anti-cancer properties of 
anthraquinones from rhubarb. Med. Res. Rev. 2007, 27, 609–630. 
(138)  Barnard, D. L.; Fairbairn, D. W.; O’Neill, K. L.; Gage, T. L.; Sidwell, R. W. Anti-human 
cytomegalovirus activity and toxicity of sulfonated anthraquinones and anthraquinone 
derivatives. Antiviral Res. 1995, 28, 317–329. 
(139)  Wuthi-udomlert, M.; Kupittayanant, P.; Gritsanapan, W. In vitro evaluation of antifungal 
activity of anthraquinone derivatives of senna alata. J Heal. Res 2010, 24, 117–122. 
(140)  Khan, N.; Karodi, R.; Siddiqui, A.; Thube, S.; Rub, R. Development of anti-acne gel 
formulation of anthraquinones rich fraction from rubia cordifolia (rubiaceae). Int. J. Appl. 
Res. Nat. Prod. 2011, 4, 28–36. 
(141)  Fairbairn, J. W. The anthraquinone laxatives. Pharmacol. Int. J. Exp. Clin. Pharmacol. 
1976, 14, 1–105. 
(142)  Van Gorkom, B. A.; De Vries, E. G.; Karrenbeld, A.; Kleibeuker, J. H. Review article: 
anthranoid laxatives and their potential carcinogenic effects. Aliment. Pharmacol. Ther. 
1999, 13, 443–452. 
(143)  Gan, K. H.; Teng, C. H.; Lin, H.-C.; Chen, K. T.; Chen, Y. C.; Hsu, M. F.; Wang, J. P.; 
Teng, C. M.; Lin, C. N. Antiplatelet effect and selective binding to cyclooxygenase by 
References 
- 194 - 
 
molecular docking analysis of 3-alkylaminopropoxy-9,10-anthraquinone derivatives. Biol. 
Pharm. Bull. 2008, 31, 1547–1551. 
(144)  Seo, E. J.; Ngoc, T. M.; Lee, S.-M.; Kim, Y. S.; Jung, Y. S. Chrysophanol-8-O-glucoside, 
an anthraquinone derivative in rhubarb, has antiplatelet and anticoagulant activities. J. 
Pharmacol. Sci. 2012, 118, 245–254. 
(145)  Baqi, Y.; Atzler, K.; Köse, M.; Glänzel, M.; Müller, C. E. High-affinity, non-nucleotide-
derived competitive antagonists of platelet P2Y12 receptors. J. Med. Chem. 2009, 52, 
3784–3793. 
(146)  Jackson, T. C.; Verrier, J. D.; Kochanek, P. M. Anthraquinone-2-sulfonic acid (AQ2S) is a 
novel neurotherapeutic agent. Cell Death Dis. 2013, 4, e451. 
(147)  Cirillo, C.; Capasso, R. Constipation and botanical medicines: an overview. Phyther. Res. 
2015, 29, 1488–1493. 
(148)  DiMarco, A.; Gaetini, M.; Dorigotti, L.; Soldatti, M.; Bellini, O. Studi sperimentali 
sull’attivita’ antineoplastica del neuovo antibiotico daunomicina. Tumori 1963, 49, 203–
217. 
(149)  Dong, X.; Fu, J.; Yin, X.; Cao, S.; Li, X.; Lin, L.; Ni, J. Emodin: a review of its 
pharmacology, toxicity and pharmacokinetics. Phyther. Res. 2016, 1207–1218. 
(150)  Teich, L.; Daub, S.; Kru, V.; Nissler, L.; Gebhardt, R.; Eger, K. Synthesis and biological 
evaluation of new derivatives of emodin. Bioorg. Med. Chem. 2004, 12, 5961–5971. 
(151)  Gewirtz, D. A. A critical evaluation of the mechanisms of action proposed for the 
antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. 
Pharmacol. 1999, 57, 727–741. 
(152)  Arcamone, F.; Cassinelli, G.; Fantini, G.; Grein, A.; Orezzi, P.; Pol, C.; Spalla, C. 
Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. 
caesius. Biotechnol. Bioeng. 1969, 6, 1101–1110. 
(153)  Harris, F.; Pierpoint, L. Mitoxantrone, more than just another topoisomerase II poison. 
Med. Res. Rev. 2012, 29, 1292–1327. 
References 
- 195 - 
 
(154)  Lawford, D. J.; White, R. G. “Daunomycin”, a new antibiotic of the rhodomycin group. 
Nature 1964, 201, 706–607. 
(155)  Tacar, O.; Sriamornsak, P.; Dass, C. R. Doxorubicin: an update on anticancer molecular 
action, toxicity and novel drug delivery systems. J. Pharm. Pharmacol. 2013, 65, 157–
170. 
(156)  Minotti, G. Anthracyclines: molecular advances and pharmacologic developments in 
antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004, 56, 185–229. 
(157)  Malik, E. M.; Müller, C. E. Anthraquinones as pharmacological tools and drugs. Med. Res. 
Rev. 2016, 36, 705–748. 
(158)  Martinelli, B. F.; Vacchi, L.; Rovaris, M.; Capra, R.; Comi, G. Mitoxantrone for multiple 
sclerosis. Cochrane Database Syst. Rev. 2013, 1–38. 
(159)  Yu, C.; Qi, D.; Sun, J.-F.; Li, P.; Fan, H. Y. Rhein prevents endotoxin-induced acute 
kidney injury by inhibiting NF-κB activities. Sci. Rep. 2015, 5, 11822. 
(160)  Nguyen, M.; Dougados, M.; Berdah, L.; Amor, B. Diacerhein in the treatment of 
osteoarthritis of the hip. Arthritis Rheum. 1994, 37, 529–536. 
(161)  U.S Department of Health and Human Services. Report on carcinogens, 4
th
 ed.; 2016. 
(162)  Bennett, M.; Cresswell, H. Factors influencing constipation in advanced cancer patients: a 
prospective study of opioid dose, dantron dose and physical functioning. Palliat. Med. 
2003, 17, 418–422. 
(163)  Denizli, A.; Pişkin, E. Dye-ligand affinity systems. J Biochem Biophys Methods. 2001, 49, 
391–416. 
(164)  Glänzel, M.; Bültmann, R.; Starke, K.; Frahm, A. W. Constitutional isomers of reactive 
blue 2 - selective P2Y-receptor antagonists? Eur. J. Med. Chem. 2003, 38, 303–312. 
(165)  Baqi, Y.; Müller, C. E. Rapid and efficient microwave-assisted copper(0)-catalyzed 
ullmann coupling reaction: general access to anilinoanthraquinone derivatives. Org. Lett. 
2007, 9, 1271–1274. 
(166)  Baqi, Y.; Müller, C. E. Synthesis of alkyl- and aryl-amino-substituted anthraquinone 
References 
- 196 - 
 
derivatives by microwave-assisted copper(0)-catalyzed ullmann coupling reactions. Nat. 
Protoc. 2010, 5, 945–953. 
(167)  Weyler, S.; Baqi, Y.; Hillmann, P.; Kaulich, M.; Hunder, A. M.; Müller, I. A.; Müller, C. 
E. Combinatorial synthesis of anilinoanthraquinone derivatives and evaluation as non-
nucleotide-derived P2Y2 receptor antagonists. Bioorg. Med. Chem. Lett. 2008, 18, 223–
227. 
(168)  Baqi, Y.; Lee, S.-Y.; Iqbal, J.; Ripphausen, P.; Lehr, A.; Scheiff, A. B.; Zimmermann, H.; 
Bajorath, J.; Müller, C. E. Development of potent and selective inhibitors of ecto-5’-
nucleotidase based on an anthraquinone scaffold. J. Med. Chem. 2010, 53, 2076–2086. 
(169)  Baqi, Y.; Müller, C. E. Convergent synthesis of the potent P2Y receptor antagonist MG 
50-3-1 based on a regioselective Ullmann coupling reaction. Molecules 2012, 17, 2599–
2615. 
(170)  Baqi, Y. Anthraquinones as a privileged scaffold in drug discovery targeting nucleotide-
binding proteins. Drug Discov Today 2016, 12, 1571-1577. 
(171)  Henkelmann, J.; Hoch, H.; Kahl, T.; Kilpper, G.; Maier, W. Preparation of 1-
nitroanthraquinone-2-carboxylic acids. U.S. Patent CA2001989 A1, 1990. 
(172)  Malik, E. M.; Baqi, Y.; Müller, C. E. Syntheses of 2-substituted 1-amino-4-
bromoanthraquinones (bromaminic acid analogues) – precursors for dyes and drugs. 
Beilstein J. Org. Chem. 2015, 11, 2326–2333. 
(173)  Hoffmann, K.; Baqi, Y.; Morena, M. S.; Glänzel, M.; Müller, C. E.; von Kügelgen, I. 
Interaction of new, very potent non-nucleotide antagonists with Arg256 of the human 
platelet P2Y12 receptor. J. Pharmacol. Exp. Ther. 2009, 331, 648–655. 
(174)  Giguere, R. J.; Bray, T. L.; Duncan, S. M. Application of commercial microwave ovens to 
organic synthesis. Tetrahedron Lett. 1986, 27, 4945–4948. 
(175)  Mehta, B.; Bhardwaj, S. Microwave induced synthesis of anthraquinone derivatives a 
solvent free path. Rasayan J. Chem. 2009, 2, 659–661. 
(176)  Hoz, A. De.; Díaz-Ortiz, Á.; Moreno, A. Microwaves in organic synthesis . thermal and 
non-thermal microwave effects Chem. Soc. Rev. 2005, 34, 164–178. 
References 
- 197 - 
 
(177)  Larhed, M.; Hallberg, A. Chemistry: a new technique in drug discovery. Drug Discov. 
Today 2001, 6, 406–416. 
(178)  Roberts, B. A.; Strauss, C. R. Toward rapid,“green”, predictable microwave-assisted 
synthesis. Acc. Chem. Res. 2005, 38, 653–661. 
(179)  Ullmann, F.; Bielecki, J. Ueber synthesen in der biphenylreihe. Berichte der Dtsch. Chem. 
Gesellschaft 1901, 34, 2174–2185. 
(180)  Ullmann, F. Ueber eine neue darstellungsweise von phenyläthersalicylsäure. Berichte der 
Dtsch. Chem. Gesellschaft 1904, 37, 853–854. 
(181)  Sperotto, E.; van Klink, G. P. M.; van Koten, G.; de Vries, J. G. The mechanism of the 
modified ullmann reaction. Dalt. Trans. 2010, 39, 10338. 
(182)  Goldberg, I. Ueber phenylirungen bei gegenwart von kupfer als katalysator. Berichte der 
Dtsch. Chem. Gesellschaft 1906, 39, 1691–1692. 
(183)  Hassan, J.; Penalva, V.; Lavenot, L.; Gozzi, C.; Lemaire, M. Catalytic alternative of the 
Ullmann reaction. Tetrahedron 1998, 54, 13793–13804. 
(184)  Kim, J. H.; Greßies, S.; Boultadakis-Arapinis, M.; Daniliuc, C.; Glorius, F. Rh(I)/NHC*-
catalyzed site-and enantioselective functionalization of c(sp
3
)–H bonds toward chiral 
triarylmethanes. ACS Catal., 2016, 6, 7652–7656. 
(185)  Parai, M. K.; Panda, G.; Chaturvedi, V.; Manju, Y. K.; Sinha, S. Thiophene containing 
triarylmethanes as antitubercular agents. Bioorg. Med. Chem. Lett. 2008, 18, 289–292. 
(186)  Mibu, N.; Yokomizo, K.; Uyeda, M.; Sumoto, K. Synthesis and antiviral activities of some 
4,4'- and 2, 2'-dihydroxytriphenylmethanes. Chem. Pharm. Bull. 2005, 53, 30–33. 
(187)  Jaratjaroonphong, J.; Sathalalai, S.; Techasauvapak, P.; Reutrakul, V. Iodine catalyzed 
friedel–crafts alkylation of electron-rich arenes with aldehydes: efficient synthesis of 
triarylmethanes and diarylalkanes. Tetrahedron Lett. 2009, 50, 6012–6015. 
(188)  Muthyala, R. A synthetic study on the preparation of triarylmethanes. Dyes Pigm. 1994, 
25, 303–324. 
(189)  Gessner, T.; Mayer, U. Triarylmethane and diarylmethane dyes. Ullmann’s Encycl. Ind. 
References 
- 198 - 
 
Chem. 2012, 37, 425–478. 
(190)  Angus, D. S.; Baker, R. S. U.; Bonin, A. M.; Callen, D.; Clark, A. M. Comparative of two 
triarylmethane food dyes in salmonella, and drosophila. Fd Cosmet. Toxicol. 1981, 19, 
419–424. 
(191)  Kienzle-Horn, S.; Vix, J.; Schuijt, C.; Piel, H.; Jordan, C. C.; Kamm, M. A. Efficacy and 
safety of bisacodyl in the acute treatment of constipation: a double-blind, randomized, 
placebo-controlled study. Aliment. Pharmacol. Ther. 2006, 23, 1479–1488. 
(192)  Hawes, R. H.; Lowry, A.; Deziel, D. A consensus document on bowel preparation before 
colonoscopy: prepared by a task force from the american society of colon and rectal 
surgeons (ASCRS), the american society for gastrointestinal endoscopy (ASGE), and the 
society of american gastrointestinal and endoscopic surgeons (SAGES). Gastrointest. 
Endosc. 2006, 63, 894–909. 
(193)  Zeniou, M.; Fève, M.; Mameri, S.; Dong, J.; Salomé1, C.; Chen1, W.; El-Habr, E. A.; 
Bousson, F.; Sy, M.; Obszynski, J.; Boh, A.; Villa, P.; Kahn, S. A.; Didier, B.; Bagnard, 
D.; Junier, M.; Chneiweiss, H.; Haiech, J.; Hibert, M.; Kilhoffer, M. Chemical library 
screening and structure-function relationship studies identify bisacodyl as a potent and 
selective cytotoxic agent towards quiescent human glioblastoma tumor stem-like cells. 
PLoS One 2015, 1–35. 
(194)  Li, H.; Liu, A.; Zhao, Z.; Xu, Y.; Lin, J.; Jou, D.; Li, C. Fragment-based drug design and 
drug repositioning using multiple ligand simultaneous docking (MLSD): identifying 
celecoxib and template compounds as novel inhibitors of signal transducer and activator of 
transcription 3 (STAT3). J. Med. Chem. 2011, 54, 5592–5596. 
(195)  Spanier, C. Identification and characterization of novel ligands for purinergic P2X 
receptors. Dr. rer. nat. thesis, Rheinische Friedrich-Wilhelms-Universität Bonn, Germany, 
2016. 
(196)  Tsang, A.; Von Korff, M.; Lee, S.; Alonso, J.; Karam, E.; Angermeyer, M. C.; Borges, G. 
L. G.; Bromet, E. J.; de Girolamo, G.; de Graaf, R.; Gureje, O.; Lepine, J. P.; Haro, J. M.; 
Levinson, D.; Oakley Browne, M. A.; Posada-Villa, J.; Seedat, S.; Watanabe, M. Common 
chronic pain conditions in developed and developing countries: gender and age differences 
References 
- 199 - 
 
and comorbidity with depression-anxiety disorders. J. Pain 2008, 9, 883–891. 
(197)  Watkins, L. R.; Maier, S. F. Glia: a novel drug discovery target for clinical pain. Nat. Rev. 
Drug Discov. 2003, 2, 973–985. 
(198)  Volpini, R.; Mishra, R. C.; Kachare, D. D.; Ben, D. D.; Lambertucci, C.; Antonini, I.; 
Vittori, S.; Marucci, G.; Sokolova, E.; Nistri, A.; Cristalli, G. Adenine-based acyclic 
nucleotides as novel P2X3 receptor ligands. J. Med. Chem. 2009, 52, 4596–4603. 
(199)  Ukponmwan, D, O.; Greenhalgh, M.; Peters, A. T. Physical characteristics of synthesized 
l-amino-4-(arylamino)anthraquinone 2-ether dyes for synthetic-polymer fibers. J. Chem. 
Eng. Data 1984, 29, 483–484. 
(200)  Malik, E. M.; Rashed, M.; Wingen, L.; Baqi, Y.; Müller, C. E. Ullmann reactions of 1-
amino-4-bromoanthraquinones bearing various 2-substituents furnishing novel dyes. Dye. 
Pigment. 2016, 131, 33–40. 
(201)  Harris, R. M.; Marriott, G. J.; Smith, J. C. The effect of alkyl groups on the properties of 
anthraquinone and fluorescein dyes. J. Chem. Soc. 1936, 1838–1844. 
(202)  Baqi, Y.; Weyler, S.; Iqbal, J.; Zimmermann, H.; Müller, C. E. Structure-activity 
relationships of anthraquinone derivatives derived from bromaminic acid as inhibitors of 
ectonucleoside triphosphate diphosphohydrolases (E-NTPDases). Purinergic Signal. 2009, 
91–106. 
(203)  Baqi, Y.; Müller, C. E. Convergent synthesis of the potent P2Y receptor antagonist MG 
50-3-1 based on a regioselective Ullmann coupling reaction. Molecules 2012, 17, 2599-
2615. 
(204)  Burnett, J. F.; Zahler, R. E. Aromatic nucleophilic substitution reactions. Chem Rev 1951, 
49, 273–412. 
(205)  Tuong, T. D.; Hida, M. Mechanism of the Ullmann condensation. I. kinetic and 
thermodynamic studies. Bull Chem Soc Jpn 1970, 43, 1763–1768. 
(206)  Malik, E. M. Synthetic access to novel anthraquinone derivatives, biological evaluation, 
and analysis of structure-activity relationships at P2Y receptors. Dr. rer. nat. thesis, 
Rheinische Friedrich-Wilhelms-Universität Bonn, Germany, 2015. 
References 
- 200 - 
 
(207)  Arai, S.; Hida, M.; Yamagishi, T.; Ototake. S. The Ullmann condensation reaction of 
haloanthraquinone derivatives with amines in aprotic solvents II. the presence of induction 
period in the condensation with 2-aminoethanol. Bull Chem Soc Jpn 1977, 50, 2982–2985. 
(208)  Arai, S.; Hashimoto, Y.; Yamagishi T.; Hida, M. The Ullmann condensation reaction of 
haloanthraquinone derivatives with amines in aprotic solvents. VI. The combination of 
Cu(I) and hydroxo or alkoxo Cu(II) as effective catalyst system. Bull Chem Soc Jpn 1989, 
62, 3143–3149. 
(209)  Gragerov, I. P.; Kasukhin, L. F. Mechanism of the Ullmann reaction. II. Effects of the 
medium, the additives and the substituents. Bull Chem Soc Jpn 1971, 44, 765–771. 
(210)  Mereyala, H. B.; Sambaru, K. Synthesis of triphenylmethane derivative : bisacodyl. Indian 
J. Chem. 2005, 44, 615–617. 
(211)  Junhui, Z.; Hongyu, L.; Jinling, L.; Shende, J. A preparation method of bisacodyl. 
CN101973932 B, 2012. 
(212)  Seelye, D. E.; Plummer, E. L. Process of preparation of tetrafluoro 2,3-
dihydrobenzofurans. U.S. Patent 4730062 A, 1988. 
(213)  Feve, M.; Zenyou-Mayer, M.; Haiech, J.; Chneiwiss, H.; Kilhoffer, M.; Mameri, S.; 
Hibert, M. Bisacodyl and analogues as drugs for treating cancer. PCT Int. Appl., 
WO2012168885 A2, 2014. 
(214)  Nath, B.; Kalita, D.; Baruah, J. B. Zwitterionic metal carboxylate complexes: in solid state. 
Solid State Sci. 2012, 14, 880–884. 
(215)  Breslin, H. J.; Chatterjee, S.; Diebold, J. L.; Dorsey, B. D.; Dunn, D.; Gingrich, D. E.; 
Hostetler, G. A.; Hudkins, R. L.; Hunter, R.; Josef, K.; Lisko, J.; Mesaros, E. F.; 
Milkiewicz, K. L.; Ott, G. R.; Sundar, B. G.; Theroff, J. P.; Thieu, T.; Tripathy, R.; 
Underiner, T. L.; Weinberg, L.; Wells, G. J.; Zificsak, G. A. Preparation of 
pyrrolotriazines as inhibitors of ALK and JAK2 kinases for treating proliferative diseases. 
PCT Int. Appl., WO2010071885 A1, 2010. 
(216)  Karthikeyan, I.; Sekar, G. Iron-catalyzed C-H bond functionalization for the exclusive 
synthesis of pyrido[1,2-a]indoles or triarylmethanols. Eur. J. Org. Chem. 2014, 2014, 
References 
- 201 - 
 
8055–8063. 
(217)  Karthikeyan, I.; Arunprasath, D.; Sekar, G. An efficient synthesis of pyrido[1,2-a]indoles 
through aza-nazarov type cyclization. Chem. Commun. 2015, 51, 1701–1704. 
(218)  Jones, C. D.; Winter, M. A.; Hirsch, K. S.; Stamm, N.; Taylor, H. M.; Holden, H. E.; 
Davenport, J. D.; Krumkalns, E. V; Suhrt, R. G. Estrogen synthetase inhibitors. 2.
1
 
comparison of the in vitro aromatase inhibitory activity for a variety of nitrogen 
heterocycles substituted with diarylmethane or diarylmet hanol groups. J. Med. Chem. 
1990, 33, 416–429. 
(219)  Greene, M. A.; Yonova, I. M.; Williams, F. J.; Jarvo, E. R. Traceless directing group for 
stereospecific nickel-catalyzed alkyl-alkyl cross-coupling reactions. Org. Lett. 2012, 14, 
4293–4296. 
(220)  Kenmoku, S.; Urano, Y.; Kanda, K.; Kojima, H. Rational design of novel photoinduced 
electron transfer type fluorescent probes for sodium cation. Tetrahedron 2004, 60, 11067–
11073. 
(221)  Altieri, A.; Alvino, A.; Ohnmacht, S.; Ortaggi, G.; Neidle, S.; Nocioni, D.; Franceschin, 
M.; Bianco, A. Xanthene and xanthone derivatives as G-quadruplex stabilizing ligands. 
Molecules 2013, 18, 13446–13470. 
(222)  Lane, F. Reduction of organic compounds with diborane. Chem. Rev. 1976, 76, 773–799. 
(223)  Koh, J. J.; Zou, H.; Lin, S.; Lin, H.; Soh, R. T.; Lim F. H.; Koh, W.L.; Li, J.; 
Lakshminarayanan R.; Verma, C.; Tan, D. T.; Cao, D.; Beuerman, R. W.; Liu, S. 
Nonpeptidic amphiphilic xanthone derivatives: structure-activity relationship and 
membrane-targeting properties. J. Med. Chem. 2016, 59, 171–193. 
(224)  O’brien, D. E.; Baiocchi, F.; Robins, R. K.; Cheng, C. C. Pyrimidines. IX. 4- and 5-
(Substituted-anilino)pyrimidines. J. Med. Chem. 1962, 5, 1085–1103. 
(225)  Carceller, G. E.; Salas, S. J.; Soliva, S. R.; Medina, M. E. F.; Martí, V. J. Preparation of 
diaminopyrimidines as modulators of histamine H4 receptor activity, PCT Int. Appl., 
WO2007031529 A1, 2007. 
(226)  Sonar, S. S.; Sadaphal, S. A.; Kategaonkar, A. H.; Pokalwar, R. U.; Shingate, B. B.; 
References 
- 202 - 
 
Shingare, M. S. Alum catalyzed simple and efficient synthesis of bis(indolyl) methanes by 
ultrasound approach. Bull. Korean Chem. Soc 2009, 30, 825–828. 
(227)  Praveen, C.; Dheenkumar, P.; Muralidharan, D.; Perumal, P. T. Synthesis, antimicrobial 
and antioxidant evaluation of quinolines and bis(indolyl)methanes. Bioorg. Med. Chem. 
Lett. 2010, 20, 7292–7296. 
(228)  Kamal, A.; Khan, M. N. A.; Reddy, K. S.; Srikanth, Y. V. V; Ahmed, S. K.; Kumar, K. P.; 
Murthy, U. S. N. An efficient synthesis of bis(indolyl)methanes and evaluation of their 
antimicrobial activities. J. Enzyme Inhib. Med. Chem. 2009, 24, 559–565. 
(229)  Balu Pawar, Vinod Shinde, A. C. n-Dodecylbenzene sulfonic acid (DBSA) as a novel 
brønsted acid catalyst for the synthesis of bis(indolyl)methanes and bis(4-
hydroxycoumarin-3-yl) methanes in water. Green Sustain. Chem. 2013, 3, 56–60. 
(230)  Ganguly, N. C.; Mondal, P.; Barik, S. K. Iodine in aqueous micellar environment: a mild 
effective ecofriendly catalytic system for expedient synthesis of bis(indolyl)methanes and 
3-substituted indolyl ketones. Green Chem. Lett. Rev. 2012, 5, 73–81. 
(231)  Mathvink, R. J.; Barritta, A. M.; Candelore, M. R.; Cascieri, M. A.; Deng, L.; Tota, L.; 
Strader, C. D.; Wyvratt, M. J.; Fisher, M. H.; Weber, A. E. Potent, selective human β3 
adrenergic receptor agonists containing a substituted indoline-5-sulfonamide 
pharmacophore. Bioorg. Med. Chem. Lett. 1999, 9, 1869–1874. 
(232)  Rostamizadeh, S.; Reza, H.; Aryan, R.; Mohammad, A. Clean one-pot synthesis of 1, 2, 4-
oxadiazoles under solvent-free conditions using microwave irradiation and potassium 
fluoride as catalyst and solid support. Tetrahedron 2010, 66, 494–497. 
(233)  Polyák, M.; Varga, G.; Szilágyi, B.; Juhász, L.; Docsa, T.; Gergely, P.; Begum, J.; Hayes, 
J. M.; Somsák, L. Synthesis, enzyme kinetics and computational evaluation of N-(β-D-
glucopyranosyl) oxadiazolecarboxamides as glycogen phosphorylase inhibitors. Bioorg. 
Med. Chem. 2013, 21, 5738–5747. 
(234)  Bora, R. O.; Bashir Dar, B.; Pradhan, V.; Farooqui M. [1, 2, 4]-Oxadiazoles: synthesis and 
biological applications. Mini-Reviews Med. Chem. 2013, 1–15. 
(235)  Vörös, A.; Mucsi, Z.; Baán, Z.; Timári, G.; Hermecz, I.; Mizsey, P.; Finta, Z. An 
References 
- 203 - 
 
experimental and theoretical study of reaction mechanisms between nitriles and 
hydroxylamine. Org. Biomol. Chem. 2014, 12, 8036–8047. 
(236)  Zotti, G.; Schiavon, G.; Zecchin, S.; Morin, J.; Leclerc, M. Electrochemical, conductive, 
and magnetic properties of 2,7-carbazole-based conjugated polymers. Macromolecules 
2002, 35, 2122–2128. 
(237)  Du, Z. T.; Lu, J.; Yu, H. R.; Xu, Y.; Li, A. P. A facile demethylation of ortho substituted 
aryl methyl ethers promoted by ALCl3. J. Chem. Res. 2010, 34, 222–227. 
(238)  Thanigaimalai, P.; Konno, S.; Yamamoto, T.; Koiwai, Y.; Taguchi, A.; Takayama, K.; 
Yakushiji, F.; Akaji, K.; Chen, S.; Tavakolian, A. N.; Schön, A.; Freire, E.; Hayashi, Y. 
Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 
scaffolds: Design, synthesis, biological evaluation, and docking studies. Eur. J. Med. 
Chem. 2013, 68, 372–384. 
(239)  Fylaktakidou, K. C.; Litinas, K. E.; Varella, E. A.; Nicolaides, D. N. Recent developments 
in the chemistry and in the biological applications of amidoximes. Curr. Pharm. Des. 
2008, 14, 1001–1047. 
(240)  Rafehi, M.; Malik, E. M.; Neumann, A.; Abdelrahman, A.; Hanck, T.; Namasivayam, V.; 
Müller, C. E.; Baqi, Y. Development of potent and selective antagonists for the UTP- 
activated P2Y4 receptor. J. Med. Chem. 2017, 60, 3020–3038. 
(241)  Hillmann, P.; Ko, G.; Spinrath, A.; Raulf, A.; Ku, I. Von; Wolff, S. C.; Nicholas, R. a; 
Kostenis, E.; Ho, H.; Müller, C. E. Key determinants of nucleotide-activated G protein-
coupled P2Y receptor function revealed by chemical and pharmacological experiments, 
mutagenesis and homology modeling key determinants of nucleotide-activated G protein-
coupled P2Y2 receptor function. J. Med. Chem. 2009, 52, 2762–2775. 
(242)  Rafehi, M. Development of tools and ligands for the uracil nucleotide-activated g protein-
coupled P2Y receptors. Dr. rer. nat. thesis, Rheinische Friedrich-Wilhelms-Universität 
Bonn, Germany, 2017. 
(243)  Wolber, G.; Langer, T. Ligandscout: 3-D pharmacophores derived from protein-bound 
ligands and their use as virtual screening filters. J. Chem. Inf. Model. 2005, 45, 160–169. 
References 
- 204 - 
 
(244)  Hawkins, P. C. D.; Nicholls, A. Conformer generation with OMEGA: learning from the 
data set and the analysis of failures. J. Chem. Inf. Model. 2012, 52, 2919–2936. 
(245)  Wolber, G.; Dornhofer, A. A.; Langer, T. Efficient overlay of small organic molecules 
using 3D pharmacophores. J. Comput. Aided. Mol. Des. 2006, 20, 773–788. 
(246)  Vuorinen, A.; Engeli, R.; Meyer, A.; Bachmann, F.; Griesser, U. J.; Schuster, D.; 
Odermatt, A. Ligand-based pharmacophore modeling and virtual screening for the 
discovery of novel 17β-hydroxysteroid dehydrogenase 2 inhibitors. J. Med. Chem. 2014, 
57, 5995–6007. 
(247)  Sanmartín, C.; Echeverría, M.; Mendivíl, B.; Cordeu, L.; Cubedo, E.; Foncillas, G. J.; 
Font, M.; Palop, A. J. Synthesis and biological evaluation of new symmetrical derivatives 
as cytotoxic agents and apoptosis inducers. Bioorg. Med. Chem. 2005, 13, 2031–2044. 
 - 205 - 
 
Acknowledgement 
Throughout the process of earning my doctoral degree, I was blessed to find the support of many 
outstanding individuals. First and foremost I would like to express my deep and sincere gratitude 
to my mentor and supervisor Prof. Dr. Christa E. Müller. This thesis would not have been 
possible without her invaluable dedication and kindness. Thank you very much for giving me the 
opportunity to be part of your research group, for inspiring me, for your thought provoking 
discussion, for your continuous support and your exceptional patience.  
I would like to thank Priv.-Doz. Dr. Anke Schiedel for her kindness and for being the second 
examiner of my PhD thesis.  
I would like also to thank Dr. Ali El-Tayeb for his sincere dedication, scientific discussion, 
technical assistance and guidance. I really appreciate that he always made himself available all 
time for discussion and giving valuable suggestions.  
I would like to say thank you to my current office mates Dr. Sanyong Lee, Salahuddin Mirza, for 
their support, and for nice atmosphere in the office. Special thanks also to my previous office 
mates Dr. Enas Malik and Dr. Thanigaimali Pillaiyer for the nice time we spent together and for 
the great moments we shared. 
I extend my sincere thanks to my friends and colleagues Dr. Ahmed Aglan, Dr. Mohamed 
Ghonim, Dr. Nader Boshta, Dr. Ahmed Elgokha, and Dr. Anais Barré, for their continuing 
encouragement and support.  
I would like to thank Dr. Aliaa Abdelrahman, Dr. Muhammad Rafehi, and Isaac Attah for 
assistance with testing the biological activity of the compounds, Dr. Vigneshwaran Namasivayam 
for helping with the pharmacophore modeling experiments, Marion Schneider for assistance with 
LC-MS spectra measurement and Sabine Terhart-Krabbe and Annette Reiner for their help with 
the NMR analysis; thank you for your training, kind help and friendship. I learned a lot from you 
over these past four years. 
I am sincerely grateful to Dr. Ralf Mayer, Dr. Marcus Hubert, Dr. Meryem Köse, and Horst 
Schmidt for their unlimited support and guidance during my work in the ‘Analyseausgabe’. I also 
 - 206 - 
 
would like to thank my mentor Prof. Dr. Gerd Bendas for his kindness and commitment 
throughout the time I spent with the Bonn International Graduate School of Drug Sciences 
(BIGS-DrugS). 
I thank from my heart all members of the Institute of Pharmaceutical Chemistry I, Bonn 
University for their kind support and assistance I have been given over the years. 
I wish to express my deep thanks and appreciation to the Egyptian Ministry of Higher Education 
for sponsoring my PhD scholarship and for providing all the essential aids for fulfilment of the 
study to completion. I also wish to thank all my colleagues in the Department of Pharmaceutical 
Chemistry, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt. 
Finally I would like to thank my parents and family, for their love and support although it would 
be hard to express my gratitude towards them without writing another hundred pages. 
Special thanks to my incredible wife Nancy and lovely daughter Layan for their unlimited 
support, continuous encouragement, love and patience during the four years of this work. Thank 
you for always being here. 
                                                                                                                             Mahmoud Rashed 
 
